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ABSTRACT 
Background: High-dose methotrexate (HD-MTX) is an essential component of 
osteosarcoma treatment. Despite supportive measures MTX-related toxicity results 
in delays in subsequent chemotherapy administration and potentially reduced 
treatment efficacy. Alternative rescue regimens utilising glucarpidase in addition to 
folinic acid may be of benefit in reducing MTX-induced toxicity.  
Patients and methods: A double blind randomised crossover clinical trial, GLU 1, 
was designed and activated to determine the efficacy and safety of routine use of 
glucarpidase after HD-MTX. To establish the frequency of MTX-induced toxicity so 
that bespoke study endpoints and sample size could be determined, the medical 
records of 56 patients with bone sarcoma treated with HD-MTX between 2004 and 
2005 at University College Hospital (UCH) were studied. Data were collected on 
MTX-related toxicity and treatment delays. In a separate review, similar data from 17 
patients aged ≥ 40 years, and 25 patients aged < 40 years treated with HD-MTX 
between 2002 and 2007 at UCH were compared. A high performance liquid 
chromatography (HPLC) assay was validated for the evaluation of plasma MTX and 
DAMPA concentrations for trial participants. In GLU 1, patients were randomised to 
receive two HD-MTX courses with folinic acid rescue (cycle FA) followed by two HD-
MTX courses with folinic acid and glucarpidase (cycle glu/FA), or cycle glu/FA first 
followed by cycle FA. The data of 16 patients enrolled up to the interim analysis of 
the trial were analysed.  
Results: MTX-related toxicity resulted in delays in half of subsequent chemotherapy 
cycles (58% in the ≥ 40 years group and 52% in the < 40 years group). In GLU 1, 
MTX toxicity resulted in delays in 43% of glu/FA cycles and 77% of FA cycles. The 
use of glucarpidase was not associated with a reduction in MTX AUC. The incidence 
and grade of MTX-induced toxicity were similar in glu/FA and FA although more 
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severe grades of mucositis were less frequent in glu/FA cycles. No glucarpidase 
toxicity was observed.  
Conclusions: Glucarpidase offers a promising addition for rescue from MTX toxicity 
and continued clinical evaluation to determine its most effective use is warranted. 
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1. INTRODUCTION 
1.1. RATIONALE AND BACKGROUND 
HD-MTX at a dose of 12 g/m2, in combination with vigorous hydration and urinary 
alkalinisation along with a pharmacokinetically guided folinic acid “rescue” schedule, 
is an essential component of osteosarcoma treatment. Folinic acid replenishes the 
intracellular source of reduced active folates. Although folinic acid rescue may 
decrease the degree of MTX toxicity, patients will remain at risk as long as elevated 
MTX levels persist in the circulation. Moreover, if extracellular MTX concentration is 
very high, rescue with folinic acid may prove inadequate.  
Despite current supportive measures, MTX-induced toxicity (myelosuppression, 
mucositis, hepatic and renal toxicity) still occurs and results in increased morbidity, 
patient discomfort, increased costs and potentially reduced treatment efficacy, due 
to suboptimal chemotherapy doses and/or delays in chemotherapy administration.  
Several studies have shown that the fewer delays in MTX administration in 
osteosarcoma treatment, the better the outcome. Frei et al. (1980) reported that 
chemotherapy response in osteosarcoma improves by increasing MTX dose and 
worsens by increasing the time between MTX administrations. The French Tumour 
Study Group (1988) revealed that delay in MTX course administration is a negative 
prognostic factor in osteosarcoma. Moreover, Bacci et al (2001) showed that 
avoiding reductions in MTX doses and /or delays in chemotherapy is crucial in 
osteosarcoma outcome. A review of 30 studies by Delepine et al. (1996) 
demonstrated that the total planned dose and dose intensity of MTX (total MTX dose 
during treatment divided by total number of weeks), correlates significantly with 
disease free survival and proposed it to be a major factor in predicting the outcome 
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of patients with localised high grade osteosarcoma. These reports indicate that 
improving rescue from MTX toxicity is a worthwhile goal.  
Glucarpidase (Voraxaze™, formerly known as Carboxypeptidase G2) is an enzyme 
that cleaves the terminal glutamate from folate and folate analogues such as MTX. 
In the case of MTX, its action results in the production of the inactive metabolite 
DAMPA (4-deoxy-4-amino-N10-methylpteroic acid). It is currently used effectively to 
treat patients with MTX-induced renal dysfunction, in order to avoid potentially fatal 
MTX-related toxicity. A single intravenous dose of 50 units/kg of glucarpidase after 
MTX results in the reduction of plasma MTX levels to the non-toxic range within 
minutes without causing toxicity (Widemann and Adamson, 2006). Glucarpidase has 
much higher affinity for MTX than folinic acid so even high circulating folinic acid 
levels are unlikely to interfere with extracellular MTX inactivation. Moreover, 
glucarpidase is a high molecular weight protein and does not gain intracellular 
access. Therefore it is unlikely that it would counteract the anti-tumour effect of MTX 
trapped intracellularly in the form of polyglutamate. Glucarpidase seems to offer a 
promising opportunity for rescue from MTX toxicity. 
Our aim is to establish the contribution of MTX-related toxicity to delays in delivering 
chemotherapy in patients with bone sarcoma and examine the role of glucarpidase 
in routine rescue after HD-MTX. Glucarpidase, if found to be effective and safe in 
maintaining the treatment intensity and reducing the incidence and severity of MTX-
induced toxicity, could optimise treatment, improve patients’ well-being, and reduce 
the use of health resources. 
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1.2. OSTEOSARCOMA AND TREATMENT OF OSTEOSARCOMA 
1.2.1. OSTEOSARCOMA 
Osteosarcoma is the most frequent primary malignant tumour of bone, deriving from 
primitive bone-forming mesenchyme and characterized by the production of osteoid 
tissue or immature bone by the malignant proliferating spindle cell stroma.  
The approximate annual incidence of osteosarcoma is 2-3 per million in the general 
population; it is <1 per million in children under the age of 5 years, 2 per million at 
the age of 5-9 years, 7 per million at the age of 10-14 years and peaks at 8-11 per 
million at the age of 15-19 years (Bielack and Bernstein, 2005). There is a second 
smaller peak in older patients, which is due to osteosarcomas arising in abnormal 
bones, such as those affected by Paget’s disease or previously treated with 
radiotherapy. Males are affected more frequently in most series (male: female ratio; 
1.4:1) (Bielack and Bernstein, 2005). It occurs in any bone of the body. Among 
young patients, the most common site is the metaphysis of a long bone. 
Approximately half of all osteosarcomas originate in the region around the knee. The 
most frequent primary site is the distal femur, followed by the proximal tibia, followed 
by the proximal humerus. Other primary sites in descending order of frequency are 
pelvis, jaw, fibula and ribs (Bielack and Bernstein, 2005). 
The World Health Organization's histologic classification of bone tumours separates 
osteosarcomas into central (medullary) and surface (peripheral) tumours and 
recognizes a number of subtypes within each group. The most common pathologic 
subtype is the conventional high-grade central osteosarcoma. It accounts for 80-
90% of all osteosarcomas and is characterized by areas of necrosis, atypical 
mitoses and malignant cartilage. The most frequent subtypes of conventional high-
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grade central osteosarcoma are osteoblastic, chondroblastic and fibroblastic 
osteosarcomas (Fletcher et al. 2002).  
There is limited understanding of the aetiology of osteosarcoma. The peak incidence 
coincides with a period of rapid bone growth in young people, a feature that 
suggests a relationship between rapid bone growth and the development of this 
tumour (Marina N et al. 2004). Osteosarcomas occur at an earlier age in girls than in 
boys, corresponding to the more advanced skeletal age and earlier adolescent 
growth spurt of girls, whereas the increased risk for osteosarcoma among boys may 
results from the larger volume of bone formed during a longer growth period (Marina 
N et al. 2004). Osteosarcoma has a predilection for the metaphyseal portions of the 
most rapidly growing bones in adolescents and tumours of the humerus tend to 
occur at a younger age than do tumours of the femur and tibia, corresponding to the 
earlier growth spurt of the humerus. An explanation to that may be that rapidly 
proliferating cells might be particularly susceptible to oncogenic agents and mitotic 
errors which lead to neoplastic transformation (Jaffe et al. 2009). Nevertheless, it 
must be recognised that osteosarcoma arises in many patients well before and long 
after the adolescent growth spurt (Marina N et al. 2004).  
Radiation is a well-documented aetiologic factor, being implicated in approximately 
3% of osteosarcomas (Jaffe et al. 2009). An increased incidence is likely to be seen, 
as more patients survive long enough after primary irradiation to develop this 
complication. The interval between irradiation and appearance of osteosarcoma 
ranges from 4 to more than 40 years (median: 12-16 years) (Huvos 1991). 
Osteosarcomas have also been associated with the use of intravenous radium 224 
and Thorotrast, a diagnostic radiocontrast agent (Loutit 1970; Harrist et al. 1979). 
Exposure to alkylating agents may also contribute to its development.  
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Approximately 2% of patients with Paget’s disease develop osteosarcoma and 
cases of osteosarcoma in patients older than 40 years are often associated with this 
premalignant condition (Huvos 1991). Other conditions associated with an increased 
risk of development of osteosarcoma, are solitary or multiple osteochondroma, 
solitary enchondroma or enchondromatosis (Ollier’s disease), multiple hereditary 
exostoses, fibrous dysplasia, chronic osteomyelitis, sites of bone infarcts and sites 
of metallic implants for benign conditions.  
The incidence of osteosarcoma is increased in several well-defined hereditary 
disorders associated with germ-line alterations of tumour suppressor genes. 
However, these account for only a few percent of all osteosarcomas. Survivors of 
hereditary retinoblastoma with germline mutations of the retinoblastoma gene RB1 
on chromosome 13q14 carry a risk which is 500 to 1000 times greater than that of 
the general population (Bielack and Bernstein, 2005). The Li-Fraumeni syndrome 
(germ-line mutations in the p53 gene) is associated with a 15-fold increase. 
Rothmund-Thomson, Bloom and Werner syndromes are also associated with an 
increase in osteosarcomas (Bielack and Bernstein, 2005).  
The most common clinical presentation of osteosarcoma is pain in the involved 
region of bone, with or without a soft tissue mass. Pain is often attributed to trauma 
or vigorous physical exercise, both of which are common in the population at risk. 
Symptoms are usually present for several months before the diagnosis is made. In 
approximately 10%, the first sign of disease is a pathologic fracture (Bielack and 
Bernstein, 2005). 10-20% of patients with osteosarcoma present with 
radiographically detectable metastatic disease, but virtually all patients have sub 
clinical, microscopic metastases (Bielack and Bernstein, 2005). The most frequent 
site for metastatic presentation is the lung. Much less frequently, metastases at 
initial diagnosis occur in other bones and soft tissues. 
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1.2.2. TREATMENT OF NEWLY DIAGNOSED OSTEOSARCOMA 
Almost all patients with high-grade osteosarcoma have at least microscopic 
metastatic disease at diagnosis. This necessitates the use of systemic 
chemotherapy in addition to surgery. In the UK, standard treatment for newly 
diagnosed osteosarcoma includes 10 weeks of neoadjuvant chemotherapy with 
Doxorubicin (Adriamycin), Cisplatin and HD-MTX (MAP), followed by surgery, 
followed by 18 weeks of adjuvant chemotherapy with the same agents (Table 1). 
Table 1: STANDARD OSTEOSARCOMA MANAGEMENT 
CYCLE WEEK TREATMENT 
1 
1 Doxorubicin, 75 mg/m
2
 + cisplatin, 120 mg/m
2
 
2  
3  
4 HD-MTX, 12 g/m
2
 
5 HD-MTX, 12 g/m
2
 
2 
6 Doxorubicin, 75 mg/m
2
 + cisplatin, 120 mg/m
2
 
7  
8  
9 HD-MTX, 12 g/m
2
 
10 HD-MTX, 12 g/m
2
 
 11 SURGERY 
3 
12 Doxorubicin, 75 mg/m
2
 + cisplatin, 120 mg/m
2
 
13  
14  
15 HD-MTX, 12 g/m
2
 
16 HD-MTX, 12 g/m
2
 
4 
17 Doxorubicin, 75 mg/m
2
 + cisplatin, 120 mg/m
2
 
18  
19  
20 HD-MTX, 12 g/m
2
 
21 HD-MTX, 12 g/m
2
 
5 
22 Doxorubicin, 75 mg/m
2
  
23  
24 HD-MTX, 12 g/m
2
 
25 HD-MTX, 12 g/m
2
 
6 
26 Doxorubicin, 75 mg/m
2
  
27  
28 HD-MTX, 12 g/m
2
 
29 HD-MTX, 12 g/m
2
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1.2.3. TREATMENT OF RELAPSED OSTEOSARCOMA 
Surgery is the cornerstone of successful relapse therapy. However, chemotherapy 
should be offered to most patients who experience a relapse within the first three 
years after diagnosis and those with multiple metastases. The choice of drugs 
should be made on an individual basis. Patients, who have been previously treated 
with MAP, could potentially receive ifosfamide and etoposide. Nevertheless, there 
are patients with relapsed disease who have not received MTX at initial diagnosis, 
such as patients on the previous randomised MRC BO06 clinical trial (Lewis IJ et al. 
2007), which compared standard and intensified doxorubicin and cisplatin regimens. 
In those patients HD-MTX would be recommended. In patients who relapsed, 
despite having received all five active chemotherapy agents (doxorubicin, cisplatin, 
MTX, ifosfamide and etoposide), but responded to MTX in the past, the use of 
further MTX can be considered.  
1.3. MTX AND THE ROLE OF HD-MTX IN TREATMENT OF OSTEOSARCOMA 
1.3.1. DESCRIPTION AND USE OF MTX 
MTX (Amethopterin, 4-NH2-4-deoxy-N
10-methyl-pteroyglutamic acid) is an analogue 
of folic acid. The molecular structure of MTX differs from folic acid only in that it has 
a 4-amino group in place of the hydroxyl group on the pteridine ring, and a methyl 
group at the N10 position. It was first used in the treatment of childhood acute 
lymphoblastic leukaemia in 1948. Since then it has been used in the treatment of 
various malignancies including osteosarcoma, non-Hodgkin’s lymphoma, Hodgkin’s 
disease, and breast cancer (Bleyer 1978; Jolivet et al. 1983; Bertino 1993). It is one 
of the few agents that can be given intrathecally and used for central nervous 
system involvement in leukaemia, lymphoma and solid tumours. Due to its 
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immunosuppressive effects, it is used in rheumatoid arthritis, psoriasis and the 
prevention of graft-versus-host disease after bone marrow transplantation.  
1.3.2. MECHANISM OF ACTION OF MTX  
MTX inhibits dihydrofolate reductase (DHFR), the enzyme responsible for converting 
folic acid to reduced folate cofactors. Reduced folates are necessary for the transfer 
of 1-carbon units in a variety of biochemical reactions, such as the biosynthesis of 
thymidylic acid, the nucleotide specific to DNA, and the biosynthesis of inosinic acid, 
the precursor of purines necessary for both DNA and RNA synthesis (Bleyer 1978).  
1.3.3. HALF LIFE AND TRANSPORT OF MTX 
After intravenous administration, the disappearance of MTX from plasma is triphasic 
(Huffman et al. 1973; Stoller et al. 1975). The initial half-life is 0.75 ± 0.11 h 
(Huffman et al. 1973). The second half-life has been reported as 2.06 ± 0.61 (Stoller 
et al. 1975), 3.49 ± 0.55 (Huffman et al. 1973) or 2.0-3.4 h (Pratt et al. 1975). The 
terminal half-life is 10.4 ± 1.8 h (Stoller et al. 1975) and begins as the plasma 
antifolate concentration approaches 10-7M, approximately 30-48 hrs after high-dose 
therapy. The first half-life is probably that of distribution and the second half-life that 
of renal clearance. The prolonged terminal phase probably represents a combined 
effect of release from deep compartments, enterohepatic circulation and renal 
tubular re-absorption, and is responsible for the major portion of gastrointestinal and 
bone marrow toxicity (Bleyer 1978).  
In human plasma, 50-70% of MTX is bound to protein, principally albumin. 
Alterations in plasma protein binding affect the amount of free extracellular MTX, 
which in turn influences the influx of MTX into cells and its rate of clearance by the 
kidneys (Bleyer 1978). 
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The transport of MTX and naturally occurring erduced folates across the cell 
membrane is mediated by three genetically dinstict and functionally diverse 
transport systems, the Reduced Folate Carrier (RFC), Folate Receptors (FR) and 
Proton-Coupled Folate Transporter (PCFT) (Desmoulin et al. 2012).  
RFC is a secondary active anionic exchanger which transports reduced folates and 
antifolates, including MTX, in mammalian cells and tissues via counter-transport with 
organic anions (Matherly et al. 2007); it has a much lower (~50-100-fold) affinity for 
folic acid than that for reduced folates. Transport with RFC is charactarised by a 
neutral pH optimum and markedly decreased transport activity below pH 7 (Matherly 
et al. 2007; Zhao et al. 2007; Zhao et al. 2009).  
Membrane-bound RFs mediate cellular uptake of folic acid, reduced folates and 
many antifolates, including MTX, via a non-classical endocytotic mechanism 
whereby folate ligands bind FRs at the cell membrane, followed by invagination and 
the formation of cytoplasmic vesicles (endosomes) (Rijnboutt et al. 1996; 
Sabharanjak et al. 2004). Release of bound ligands occurs upon endosomal 
acidification which facilitates dissociation of the ligand-FR complex, and exit of the 
folate ligand from the endosome to the cytoplasm by diffusion or a transport-
mediated process that operates at acidic pH (Kamen et al. 1988).  
PCFT is the third transport system; it is a proton-folate symporter that functions 
optimally at acidic pH (maximal transport at pH 5-55) by coupling the flow of protons 
down an electrochemical concentration gradient to the uptake of reduced folates, 
folic acid and antifolates, including MTX and pametrexed, into cells (Zhao et al. 
2007; Qiu et al. 2006; Umapathy et al. 2007; Nakai et al. 2007).  
At high extracellular concentrations (MTX serum levels >100 µmol/L), MTX also 
enters cells by passive diffusion (Hill et al. 1979). This appears to be the principal 
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means of drug accumulation by MTX resistant cells that are deficient in carrier-
mediated transport. 
Once inside the cell, MTX undergoes polymerisation of the glutamic acid chain, 
similar to endogenous folates, to form methotrexate polyglutamates (MTX-PG). 
While both MTX and MTX-PG competitively inhibit DHFR, MTX-PG has enhanced 
binding to and inhibition of the enzyme and serves to enhance the retention and 
potency of MTX against target enzymes. Formation of the MTX-PG is dependent 
upon intracellular MTX concentration and the duration of exposure.  
1.3.4. METABOLISM AND EXCRETION OF MTX  
Several metabolites have been found in human urine and plasma, particularly in 
patients receiving the highest doses of MTX (Bleyer, 1978). The metabolites 
account for <10% of the total dose administered if MTX is given intravenously at 
30mg/m2. If given orally at the same dose, as much as 35% of the absorbed dose 
may be excreted as metabolites. The higher amount of metabolites after oral 
administration than after intravenous injection is consistent with the hypothesis that 
MTX metabolism in man occurs primarily in the gastrointestinal tract or 
enterohepatic circuit.  
Under conditions of normal renal function MTX clearance from plasma is 110 
cc/min/m2, 103 cc/min/m2 of which is due to renal clearance (Liegler et al. 1969). 
Approximately 41% of an intravenously administered dose is excreted unchanged in 
the urine within 6 h after administration, 90% within 24 h, and 95% within 30h (Pratt 
et al. 1975; Henderson et al. 1965; Wang et al. 1976). At very low plasma 
concentrations, MTX appears to be reabsorbed by the kidney (Huffman et al. 1973). 
At higher concentrations, renal clearance of MTX is relatively constant (Huffman et 
al. 1973) and exceeds that of inulin (Liegler et al. 1969), suggesting that MTX is not 
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only filtered but also actively secreted by renal tubular cells. 1 to 2% of intravenously 
administered dose is excreted in the stool as the parent combound and metabolites 
(Bleyer 1978). 
1.3.5. MTX RESISTANCE 
Resistance to MTX may develop through a variety of mechanisms, including 
impaired transport of drug into the cell via the RFC (Sirotnak FM et al. 1981), 
alterations in the affinity of DHFR for MTX (Goldie et al. 1980; Flintoff et al. 1980), 
increase in DHFR due to gene amplification or increased transcription (Alt et al. 
1978; Melera et al. 1980), and diminished intracellular retention secondary to 
decreased polyglutamation (Cowan et al. 1984). 
In patients with osteosarcoma, therapy with conventional MTX doses is ineffective; 
thus HD-MTX is used. Several retrospective studies have suggested that a 
threshold peak MTX level needs to be achieved to obtain good histological response 
to chemotherapy. Guo et al. (1999) demonstrated that 65% of high grade OS 
samples at the time of initial biopsy were found to have decreased RFC expression, 
which suggests that impaired transport of MTX may be an important mechanism of 
intrinsic resistance in OS. This may partly explain why conventional dose of MTX is 
ineffective in the treatment of OS, as high doses may be needed to allow transport 
through alternatives means, such as passive diffusion. In the same study, although 
increased expression of DHFR was rare in the biopsy material, it was frequent in the 
recurrent pulmonary metastases and excision samples. Therefore it is possible that 
increased DHFR expression represents acquired MTX resistance, either through 
acquired alteration in tumour cells or through selection of a previously resistant 
clone. In addition, Meyer et al. (1990) reported that xenografts of osteogenic 
sarcoma cells form predominantly short chain MTX polyglutamates, suggesting 
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either relatively low FPGS activity, relatively high FPGH activity or a combination of 
these features.  
Theoretically, all known mechanisms of MTX resistance could be overcome using 
HD-MTX. At high extracellular concentrations, passive diffusion of MTX may 
overcome resistance due to impaired membrane transport and the high intracellular 
levels achieved could overcome resistance due to the presence of increased DHFR 
levels or altered enzyme affinity. In addition, the availability of large amounts of free 
intracellular MTX might promote conversion to polyglutamate derivatives of the drug 
(Bleyer 1978). 
1.3.6. ROLE OF HD-MTX IN OSTEOSARCOMA 
Before the use of chemotherapy, 80-90% of patients with non-metastatic 
osteosarcoma died despite early radical surgery. With the use of multidrug 
chemotherapy, approximately two thirds of patients with non-metastatic resectable 
primary tumours can be cured (Link et al. 1986). The improved outcome has been 
attributed, in part, to the use of HD-MTX with folinic acid rescue as described by 
Jaffe (1972) and Jaffe et al. (1973; 1977) and emphasized by Rosen et al. (1974; 
1975; 1979). 
The first effective drugs to be introduced into the treatment of osteosarcoma were 
doxorubicin and HD-MTX (Jaffe et al. 1973 and 1977; Rosen et al. 1974, 1975 and 
1979; Cortes et al. 1972). Rosen et al. (1975) combined these two drugs together 
with cyclophosphamide; bleomycin, cyclophosphamide and dactinomycin; and 
cisplatin. This innovative approach of aggressive multidrug chemotherapy provoked 
controversy and the role of HD-MTX was questioned in particular. Subsequently 
data from the study by Rosen et al. (1975) were analyzed by Meyers et al. (1992), 
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who convincingly showed a histologically proven 19% response rate of single-drug 
HD-MTX in 54 patients.    
Since then, Delepine et al. (1996), in a review of 30 studies, revealed that the total 
planned dose and dose intensity of HD-MTX correlates significantly with disease 
free survival in patients with localised high grade osteosarcoma. However, there is 
still controversy regarding the optimal MTX plasma levels and/or the duration of 
exposure that must be achieved for optimum efficacy. Some studies suggest that 
MTX plasma levels of ≥ 700 μM (Bacci et al. 1996 and 1998) or ≥ 1000 μM 
(Delepine 1988; Graf et al. 1994) at the end of a 4-6 h infusion improves histologic 
response and event free survival. These levels are achievable at the end of a 4 h 
intravenous MTX infusion of 12 g/m2 (Crews et al. 2004). However, Crews et al. 
(2004) reported that mean peak MTX levels >1500 μM is associated with lower 
event free survival, possibly because higher MTX levels are associated with more 
toxicity and therefore decreased dose intensity, or because increased folinic acid 
dosing in patients with very high MTX exposures may have compromised the 
antitumour effect of MTX. Others have observed significant differences in the 
disease free survival between patients whose mean area under the curve (AUC) 
was below or above 4000 μMh and recommended that the MTX dose should be 
increased such as to obtain an AUC >4000 μMh (Aquerreta et al. 2004).  
1.3.7. HD-MTX INDUCED TOXICITY 
Despite currently used supportive measures, MTX-induced toxicity still occurs, 
resulting in increased morbidity, suboptimal chemotherapy doses, delays in 
subsequent chemotherapy administration and possibly poorer outcome (Frei at al., 
1980; French Tumour Study Group, 1988; Bacci et al., 2001; Delepine et al., 1996).  
There is wide inter- and intra-patient variability in relation to methotrexate tolerance 
(Bacci et al. 1996 and 1998; Zelcer et al. 2005; Ferrari et al. 1993; Delepine et al. 
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1995), the primary determinant of which appears to be variation in the 
pharmacokinetics of the drug.   
Correlation of the toxic reactions with the drug’s pharmacokinetics discloses certain 
time- and concentration-dependent relationships which appear to determine which 
target tissue is at risk of toxicity. For bone marrow and gastrointestinal epithelium, 
the plasma concentration- and time-threshold appear to be 2 x 10-8 M and about 42 
hours, respectively (Levitt et al. 1973; Young et al. 1973). The severity of toxicity is 
positively associated with the duration of MTX exposure beyond the time-threshold, 
and relatively less dependent on the magnitude of MTX elevation above the 
extracellular concentration-threshold (Goldie et al. 1972).  
The major focus of osteosarcoma research has been on maximising survival and 
there are almost no dedicated studies of complications of osteosarcoma therapy. In 
most publications of osteosarcoma clinical trials which included HD-MTX in their 
treatment regimen, data on chemotherapy-related toxicity were not documented or 
the information on toxicity was either not specific to HD-MTX or minimal (Rosen et 
al., 1982; Meyers et al., 1992; Meyers et al., 1998; Saeter et al.; 1991; Provisor et 
al., 1997; Goorin et al., 1987; Winkler et al., 1984; Winkler et al., 1988; Fuchs et al., 
1998; Bacci et al., 1990; Bacci et al., 1993; Bramwell et al., 1992; Souhami et al., 
1997; Meyers et al., 2005; and Ferrari et al., 2005).  
Toxicity related to HD-MTX includes mucositis, hepatotoxicity, nephrotoxicity, 
myelosuppression, and less commonly dermatitis and encephalopathy. Available 
information in the literature on the incidence and severity of MTX-related toxicity is 
as follows: 
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a. MUCOSITIS 
Sonis at al. (2004) reviewed three studies involving 132 patients receiving 
methotrexate chemotherapy, 23% developed grade 3-4 oral mucositis (Sonis et al., 
2004). Saeter et al. (1991) reviewed 376 HD-MTX courses (8-12 g/m2) given 
preoperatively in 97 patients with osteosarcoma (median age 16 years). Oral 
mucositis complicated 20% of those and was mild in the majority of the courses. In 
another review of 65 consecutive patients with osteosarcoma treated with 288 
courses of HD-MTX courses at a dose of 12 g/m2 (Holmboe et al., 2012), mucositis 
grade 1, 2, 3 and 4 (CTCAE v3.0) complicated 13%, 8%, 15% and 0% of those 
respectively. 
b. HEPATOTOXICITY 
Saeter et al. (1991) reported transient liver dysfunction in 80% of patients (mean 
ALT levels of 175 U/L), but almost all episodes were benign in consequence and 
reversible. In the review by Holmboe et al. (2012), hyperbilirubinaemia grade 1 and 
2 (CTCAE v3.0) complicated 35% and 24% of methotrexate courses respectively 
whereas grade 3 and 4 (CTCAE v3.0) were not documented. Bilirubin was not 
affected in 42% MTX courses. Raised ALT grade 1, 2, 3 and 4 (CTCAE v3.0) 
complicated 14%, 25%, 42% and 17% of MTX courses respectively and only 2% of 
MTX were not associated with a rise in ALT. Zelcer et al. (2008) retrospectively 
reviewed the treatment of 82 osteosarcoma patients who received 708 MTX courses 
at the Memorial Sloan-Kettering Cancer Centre between 1996 and 2002 at a dose of 
12 g/m2. Most patients had transient elevation in ALT and bilirubin which were 
completely reversible. 
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c. RENAL DYSFUNCTION  
The most comprehensive review on MTX-related nephrotoxicity was published by 
Widemann et al. (2004). In this review, 1.8% patients (68 of 3887 patients) 
developed MTX-related nephrotoxicity that was either ≥ grade 2 or significant 
enough to be reported and 23 patients (0.6%) developed grade 3 or 4 toxicity. Renal 
toxicity was graded using the World Health Organization criteria (Grade 1, serum 
creatinine levels < 1.5 x ULN; Grade 2, 1.5-3.0 x ULN; Grade 3, 3.1-6.0 x ULN; and 
Grade 4, > 6.0 x ULN, similar to CTCAE v3.0 grading). The mortality rate among 
those patients was 4.4% (3/68). 
Holmboe et al. (2011) reviewed 65 consecutive patients with osteosarcoma (median 
age 18 years) treated with 288 courses of HD-MTX courses (at a dose of 12 g/m2) 
on SSG VIII, ISG/SSG-I, ISG/SSG-II and ISG/SSG-XIV clinical trials between 1994 
and 2003. Creatinine remained within normal range in 95% of MTX courses. 
Creatinine rise grade 1 and 2 (CTCAE v3.0) was noted in 3% and 2% of treatment 
courses respectively. 
Zelcer et al. (2008) reviewed the treatment of 82 osteosarcoma patients who 
received 708 MTX courses (at a dose of 12 g/m2) at the MSKCC between 1996 and 
2002. The majority (98-99%) of the courses resulted in no significant elevation in 
creatinine levels (grade 0 and 1 as per NCI CTC v.2.0). Moderate to severe 
nephrotoxicity (grade 3 and 4) was not observed. 
The above papers describe the incidence and severity of renal toxicity after 
treatment with HD-MTX. However, chemotherapy for osteosarcoma includes other 
nephrotoxic agents such as cisplatin and cumulative renal burden due to cisplatin 
should be taken into account.   
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d. MYELOSUPPRESSION 
Saeter et al. (1991) reviewed 376 HD-MTX courses (8-12 g/m2) given preoperatively 
in 97 patients with osteosarcoma (median age 16 years) on the SSG-II clinical trial 
between 1982 and 1989. Severe bone marrow toxicity (WHO III or IV) complicated 
0.5% of courses whereas 19% of courses were associated with grade I bone 
marrow toxicity. Holmboe et al. (2012) reviewed 65 consecutive patients with 
osteosarcoma (median age 18 years) treated with 288 courses of HD -MTX courses 
at a dose of 12 g/m2. Leucopenia grade 1, 2, 3 and 4 (CTCAE v3.0) complicated 
5%, 30%, 27% and 6% of MTX courses respectively. MTX did not lead to 
leucopenia in 32% of the courses. Thrombocytopenia grade 1, 2, 3 and 4 (CTCAE 
v3.0) complicated 20%, 7%, 10% and 10% of MTX courses respectively although 
MTX did not lead to thrombocytopenia in 32% of the courses. Also, Zelcer et al. 
(2008) reviewed the treatment of 82 osteosarcoma patients who received 708 MTX 
courses at MSKCC between 1996 and 2002 at a dose of 12 g/m2. 16%, 9% and 3% 
of the courses were associated with grade 3 and 4 neutropenia, leucopenia and 
anaemia/thrombocytopenia respectively. 
e. NEUROTOXICITY  
Acute transient neurological dysfunction following HD-MTX is reported in the 
literature to occur in 0.4-5% of children treated for osteosarcoma (Goorin et al. 2003, 
Walker et al. 1986, Packer et al. 1983, Saeter et al. 1991).  
f. SKIN TOXICITY  
Skin toxicity is reported to complicate 1.3% of MTX courses (Saeter et al. 1991)  
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1.3.8. ROLE OF FOLINIC ACID RESCUE AFTER HD-MTX 
Folinic acid is a racemic mixture of the stereoisomers of N5-formyl-FH4. The D- and 
L-isomers differ significantly in their cellular and clinical pharmacology, with only the 
L-isomer having the capacity to rescue cells from MTX toxicity. Following oral or 
parenteral administration, folinic acid is readily converted to N5-methyl-FH4, the 
primary circulating folate in humans (Ackland et al. 1987). 
The rationale for the use of folinic acid rescue is that provision of reduced folate to 
normal cells should circumvent the metabolic block produced by MTX and allow 
resumption of purine and pyrimidine synthesis. However, the selective rescue of 
normal tissues and not tumour cells has not been adequately explained, except 
perhaps when tumour cell resistance to MTX is caused by loss of the membrane 
transport system for reduced folates, thus excluding folinic acid from tumour cells 
(Ackland et al. 1987). 
Folinic acid competes with MTX for entry into the cell because it is actively 
transported by the same cell transport system as MTX. This observation forms the 
basis for one of the hypotheses of selectivity, because tumour cells with a defect in 
the folate transport system would not be rescued since insufficient folate would enter 
the cell. This is in contrast to normal cells with intact folate transport, which could be 
more easily rescued.   
Experimental observations have shown that folinic acid is able to competitively 
displace MTX from DHFR allowing its reactivation (Matherly et al. 1986). However, 
in the presence of MTX polyglutamates, such competitive displacement does not 
occur, and DHFR inhibition is sustained. The observation that most tumour cells 
synthesize much greater quantities of MTX polyglutamates than normal cells is 
central to understanding the selectivity of folinic acid rescue. In normal cells, such as 
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bone marrow precursors, which have few MTX polyglutamates, folinic acid 
administration promotes dissociation of MTX from DHFR, with consequent 
reactivation of the enzyme. Cellular levels of MTX polyglutamates then decrease 
rapidly, enabling reactivation of purine and thymidylate biosynthesis as reduced 
folate pools are restored. In tumour cells however, accumulation of MTX 
polyglutamates prevents competitive displacement from DHFR by folinic acid and 
DHFR inhibition is sustained. Thus cellular levels of MTX polyglutamates remain 
high and directly inhibit purine biosynthesis (Ackland et al. 1987). 
An important issue to consider is that the concentration of folinic acid needed to 
rescue normal cells from MTX is dependent upon the concentration of MTX present. 
The concentration of folinic acid must be high enough to compete effectively for 
transport into the cells of normal tissue. Importantly, with high MTX concentrations, 
even ten-fold higher folinic acid concentrations (concentrations that theoretically are 
achieved with supra-pharmacologic dosing of folinic acid) are unable to rescue 
normal haematopoietic cells (Pinedo et al. 1976). 
1.3.9. DELAYS IN OSTEOSARCOMA TREATMENT DUE TO MTX TOXICITY  
Although several studies have shown that the fewer delays in MTX administration in 
osteosarcoma treatment, the better the outcome (Frei et al. 1980; French Bone 
Tumour Study Group 1988; Bacci et al. 2001; Delepine et al. 1996), there is 
currently no available literature on the incidence of delays in subsequent 
chemotherapy due to MTX toxicity in patients with osteosarcoma.  
Information is only available on the incidence of delayed MTX elimination in patients 
with osteosarcoma which may then result in subsequent chemotherapy delays. 
Saeter et al. (1991) reviewed 376 HD-MTX courses (8-12 g/m2) given preoperatively 
in 97 patients with osteosarcoma (median age 16 years) on the SSG-II clinical trial 
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between 1982 and 1989. Twenty-nine patients (30%) experienced delayed excretion 
constituting 15% of all HD-MTX courses. Winkler et al. (1988) reviewed the results 
of the COSS-82 clinical trial and reported that HD-MTX (12 g/m2) toxicity led to 
delays in 36 of 495 observed cycles (7%). This is in keeping with Bacci et al. (2006) 
who reviewed 336 patients with osteosarcoma treated on three protocols of 
neoadjuvant chemotherapy including HD-MTX at Instituti Orthopedici Rizzoli 
between 1983 and 2004. Delayed MTX elimination and therefore delay to 
subsequent treatment complicated 3.1% of HD-MTX courses (8-12 g/m2). This 
differed with different dose of MTX with 1.2%, 3.5% and 4.7% of MTX courses at a 
dose of 8, 10 and 12 g/m2 respectively being complicated with delayed MTX 
excretion. In contrast, Zelcer et al. (2008) reviewed the treatment of 82 patients 
(median age 16 years) who received 708 MTX courses (12 g/m2) at the MSKCC 
between 1996 and 2002 and reported that delayed MTX elimination complicated 
38% of courses. 
1.4. GLUCARPIDASE (VORAXAZE™) AND ITS RESCUE ROLE AFTER  
HD-MTX 
Glucarpidase (formerly Carboxypeptidase G2) is an enzyme originally isolated from 
Pseudomonas sp strain RV-308, cloned and now produced in Escherichia coli.  it 
has a sub-unit molecular mass of 41,440 Da and dimeric molecular weight of 
approximately 83,000 Da (Minton et al. 1983). It is presented as a sterile, white 
lyophilized powder intended for single-use intravenous administration after 
reconstitution with 1 ml of sterile normal saline solution.  Each vial of Voraxaze 
contains 1000 units of glucarpidase. One unit corresponds to the enzyme activity 
that cleaves 1 µmol/L MTX/min at 37°C.  The product also contains approximately 
10 mg of lactose as an inactive ingredient buffered to pH 7.0 to 8.0 (Voraxaze™ 
Investigator’s Brochure, 2009).  
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Glucarpidase is currently used effectively to treat patients with MTX-induced renal 
dysfunction, in order to avoid potentially fatal MTX-related toxicity (Widemann BC, 
2006). A single intravenous dose of 50 units/kg of glucarpidase after MTX results in 
the reduction of plasma MTX levels to the non-toxic range within minutes without 
causing toxicity. 
1.4.1. MECHANISM OF ACTION OF GLUCARPIDASE  
Glucarpidase hydrolyses the carboxyl terminal glutamate residue from folic acid and 
its analogues (e.g. MTX) (Sherwood et al. 1985).  It follows Michaelis-Menten 
kinetics (Michaelis L et al. 2011) with Km values of 4 µmol/L for folate, 8 µmol/L for 
MTX, 34 µmol/L for 5-methyl-FH4, and 120 µmol/L for 5-formyl-FH4 (folinic acid).  
Glucarpidase has >10-fold lower affinity for folinic acid than for MTX, which is of 
significance when considering the potential combined use of glucarpidase and folinic 
acid for HD-MTX rescue (Sherwood et al. 1985). Glucarpidase cleaves the MTX 
molecule into inactive metabolites, DAMPA and glutamate, which are metabolised 
by the liver, and thus provides an alternative route of MTX elimination (Donehower 
et al. 1979). This is particularly important in patients who develop renal dysfunction 
due to MTX nephrotoxicity (Adamson et al. 1991; Monty et al. 2000; Von Poblozki et 
al. 2000; Widemann et al. 2000) and would therefore not be able to renally excrete 
MTX.  
1.4.2. CLINICAL STUDIES WITH GLUCARPIDASE 
The safety and effectiveness of glucarpidase on systemic MTX concentrations and 
MTX toxicities has been assessed in three clinical studies, the Berlin Study, PR001-
CLN-001 (Schwartz et al. 2004) the NCI Study, PR001-CLN-002 (Adamson et al. 
2005; Buchen et al. 2005) and the PD Study, PR001-CLN-006 (Voraxaze™ 
Investigator’s Brochure, 2009).  A study to determine the pharmacokinetics of 
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glucarpidase in eight healthy normal subjects and four patients with severe renal 
impairment was also performed (PK Study: PR001-CLN-005, Voraxaze™ 
Investigator’s Brochure, 2009). In addition, an interaction study between 
glucarpidase and folinic acid (LV Interaction Study: PR001-CLN-010) was performed 
since it is known that folinic acid is also a substrate of glucarpidase (Voraxaze™ 
Investigator’s Brochure, 2009). 
1.4.2.1. PK STUDY (VORAXAZE™ INVESTIGATOR’S BROCHURE, 2009).  
The PK study was an open-label, single site, pharmacokinetic study of glucarpidase 
administered intravenously at a dose of 50 units/kg to eight subjects with normal 
renal function and four subjects with severe renal impairment. Two assay methods 
were used to quantify serum glucarpidase concentration, one measured 
glucarpidase enzyme activity and the other total glucarpidase. The pharmacokinetic 
data based on total glucarpidase indicated about 7% lower mean Cmax in subjects 
with impaired renal function relative to those with normal renal function. However, 
the total glucarpidase exposure, as determined by AUC0-∞, was marginally higher, 
by about 5%, in subjects with impaired renal function relative to those with normal 
renal function. The median time to maximum serum concentration (Tmax) was short 
for subjects with normal renal function, indicating a rapid equilibration of 
glucarpidase after completion of the short infusion. There is little effect in patients 
with renal dysfunction compared to healthy volunteers with mean half life of 
glucarpidase of 10 and 9 hours, respectively, after a dose of 50 units/kg of 
intravenous glucarpidase (Phillips et al. 2008). Large variability was noted especially 
for AUC0-t and AUC0-∞, in the renally impaired subject group, with one subject having 
a higher exposure relative to the other three. Overall, the results of the PK Study 
showed little effect of renal impairment on the serum pharmacokinetics of 
glucarpidase. 
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1.4.2.2. LV INTERACTION STUDY (VORAXAZE™ INVESTIGATOR’S 
BROCHURE, 2009). 
This study was a double-blind, placebo controlled, randomised, two-period 
crossover pharmacokinetic study. The primary objective was to assess the effect of 
glucarpidase on the pharmacokinetics of the active L-stereoisomer of folinic acid, 
(6)L/S-LV, following repeated doses of folinic acid. The secondary objectives of the 
study were to assess the effect of glucarpidase on the pharmacokinetics of 5-
methyl-tetrafydrofolate, (6)L/S-LV-THF, the active metabolite of (6)L/S-LV. The 
study demonstrated that glucarpidase reduces the systemic availability of (6)L/S-LV, 
by up to 50%, and its active metabolite (6)L/S-LV-THF, but does not completely 
eliminate them. The reduced availability of (6)L/S-LV and its active metabolite could 
potentially lead to a reduction in the efficacy of folinic acid. 
1.4.2.3. PD, NCI AND BERLIN STUDIES (SCHWARTZ ET AL. 2004; 
ADAMSON ET AL. 2005; BUCHEN ET AL. 2005; VORAXAZE™ 
INVESTIGATOR’S BROCHURE, 2009). 
The above three studies were all compassionate use, multiple site, single arm, open 
label studies to provide access to the drug and assess the safety of 50 units/kg of 
glucarpidase given intravenously to patients with delayed elimination of MTX due to 
renal impairment. The majority of patients (65%) were enrolled in the NCI Study. 
The primary efficacy endpoint for all three studies was the proportion of patients who 
achieved a clinically important reduction (CIR) in plasma MTX concentration as 
measured by HPLC. A CIR is defined as a plasma or serum MTX concentration that 
has decreased to ≤ 1 µmol/L in all post glucarpidase samples, indicating a sustained 
reduction of MTX. The primary efficacy evaluation was performed on patients (the 
Eficacy Subset, ES) with valid primary efficacy data which included a pre-
glucarpidase MTX concentration ≥ 1 µmol/L determined by HPLC and at least one 
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MTX concentration by HPLC after the last glucarpidase dose. A comparison across 
the three studies regarding demographics, diagnosis, renal function, MTX level at 
entry and glucarpidase doses, is shown in Table 2. Comparison of the Primary 
Efficacy Subsets across the studies is shown in Table 3. 
Table 2: COMPARISONS ACROSS STUDIES - PD, NCI, BERLIN STUDIES 
Demographics 
PD Study NCI Study Berlin Study 
No. (%
a
) of patients No. (%
a
) of patients No. (%
a
) of patients 
Paediatric Adult Paediatric Adult Paediatric Adult 
Number of 
patients 
68 227 42 
Age-Number of 
patients with 
data 
67/68 216/227 42/42 
Age by 
paediatric or 
adult (≥ 18)      
[≥ 65] 
31 (46%) 
36 
(54%) 
[7(10%)] 
115 (53%) 
101 
(46%) 
[31(14%)] 
1 (2%) 
41 
(98%) 
[7(17%)] 
Age range 
(median) 
2-84 (20) 0-82 (17) 10-78 (52) 
Gender – No. 
of patients with 
data 
N=68/68 N=197/227 N=0/42 
Male 42 (62%) 127 (58%) - 
Female 26 (38%) 70 (32%) - 
Cancer 
diagnosis
b 
No. patients 
68/68 (67 with age) 188/216 42/42 
Osteosarcoma 
(102) 
17/25 7/25 55/77 22/77 - - 
Leukaemia (61) 9/13 4/13 24/36 12/36 1/12 11/12 
Lymphoma 
(122) 
3/24 21/24 22/70 48/70 - 28/28 
Other cancers 
(12) 
2/6 4/6 - 4/4 - 2/2 
Non Cancer (1)   - 1/1 - - 
Unknown Total 
(28) 
- - 14 14 - - 
Patients with  
serum 
creatinine  
> 2.2 mg/dL
c
 
15/28 
(54%) 
30/34 
(88%) 
58/105 
(55%) 
70/86 
(81%) 
0/1 
(0%) 
22/41 
(54%) 
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Demographics 
PD Study NCI Study Berlin Study 
No. (%
a
) of patients No. (%
a
) of patients No. (%
a
) of patients 
Paediatric Adult Paediatric Adult Paediatric Adult 
MTX  
Dose range in 
g/m
2
 (median) 
1.0-20 (6.7) 0.4-19 (5.5) 0.9-12 (3) 
Pre-
glucarpidase 
concentration in 
µmol/L 
(median) 
3.47 - 708 (40.2) 
ES (23 patients) 
1.1-849.10 (34.7) 
ES (70 patients) 
1.1-166 (5.8) 
ES (23 patients) 
Glucarpidase 
dose range in 
Units/kg 
(median) 
29.2-55 (50) 10.9-63.7 (49.8) 9.8-58 (50) 
Source: adapted from Voraxaze Investigator’s Brochure edition number PR001-
CLN-IB007 
a Percentages have been rounded to the nearest whole number. 
b One patient in the NCI Study did not have cancer and one patient in the PD 
Study had a diagnosis of osteosarcoma but age was not available. 
c Patients with impairment equivalent to serum creatinine >1.5 x ULN post-
MTX but pre-glucarpidase 
Table 3: COMPARISONS OF THE PRIMARY EFFICACY SUBSETS ACROSS 
STUDIES - PD, NCI, BERLIN STUDIES 
Demographic 
PD Study NCI Study Berlin Study 
No. (%
a
) of 
patients 
No. (%
a
) of patients 
No. (%
a
) of 
patients 
Paediatric Adult Paediatric Adult Paediatric Adult 
Number of patients 23/68 70/227 23/42 
Age – number of 
patients with data 
23/23 68/70 NA 
Age by paediatric 
or adult (≥18) 
13 (57%) 
10 
(43%) 
39 (57%) 
29 
(43%) 
NA NA 
Gender – number 
of patients with 
data 
23/23 61/70 0/23 
Male 14 (61%) 35 (50%) - 
Female 9 (39%) 26 (37%) - 
Cancer diagnosis
 
number of patients 
23/23 57/70 23/23 
Osteosarcoma 
(102) 
11 (48%) 35 (61%) - 
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Demographic 
PD Study NCI Study Berlin Study 
No. (%
a
) of 
patients 
No. (%
a
) of patients 
No. (%
a
) of 
patients 
Paediatric Adult Paediatric Adult Paediatric Adult 
Leukaemia (61) 3 (13%) 7 (12%) 8 (35%) 
Lymphoma (122) 8 (35%) 12 (21%) 13 (56%) 
Other cancers (12) 1 (4%) 3 (5%) 2 (9%) 
Non Cancer (1) - - - 
Unknown Total 
(28) 
- 13 - 
MTX  
Dose range in g/m
2
 
(median) 
1.4-20 (8) 
 
0.4-19 (8) 
(69 patients) 
1.1-4.6 (2.9) 
 
Pre-glucarpidase 
concentration in 
µmol/L (median) 
3.47 - 708 (40.2) 
 
1.1-849.10 (34.7) 
 
1.1-166 (5.8) 
 
Time between MTX 
& 1
st
 dose 
glucarpidase  
(median) 
1-6 (2) days 1-9 (3) days 1-4 (2) days 
Glucarpidase dose 
range in Units/kg 
(median) 
39-52 (50) 15-55 (50) 11-58 (50) 
Source: adapted from Voraxaze Investigator’s Brochure edition number PR001-
CLN-IB007 
a Patients with serum or plasma MTX concentration by HPLC prior to 
Voraxaze dosing, and in at least one sample after the last dose of 
Voraxaze and who had MTX ≥ 1 µmol/L prior to Voraxaze. 
In all three studies the majority of patients treated with glucarpidase achieved CIR in 
MTX and thus met the primary endpoint. The reductions in MTX were consistently 
attained, rapid and generally sustained. The proportion of patients achieving CIR 
was 57% (13/23) for the PD Study, 57% (40/70) for the NCI Study and 83% (19/23) 
for Berlin Study. The primary analyses of CIR in all three studies were repeated for 
subgroups of patients based on pre-glucarpidase plasma/serum MTX 
concentrations, a diagnosis of osteosarcoma, gender and age (Table 4). In 
summary, a CIR was seen in 62% (72/116) of patients in the ES across studies and 
> 50% of patients in the ES of each study had a CIR. The incidence of CIR was 
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lower for the subgroups with higher pre-glucarpidase MTX concentrations, lower for 
patients with osteosarcoma, lower for female patients and higher for adult patients. 
Table 4: EXPLORATORY SUB-GROUP ANALYSES OF CIR BASED ON PRE-
VORAXAZE PLASMA/SERUM MTX CONCENTRATION, CANCER 
DIAGNOSIS AND GENDER – PD, NCI AND BERLIN STUDIES 
 
Proportion of patients with a clinically important reduction 
(CIR) in plasma MTX [percentage] (95% CI)
a
 
Pre-Voraxaze 
plasma/serum MTX 
concentration 
PD 
Study 
NCI 
Study 
Berlin 
Study 
<1 µmol/L 
3/3 [100%] 
(44% to 100%) 
4/4 [100%] 
(51% to 100%) 
3/3 [100%] 
(44% to 100%) 
≥1 µmol/L and  
<10 µmol/L 
4/5 [80%] 
(38% to 96%) 
20/22 [91%] 
(72% to 97%) 
13/14 [93%] 
(69% to 99%) 
≥10 µmol/L and  
<100 µmol/L 
7/11 [64%] 
(35% to 85%) 
13/27
 
[48%] 
(31% to 66%) 
6/8 [75%] 
(41% to 93%) 
≥100 µmol/L 
2/7 [29%] 
(8% to 64%) 
7/21 [33%] 
(17% to 55%) 
0/1 [0%] 
(0% to 79%) 
Cancer diagnosis of 
osteosarcoma? 
   
Yes 
3/11 [27%] 
(10% to 57%) 
17/35
 
[49%] 
(33% to 64%) 
ND 
No 
10/12 [83%] 
(55% to 95%) 
14/22
 
[64%] 
(43% to 80%) 
ND 
Gender    
Male 
11/14 [79%] 
(52% to 92%) 
23/35
 
[66%] 
(49% to 79%) 
NK 
Female 
2/9 [22%] 
(6% to 55%) 
12/26 [46%] 
(29% to 65%) 
NK 
Source: adapted from Voraxaze Investigator’s Brochure edition number PR001-
CLN-IB007 
ND = Not done (no patient in the Berlin Study had osteosarcoma); NK = Not 
known (gender was not recorded in the Berlin Study), a Using the 
Newcombe & Altman statistical method 
Secondary efficacy endpoints for the three clinical studies included the 
measurement of the reduction in plasma/serum MTX concentrations by HPLC 
immediately after the administration of glucarpidase (immediate reduction) and in all 
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samples taken post glucarpidase (sustained reduction). Immediately (10-50 minutes, 
median 15 minutes) after glucarpidase administration, plasma MTX concentrations 
for patients had fallen by >95% in the PD and NCI Studies and by > 97.8% in the 
Berlin Study. There was a gradual increase in MTX concentration following the 
immediate post-glucarpidase reduction, presumably due to some MTX being 
redistributed out of the cells. When expressed as a ratio of pre-glucarpidase value, 
the median sustained reduction in MTX was 98.7%, 97.8% and 96.5% for the PD, 
NCI and Berlin Studies, respectively. 
For patients at risk of MTX toxicity due to delayed MTX elimination or inadvertent 
overdose, glucarpidase rescue has been shown to be a safe and effective addition 
to folinic acid rescue. Glucarpidase allows patients to then be managed with 
standard doses of folinic acid and, if administered early, greatly diminishes the risk 
of serious and/or life-threatening MTX toxicity.  Moreover, patients avoid the risks 
associated with extracorporeal methods of MTX removal such as dialysis. 
Glucarpidase rapidly converts MTX to the inactive metabolite DAMPA. DAMPA is 
normally a minor metabolite of MTX accounting for < 5% of the total dose of the 
drug that is excreted in urine (Donehower et al. 1979). It is presumably formed from 
MTX that is excreted via the bile into the intestinal tract, hydrolysed by bacterial 
carboxypeptidases, and then reabsorbed. In vitro experiments have shown that 
DAMPA has no cytotoxic potential and does not enhance MTX cytotoxicity 
(Donehower et al. 1979; Widemann et al 1999). DAMPA is approximately 10-fold 
less water soluble than MTX (aqueous solubility at pH 7.0: DAMPA 0.85 mg/ml, 
MTX 9.04 mg/ml), and persistently high concentrations of DAMPA could 
theoretically lead to further renal toxicity by precipitation in the renal tubules 
(Donehower et al. 1979; Widemann et al 1997). However, in patients treated for 
MTX-induced nephrotoxicity with glucarpidase, DAMPA plasma concentrations 
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declined more rapidly than MTX concentrations, which suggest a non-renal route of 
elimination for DAMPA. Data from the PD, NCI and Berlin Studies confirmed that 
DAMPA was effectively eliminated in patients with a median half-life of about 11 
hours, even though almost all of them had renal insufficiency (Voraxaze™, 
Investigator’s Brochure 2009).   
Glucarpidase has >10-fold lower affinity for folinic acid than for MTX. However, 
folinic acid is a substrate for glucarpidase and thus may compete with MTX for 
glucarpidase binding sites. Hence, glucarpidase has the potential to reduce the 
efficacy of folinic acid. When glucarpidase was administered in healthy subjects (LV 
interaction study), their exposure to folinic acid was reduced by about 50%, in the 
absence of MTX; exposure to folinic acid was reduced for about 26 hours. 
Therefore, in order to minimize any potential interaction, it is recommended that 
folinic acid should not be administered in the 2-4 hours prior to or in the 2-4 hours 
following glucarpidase. In order to compensate for any reduced exposure to folinic 
acid caused by its potential interaction with glucarpidase, it is advised that the dose 
of folinic acid should be based upon the pre-glucarpidase MTX plasma levels and 
maintained at this dose for at least 48 hours after the dosing with glucarpidase.  
1.4.3. ADVERSE EFFECTS RELATED TO GLUCARPIDASE 
Glucarpidase is a pure enzyme (> 98% purity) with a specific activity to hydrolyse 
the N-carboxy terminal of folate-related molecules. It is administered specifically to 
hydrolyse MTX. It is not expected to have any adverse effects related to its 
pharmacological action when given as a single dose for the treatment of a single 
MTX course.  
In the previously described PD, NCI and Berlin studies 52 glucarpidase-related 
adverse events (AEs) were reported in 8% (26/318) patients (Table 5); only two of 
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the glucarpidase-related AEs were reported as serious. No glucarpidase-related 
AEs were reported in the PK study. One treatment related AE was reported in the 
LV study (pain at injection site) although this event was also recorded by the same 
subject associated with the saline control injection. 
Allergic reaction was the most common glucarpidase-related AE, occurring in 45 of 
patients treated. Allergic reactions consisted principally of temporally related 
symptoms of flushing, paraesthesia, and feeling hot/burning sensation. These 
reactions occurred primarily on the same day as dosing and all were transient. No 
anaphylactic reactions have been reported in any of the studies. The most common 
non-allergic AE considered related to treatment with glucarpidase was paraesthesia 
(0.6% of patients). Two serious adverse events (SAEs) hypertension and arrhythmia 
that may have been related to glucarpidase administration occurred on the NCI and 
PD Studies, respectively.  
Table 5: ALL ADVERSE EVENTS CONSIDERED RELATED TO 
GLUCARPIDASE- PD, NCI AND BERLIN STUDIES  
Body System/Adverse Event 
No. of patients 
with AE 
(N= 318
a
) 
Percentage of 
patients 
ALL 26 8.2% 
Blood and lymphatic system disorders 1 0.3 
 Pancytopenia 1 0.3 
Cardiac disorders 2 0.6 
 Arrhythmia 1 0.3 
 Tachycardia 1 0.3 
Gastrointestinal disorders 4 1.3 
 Abdominal pain 1 0.3 
 Diarrhoea 1 0.3 
 Nausea 2 0.6 
 Oral discomfort 1 0.3 
 vomiting 1 0.3 
General disorders and administration site conditions 4 1.3 
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Body System/Adverse Event 
No. of patients 
with AE 
(N= 318
a
) 
Percentage of 
patients 
ALL 26 8.2% 
 Feeling hot 3 0.9 
 Pyrexia 1 0.3 
Immune system disorders 1 0.3 
 Hypersensitivity 1 0.3 
Investigations 2 0.6 
 Aspartate aminotransferase increased 1 0.3 
 Blood creatinine increased 1 0.3 
 Blood urea increased 1 0.3 
Metabolism and nutrition disorders 1 0.3 
 Hypokalaemia 1 0.3 
 Hyponatraemia 1 0.3 
Nervous system disorders 11 3.5 
 Burning sensation 3 0.9 
 Headache 3 0.9 
 Paraesthesia 7 2.2 
 Tremor 2 0.6 
Renal and urinary disorders 1 0.3 
 Oliguria 1 0.3 
Respiratory, thoracic and mediastinal disorders 2 0.6 
 Dyspnoea 1 0.3 
 Throat irritation 1 0.3 
 Throat tightness 1 0.3 
Skin and subcutaneous tissue disorders 2 0.6 
 Dermatitis allergic 1 0.3 
 Hyperhidrosis 1 0.3 
 Pruritus 1 0.3 
Vascular disorders 11 3.5 
 Flushing 7 2.2 
 Hot flush 1 0.3 
 Hypertension 1 0.3 
 Hypotension  2 0.6 
Source: Voraxaze Investigator’s Brochure edition number PR001-CLN-IB007 
a Although 329 patients were treated in these studies and included in the study 
reports, data from follow-up assessments after glucarpidase dosing is only available 
for 318. 
53 
Glucarpidase is a recombinant bacterial protein and it therefore has the potential to 
induce an immune response. This could produce an allergic reaction on subsequent 
administration of glucarpidase or reduce its efficacy by neutralizing the activity of 
glucarpidase.  
Across the PD, NCI, Berlin and PK Studies 43% (26/61) of subjects developed anti-
glucarpidase antibodies after administration of glucarpidase. Of the positive 
samples, 19% (5/26) subjects inhibited the activity of glucarpidase. The reduction in 
enzyme activity in the five patients who had samples which caused a reduction were 
35%, 49% and 84% for the PD Study, 23% for the Berlin Study and 44% for the PK 
Study.  
1.5. AIMS 
Current literature suggests that the fewer MTX-related chemotherapy delays in 
osteosarcoma treatment, the better the outcome (Frei et al. 1980; French Bone 
Tumour Study Group 1988; Bacci et al. 2001; Delepine et al. 1996). However, there 
is no available data on the incidence chemotherapy delays due to MTX toxicity.  
Our first aim was to establish the incidence of chemotherapy delays due to MTX-
related toxicity in patients with osteosarcoma, treated with doxorubicin, cisplatin and 
HD-MTX (MAP).  
Medical records of patients with osteosarcoma treated with MAP at the University 
College Hospital in London were reviewed, and data were collected on age, gender, 
chemotherapy dates, surgery dates, folinic acid rescue regimens, MTX toxicity and 
causes of any chemotherapy delays.  In a separate review, the tolerance of HD-
MTX (12 g/m2) in patients aged ≥ 40 years was studied and compared with that of 
younger patients, aged < 40 years.   
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Our second aim was to examine the role of glucarpidase in routine rescue after HD-
MTX in patients with bone sarcoma. Glucarpidase seemed to offer a promising 
opportunity for rescue from MTX toxicity and if found to be effective and safe in 
maintaining the treatment intensity and reducing the incidence and severity of MTX-
induced toxicity, could optimize treatment, improve patients’ well-being, and reduce 
the use of health resources. 
In order to investigate the role of glucarpidase after HD-MTX and whether routine 
rescue with glucarpidase reduces delays to subsequent cycles of chemotherapy due 
to MTX toxicity, a randomised, cross-over, phase II clinical trial was set up. Trial 
patients were treated with 4 doses of HD-MTX (12 g/m2); 2 of them were given with 
standard folinic acid rescue and the other 2 with glucarpidase and folinic acid 
rescue. Delays to subsequent chemotherapy were examined. Reduction of serum 
MTX levels after glucarpidase, MTX-related toxicity after glucarpidase with standard 
rescue and after standard rescue alone, glucarpidase-related adverse reactions and 
anti-glucarpidase antibody response were also examined. 
DAMPA, the catabolic product of glucarpidase action on MTX, is known to cross-
react with MTX in most commercial immunological MTX assays (Albertioni et al. 
1996; Widemann et al. 1997). Therefore, a high performance liquid chromatography 
(HPLC) assay was validated as part of this project for the evaluation of plasma MTX 
and DAMPA levels and used for the trial patients.  
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2. MATERIALS AND METHODS 
2.1. REVIEW ON MTX RELATED TOXICITY AND RESULTING DELAY IN 
SUBSEQUENT CHEMOTHERAPY ADMINISTRATION 
In order to determine the incidence of delays in chemotherapy due to MTX toxicity in 
patients with osteosarcoma treated with doxorubicin, cisplatin and HD-MTX (MAP), 
we reviewed the medical records of 56 patients with osteosarcoma, treated with 
MAP in the University College Hospital, London, UK, between January 2004 and 
January 2005. Data were collected on age, gender, chemotherapy dates, surgery 
dates and folinic acid rescue regimens. Delayed chemotherapy courses were 
identified and further information was collected on delays due to MTX toxicity.   
A further review was carried in order to study the tolerance of HD- MTX (12 g/m2) in 
patients ≥ 40 years. 17 patients, aged ≥ 40 years and treated with MAP in the 
University College Hospital, London, UK, between December 2002 and October 
2007, were identified. 25 patients, aged < 40 years and treated with MAP in the 
University College Hospital, London, UK, between December 2002 and October 
2007, were also identified. Data were collected on age, gender, chemotherapy 
dates, surgery dates, and daily MTX plasma levels, number of received MTX 
courses, folinic acid doses, MTX-related toxicity and delays in subsequent 
chemotherapy due to MTX-related toxicity. Data from different age groups were 
compared. 
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2.2. GLU 1 CLINICAL STUDY: A BLIND RANDOMISED, CROSS-OVER, PHASE 
II CLINICAL TRIAL, TO INVESTIGATE THE EFFICACY AND SAFETY OF 
GLUCARPIDASE FOR ROUTINE USE AFTER HD-MTX IN PATIENTS WITH 
BONE SARCOMA 
In order to investigate the role of routine glucarpidase rescue after HD-MTX, the 
GLU 1 clinical trial was set up. GLU 1 was a blind randomised, cross-over, phase II 
clinical trial, to investigate the efficacy and safety of glucarpidase for routine use 
after HD-MTX in patients with bone sarcoma (Appendix 1: GLU 1 clinical trial 
protocol; latest version). My responsibilities included the following: designing of 
the trial and writing of the trial protocol, submission to the Regulatory Authorities and 
Ethics Committee of all appropriate documentation and subsequent amendments to 
the trial protocol, validation of a high performance liquid chromatography (HPLC) 
assay for the measurement of MTX and DAMPA plasma levels, assessment of MTX 
and DAMPA plasma levels for trial patients with HPLC, informed consent and 
enrolment of trial participants, involvement in the clinical care of trial participants, 
nursing and medical staff training on the trial, data management and safety 
management of the trial. 
2.2.1. STUDY OBJECTIVES AND ENDPOINTS 
The primary objective of the GLU 1 study was to investigate whether glucarpidase 
rescue after HD-MTX reduces delay to subsequent cycles of chemotherapy due to 
MTX toxicity. In order to meet our primary objective trial participants were assessed 
for fitness to receive chemotherapy on day 15 of each cycle. Patients were 
considered fit to receive chemotherapy if ALL the following 8 criteria were fulfilled: 
 Neutrophils ≥ 0.75x109/L or WCC ≥ 2x109/L 
 Platelets ≥ 100x109/L 
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 Bilirubin ≤ 1.5xULN 
 GFR (estimated) ≥ 70 ml/min/1.73m2 
 Mucositis (clinical and functional): grade ≤ 1 (CTCAE v3.0) 
 No clinical evidence of infection 
 No pyrexia 
 Good overall clinical condition 
Secondary objectives included the following:  
1. To investigate whether glucarpidase rescue after HD-MTX reduces the 
incidence, severity and duration of MTX associated adverse effects  
2. To study the pharmacokinetics of MTX and DAMPA after glucarpidase 
administration  
3. To evaluate any adverse effects associated with the use of glucarpidase  
4. To investigate the economic impact of using glucarpidase versus standard 
rescue 
5. To investigate the effect of glucarpidase on the quality of life of patients treated 
with HD-MTX 
6. To assess the anti-glucarpidase antibody response 
In order to meet our secondary objectives the following were evaluated:   
 Incidence and grading of mucositis, renal toxicity, liver toxicity, neutropenia, 
thrombocytopenia and infections 
 Plasma MTX and DAMPA concentrations  
 Incidence of glucarpidase related adverse effects 
 Number of days required in hospital per cycle and total dose of folinic acid 
required per cycle  
 Quality of life in study participants 
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 Serum anti-glucarpidase IgG levels following glucarpidase administration 
2.2.2. STUDY DESIGN 
The GLU 1 clinical trial was conducted in compliance with the principles of ICH 
GCP, the Declaration of Helsinki, the Medicines for Human Use (Clinical Trials) 
Regulations 2004 and all applicable regulatory requirements. 
Patients participating in the study received four consecutive MTX courses. Two of 
those were given with standard folinic acid rescue (courses M: MTX at a dose of 12 
g/m2 given intravenously with standard folinic acid rescue and placebo, 0.9% 
Normal Saline injection BP). The other two were given with a combination of folinic 
acid and glucarpidase rescue (courses GluM: MTX at a dose of 12 g/m2 x 1 given 
intravenously with folinic acid and glucarpidase rescue at a dose of 50 units/kg given 
intravenously).  
Study participants were randomised to arm A or B in a 1:1 randomisation. Each arm 
consisted of two cycles. In arm A patients received cycle M first followed by cycle 
GluM, whereas in arm B, they received cycle GluM first followed by cycle M. 
Arm A: 
 Cycle 1: M 
 
 Cycle 2: GluM 
 M1 M2   GluM1 GluM2  
 Day  1 8 15     1 8 15  
Cycle M started with course M1 on day 1 followed by course M2 planned for day 8. 
Cycle GluM started with course GluM1 on day 1 followed by GluM2 planned for 
day 8. Cycle GluM was not planned to start for a minimum of 14 days from the 
beginning of course M2, or until bone marrow, renal and hepatic functions  
completely recovered and study participants were clinically ready to receive further 
59 
chemotherapy (minimum requirements are described in Section 2.2.5). A minimum 
of 14 days from M2 to the beginning of the second cycle seemed appropriate to 
allow complete recovery. 
Arm B: 
 Cycle 1: GluM 
 
 Cycle 2: M 
 GluM1 GluM2   M1 M2  
Day 1 8 15  1 8 15  
Cycle GluM started with course GluM1 on day 1 followed by GluM2 planned for 
day 8. 
Cycle M started with course M1 on day 1 followed by course M2 planned for day 8. 
Cycle M was not planned to start for a minimum of 14 days from the beginning of 
course GluM2, or until bone marrow, renal and hepatic function completely 
recovered and study participants were clinically ready to receive further 
chemotherapy (minimum requirements are described in Section 2.2.5.). 
GLU 1 was undertaken at the University College Hospital (UCH), London, UK and 
Harley Street at UCH, London, UK. The London Sarcoma Service at UCH is the 
largest clinical practice treating bone sarcomas in the UK and one of the largest in 
Europe, treating 30-40 patients with osteosarcoma every year.  Anticipated accrual 
for the trial was 10 patients per year. 
Double-blinding (ie patients and investigators / assessors) was used to reduce any 
investigator’s bias in describing subjective assessments, such as mucositis grading. 
Patients’ responses to Quality of Life Questionnaires were not biased either. UCH 
Pharmacy Department held the master randomisation list for the study.  
Individual treatment could be unblinded only if: 
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 Serum MTX concentration was ≥ 100 μmol/L at 24 hours or ≥ 10 μmol/L at 48 
hours after MTX administration and there was a rise in serum creatinine of ≥ 
100% within 24 hours of MTX administration 
 Patient experienced a grade 4 allergic reaction after glucarpidase/placebo 
administration, although he/she remained on study. 
In addition, treatment could be unblinded for SUSAR (Suspected Unexpected 
Serious Adverse Reaction) regulatory reporting by the trial Sponsor. 
2.2.3. PATIENT RECRUITMENT 
Eligible patients were registered following fully informed consent (Appendix 2: 
Patient and parent information sheets; Appendix 3, GP information sheets; Appendix 
4, patient and parent consent form). There was no time limit between confirmation of 
diagnosis and registration. A registration form for each patient was completed for 
each enrolled patient and a unique study number was assigned to each participant 
(Appendix 5: GLU 1 clinical trial registration form). The registration form was 
emailed and faxed to UCH Pharmacy Department within 24 hours from registration. 
UCH Pharmacy assigned the next available treatment slot according to the 
randomisation list provided by the UCLH Medical Statistics Department. The 
randomisation list was computer generated and blocked to ensure approximately 
equal number of patients were allocated to the two sequences. For participants 
treated at Harley Street at UCH, UCH Pharmacy faxed the randomisation details to 
020 7691 5867, for the attention of Aoife Shields, Pharmacy Departrment, Harley 
Street at UCH.  
In order to minimize any cumulative dose effect which might have interfered with the 
pharmacokinetics of MTX and any MTX-related toxicity, half of the patients followed 
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arm A and half, arm B. The cross-over design allowed smaller sample size, since 
patients acted as their controls.  
Based on our audit findings (sections 2.1 and 3), nearly 55% of the patients in the 
standard rescue group were expected to be treatable on day 15 of each cycle. The 
sample size calculation for the GLU 1 study was based on a McNemar’s test with an 
assumption that the responses to glucarpidase and folinic acid rescue were 
independent (Machin D et al., 1997). With anticipated proportions of responses to 
folinic acid alone and glucarpidase with folinic acid of 55% and 90% respectively, 
GLU 1 required 28 patients to give 80% power at a significance level of 5% and to 
allow for up to 5% drop-out during the study.  
The planned duration of the study was 6 weeks for each participant, 21 days after 
starting cycle 2. However, patients were followed up on day 30 after starting their 
second chemotherapy cycle, to investigate anti-glucarpidase antibody response. If 
anti-glucarpidase antibodies were present on that day, patients were followed up 
with a further blood test, at 3 and 6 months after starting cycle 2. 
Inclusion Criteria 
 Patients had to fulfill the following criteria for registration on the trial: 
 Written informed consent from patient or parent/guardian  
 Diagnosis of high grade osteosarcoma, localised or metastatic, or high grade 
osteosarcoma as a second malignancy, or spindle cell sarcoma of bone, or 
relapsed high grade osteosarcoma  
 Age: 5-50 years at registration 
 Ability to comply with study and follow up procedures (WHO performance scale 
0-2) (Appendix 7: Performance status) 
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 No concomitant anti-cancer or investigational drugs during the study and 
complete resolution of toxicity related to previous treatment  
 Life expectancy of at least 3 months 
 Haematopoietic function: absolute neutrophil count ≥ 0.75 x109/L, platelets ≥ 
100 x109/L 
 Hepatic function: Bilirubin ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Albumin > LLN 
 Renal function: Glomerular Filtration Rate (radioisotope) ≥ 70 ml/min/1.73m2 
Exclusion Criteria 
 Previous treatment with glucarpidase 
 Pregnant or breast feeding women (patients with reproductive potential of either 
gender had to use contraception as per Table 6)  
 Concomitant treatment with agents which interact with MTX metabolism or 
excretion (Appendix 8: Drug interactions with MTX) 
 Serous effusions, including ascites and pleural effusions 
Table 6: ADEQUATE MEANS OF CONTRACEPTION FOR THE GLU 1 
PARTICIPANTS 
    Adequate means of contraception 
 Combined oral contraceptive pill 
 Long acting progesterone only methods (such as the 3-monthly depo injection or the 
implant) 
 Intrauterine contraceptive device or intrauterine device 
 Contraceptive patch 
 Sterilisation 
 
63 
2.2.4. STUDY ASSESSMENTS 
INVESTIGATIONS / 
PROCEDURES 
CYCLE 1 CYCLE 2 
DAY OF CYCLE -7 to 0 1 2 8 9 15 1 2 8 9 15 30 90 180 
DAY OF STUDY -7 to 0 1 2 8 9 15 22 23 29 30 36 51 111 201 
Eligibility & Consent X              
Medical history X              
Physical examination,  
performance status, 
weight 
 X  X  X X  X  X    
Methotrexate 
administration 
 X  X   X  X      
Glucarpidase / Placebo 
administration 
  X  X   X  X     
Haematology X   Xa  X X  Xa  X    
Biochemistry / LFTs Xb   Xb  X Xb  Xb  X    
Glomerular Filtration 
Rate 
Xc   Xd  Xd Xd  Xd  Xd    
Concomitant medication X   X  X X  X  X    
[MTX] & [DAMPA] by 
HPLC analysis 
 Xe  Xe   Xe  Xe      
[MTX]  estimation by 
immunoassay 
 Xf  Xf   Xf  Xf      
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INVESTIGATIONS / 
PROCEDURES 
CYCLE 1 CYCLE 2 
Anti-glucarpidase 
antibodies and enzyme 
neutralisation assay 
X   X  X X  X  X X Xg Xg 
Glucarpidase adverse 
events 
  Xh  Xh   Xh  Xh     
MTX toxicity 
assessment 
 X  X  X X  X  X    
Quality of Life 
questionnaires 
 X  X  X X  X  X    
a:  and at least every 3rd day until haematological recovery; b: and at least daily until completion of rescue; c: GFR (radio-isotopic 
assay); d: estimated GFR (see Appendix 7); e: at 0, 4, 24, 24:20*, 48, 72 hours after starting methotrexate and then daily until 
methotrexate plasma levels <0.2 µmol/L (*for glucarpidase cycles only); f:  at 24, 48, 72 hours after starting methotrexate and then 
daily until methotrexate plasma levels <0.2 µmol/L; g: if  positive antiglucarpidase antibody response on day 30 of cycle 2; h: daily 
until discharge from hospital  
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2.2.5. STUDY MEDICATION AND TREATMENT PLAN 
2.2.5.1. AGENTS USED  
The following agents were used in this study: 
 MTX 
 Folinic Acid 
 Glucarpidase (Voraxaze™) 
MTX and folinic acid were obtained from UCH Pharmacy or Harley Street at UCH 
Pharmacy. The supplier’s recommendations regarding storage, stability, dilution, 
incompatibilities, and measures of caution were followed.  
Glucarpidase (Voraxaze™) was the Investigational Medicinal Product in this trial. 
Labelled vials of Voraxaze™, containing sterile, lyophilised glucarpidase (1000 
units/vial), were supplied. The drug substance was manufactured by Eurogentec 
S.A. Rue du Bois Saint Jean, 14 Liege Science Park B-4102 Seraing (Liege), 
Belgium. The sterile filling and freeze-drying was performed by Cangene 
Corporation, 104 Chancellor Matheson Road, Winnipeg, Manitoba, Canada R3T 
5Y3. The unlabelled drug product was then released by a qualified person by 
Protherics UK Limited, Blaenwaun, Ffostrasol, Llandysul, Ceredigion, Wales, UK, 
SA44 5JT. The final labelled drug product was then supplied by Biotec Distribution 
Wales Ltd, 17 St Theodore’s Way, Brynmenyn Industrial Estate, Bridgend, CF32 
9TZ, UK. An approved copy of the label was submitted to the Regulatory Authorities. 
Voraxaze™ was supplied together with batch numbers and a certificate of release 
authorised by Protherics. 
UCH Pharmacy and Harley Street at UCH Pharmacy were responsible for 
appropriate storage of Voraxaze™ vials according to the supplier’s 
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recommendations, to ensure stability and integrity. UCH Pharmacy and Harley 
Street at UCH Pharmacy were also responsible for maintaining a careful record of 
receipt, use and disposition of unused supplies of Voraxaze™. Samples of the batch 
of Voraxaze™ used in the study were to be retained by Protherics for 2 years after 
completion of the study. Following completion of the study and sponsor review of 
accountability, all unused supplies were to be destroyed and certificates of 
destruction provided to the sponsor and Protherics. 
Normal saline (0.9% Sodium Chloride injection BP) intravenously was used as 
placebo. The volume of placebo was the same as if calculating the volume for 
glucarpidase. 
2.2.5.2. PRESCRIPTION OF MTX, FOLINIC ACID AND 
GLUCARPIDASE/PLACEBO 
MTX and glucarpidase/placebo were prescribed on ChemoCare® by qualified 
medical staff. Folinic acid was prescribed on ChemoCare® by qualified medical staff, 
and also on standard UCH and Harley Street at UCH drug charts. All prescriptions 
were kept within the participants’ notes. 
2.2.5.3. MANDATORY ASSESSMENTS PRIOR TO EACH CHEMOTHERAPY 
COURSE 
 Height, weight and surface area 
 Clinical examination and concomitant medication 
 Full blood count and differential white cell count 
 Blood chemistry (creatinine, urea, sodium, potassium, magnesium, phosphate, 
albumin, alanine transaminase, bilirubin) 
 Measurement of glomerular filtration rate (GFR):  
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- by radio-isotopic method prior to the first course of cycle 1 for all patients  
- by estimation prior to all other courses (Appendix 9: Measuring renal 
function) 
 Mucositis assessment (Section 2.2.9) 
 Quality of life assessment (Appendix 10) 
 Performance status (Appendix 7) 
 Blood sample for anti-glucarpidase antibodies and enzyme neutralisation assay 
2.2.5.4. MINIMUM REQUIREMENTS PRIOR TO COURSE M1 AND GLUM1 IN 
BOTH ARMS 
 General clinical condition permitting chemotherapy including no evidence of 
infection, no pyrexia, mucositis or diarrhoea 
 No serous effusions including ascites and pleural effusions 
 Neutrophils ≥ 0.75 x 109/L and platelets ≥ 100 x 109/L 
 GFR ≥ 70 ml/min/1.73m2  
 Bilirubin ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Albumin > LLN 
 Urinary pH >7.0 immediately prior to MTX and good urine output 
2.2.5.5. MINIMUM REQUIREMENTS PRIOR TO COURSE M2 AND GLUM2 IN 
BOTH ARMS 
 General clinical condition permitting chemotherapy including resolving mucositis 
≤ grade 1 but no evidence of infection, no pyrexia 
 No serous effusions including ascites and pleural effusions 
 Neutrophils ≥ 0.25 x 109 /L and platelets ≥ 50 x 109/L 
 Bilirubin ≤ 1.5 x ULN 
 Transaminases: any value in the absence of other causes of liver dysfunction 
 GFR ≥ 70 ml/min/1.73m2  
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 Urinary pH >7.0 immediately prior to MTX and good urine output 
2.2.5.6. ADMINISTRATION OF MTX (GLUM1, GLUM2, M1 AND M2 COURSES) 
Administration of GluM1, GluM2, M1 and M2 courses was as follows: 
 At -6 hours: patients were hydrated with 800 ml/m2 4% glucose + 0.18% sodium 
chloride intravenously (iv) over 6 hours, with potassium chloride 20 mmol/L and 
sodium bicarbonate 50 mmol/L. Prehydration was continued for at least 6 hours 
and until urinary pH >7. 
 At 0 hours: blood sample for plasma MTX levels was taken immediately prior to 
starting MTX (HPLC analysis). Extra sodium bicarbonate at a dose of 50-100 
mmol, intravenously or orally, was occasionally necessary to maintain alkaline 
urine (pH 7-8). Provided that urinary pH >7, MTX 12 g/m2 was infused in 1000 
ml 5% glucose over 4 hours along with iv hydration 4% glucose + 0.18% sodium 
chloride with potassium chloride 20 mmol/L and sodium bicarbonate 50 mmol/L, 
maintaining a total rate of 125 ml/m2/h. At the end of MTX infusion, blood 
sample was taken for plasma MTX levels (HPLC analysis). 
 At +4 hours: post hydration was initiated, maintaining a combined oral/iv (4% 
glucose + 0.18% sodium chloride with potassium chloride 20 mmol/L and 
sodium bicarbonate 50 mmol/L) fluid intake at 3 L/m2/day. Post hydration was 
continued until plasma MTX levels were < 0.2 µmol/L and for a minimum of 72 
hours from the beginning of MTX infusion. 
  At +24 hours: blood sample was taken for plasma MTX levels for immunoassay 
and HPLC analysis (pre-glucarpidase plasma MTX levels). 
Glucarpidase/Placebo was given as a slow intravenous injection over 5 min. 
Patients were observed for 1 hour after completion of glucarpidase/placebo 
infusion for hypersensitivity reactions.  
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 At +24:20 hours: blood sample was taken for plasma MTX and DAMPA levels 
for HPLC analysis.  
 At +26:00 hours: folinic acid rescue was started and continued every 6 hours. 
Apart from the first dose of folinic acid which was standard (15 mg/m2 orally), all 
other folinic acid doses were adjusted according to plasma MTX levels. For the 
first 48 hours after glucarpidase/placebo, folinic acid dose was adjusted based 
upon the pre-glucarpidase/placebo plasma MTX levels. After that, folinic acid 
dose was adjusted according to MTX plasma levels measured by HPLC. In 
patients who did not tolerate folinic acid orally (due to vomiting, nausea etc), the 
same dose was given intravenously. 
 At +48 hours: blood sample was taken for MTX and DAMPA levels for 
immunoassay and HPLC analysis.  
 At +72 hours: blood sample was taken for MTX and DAMPA levels for 
immunoassay and HPLC analysis. Folinic acid dose was adjusted according to 
plasma MTX levels measured by HPLC. 
 Plasma MTX and DAMPA levels were evaluated every 24 hours by 
immunoassay and HPLC analysis until plasma MTX levels were < 0.2 µmol/L 
and for a minimum of 72 hours from the start of MTX infusion. Folinic acid 
rescue, hydration and urinary alkalinisation were continued until plasma MTX 
levels were < 0.2 µmol/L, for a minimum of 72 hours from the start of MTX 
infusion. In order to compensate for any reduced potential exposure to folinic 
acid caused by its potential interaction with glucarpidase, the dose of folinic acid 
was based upon the pre-glucarpidase/placebo MTX plasma levels and 
maintained for at least 48 hours after the dosing with glucarpidase. After that, 
folinic acid dose was adjusted according to plasma MTX levels measured by 
HPLC. Urinary output and urinary pH were maintained at all times at >1 ml/kg/h 
and pH >7, respectively. 
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2.2.5.7. GLUCARPIDASE DOSE AND ADMINISTRATION  
The Pharmacy Department of the appropriate centre (UCH Pharmacy or Harley 
Street at UCH Pharmacy) was informed the day prior to any elective admissions of 
the GLU 1 participants for HD-MTX. Each vial of Voraxaze™ was reconstituted in 
with 1 ml sodium chloride 0.9%. The vials were stored in the fridge (at 2° to 8°C) 
and once reconstituted were kept in room temperature and used within 8 hours.  
Glucarpidase was administered by qualified nursing staff, at a dose of 50 units/kg, 
by a slow intravenous injection over 5 minutes, 24 hours after the start of MTX 
infusion. Date and time of administration were clearly signed and documented in the 
patient’s ChemoCare® chart. The ChemoCare® chart was subsequently filed in the 
patient’s notes. 
Patients were monitored for allergic reaction (rash, wheezing, pyrexia) and have 
their vital signs monitored (heart rate, blood pressure and temperature) prior to 
glucarpidase and every 15 min minutes until 1 hour after glucarpidase. 
If a trial participant suffered with grade 1 (CTCAE v3.0) anaphylactic reaction after 
glucarpidase, hydrocortisone (≤ 5 years: 50mg, ≥ 6 years: 100mg) was 
administered, by slow intravenous injection 30 min prior to any subsequent injection 
of glucarpidase/placebo. If a trial participant experienced grade 2-4 anaphylaxis, 
he/she was removed from the study.  
2.2.5.8. FOLINIC ACID DOSE CALCULATION 
Total daily dose of folinic acid (mg) = 
Patient’s serum MTX levels x standard daily dose of folinic acid* 
Upper limit of plasma MTX levels for day and time** 
*    Standard daily dose is 60 mg/m2 
**  Upper limits for plasma MTX levels were: 
at 24 h: 20 µmol/L  
at 48 h: 2 µmol/L  
at 72 h: 0.2 µmol/L  
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Folinic acid at a dose of ≥ 45 mg was given intravenously in view of its decreased 
gastric absorption at higher doses. 
2.2.5.9. MTX INDUCED RENAL FAILURE AND DELAYED MTX EXCRETION 
In case that plasma MTX concentration was ≥ 100 μmol/L at 24 hours or ≥ 10 
μmol/L at 48 hours after MTX administration and there was a rise in serum 
creatinine of ≥ 100% within 24 hours of MTX administration, there was a risk that 
MTX elimination would be delayed. In such case patients’ treatment was unblinded, 
although they remained on study. If they were found to have received placebo, 
intervention with glucarpidase was considered.  
2.2.6. MTX AND DAMPA PHARMACOKINETIC ASSESSMENTS 
DAMPA is known to cross-react with MTX in most commercial immunological MTX 
assays (Albertioni et al. 1996; Widemann et al. 1997). Consequently MTX levels 
determined by commercial laboratories are unreliable following treatment with 
glucarpidase. In the GLU 1 clinical trial plasma MTX levels were measured by both 
immunoassay and high performance liquid chromatography (HPLC). Plasma 
DAMPA levels were measured by HPLC.  
In order to minimise any potential for ex vivo conversion of MTX to DAMPA, all 
samples taken for HPLC analysis were put on ice as soon as they were taken and 
spun to separate the plasma as soon as practical. The plasma was then 
immediately transferred to tubes containing hydrochloric acid at a volume ratio of 10 
parts plasma to 1 part acid. 
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2.2.6.1.   ANALYSIS OF MTX PLASMA LEVELS BY IMMUNOASSAY  
The TDx/TDxFLx Methotrexate II assay (Abbott Laboratories), which utilizes 
Fluorescence Polarization Immunoassay (FPIA) technology, was used to measure 
plasma MTX levels. 
Following each of the four HD-MTX doses (on days 1 & 8 of cycles 1 and 2), blood 
samples were collected at the following time points: at 24 hours (prior to 
glucarpidase/placebo administration), 48 hours and 72 hours after starting MTX and 
then daily until plasma MTX levels were < 0.2 μmol/L. At each time point, 5 mls of 
blood in a plain (red top) bottle was sent for analysis to Clinical Biochemistry UCL 
Hospitals, 60 Whitfield St, London, W1T 4EU where they were analysed by UCLH 
biochemistry staff. 
2.2.6.2. ANALYSIS OF MTX AND DAMPA PLASMA LEVELS BY HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY 
A HPLC assay was validated for the GLU 1 study and used for the analysis of MTX 
and DAMPA plasma levels for trial participants. The validation of the HPLC assay is 
described in section 4. 
Following each of the four HD-MTX doses (on days 1 & 8 of cycles 1 and 2), blood 
samples were collected for MTX and DAMPA HPLC analysis at the following time 
points: at 0 hours (prior to starting the MTX infusion), 4 hours (immediately prior to 
the end of the infusion), 24 hours (prior to glucarpidase/placebo administration), 
24:20 hours (15 minutes after glucarpidase/placebo administration), 48 hours and 
72 hours after starting MTX infusion and then daily until plasma MTX levels were 
<0.2 μmol/L (as measured by HPLC).   
At each time point, 6 mls of blood were collected in an EDTA bottle. Patient’s trial 
number, hospital number and date of birth were documented on the sample label as 
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well as the date and time of sample collection. All samples were immediately placed 
on ice and taken to the University College London Cancer Institute, Paul O’Gorman 
Building, 72 Huntley Street, London, WC1E 6BT. All samples were then centrifuged 
at 2000 rpm for 10 minutes and the plasma aliquoted into 3x1 ml freezer vials 
containing hydrochloric acid at a volume ratio of 10 parts plasma to 1 part acid. 
Samples which were not analysed immediately were labelled and frozen at -80°C. A 
sample log was kept for all stored samples.  
All HPLC assessments for the GLU 1 study were carried out by me at the University 
College London, Cancer Institute, the Paul O’Gorman Building, 72 Huntley Street, 
London, WC1E 6BT. 
2.2.7. ASSESSMENT OF ANTI-GLUCARPIDASE ANTIBODY RESPONSE 
2.2.7.1. BACKGROUND 
Since two doses of glucarpidase were planned for each GLU 1 participant, it 
seemed important to study the anti-glucarpidase antibody response.  
The presence of antiglucarpidase IgG antibodies was determined by a validated 
qualitative ELISA assay. In addition, serum samples containing anti-glucarpidase 
antibodies were evaluated for their ability to reduce the enzyme activity of 
glucarpidase by the use of a validated enzyme inhibition assay.   
2.2.7.2. BLOOD SAMPLING SCHEDULE 
Blood samples for anti-glucarpidase antibody assessment and enzyme 
neutralisation assay were collected on days 0, 1, 8 and 15 of cycle 1 and days 1, 8, 
15 and 30 of cycle 2. If there was positive anti-glucarpidase antibody response on 
day 30 of cycle 2, two further blood samples were collected at 3 and 6 months after 
starting cycle 2. 
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2.2.7.3. SAMPLING PROCEDURES 
At each time point, 5 mls of blood was collected in plain tube (red top) and sent to: 
University College London Cancer Institute, Paul O’Gorman Building, 72 Huntley 
Street, London, WC1E 6BT. Samples were then centrifuged at 2000 rpm for 10 
minutes and 1 ml of serum put in a 1 ml freezer vial, labelled and frozen at -70°C. 
Patients’ trial number, hospital number and date of birth were documented on the 
sample label as well as the date and time of sample collection. Samples were 
subsequently sent on dry ice to Covance Laboratories Limited, Biotechnology 
Division, Otley Road, Harrogate, North Yorkshire, HG3 1PY.  Following receipt at 
Covance, one serum aliquot was stored appropriately for anti-glucarpidase antibody 
neutralisation analysis and the second aliquot was shipped to BioAnaLab Limited, 
Florey House, 3 Robert Robinson Avenue, the Oxford Science Park, Oxford OX4 
4GP for anti-glucarpidase antibody analysis. Following analysis of samples by 
BioAnaLab for anti-glucarpidase antibody, all positive samples were identified to 
Covance who then performed the anti-glucarpidase antibody neutralisation analysis 
using the second aliquot.  
2.2.8. ASSESSMENT OF GLUCARPIDASE AND MTX RELATED TOXICITY 
2.2.8.1. DEFINITIONS  
ADVERSE EVENT 
An adverse event (AE) is any untoward medical occurrence in a clinical trial subject 
administered a medicinal product, including occurrences which are not necessarily 
caused by or related to the medicinal product. 
ADVERSE REACTION 
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An adverse reaction (AR) is any untoward and unintended response in a subject to 
an investigational medicinal product which is related to any dose administered to 
that subject. 
SERIOUS ADVERSE EVENT OR REACTION 
A serious adverse event (SAE) or serious adverse reaction (SAR) is an adverse 
event or adverse reaction that: 
 results in death regardless of its cause  
 is life-threatening 
 requires hospitalisation or prolongation of an existing hospitalisation. Not every 
hospitalisation constitutes a reportable serious adverse event (exceptions in 
“Clarifications and exceptions for GLU 1”). 
 results in persistent or significant disability or incapacity (exceptions in 
“Clarifications and exceptions for GLU 1”) 
 is a congenital anomaly or birth defect 
 any other medically important condition such as abnormal biological or vital 
signs, pregnancy and secondary malignancies (exceptions in “Clarifications and 
exceptions for GLU 1”). 
SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTION 
A suspected unexpected serious adverse reaction (SUSAR) is a SAR, the nature or 
severity of which is not consistent with the applicable product information. 
Examples include: 
 an expected SAR with an unexpected outcome (e.g. fatal outcome) 
 “acute renal failure”  is an expected AR, a subsequent new report of “interstitial 
nephritis” is more specific and, therefore, unexpected 
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 an increase in the rate of occurrence of an expected AR which is judged to be 
clinically important is considered unexpected. 
CLARIFICATIONS AND EXCEPTIONS FOR GLU 1 
 Any death during the study was to be reported as an SAE, including death due 
to disease progression. 
 The term “life-threatening” referred to an event where the patient was at 
immediate risk of death at the time of the event (e.g. required immediate 
intensive care treatment).  
 Hospitalisation was defined as at least one unplanned overnight admission. 
 Hospitalisation for HD-MTX was not reported as an SAE. In addition, expected 
methotrexate side-effects, listed in the product information (section 2.2.8.2 
Expected Adverse Events), were not reported on an SAE form, unless they 
unexpectedly prolonged hospitalisation or required intensive care therapy. 
 Hospitalisation due to signs and symptoms associated with disease progression 
were not considered an SAE, unless outcome leads to death during the study. 
 Elective hospitalization for pre-existing condition that had not worsened did not 
constitute a SAE. 
 Disability was defined as a substantial disruption in a person’s ability to conduct 
normal life functions. Disability directly due to osteosarcoma did not constitute a 
SAE. 
 Other medically important conditions were important medical events which in 
the opinion of the investigator might not have been immediately life-threatening 
or resulted in death or hospitalisation but might have jeopardised the patient or 
might have required intervention to prevent one of the other outcomes listed in 
the definition above (e.g. anaphylaxis). Expected serious adverse reactions 
(SAR) such as haematological toxicity or increase in liver enzymes after 
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methotrexate which resolved were examples of SARs which were not 
considered reportable as SAE.   
2.2.8.2. EXPECTED ADVERSE EVENTS 
Expected adverse events associated with glucarpidase are described in 
Section 1.4.3.  
Expected adverse events associated with methotrexate are shown on Table 7. 
Table 7: EXPECTED ADVERSE EVENTS RELATED TO MTX  
 Expected adverse events related to methotrexate 
 
Happen to 21-100 
patients out of every 100 
Happen to 5-20 
patients out of 
every 100 
Happen to <5 patients 
out of every 100 
Immediate: 
Within 1-2 
days of 
receiving drug _ 
Nausea, vomiting, 
anorexia 
Dizziness, malaise, 
blurred vision, allergic 
reaction, peeling, 
redness, and 
tenderness of the skin, 
especially the soles 
and palms 
Prompt: 
Within 2-3 
weeks, prior  to 
the next course 
Transaminase elevations Diarrhoea, 
myelosuppression, 
stomatitis, 
photosensitivity 
Alopecia, folliculitis, 
renal toxicity, 
leukoencephalopathy 
(L), seizures, acute 
neurotoxicity 
Delayed: 
Any time later 
during therapy, 
excluding the 
above 
conditions 
_ _ 
Lung damage (L), 
hyperpigmentation, 
liver damage (L), 
osteoporosis (L) 
Learning disability (L) 
Late: 
Any time after 
completion of 
treatment 
_ _ 
Progressive CNS 
deterioration 
Unknown Frequency and Timing: **Foetal and teratogenic toxicities 
Source: extract from EURAMOS 1 clinical trial protocol 
**Methotrexate crosses the placenta to the foetus. Foetal toxicities and teratogenic 
effects of methotrexate (either alone or in combination with other 
antineoplastic agents) have been noted in humans. The toxicities include: 
congenital defects, chromosome abnormalities, malformation, severe 
newborn myelosuppression, pancytopenia, and low birth weight. 
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**Methotrexate is excreted into breast milk in low concentrations. However, because 
the drug may accumulate in neonatal tissues, breast feeding is not 
recommended. Methotrexate is considered to be contraindicated during 
breast feeding because of several potential problems, including immune 
suppression, neutropenia, adverse effects on growth, and carcinogenesis. 
(L): Toxicity may also occur later 
2.2.8.3. REPORTING ADVERSE EVENTS IN THE GLU 1 CLINICAL TRIAL 
All AEs related to the study participants were documented in the individual’s Case 
Record Form (CRF) (Appendix 6: GLU 1 clinical trial, Case Record Form) and 
graded for severity according to Common Terminology for Adverse Events v.3.0 
(CTCAE). 
AEs related to glucarpidase were recorded in the Glucarpidase Adverse Event form 
(part of the CRF) and followed-up until their resolution. AEs not related to 
glucarpidase were followed until the end of study, i.e. day 21 of cycle 2. 
2.2.8.4. REPORTING SERIOUS ADVERSE EVENTS IN THE GLU 1 CLINICAL 
TRIAL 
All SAEs regardless of causal relationship were notified within 24 hours to the Joint 
UCLH/UCL Biomedical Research Unit (JBRU). Notification was promptly followed by 
a detailed, written report using the Joint UCLH/UCL Serious Adverse Report Form 
which was faxed to the JBRU on 020 7380 9937. An email was sent to the Lead trial 
co-ordinator in the JBRU. All SAE forms were also emailed to Dr Karen Maubach, 
Clinical Development Executive, Protherics at karen.maubach@btgplc.com. In 
addition, the UCLH NHS Foundation Trust incident form was completed.  
If the SAE was classified as a SUSAR the report was sent to the MHRA within the 
required timeframe by the JBRU (7 days if the event was fatal or life-threatening with 
a further follow-up in 8 days or 15 days for all other events categorised as SUSARs). 
The report was also sent by the JBRU to the appropriate research ethics committee. 
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In addition, the report was sent to Dr Karen Maubach at 
karen.maubach@btgplc.com who forwarded the information to Protherics Inc. 
(Nashville, USA). Protherics ensured that the necessary reporting of SAEs was 
undertaken in the USA. 
2.2.9. ASSESSMENT OF MUCOSITIS IN STUDY PARTICIPANTS  
No single severity scale meets all requirements of a mucositis assessment tool or is 
universally accepted. Therefore, in this study four different assessment tools were 
used: 
 World Health Organisation Toxicity Criteria for Oral Mucositis (World Health 
Organization 1979)  
 National Cancer Institute Common Terminology criteria for Adverse Events, 
version 3.0 (NCI CTCAE v 3.0) (NCI 2003) 
 Oral Assessment Guide (Eilers et al. 1988) 
 Oral Mucositis Weekly Questionnaire (Stiff et al. 2006) 
All four mucositis assessment tools are described in Appendix 11. 
The NCI CTCAE v3.0 and WHO scoring scales were chosen as assessment tools in 
view of their widespread use in studies examining mucositis. Both these scales 
measure anatomical, symptomatic and functional components of oral mucositis.  In 
addition, the NCI CTCAE v3.0 scale also grades enteritis, colitis, diarrhoea and 
abdominal distension /bloating.  
The Oral Assessment Guide is a validated instrument which has been extensively 
used in adults with cancer. It is designed to objectively assess the physiological 
changes of the oral cavity following the administration of chemotherapy and 
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radiotherapy. An adapted version has now been validated for paediatric use (Glenny 
et al. 2010). 
The Oral Mucositis Weekly Questionnaire was adapted from the Oral Mucositis 
Daily Questionnaire, which is developed as a mucositis specific questionnaire to 
assess patient-reported outcomes (Bellm et al. 2002). It is designed to assess the 
severity and impact of oral mucositis by evaluating mouth and throat soreness and 
the degree to which these interfere with activities of daily life such as eating, 
swallowing, drinking, talking and sleeping. It also assesses the overall health of the 
patient and the severity of diarrhoea. It has been shown to be a feasible, reliable, 
valid and responsive patient-reported measure of oral mucositis toxicity (Stiff et al. 
2006). 
2.2.10. ASSESSMENT OF QUALITY OF LIFE IN STUDY PARTICIPANTS 
For study participants aged 15 and under, Quality of Life was assessed using the 
“PedsQL 3.0 Cancer Module Acute Version questionnaire” (Appendix 10: Quality of 
Life questionnaires). It encompasses 8 scales: pain and hurt (2 items), nausea (5 
items), procedural anxiety (3 items), treatment anxiety (3 items), worry (3 items), 
cognitive problems (5 items), perceived physical appearance (3 items), and 
communication (3 items). PedsQL (Varni et al. 2002) has questionnaires for different 
age groups including 5-7 years, 8-12 years and 13-18 years. There are self-report 
questionnaires and parent proxy reports. Both the self-reporting and the parent 
proxy questionnaire had to be completed.  
For study participants aged 16 and over at registration, quality of life was assessed 
using the EORTC (European Organisation for Research and Treatment of Cancer) 
QLQ-C30 version 3 (Aaronson et al. 1993; Fayers et al 2001) and the FACT-G 
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(Functional Assessment of Cancer Therapy Scale-General) (Cella et al. 1993) 
questionnaires (Appendix 10: Quality of Life questionnaires).  
The QLQ-C30 questionnaire is a reliable and valid measure of the quality of life of 
cancer patients in multicultural clinical research settings. It incorporates nine multi-
item scales: five functional scales (physical, role, cognitive, emotional and social); 
three symptom scales (fatigue, pain, nausea and vomiting); and a global health and 
quality of life scale. The average time required to complete the questionnaire is 11 
minutes, and most patients do not require assistance (Aaronson et al. 1993). 
The FACT-G is a 33-item questionnaire that can be easily completed in 5 minutes, 
usually without assistance (Cella et al. 1993). It meets all requirements for use in an 
oncology clinical trial including ease of administration, brevity, reliability, validity and 
responsiveness to clinical change. It includes questions on physical, social/family, 
emotional and functional well-being along with questions on relationship with the 
doctor. 
2.2.11. INTERIM ANALYSIS 
An interim analysis was planned after treatment data for half of the planned number 
of patients was obtained. The Independent Data Monitoring Committee (IDMC) of 
the GLU 1 study was asked to make a recommendation about the continuation of 
the trial as instructed by the trial protocol (Appendix 1).  In particular, termination of 
the trial would have been considered if review of the primary outcome showed a 
statistically significant benefit of glucarpidase, treatment with glucarpidase and 
folinic acid was significantly worse than standard treatment, glucarpidase associated 
adverse events outweighed its benefit and recruitment rate appeared inadequate to 
achieve the required sample size for the trial. In examining efficacy based on the 
primary outcome, the O’Brien-Fleming method for judging significance of results 
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from a McNemar’s test was used (O’Brien and Fleming TR, 1979). A significance 
level of 0.005 was used for the interim analysis. To assess whether glucarpidase 
may be delaying further chemotherapy, the McNemar’s test with a one sided 
significance level of 5% was used. 
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3. CHEMOTHERAPY DELAYS DUE TO MTX TOXICITY 
In order to determine the incidence of delays in chemotherapy due to MTX toxicity, 
medical records of patients with osteosarcoma treated with MAP at the University 
College Hospital in London were reviewed, and data were collected on age, gender, 
chemotherapy dates, surgery dates, folinic acid rescue regimens, MTX toxicity and 
causes of chemotherapy delays (review A). In a separate review, the tolerance of 
HD-MTX (12 g/m2) in patients aged ≥ 40 years was studied and compared with that 
of younger patients, aged < 40 years (review B).   
3.1. REVIEW A: MAP REGIMEN AND CHEMOTHERAPY DELAYS DUE TO MTX 
TOXICITY 
The medical records of 56 patients with osteosarcoma, treated with MAP in 
University College Hospital, London, UK, between January 2004 and January 2005 
were reviewed. Data were collected on age, gender, chemotherapy dates, surgery 
dates and folinic acid rescue regimens. Delayed chemotherapy courses were 
identified and further information was collected on delays due to MTX toxicity.   
Of the 56 patients studied, 35 were males and 21 were females, with a male to 
female ratio of 1.6:1 and a median age of 20 years. A total of 235 MAP 
chemotherapy cycles were reviewed. The median number of cycles received per 
patient was 5. 175 cycles were “applicable” for analysis of the incidence of 
subsequent delays in chemotherapy administration due to MTX toxicity. Treatment 
cycles were not applicable for analysis if there was not enough data in patients’ 
notes related to the toxicity these cycles resulted in. For example, last chemo cycles 
were often not applicable as there were no toxicity data in patients’ notes after the 
last inpatient admission. Similarly cycles preceding surgery were usually not 
applicable; surgery did not take place at UCH and patients were not reviewed at 
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UCH prior to surgery in order to have their toxicity documented. The median number 
of “applicable cycles” received per patient was 4 (Table 8).  
52% of chemotherapy cycles (92/175) were delayed due to MTX toxicity by a 
median of seven days (range 1-28 days), (tables 8 and 9, figure 2). The median 
number of delayed cycles per patient was 1.5. Causes of delay in starting 
subsequent chemotherapy included mucositis in 51% of cycles, bone marrow 
suppression in 28%, infection (12%), nephrotoxicity (8%) and elevated liver 
enzymes (1%), (figure 3). There were no deaths associated with MTX toxicity in the 
studied set of patients. 
Out of 350 planned MTX courses, 5% (18/350) were omitted due to previous MTX 
toxicity. Treatment with MTX was discontinued early in 10% (6/56) of patients due to 
MTX toxicity (Table 9).  
Two folinic acid rescue regimens were used in the period studied. In regimen A, 
folinic acid rescue was started at 24 hours after starting the infusion of MTX at a 
dose of 15 mg/m2, every six hours, orally or intravenously. MTX plasma levels were 
measured at 48 hours after starting MTX and then daily until they were < 0.2 µmol/L. 
The dose of folinic acid was adjusted according to the 48 hour MTX plasma levels 
and subsequent daily levels thereafter. The following formula was used to adjust the 
dose of folinic acid.  
Total daily dose of folinic acid (mg) = 
Patient’s serum MTX levels x standard daily dose of folinic acid* 
Upper limit of plasma MTX levels for day and time** 
*    Standard daily dose is 60 mg/m2, given in 4 divided doses 
**  Upper limits for plasma MTX levels: 
- at 24 h: 20 µmol/L  
- at 48 h: 2 µmol/L  
- at 72 h: 0.2 µmol/L  
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In regimen B, which replaced regimen A towards the end of 2004, folinic acid 
rescue was also started at 24 hours after starting the infusion of MTX at a dose of 
15 mg/m2, every six hours, orally or intravenously. MTX plasma levels were 
measured at 24 hours after starting methotrexate and then daily until <0.2 µmol/L. 
The dose of folinic acid was adjusted according to the 24 hour MTX plasma level 
and subsequent daily levels thereafter. The above described formula was used to 
adjust the dose of folinic acid. 
Regimen A was used in 98 cycles of which 57% (56/98) were delayed due to MTX 
toxicity (median 7 days, range 1-28 days), (Table 9 and Table 10, Figure 3).  
Regimen B was used in 77 cycles of which 47% (36/77) were delayed due to MTX 
toxicity (median 7 days, range 3-27 days), (Table 9 and Table 10, Figure 2).  Early 
folinic acid dose adjustment, at 24 hours versus 48 hours after starting the infusion 
of MTX resulted in a decrease in MTX-induced chemotherapy delays by 20%. 
Despite early folinic acid dose adjustment almost half of chemotherapy cycles (47%) 
were not given on time due to MTX toxicity.  
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Table 8: PATIENTS’ CHARACTERISTICS, DELAYED CYCLES/APPLICABLE TO REVIEW CYCLES, DISCONTINUATION OF 
TREATMENT WITH MTX DUE TO MTX TOXICITY 
Age  Sex 
Total 
no. of 
cycles 
Number of 
delayed 
cycles/applicable 
to review cycles 
Cycle 2 
no. of days 
delayed by: 
Cycle 3 
no. of days 
delayed by: 
Cycle 4 
no. of days 
delayed by: 
Cycle 5 
no. of days 
delayed by: 
Cycle 6 
no. of days 
delayed by: 
Omitted 
courses of 
MTX due to 
MTX toxicity  
MTX 
discontinuation 
due to MTX 
toxicity 
12 M 6 5/5 10 N/A 7 9 >7 5c* NO 
12 M 6 2/4 0 0 N/A 17 14 NO NO 
10 M 6 1/4 0 N/A 0 0 7 NO NO 
6 M 6 1/4 >7 N/A 0 0 0 1c* NO 
11 F 6 0/4 0 N/A 0 0 0 NO NO 
8 M 6 2/4 0 N/A 0 7 16 NO NO 
12 F 6 2/3 12 N/A 6 N/A 0 NO NO 
10 F 3 0/2 0 0 N/A 
changed to 
different 
regimen 
changed to 
different 
regimen 
NO NO 
6 F 6 2/4 0 N/A 0 8 7 NO NO 
8 M 1 1/1 13 
not received 
yet 
not received 
yet 
not received 
yet 
not received 
yet 
NO NO 
12 F 1 0/1 0 
not received 
yet 
not received 
yet 
not received 
yet 
not received 
yet 
NO NO 
37 M 1 0/1 0 
not received 
yet 
not received 
yet 
not received 
yet 
not received 
yet 
NO NO 
87 
Table 8: PATIENTS’ CHARACTERISTICS, DELAYED CYCLES/APPLICABLE TO REVIEW CYCLES, DISCONTINUATION OF 
TREATMENT WITH MTX DUE TO MTX TOXICITY 
Age  Sex 
Total 
no. of 
cycles 
Number of 
delayed 
cycles/applicable 
to review cycles 
Cycle 2 
no. of days 
delayed by: 
Cycle 3 
no. of days 
delayed by: 
Cycle 4 
no. of days 
delayed by: 
Cycle 5 
no. of days 
delayed by: 
Cycle 6 
no. of days 
delayed by: 
Omitted 
courses of 
MTX due to 
MTX toxicity  
MTX 
discontinuation 
due to MTX 
toxicity 
47 M 2 1/2 0 28 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
2c* YES 
17 F 1 0/1 0 
not received 
yet 
not received 
yet 
not received 
yet 
not received 
yet 
NO NO 
17 M 4 0/3 0 N/A 0 0 
not received 
yet 
NO NO 
15 M 5 3/4 0 N/A 9 6 3 NO NO 
17 F 4 0/3 0 N/A 0 0 
not received 
yet 
NO NO 
16 M 3 0/2 0 N/A 0 
not received 
yet 
not received 
yet 
NO NO 
23 F 1 1/1 4 
not received 
yet 
not received 
yet 
not received 
yet 
not received 
yet 
NO NO 
20 M 1 1/1 >7 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
1c* YES 
24 M 6 2/4 8 N/A 0 13 0 NO NO 
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Table 8: PATIENTS’ CHARACTERISTICS, DELAYED CYCLES/APPLICABLE TO REVIEW CYCLES, DISCONTINUATION OF 
TREATMENT WITH MTX DUE TO MTX TOXICITY 
Age  Sex 
Total 
no. of 
cycles 
Number of 
delayed 
cycles/applicable 
to review cycles 
Cycle 2 
no. of days 
delayed by: 
Cycle 3 
no. of days 
delayed by: 
Cycle 4 
no. of days 
delayed by: 
Cycle 5 
no. of days 
delayed by: 
Cycle 6 
no. of days 
delayed by: 
Omitted 
courses of 
MTX due to 
MTX toxicity  
MTX 
discontinuation 
due to MTX 
toxicity 
23 M 1 0/1 0 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
NO NO 
22 M 2 1/2 0 >7 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
NO NO 
40 M 3 1/3 5 0 0 
not received 
yet 
not received 
yet 
NO NO 
32 F 2 2/2 >7 >7 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
1c and 2c* YES 
26 M 4 1/3 0 1 0 0 
not received 
yet 
NO NO 
34 M 1 1/1 25 
not received 
yet 
not received 
yet 
not received 
yet 
not received 
yet 
NO NO 
20 M 6 2/4 11 N/A 0 2 
not received 
yet 
NO NO 
40 M 5 1/4 0 0 N/A 0 3 NO NO 
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Table 8: PATIENTS’ CHARACTERISTICS, DELAYED CYCLES/APPLICABLE TO REVIEW CYCLES, DISCONTINUATION OF 
TREATMENT WITH MTX DUE TO MTX TOXICITY 
Age  Sex 
Total 
no. of 
cycles 
Number of 
delayed 
cycles/applicable 
to review cycles 
Cycle 2 
no. of days 
delayed by: 
Cycle 3 
no. of days 
delayed by: 
Cycle 4 
no. of days 
delayed by: 
Cycle 5 
no. of days 
delayed by: 
Cycle 6 
no. of days 
delayed by: 
Omitted 
courses of 
MTX due to 
MTX toxicity  
MTX 
discontinuation 
due to MTX 
toxicity 
20 M 3 0/2 0 N/A 0 
not received 
yet 
not received 
yet 
NO NO 
18 M 6 1/4 >7 N/A 0 0 0 1c* NO 
17 M 6 3/4 3 N/A 5 >7 >7 4c* NO 
43 M 4 2/3 0 10 7 N/A 
changed to 
different 
regimen 
NO NO 
21 F 6 3/5 >7 3 0 12 0 1c* NO 
37 F 5 1/4 0 N/A 0 0 >7 NO NO 
14 M 6 4/5 9 >7 15 0 7 2c* NO 
20 F 6 3/4 11 N/A 17 7 0 NO NO 
24 M 4 2/4 5 0 0 4 
changed to 
different 
regimen 
NO NO 
18 M 2 2/2 >7 >7 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
1c and 2c* YES 
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Table 8: PATIENTS’ CHARACTERISTICS, DELAYED CYCLES/APPLICABLE TO REVIEW CYCLES, DISCONTINUATION OF 
TREATMENT WITH MTX DUE TO MTX TOXICITY 
Age  Sex 
Total 
no. of 
cycles 
Number of 
delayed 
cycles/applicable 
to review cycles 
Cycle 2 
no. of days 
delayed by: 
Cycle 3 
no. of days 
delayed by: 
Cycle 4 
no. of days 
delayed by: 
Cycle 5 
no. of days 
delayed by: 
Cycle 6 
no. of days 
delayed by: 
Omitted 
courses of 
MTX due to 
MTX toxicity  
MTX 
discontinuation 
due to MTX 
toxicity 
16 M 6 1/4 >7 N/A 0 0 0 1c* NO 
17 M 6 2/4 4 N/A 0 0 7 NO NO 
22 M 3 2/2 5 N/A 10 
changed to 
different 
regimen 
changed to 
different 
regimen 
NO NO 
30 F 5 2/4 0 N/A 0 4 4 NO NO 
14 M 6 4/4 5 >7 7 N/A 6 2c* NO 
31 M 2 1/2 0 9 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
NO NO 
21 F 6 5/5 10 >7 3 10 10 2c* NO 
31 F 6 3/3 8 >7 >7 N/A N/A 2c and 3c* NO 
19 F 6 1/4 0 N/A 0 14 0 NO NO 
14 M 6 0/4 0 N/A 0 0 0 NO NO 
14 F 6 2/4 0 N/A 8 27 0 NO NO 
34 M 6 2/4 5 N/A 0 0 15 NO NO 
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Table 8: PATIENTS’ CHARACTERISTICS, DELAYED CYCLES/APPLICABLE TO REVIEW CYCLES, DISCONTINUATION OF 
TREATMENT WITH MTX DUE TO MTX TOXICITY 
Age  Sex 
Total 
no. of 
cycles 
Number of 
delayed 
cycles/applicable 
to review cycles 
Cycle 2 
no. of days 
delayed by: 
Cycle 3 
no. of days 
delayed by: 
Cycle 4 
no. of days 
delayed by: 
Cycle 5 
no. of days 
delayed by: 
Cycle 6 
no. of days 
delayed by: 
Omitted 
courses of 
MTX due to 
MTX toxicity  
MTX 
discontinuation 
due to MTX 
toxicity 
22 F 2 1/1 11 N/A 
changed to 
different 
regimen 
changed to 
different 
regimen 
changed to 
different 
regimen 
NO NO 
24 F 3 2/3 0 13 10 
changed to 
different 
regimen 
changed to 
different 
regimen 
NO YES 
20 M 6 2/4 13 0 0 N/A 13 NO NO 
23 F 4 3/4 >7 0 10 15 
changed to 
different 
regimen 
1c* YES 
13 F 6 5/5 9 4 6 7 6 NO NO 
FOLINIC ACID RESCUE REGIMENS 
 
Regimen A 
 
Regimen B 
 
*1a, 1b, 1c, 2a, 2b, 2c etc.: numbers refer to the cycle of chemotherapy and letters refer to treatment course; a=doxorubicin & cisplatin, b=1
st
 MTX in each cycle, c=2
nd
 MTX in each cycle; for 
example 4a means doxorubicin &cisplatin in cycle 4.
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Table 9: INCIDENCE OF DELAYED CHEMOTHERAPY CYCLES DUE TO MTX 
TOXICITY  
 Total number 
of cycles 
Delayed 
cycles 
Incidence of 
delay 
Median delay, 
days (range) 
Regimen A 
(Late rescue) 
98 56 57% 7(1-28) 
Regimen B 
(Early rescue) 
77 36 47% 7(3-27) 
Both regimens 175 92 52% 7(1-28) 
 
Figure 1: INCIDENCE OF DELAYED CHEMOTHERAPY CYCLES DUE TO MTX 
TOXICITY  
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93 
Figure 2: CAUSES OF DELAY IN STARTING SUBSEQUENT CHEMOTHERAPY 
 
 
Table 10: INCIDENCE OF CHEMOTHERAPY DELAY PER CYCLE FOR BOTH 
FOLINIC ACID REGIMENS AND FOR EACH FOLINIC ACID REGIMEN 
INDIVIDUALLY  
 Both FA regimens Regimen A Regimen B 
Cycles Incidence 
of delay 
Median 
delay, 
days 
(range) 
Incidence 
of delay 
Median 
delay, 
days 
(range) 
Incidence 
of delay 
Median 
delay, 
days 
(range) 
Cycle 2 52% 
(29/56) 
7 
(3-25) 
66.6% 
(18/27) 
7 
(3-13) 
38% 
(11/29) 
7 
(5-25) 
Cycle 3 66% 
(14/21) 
7 
(1-28) 
63.6% 
(7/11) 
7 
(3-10) 
70% (7/10) 7 
(1-28) 
Cycle 4 38.5% 
(15/39) 
7 
(3-17) 
43.5% 
(10/23) 
7 
(3-17) 
31% (5/16) 9 
(6-15) 
Cycle 5 55% 
(17/31) 
8 
(2-27) 
68.5% 
(13/19) 
9 
(4-27) 
33% (4/12) 6.5 
(2-17) 
Cycle 6 60.7% 
(17/28) 
7 
(3-16) 
44.5% 
(8/18) 
7 
(4-13) 
90% 
(9/10) 
7 
(3-16) 
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Figure 3: INCIDENCE OF CHEMOTHERAPY DELAY PER CYCLE FOR BOTH 
FOLINIC ACID REGIMENS AND FOR EACH FOLINIC ACID REGIMEN 
INDIVIDUALLY  
 
3.2. REVIEW B: TOLERANCE OF HD-MTX (12 g/m2) IN PATIENTS ≥ 40 YEARS  
A further review was carried in order to study the tolerance of HD-MTX (12 g/m2) in 
patients ≥ 40 years. 17 patients, aged ≥ 40 years who were treated with MAP 
regimen in the University College Hospital, London, UK, between December 2002 
and October 2007, were identified. 25 patients, aged < 40 years who were treated 
with MAP regimen in the University College Hospital, London, UK, between June 
2003 and September 2006, were also identified. Data were collected on age, 
gender, chemotherapy dates, surgery dates, and daily MTX plasma levels, number 
of received MTX courses, folinic acid doses, MTX-related toxicity and delays in 
subsequent chemotherapy due to MTX-related toxicity. Data from different age 
groups were compared. 
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PATIENTS ≥ 40 YEARS 
17 eligible patients were identified, although medical notes of 16 patients were 
retrieved. The age of the patients ranged between 40-50 years with a median age of 
44.5 years. 9 of those were males and 7 were females. On average each patient 
received 4.9 courses of MTX (range: 2-12). 55 chemotherapy cycles reviewed, and 
41 of those were applicable for analysis of the incidence of subsequent delays in 
chemotherapy administration due to MTX toxicity.  24 out of the 41 applicable MAP 
cycles were delayed (58.5%) by 2-26 days (median 7.5 days) due to MTX related 
toxicity. Causes of delay in starting subsequent chemotherapy included: mucositis in 
37.5% MAP cycles (9/24), renal impairment in 20.8% (5/24), mucositis and bone 
marrow suppression in 16.6% (4/24), mucositis and renal impairment in16.6% (4/24) 
and bone marrow toxicity in 8.3% (2/24). 
In 15 out of a total of 16 reviewed patients, treatment with MTX was stopped early. 
Only one patient completed all planned 12 MTX courses. In 12 of those 15 patients, 
MTX treatment was stopped early due to MTX related toxicity. Reasons for stopping 
MTX treatment early included renal impairment in 50% (6/12) of the patients and 
mucositis in the other 50% (6/12) of the patients. 
MTX plasma levels at 24 hours after starting MTX ranged from 2.95 to 115.66 µM 
(median: 25.89 µM, average 40.30 µM). Days required to clear MTX ranged from 2 
to 9 (median: 3, average 3.7). With regards to folinic acid regimen used 10/16 of 
patients (72%) had 3 hourly doses for the first 24 hours and then 6 hourly and 4/16 
of patients (28%) had 6 hourly doses from the start of their folinic acid rescue. 
PATIENTS < 40 YEARS 
The medical noted of 25 eligible patient were retrieved and reviewed. The age of the 
patients ranged between 7-39 years with a median age of 15 years. 17 of those 
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were males and 8 were females. On average each patient received 10.26 courses of 
MTX (range: 1-12). 135 chemotherapy cycles were reviewed, and 92 of those were 
applicable for analysis of the incidence of subsequent delays in chemotherapy 
administration due to MTX toxicity.  48 out of the 92 applicable MAP cycles were 
delayed (52.2%) due to MTX related toxicity. Causes of delay in starting subsequent 
chemotherapy included: mucositis in 29% MAP cycles (14/48), bone marrow toxicity 
in 25% (12/48), infection in 23% (11/48), mucositis and bone marrow suppression in 
12.5% (6/48), mucositis and renal impairment in 8% (4/48), elevated liver enzymes 
in 4% (2/48) and renal impairment in 4% (2/48).  
In 5 out of a total of 25 reviewed patients, treatment with MTX was stopped early. In 
3 of those 5 patients, MTX treatment was stopped early due to MTX related toxicity. 
Reasons for stopping MTX treatment early included renal impairment in 2/3 of 
patients and patient’s request in 1/3 of patients. Fifteen patients completed all 
planned 12 MTX courses. 
MTX plasma levels at 24 hours for this group of patients ranged from 1.61 to 160.63 
µM (median: 12.13 µM, average 17.5 µM). Days required to clear MTX ranged from 
2 to more than 10 (median: 3, average 3.11).  
Data from the two different age groups are shown on Table 11. 
Table 11: TOLERANCE OF HD-MTX (12 g/m2) IN PATIENTS ≥ 40 YEARS AND < 
40 YEARS 
  ≥ 40 years < 40 years 
Number of patients 16 25 
Age  40-50 years, median 44.5 
years  
7-39 years, median 15 years 
Delayed/applicable 
cycles 
24 / 41 cycles were delayed 
(58.5%) 
48 / 92 cycles were delayed 
(52.2%) 
MTX courses 
received  
 average 4.9 courses of MTX 
(2-12) 
average 10.26 courses of MTX 
(1-12) 
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  ≥ 40 years < 40 years 
Reason for delay Mucositis 37.5% (9/24) 
Renal impairment 20.8% (5/24) 
Mucositis & BM suppression 
16.6% (4/24) 
Mucositis & renal impairment 
16.6% (4/24) 
BM suppression 8.3% (2/24) 
Mucositis 29% (14/48) 
BM toxicity 25% (12/48) 
Infection 23% (11/48)  
Mucositis & BM suppression 
12.5% (6/48) 
Mucositis & renal impairment 8% 
(4/48) 
Elevated liver enzymes 4% 
(2/48) 
Renal impairment 4% (2/48) 
Reason for early 
termination of MTX 
treatment 
Renal impairment 50% (6/12) 
Mucositis 50% (6/12) 
Renal impairment  2/3 
Patient’s request 1/3 
Days to clear MTX 2-9 (median: 3, average 3.7) 2->10 (median: 3, average 3.11) 
24 hr MTX plasma 
level 
2.95 -115.66 µM  
(median: 25.89 µM, average 
40.30 µM) 
1.61 -160.63 µM  
(median: 12.13 µM, average 
17.5 µM) 
 
CONCLUSIONS 
 There was only a small difference in the number of subsequent chemotherapy 
delays due to MTX toxicity in the studied patient groups. In the ≥ 40 year-group, 
58.5% (24/41) of MAP cycles were delayed due to MTX related toxicity. In the < 
40 year-group, 52.2% (48/92) of MAP cycles were delayed due to MTX related 
toxicity.  
 There was a large difference in the number of received MTX courses. In the ≥ 
40 year-group, treatment with MTX was stopped early in 15/16 patients and only 
1/6 of patients completed all planned 12 MTX courses. In 12/15 of patients, 
MTX treatment was stopped early due to MTX related toxicity. In the < 40 year-
group, treatment with MTX was stopped early in 5/25 of patients. In 3/5 of 
patients treatment with MTX was stopped early due to MTX related toxicity. 
15/25 of patients completed all planned 12 MTX courses. 
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4. VALIDATION OF MEASUREMENT OF MTX AND DAMPA IN HUMAN 
PLASMA WITH HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
(HPLC) 
4.1. INTRODUCTION 
DAMPA, the catabolic product of glucarpidase action on MTX, is known to cross-
react with MTX in most commercial immunological MTX assays (Albertioni et al. 
1996; Widemann et al. 1997). Therefore, a HPLC assay for the evaluation of plasma 
MTX and DAMPA levels for trial patients was validated. The bioanalytical method is 
based on a published HPLC method (Albertioni et al. 1995).  
In a previous validation study carried out by Protherics plc / Huntington Life 
Sciences Limited, fluorescence detection was used (personal correspondence; 
Study PTU/018: “Validation of a high performance liquid chromatographic method 
for measurement of methotrexate and DAMPA in human plasma”). However, in our 
laboratory UV detection at 313 nm was shown to produce a better linear standard 
curve over the range of 0-50 µmol/L for both MTX and DAMPA. MTX had a lower 
limit of detection at 0.2 µmol/L compared with 0.5 – 1 µmol/L for DAMPA (Figure 4a, 
5b and 5c). 
The method involved the extraction of MTX and DAMPA from aliquots of human 
plasma (1 mL) mixed with hydrochloric acid (111 µL, 1 M) using C18 Strata™ (500 
mg, 3 mL) extraction cartridges. The extraction cartridges were conditioned with 
methanol (3 mL), water (3 mL) and sodium phosphate buffer (2 X 3 mL, 0.1 M, pH 
6.5). The acidified plasma sample was applied to the cartridge which was then 
washed with sodium phosphate buffer (3 mL, 0.1 M, Ph 6.5). MTX and DAMPA were 
eluted from the extraction cartridges with methanol (3 mL) and the eluates were 
evaporated to dryness under a stream of nitrogen at nominally +50°C. The residues 
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were reconstituted in mobile phase (200 µL) and aliquots (10 µL) were injected onto 
a Phenomenex Luna 5 µ, C18 (2) 100A, (150 X 4.6 mm) analytical column. MTX 
and DAMPA were chromatographed isocratically and detected by UV at 313 nm. A 
comprehensive description of the method is described in Section 4.4. The assay 
was validated producing standard curves for MTX and DAMPA in both buffer and 
plasma and running the analysis to test linearity, precision, accuracy, sensitivity, 
recovery, specificity, dilution and stability. 
Figure 4: REPRESENTATIVE STANDARD CURVES WITH UV AND 
FLUORESCENCE DETECTION  
MTX and DAMPA standards were prepared in phosphate buffer at concentrations of 
0.2, 0.5, 1, 5, 10, 20, and 50 M. These were run on the standard HPLC method 
and processed both with UV (313 nm) and fluorescence (excitation 350 nm, 
emission 435 nm) detection. Figures 5b and 5c show that UV detection gives linear 
response from 0-50 M, whereas the fluorescence detection shows linearity from 0-
20 M only (Figure 4a). Therefore UV detection (313 nm) has been used throughout 
this validation report. 
Figure 4a: FLU CURVES 
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Figure 4b: DAMPA UV ANALYSIS 
 
Figure 4c: MTX UV ANALYSIS 
 
 
4.2. STUDY SCHEDULE 
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4.3. TEST SUBSTANCES 
MTX 
Lot/batch no.              : 044K07351 
Grade/purity               : 99% 
Supplied by                 : SIGMA-ALDRICH 
Storage                      : Room temperature 
Molecular weight         : 454.44 
Chemical structure      :  
 
 
DAMPA 
Lot/batch no.              : 11502KC 
Grade/purity               : 95% 
Supplied by                 : SIGMA-ALDRICH 
Storage                      : Room temperature 
Molecular weight         : 343.56 
Chemical structure      : 
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4.4. BIOANALYTICAL METHOD 
a. Instrumentation 
Waters 2695 Separations Module  
Waters 2996 Photodiode Array Detector 
Empower Pro software 
b. Equipment 
Analytical balance: Sartorius Research, R160P 
Automatic pipettes: FinnPipette®, various sizes 
Centrifuge: Heraeus Megafuge 1.0 and Eppendorf Centrifuge 5415D 
Filtration apparatus: Millipore (UK) Ltd, Watford, UK, 0.2 µ 
Micro test tubes: Ependorf® tubes, VWR, International, Poole, UK 
pH meter: Hanna Instruments, pH 210, VWR, International, Poole, UK 
Sample concentrator: SC-2, DB3, Techne Ltd, Cambridge, UK 
Solid phase cartridges: Strata™ C18 (500 mg, 3 ml), Phenomenex, Macclesfield 
SPE apparatus: Spe-ed Mate™-30, Applied Separations, Lehigh Valley, PA, USA 
Top-loading balance: METTLER PJ400 
Vortex mixer: AUTOVORTEX MIXER SA2, STUART SCIENTIFIC, UK 
Water purification: USF ELGASTAT, Elga Ltd, High Wycombe, UK 
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c. Test Substances 
Methotrexate was stored in a closed container, in the dark, with a desiccant at 
nominally -20°C. DAMPA was stored in a closed container, in the dark, with a 
desiccant at room temperature.  
d. Materials 
Acetonitrile: HPLC grade, Rathburn Chemicals, RH1016 
Blank human plasma: Plasma pool from UCLH Blood Bank 
Dimethylsulfoxide (DMSO): BDH AnalaR, VWR, International, Poole, UK 
Hydrogen Peroxide (H202): 30% solution in water (w/w), SIGMA ALDRICH 
Methanol: HPLC grade, Rathburn Chemicals, RH1019 
Sodium dihydrogen orthophosphate dihydrate: BDH AnalaR, VWR, International, 
Poole, UK 
Disodium hydrogen orthophosphate dihydrate: BDH AnalaR, VWR, International, 
Poole, UK 
Water: Ultra High purity (UHP) grade obtained from Elgastat water purification 
system 
e. Reagents 
Sodium dihydrogen orthophosphate dihydrate (0.1M) 
This was prepared by dissolving sodium dihydrogen orthophosphate dihydrate 
(15.601 g) in water and making up to a final volume (1000 ml) with water. 
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Disodium hydrogen orthophosphate dihydrate (0.1M) 
This was prepared by dissolving disodium hydrogen orthophosphate dihydrate 
(17.789 g) in water and making up to a final volume (1000 ml) with water. 
Phosphate buffer (0.1M, pH 6.5) 
This was prepared by mixing sodium dihydrogen orthophosphate dehydrate solution 
(0.1 M) and disodium hydrogen orthophosphate dihydrate solution (0.1 M) in a ratio 
2:1 and checking the pH. 
Mobile Phase 
The Solvent Manager System mixed the mobile phase 90:10 of a:b where a = 
phoshate buffer (900 ml, 0.1 M, pH 6.5) plus 2 ml 30% w/w hydrogen peroxide, and 
b = acetonitrile. Buffer a was filtered and degassed by vacuum filtration through 
glass fibre filter paper. The final mobile phase was degassed by on-line vacuum 
degassing. 
Column wash 
100% water wash, followed by 50% acetonitrile & 50% water wash. Additionally, 
after every 5 assays 100% water wash, followed by 50% acetonitrile & 50% water 
wash, followed by 100% acetonitrile wash, followed by 50% acetonitrile & 50% water 
wash. Each stage run for 15 min. 
Needle wash 
This was prepared by mixing 50% methanol and 50% water. 
All reagents were stored at room temperature (nominally +22°C), unless stated 
otherwise, and used for up to one month, except for the buffer phosphate which was 
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mixed with hydrogen peroxide (part of the mobile phase) which was used for up to 
15 days. Different volumes of reagents were prepared on a pro rata basis. 
f. Standard Solutions 
MTX primary standard solution (10 mmol/L) 
A primary standard solution of MTX was prepared at concentration of 10 mmol/L by 
accurately weighing methotrexate and dissolving it in DMSO to a concentration of 
4.54 mg/ml (~10 mmol/L). 
DAMPA primary standard solution (10 mmol/L) 
A primary standard solution of DAMPA was prepared at concentration of 10 mmol/L 
by accurately weighing DAMPA and dissolving it in DMSO to a concentration of 3.43 
mg/ml (~10 mmol/L). 
MTX and DAMPA secondary standard solution (1 mmol/L) 
The MTX primary standard solution (1 mmol/L) and DAMPA primary standard 
solution (1mmol/L) were prepared by 10-fold dilution with phosphate buffer (0.1 
mmol/L, pH 6.5). 
MTX and DAMPA working standard solutions 
Aliquots of appropriate MTX and DAMPA standard solutions were transferred to 
Eppendorf® tubes and diluted with phosphate buffer (0.1 mmol/L, pH 6.5) to produce 
working standard solutions at concentrations of 0.4-40 µmol/L of MTX and DAMPA 
as detailed below: 
Concentration of 
standard solution 
(µmol/L) 
Volume of standard 
solution (L) 
Final volume (L) 
Concentration of 
working standard 
(µmol/L) 
1000 40 1000 40 
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Concentration of 
standard solution 
(µmol/L) 
Volume of standard 
solution (L) 
Final volume (L) 
Concentration of 
working standard 
(µmol/L) 
1000 20 1000 20 
20 500 1000 10 
40 100 1000 4 
20 100 1000 2 
10 100 1000 1 
4 100 1000 0.4 
 
All standard solutions were stored in the dark at nominally +4°C in Eppendorf® 
tubes. Different volumes of standards were prepared on a pro rata basis. 
g. Calibration Standards 
Equal aliquots of MTX and DAMPA working standard solutions (100 L) were mixed 
together to produce buffer calibration standards at concentrations of 0.2-20 µmol/L. 
h. Quality Control Samples 
QC samples were prepared independently for use during method validation, and to 
monitor the performance of the method during routine sample analysis. These were 
prepared in bulk by the addition of MTX and DAMPA standards in phosphate buffer 
(0.1 M, pH 6.5) to Eppendorf® tubes and made up to volume with blank plasma to 
give concentrations of 0.1, 0.2, 0.5, 10 and 50 µmol/L as detailed below: 
Concentration of 
standard solution 
(µmol/L) 
Volume of 
standard solution 
(L) 
Final volume (mL) 
Concentration of QC 
(µmol/L) 
2 500 10 0.1 
4 500 10 0.2 
10 500 10 0.5 
200 500 10 10 
1000 500 10 50 
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The bulk QC samples were divided into 1 mL aliquots and stored in Eppendorf® 
tubes at nominally -20°C until taken for analysis. 
i. Dilution Samples 
In many circumstances, it was necessary to dilute test samples with expected 
analyte concentrations greater than the highest calibration standard in order to be 
able to measure the analyte in the validated calibration range. For example, a 1 in 
10 dilution factor was validated by dilution of the highest QC standard (50 mol/L) 
with blank plasma before being extracted and analysed. 
j. System Suitability  
Prior to analysis of a batch of samples, a standard mixture containing MTX and 
DAMPA in phosphate buffer (0.1mmol/L, pH 6.5) was injected to check the 
performance of the chromatographic system in terms of retention times, peak 
shapes, resolution and instrument response. 
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k. Sample Preparation Procedure 
 
l. Chromatography Conditions 
Auto sampler           Injection volume: 10 µL 
                     Analysis time: 11 min 
          Sample temperature: ambient (nominally +22°C) 
Pump                      Flow rate: 1 mL/minute 
Detector                  Waters 2996 Photodiode Array Detector monitoring at 313 nm 
Analytical column    Luna 5u C18 (2) 100A, Phenomenex 
Guard column         C18 (ODS, Octadecyl, 4 mm L x 3.0 mm ID), Phenomenex. 
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Mobile phase           Phosphate buffer (0.1 M, pH 6.5): acetonitrile: hydrogen 
peroxide (2 ml, 30% w/w) (90:10:0.2, v/v/v) 
Software                   Empower Pro 
Under these conditions the retention times of MTX and DAMPA were expected to be 
ca 4-5 minutes and ca 9 minutes respectively (Figure 6). 
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Figure 5: REPRESENTATIVE CHROMATOGRAMS OF CALIBRATION 
STANDARDS EXTRACTS MADE UP IN PLASMA 
 
         Std 1: 0.2 µmol/L of MTX and DAMPA 
                      Std 2: 0.5 µmol/L of MTX and DAMPA 
          Std 3: 1 µmol/L of MTX and DAMPA 
         Std 4: 2 µmol/L of MTX and DAMPA 
         Std 5: 5 µmol/L of MTX and DAMPA 
         Std 6: 10 µmol/L of MTX and DAMPA 
         Std 7: 20 µmol/L of MTX and DAMPA 
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m. Data Processing 
All data was processed using Empower Pro, Waters, 2002 software. 
4.5. DATA FORMAT AND STATISTICS 
All plasma concentrations of methotrexate and DAMPA measured as part of the 
study were reported to 3 significant figures. All statistics (e.g. mean, SD, CV (%) and 
RE (%)) presented in this report were based upon the rounded numbers from the 
original database. 
4.6. UNEXPECTED EVENTS 
Incorrect preparation of DAMPA standards on 23 January 2007 
4.7. LOCATION OF STUDY RECORDS 
This report was compiled from original data generated in the Department of 
Oncology, University College London, 91 Riding House Street, London, W1W 7BS. 
All the original data has been stored on password controlled COMPAC PC initially at 
the Department of Oncology, University College London, 91 Riding House Street, 
London, W1W 7BS and subsequently at the Department of Oncology, University 
College London, the Paul O’Gorman Building, 72 Huntley Street, London, WC1E 
6BT. The data were backed up to a CD and stored in fireproof safe on the 4th floor of 
the Paul O’Gorman Building, 72 Huntley Street, London, WC1E 6BT. 
4.8. RESULTS 
a. Linearity 
 MTX gave a linear standard curve over the range 0-50 M with UV detection at 
313nm. Mean R squared value was 0.997 (Table 12 and Figure 4c). 
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 DAMPA gave a linear standard curve over the range 0-50 M with UV detection 
at 313 nm. Mean R squared value was 0.996 (Table 12 and Figure 4b). 
Representative chromatograms of extracts of plasma spiked with calibration 
standards are shown in Figure 6. Daily calibration measurements are summarised in 
Table 13. 
Table 12: BUFFER STANDARDS PROCESSED WITH UV AND 
FLUORESCENCE DETECTION 
Conc M 
MTX PK Area 
FLU 
DAMPA PK 
Area FLU 
MTX PK Area 
UV 
DAMPA PK 
Area UV 
0.2 77404 140999 2058  
0.5 191446 340869 6236  
1 362716 690589 13223 6437 
5 1541751 3208191 64877 27762 
10 2906894 5727359 119932 55122 
20 5507770 9887589 236241 111971 
50 9272649 17648658 607423 277641 
R
2
 0.968 0.961 0.999 1.000 
 
Table 13: DAILY CALIBRATION MEASUREMENTS 
MTX: Calibration parameters 
Date of analysis Slope Intercept R Squared 
14-Feb-07 10700 0 0.998 
19-Feb-07 10000 0 0.997 
22-Feb-07 11000 0 0.994 
15-March-07 10000 0 0.999 
Mean 10425 0 0.997 
SD 438   
CV (%) 4.2   
MTX: Measured values of peak area 
Concentration 
(µmol/L) 
14 Feb 
07 
19 Feb 
07 
22 Feb 
07 
15 Mar 
07 
Mean SD 
CV 
(%) 
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Table 13: DAILY CALIBRATION MEASUREMENTS 
0.2 1926 1678 2103 2578 2071.25 380.152 18 
0.5 4684 4678 5563 5746 5167.75 566.999 10 
1 10289 10024 10469 9861 10160.75 270.811 2.7 
2 22150 20518 22629 22022 21829.75 912.690 4.1 
5 54738 52325 49279 49470 51453 2595.520 5.0 
10 94972 88858 89414  91081 3380.865 3.7 
20 208316 205559 223931 225786 215898 10435.249 4.8 
MTX: Back-calculated values of concentration 
Concentration 
(µmol/L) 
14 Feb 
07 
19 Feb 
07 
22 Feb 
07 
15 Mar 
07 
Mean SD 
CV 
(%) 
0.2 0.19 0.17 0.19 0.23 0.195 0.02516 12 
0.5 0.46 0.47 0.5 0.51 0.485 0.02380 4.9 
1 1 1  0.88 0.960 0.06928 7.2 
2 2.15 2 2 1.96 2.030 0.08381 4.1 
5 5.3 5.22 4.4 4.4 4.830 0.49759 10 
10 9.24 8.9 8.7  8.970 0.27300 3.0 
20 20.3 20.5 20.8 20 20.400 0.33665 1.6 
DAMPA: Calibration parameters 
Date of analysis Slope Intercept R Squared 
14-Feb-07 4640 0 0.998 
19-Feb-07 4690 0 0.996 
22-Feb-07 5200 0 0.996 
15-March-07 
4710 0 0.996 
 
Mean 4810 0 0.9965 
SD 226   
CV (%) 4.7   
DAMPA: Measured values of peak area 
Concentration 
(µmol/L) 
14 
Feb 
07 
19 Feb 
07 
22 Feb 
07 
15 Mar 
07 
Mean SD 
CV 
(%) 
0.5 1714 1541 2622 3563 2360 931.652 39 
1 3147  4968 5461 4525.33 1218.857 26 
2 7469 8203 9569 9279 8630 971.797 11 
5 24820 23274 21922 23238 23313 1185.056 5.0 
10 42659 41179 46421 51296 45388 4514.224 9.9 
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Table 13: DAILY CALIBRATION MEASUREMENTS 
20 94500 96796 
10801
4 
10069
9 
100002 5922.510 5.9 
DAMPA: Back-calculated values of concentration 
Concentration 
(µmol/L) 
14 
Feb 
07 
19 Feb 
07 
22 Feb 
07 
15 Mar 
07 
Mean SD 
CV 
(%) 
0.5 0.37 0.33 0.5 0.7 0.475 0.16663 35 
1 0.68  0.95 1.08 0.903 0.20404 22 
2 1.6 1.7 1.8 1.8 1.725 0.09574 5.5 
5 5.3 4.9 4.2 4.6 4.750 0.46547 9.7 
10 9.2 8.8 8.9 10.2 9.270 0.63966 6.8 
20 20.4 20.6 20.7 20 20.420 0.30956 1.5 
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Figure 6: REPRESENTATIVE CHROMATOGRAMS OF BLANK PLASMA 
EXTRACTS 
 
 
Blank plasma sample 1 
Blank plasma sample 2 
Blank plasma sample 3 
Blank plasma sample 4 
Blank plasma sample 5 
Blank plasma sample 6 
Blank plasma pool (from UCLH Blood Bank) 
b. Precision 
 Within batches of extracted plasma samples spiked with 0.1-10 µmol/L MTX and 
DAMPA, prepared on three separate dates and each analysed 3-5 times, CV’s 
of MTX analysis ranged from 2.3-10%, mean 5.2% (analysed 5 times between 
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15-21 Nov 2006), 7.0-11.2%, mean 8.5% (analysed 5 times between 4-8 Dec 
2006) and 6.3-17.3%, mean 9.6% (analysed 3 times between 14-16 Feb 2007) 
(Table 14). 
 Within batches of extracted plasma samples spiked with 0.1-10 mol/L MTX and 
DAMPA, prepared on three separate dates and each analysed 3-5 times, CV’s 
of DAMPA analysis ranged from 3.6-5.9%, mean 4.1% (analysed 5 times 
between 15-21 Nov 2006), 1.9-9.7%, mean 4.1% (analysed 5 times between 
Dec 4-8) and 4.3-11.7%, mean 4.4% (analysed 3 times between 14-16 Feb 
2007) (Table 14). 
 The overall mean CV’s for the three batches were 6.2-13.6% for MTX and 4.2-
6.5% for DAMPA (Table 15).  
 Variations between extracted plasma samples, spiked with MTX and DAMPA 
(0.1-10 mol/L) from three separate weighings of primary standards were low. 
CV values were 8.7-9.9% (mean 8.3%) and 1.5-4.6% (mean 3.6%) respectively 
refer to (Table 16).  
Table 14: WITHIN-BATCH PRECISION AND ACCURACY MEASUREMENTS 
MTX Batch 1 (extracted on 15 Nov 2006, analysed on 15,16,17,20 and 21 Nov 2006) 
Concentration 
(µmol/L) 
15 
Nov 
16 
Nov 
17 
Nov 
20 
Nov 
21 
Nov 
Mean SD 
CV 
(%) 
RE 
(%) 
0.1 0.11 0.092 0.12 0.1 0.11 0.100 0.01071 10 6.4 
0.2 0.19 0.19 0.22 0.19 0.2 0.200 0.01303 6.5 -1.0 
0.5 0.54 0.52 0.55 0.492 0.51 0.520 0.02321 4.4 4.0 
1 1.02 1.12 1.1 1.01 1.06 1.060 0.04816 4.5 2.6 
2 2.1 2 2.2 2.06 2.2 2.110 0.08786 4.1 5.6 
5 4.82 4.9 5.2 5.14 5.3 5.070 0.20376 4.0 1.4 
10 10.5 10.5 11 10.7 11 10.700 0.25099 2.3 7.4 
MTX Batch 2 (extracted on 4 Dec 2006, analysed on 4, 5, 6, 7 and 8 Dec 2006) 
Concentration 
(µmol/L) 
4 Dec 5 Dec 6 Dec 7 Dec 8 Dec Mean SD 
CV 
(%) 
RE 
(%) 
0.2 0.18 0.19 0.21  0.16 0.185 0.0208 11.2 -7.5 
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Table 14: WITHIN-BATCH PRECISION AND ACCURACY MEASUREMENTS 
0.5 0.48 0.56 0.49 0.45 0.49 0.494 0.0404 8.2 -1.2 
1 1 1.08 1.02 0.9  1.000 0.0748 7.5 0 
2 1.96 2.18 1.99 1.75 1.9 1.956 0.1556 7.9 -2.2 
5 5.18 5.3 5.3 4.5 4.8 5.016 0.3539 7.0 0.3 
10 10.56 11.2 10.8 8.9 9.6 10.212 0.9406 9.2 2.0 
MTX Batch 3 (extracted on 14 Feb 2007 and analysed on 14, 15 and 16 Feb 2007) 
Concentration 
(µmol/L) 
14 Feb 15 Feb 16 Feb Mean SD 
CV 
(%) 
RE 
(%) 
0.1 0.11 0.11 0.08 0.1 0.01732 17 0 
0.2 0.19 0.17 0.19 0.18 0.01154 6.2 -10 
0.5 0.46 0.48 0.38 0.44 0.05291 12 -12 
10 10 10.2 8.8 9.66 0.75718 7.8 -3.4 
DAMPA Batch 1 (extracted on 15 Nov 2006, analysed on 15,16,17,20 and 21 Nov 2006) 
Concentration 
(µmol/L) 
15 
Nov 
16 
Nov 
17 
Nov 
20 
Nov 
21 
Nov 
Mean SD 
CV 
(%) 
RE 
(%) 
0.5 0.46 0.5 0.5 0.54 0.52 0.500 0.02966 5.8 0.8 
1 1.06 1.05 1.06 1.14 1.06 1.070 0.03714 3.4 7.4 
2 2.16 2.36 2.18 2.32 2.34 2.270 0.09444 4.1 13.6 
5 5.04 5.52 5.1 5.2 5.3 5.230 0.18899 3.6 4.6 
10 12 13.08  12.4 12.4 12.400 0.44825 3.5 24.7 
DAMPA Batch 2 (extracted on 4 Dec 2006, analysed on 4, 5, 6, 7 and 8 Dec 2006) 
Concentration 
(µmol/L) 
4 Dec 5 Dec 6 Dec 7 Dec 8 Dec Mean SD 
CV 
(%) 
RE 
(%) 
0.5 0.48 0.54 0.46 0.5 0.44 0.484 0.03847 7.9 -3.2 
1 0.92 1.12 1.12 0.94 0.97 1.014 0.09838 9.7 1.4 
2 1.92 1.78 1.94 1.96  1.900 0.08164 4.2 -5 
5 5.5 4.6 5.04 5.5 4.74 5.076 0.41842 8.2 1.52 
10  9.26   9.52 9.390 0.18384 1.9 -6.1 
DAMPA Batch 3 (extracted on 14 Feb 2007 and analysed on 14, 15 and 16 Feb 2007) 
Concentration 
(µmol/L) 
14 Feb 15 Feb 16 Feb Mean SD CV (%) 
RE 
(%) 
0.5 0.46 0.48 0.44 0.460 0.02 4.3 -8.0 
5 4.9 4.9 5 4.930 0.05773 1.1 -1.4 
10 10.7 9.22 10.3 10.070 0.76559 7.6 0.7 
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Table 15: OVERALL-BATCH PRECISION AND ACCURACY MEASUREMENTS 
 
MTX concentration 
(µmol/L) 
Mean SD CV (%) RE (%) n 
Summary of combined measurements in batches 1 to 3 for MTX and DAMPA 
0.1 0.103 0.01401 13.6 0 8 
0.2 0.189 0.01513 8.0 -5 12 
0.5 0.485 0.03883 7.9 -4 13 
1 1.031 0.06149 5.9 3 9 
2 2.034 0.12176 5.9 1.5 10 
5 5.044 0.27885 5.5 0.8 10 
10 10.476 0.64959 6.2 4.8 13 
DAMPA Concentration 
(µmol/L) 
Mean SD CV (%) RE (%) n 
0.5 0.483 0.02937 6.0 -4 13 
1 1.044 0.06776 6.5 4 10 
2 2.086 0.08804 4.2 4.5 9 
5 5.080 0.22171 4.3 1.6 13 
10 10.644 0.46589 4.3 6.4 9 
 
Table 16: PRIMARY STANDARDS STABILITY IN PLASMA  
MTX 
(µmol/L) 
Spike A Spike B Spike C Mean SD CV (%) 
0.2 0.18 0.21 0.21 0.200 0.01732 8.6 
0.5 0.46 0.55 0.52 0.510 0.04582 8.9 
1 0.93 1.05 1.04 1.000 0.06658 6.6 
2 1.83 2.18 2 2.000 0.17502 8.7 
5 4.7 5.3 5.4 5.130 0.37859 7.3 
10 9.12 10.9 10.9 10.300 1.02768 9.9 
DAMPA 
(µmol/L) 
Spike A Spike B Spike C Mean SD CV (%) 
5 4.99 4.6 5 4.860 0.22810 4.6 
10 9.9 10.3 10.7 10.300 0.40000 3.8 
20 20.1 20.6 20 20.230 0.32145 1.5 
50 49.9 46.1 49.7 48.560 2.13853 4.4 
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c. Accuracy 
Within batches of extracted plasma samples spiked with 0.1-10 mol/L MTX and 
DAMPA, prepared on three separate dates and each analysed 3-5 times, RE’s of 
MTX analysis ranged from -1 to 7.4% (15-21 Nov 2006), -7.5 to 2% (4-8 Dec 2006) 
and -12 to 0% (14-16 Feb 2007), (Table 14). 
Within batches of extracted plasma samples spiked with 0.1-10 mol/L MTX and 
DAMPA, prepared on three separate dates and each analysed 3-5 times, RE’s of 
DAMPA analysis ranged from 0.8 to 24.7% (15-21 Nov 2006), -6.1 to 1.5% (4-8 Dec 
2006) and -8 to 0.7% (14-16 Feb 2007), (Table 14). 
The overall mean RE’s for the three batches were -5 to 4.8 % for MTX and -4 to 
6.4% for DAMPA, (Table 15).  
d. Sensitivity (Lower limit of quantification) 
At 0.2 µmol/L the QC precision for MTX is 3.4% and the inaccuracy of measurement 
is 15% (Table 17). 
At 0.5 µmol/L the QC precision for DAMPA is 11% and the inaccuracy of 
measurement is 0% (Table 17). 
 
Table 17: QC STABILITY IN PLASMA 
MTX 
QC 
Jan-23 Feb-13 Mar-21 Mean SD CV (%) 
0.1 0.099 0.11 0.08 0.096 0.01517 15 
0.2 0.16 0.17 0.17 0.166 0.00577 3.4 
0.5  0.48 0.43 0.455 0.03535 7.7 
10 9.6 10.2 9.6 9.800 0.34641 3.5 
*50 45 46.5 55 48.833 5.39289 11 
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DAMPA 
QC 
Jan-23 Feb-13 Mar-21 Mean SD CV (%) 
0.2 ** 0.14 0.21 0.175 0.04949 28 
0.5 ** 0.46 0.54 0.500 0.05656 11 
10 ** 10.7 9.4 10.050 0.91923 9.1 
*50 ** 49 54 51.500 3.53553 6.8 
*Sample diluted 10 fold for analysis 
** Incorrect buffer standard prepared 
e. Recovery 
 Mean recovery of MTX from plasma samples spiked with MTX and DAMPA at 
0.2 mol/L, 0.5 mol/L and 10 mol/L, was 100.48%, CV 10.9% and 100.6%, 
CV 7.6% and 101.96%, CV 3.2% respectively (Table 18). 
 Mean recovery of DAMPA from plasma samples spiked with MTX and DAMPA 
at 0.5 mol/L and 10mol/L, was 100.99%, CV 7.2% and 101.3%, CV 5.8% 
respectively (Table 18). 
Table 18: RECOVERY 
Analyte 
Theoretical 
Concentration 
(mol/L) 
Mean recovery 
(%) 
SD CV (%) n 
MTX 
0.2 100.48 11.03 10 5 
0.5 100.63 7.64 7.5 5 
10 101.96 3.30 3.2 5 
DAMPA 
0.5 100.99 7.28 7.2 5 
10 101.30 5.82 5.7 5 
 
f. Specificity 
HPLC analysis of plasma samples from 6 healthy volunteers showed no interfering 
peaks at the retention times for MTX and DAMPA (Figure 7). 
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There was an endogenous peak with a retention time of ca 1-2 minutes in the 
chromatograms of human plasma extracts, but it did not have any effect on the 
measurement of MTX and DAMPA. 
Chromatograms of buffer and calibration standards demonstrate that there was no 
carry-over between injections as shown in Figure 8. 
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Figure 7: REPRESENTATIVE CHROMATOGRAMS DEMONSTRATING THE 
ABSENCE OF CARRY-OVER 
 
_______ Buffer injection (date acquired: 14/02/2007 at 13.37) 
_______ Calibration standard injection (date acquired: 14/02/2007 at 13.21) 
 
g. Dilution 
 A 10-fold dilution of plasma samples containing 50 or 100 mol/L MTX and 
DAMPA gave good agreement with the theoretical concentration. RE values for 
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MTX were -8.4 at 50 mol/L and 4.5 at 100 mol/L. RE values for DAMPA were 
-3.2 at 50 mol/L and 11.25 at 100 mol/L (Table 19). 
 A 100-fold dilution of plasma samples containing 1000 mol/L MTX and DAMPA 
gave good agreement with the theoretical concentration. RE value for MTX was 
-8.0 and 2.5 for DAMPA (Table 19). 
Table 19: PRECISION AND ACCURACY MEASUREMENTS IN PLASMA 
AFTER DILUTION  
Theoretical MTX concentration (mol/L), analysed on 29 March 2007 
Before 
dilution 
After 
dilution 
Measured 
Concentration 
(mol/L) 
Mean 
Concentration 
(mol/L) 
SD CV (%) RE (%) 
50 5 
4.6 
4.58 0.14 3.0 -8.4 
4.74 
4.4 
4.6 
100 10 
10.0 
10.450 0.72 6.88 4.5 
10.6 
9.8 
11.4 
1000 10 
9.8 
9.20 0.40 4.3 -8.0 
9.0 
9.0 
9.0 
Theoretical DAMPA concentration (mol/L), analysed on 29 March 2007 
Before 
dilution 
After 
dilution 
Measured 
Concentration 
(mol/L) 
Mean 
Concentration 
(mol/L) 
SD CV (%) RE (%) 
50 5 
4.92 
4.840 0.24 4.97 -3.2 
4.6 
5.14 
4.7 
100 10 
10.5 
11.125 0.45 4.1 11.25 11.2 
11.2 
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Table 19: PRECISION AND ACCURACY MEASUREMENTS IN PLASMA 
AFTER DILUTION  
11.6 
1000 10 
9.6 
10.250 0.55 5.3 2.5 
10.0 
10.6 
10.8 
h. Stability 
Primary standards stability 
Primary standards made in DMSO on 10 October 2006, 21 November 2006 and 7 
December 2006, at a concentration of 10 mmol/L, were stable for at least 3 months 
at -20°C (Table 16). Spikes A, B and C were prepared in plasma and run on 5 
January 2007, using primary standards made in DMSO on 10 October 2006, 21 
November 2006 and 7 December 2006, respectively. Short and long term freeze-
thaw stability (4 cycles) of primary standards was demonstrated (Table 20, Figure 
8a, Figure 8b). 
Table 20: STABILITY OF MTX AND DAMPA PRIMARY STANDARDS, 4x 
FREEZE-THAW CYCLES 
MTX 
Concentration 
(µmol/L) 
F/T 1 
(peak 
area) 
F/T 2 
(peak 
area) 
F/T 3 
(peak 
area) 
F/T 4 
(peak 
area) 
Mean 
(peak 
area) 
SD 
CV 
(%) 
0.2 2058 2255 2630 2224 2291.75 241.517943 10.5 
0.5 6236 5973 6617 5668 6123.5 402.628447 6.5 
1 12223 12435 12133 10289 11770 995.416831 8.4 
5 64877 60376 59049 59738 61010 2634.3342 4.3 
10 119932 125719 118477  121376 3830.86061 3.1 
20   239410 225399 232404.5 9907.27311 4.2 
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DAMPA 
Concentration 
(µmol/L) 
F/T 1 
(peak 
area) 
F/T 2 
(peak 
area) 
F/T 3 
(peak 
area) 
F/T 4 
(peak 
area) 
Mean 
(peak 
area) 
SD 
CV 
(%) 
1 3805 3945 3821 3742 3828.25 84.975977 2.2 
5 24513 25730 25390 22352 24496.25 1518.66353 6.2 
10 47970 49429 52689 49607 49923.75 1984.00729 3.9 
20 100246 99047 104539 102976 101702 2506.03312 2.4 
50 277641 256386 288355 276375 274689.25 13333.12 4.8 
 
Figure 8: STABILITY OF MTX AND DAMPA PRIMARY STANDARDS, 4 x 
FREEZE-THAW CYCLES 
Figure 8a: STABILITY OF PRIMARY MTX STANDARD 
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Figure 8b: STABILITY OF PRIMARY DAMPA STANDARD  
 
Callibration standards stability 
Calibration standards made from primary standards (prepared on 7 December 
2006), prepared on 13 December and run on HPLC on 14 February 2007, 22 
February 2007 and 15 March 2007, remained stable for 1 month at 4°C. However, 
the CVs from lower concentrations of DAMPA were high (Table 21). 
Table 21: CALIBRATION STANDARDS STABILITY 
MTX 
(buffer) 
Feb-14 
(peak 
area) 
Feb-22 
(peak 
area) 
Mar-15 
(peak 
area) 
Mean (peak 
area) 
SD CV (%) 
0.2 1926 2103 2578 2202.330 337.15921 15 
0.5 4684 5563 5746 5331.000 567.74025 10 
1 10289 10469 9861 10206.330 312.31607 3.0 
2 22150 22629 22022 22267.000 319.96718 1.4 
5 54738 49279 49470 51162.330 3098.0904 6.0 
10 94972 89414  92193.000 3930.0994 4.2 
20 208316 223931 225786 219344.330 9595.7468 4.3 
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DAMPA 
(buffer) 
Feb-14 
(peak 
area) 
Feb-22 
(peak 
area) 
Mar-15 
(peak 
area) 
Mean (peak 
area) 
SD CV (%) 
0.5 1714 2622 3563 2633.000 924.54907 35 
1 3147 4968 5461 4525.330 1218.8577 26 
2 7469 9569 9279 8772.330 1137.99531 12 
5 24820 21922 23238 23326.660 1451.03319 6.2 
10 42659 46421 51296 46792.000 4330.43565 9.2 
20 94500 108014 100699 101071.000 6764.67567 6.6 
 
Extracted samples stability 
Extracted samples gave reproducible results stable for 1 week at 4°C. They were 
prepared on 15 November 2006 and run on 15, 16, 17 20, 21 November 2006 
(Table 14). 
QCs (frozen plasma samples) 
QCs (frozen plasma samples) were stable for over a month at -20°C. They were all 
prepared on 22 January 2007 using primary standards weighed on 7 December 
2006. Plasma samples were spiked, stored at -20°C and then extracted and 
analysed on 23 January 2007, 13 February 2007 and 21 March 2007 (Table 17).  
i. System suitability 
Prior to analysis of a batch of samples, a standard mixture containing methotrexate 
and DAMPA in phosphate buffer (0.1 mmol/L, pH 6.5) was injected to check the 
performance of the chromatographic system in terms of retention times, peak 
shapes, resolution and instrument response. To maintain consistency of these 
parameters remedial action was taken as required (e.g. guard column replaced, 
analytical column replaced or fresh mobile phase prepared). 
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4.9. CONCLUSIONS 
In conclusion an HPLC-UV method for the measurement of MTX and DAMPA in 
human plasma has been successfully validated for use in the Department of 
Oncology, University College London, 91 Riding House Street, London, W1W 7BS 
and subsequently in the Department of Oncology, University College London, the 
Paul O’Gorman Building, 72 Huntley Street, London, WC1E 6BT, for the GLU 1 
clinical trial. 
Acceptable linearity, precision, accuracy and specificity were observed over the 
concentration ranges 0.2-50 mol/L. 
The lower limit of quantification was 0.2 µmolL for MTX and 0.5 µmolL for DAMPA. 
The recovery of MTX and DAMPA from plasma was consistent over the calibration 
range. 
There were no interfering peaks in human plasma that affected the measurement of 
MTX and DAMPA. 
Plasma samples containing concentrations of MTX and DAMPA in excess of the 
validated range could be measured precisely and accurately after a 10- or 100-fold 
dilution with blank plasma, to enable measurement up to a maximum concentration 
of 2000 mol/L using this method. 
MTX and DAMPA were shown to be stable in plasma for over a month at -20°C. 
MTX and DAMPA were also stable in extracted samples for 1 week at 4°C. Primary 
standards made in DMSO were stable for at least 3 months at -20°. Calibration 
standards remained stable for 1 month at 4°C.  
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4.10. GLOSSARY 
CV: Coefficient of variation 
HPLC: High performance liquid chromatography 
LLOQ: Lower limit of quantification 
MTX: Methotrexate 
DAMPA: 4-[[2,4-diamino-6-(pteridinyl)methyl]-methylamino] benzoic acid 
n: Number of replicates 
QC: Quality control 
R: Correlation coefficient 
RE: Relative error of measurement 
SD: Standard deviation 
UCLH: University College London Hospitals 
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5. GLU 1 CLINICAL TRIAL 
5.1. INTRODUCTION 
The two previously described reviews (Sections 3.1 and 3.2), highlighted that the 
incidence of chemotherapy delays due to MTX toxicity in patients with osteosarcoma 
is high. Early adjustment of folinic acid dose according to plasma MTX levels at 24 
hours appears to somewhat reduce the incidence of chemotherapy delay. 
Nevertheless, improving rescue from MTX toxicity seemed a worthwhile goal. 
Our second aim was to examine the role of glucarpidase in routine rescue after HD-
MTX in patients with bone sarcoma. Glucarpidase seemed to offer a promising 
opportunity for rescue from MTX toxicity and if found to be effective and safe in 
maintaining the treatment intensity and reducing the incidence and severity of MTX-
induced toxicity, could optimise treatment, improve patients’ well-being, and reduce 
the use of health resources. 
In order to investigate the role of glucarpidase in routine rescue after HD-MTX, the 
following needed to be evaluated: 
 Reduction of plasma MTX levels after glucarpidase 
 MTX related toxicity following glucarpidase 
 Comparison of toxicity related to MTX when administered with normal 
supportive measures versus MTX related toxicity following glucarpidase 
 Adverse reactions related to glucarpidase 
 Anti-glucarpidase antibody response  
The above objectives were studied in the GLU 1 trial, a randomised, cross-over, 
phase II clinical trial, to investigate the efficacy and safety of glucarpidase for routine 
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use after HD-MTX in patients with bone sarcoma, as described in details in 
Section 2.2. 
The interim analysis of the GLU 1 clinical trial took place in May 2009. The study is 
still ongoing. The results of the study up to the point of the interim analysis are 
discussed here.  
5.2. GLU 1 CLINICAL TRIAL: PATIENT CHARACTERISTICS 
All enrolled patients received appropriate for age patient or parent/guardian 
information sheet and signed an informed consent form prior to trial entry as per trial 
protocol (Appendices 2 and 4). They all had glomerular filtration rate > 70 
ml/min/1.73m2 and were able to comply with the study and follow up procedures 
(WHO performance scale 0-2). None of the patients were on concomitant anti-
cancer or investigational drugs during the study and they all had complete resolution 
of toxicity related to previous treatment. In addition, they all had life expectancy of at 
least 3 months at trial entry and complied with the GLU 1 clinical trial laboratory 
eligibility criteria. Moreover, none of the enrolled patients had previous treatment 
with glucarpidase, and no female participants were pregnant or lactating. No 
participants were on concomitant treatment with agents which interact with 
methotrexate metabolism or excretion at trial entry. One patient had a very small 
pleural effusion thought to be clinically unremarkable. 
16 patients enrolled to the GLU 1 clinical trial up to the point of the interim analysis 
of the study, between 13 June 2007 and 29 January 2009. Among them, 13 (81%) 
were male and 3 (19%) were female, with male to female ratio of 4.3:1 (Table 22). 
Patient ages ranged from 13 to 47 years with a median age at trial entry of 19 years. 
12 patients (12/16, 75%) had high grade conventional osteosarcoma, 2 patients 
(2/16, 12.5%) had high grade telangiectatic osteosarcoma and 2 patients (2/16, 
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12.5%) had high grade spindle cell sarcoma. The most frequent primary site was the 
proximal tibia in 3 patients (3/16, 18.75%), followed by the distal femur in 2 (2/16, 
12.5%) patients, distal tibia in 2 (2/16, 12.5%), proximal humerous in 2 (2/16, 12.5%) 
and pelvis in 2 (2/16, 12.5%), followed by the ribs in 1 (1/16, 6.25%) patient, 
vertebrae in 1 (1/16, 6.25%) patient, maxilla in 1 (1/16, 6.25%) patient, metatarsal in 
1 (1/16, 6.25%) patient and sphenoid bone in 1 (1/16, 6.25%) patient. 10 patients 
(10/16, 62.5%) had localised disease and 6 (6/16, 37.5%) had metastases at trial 
entry. One patient developed osteosarcoma which was likely secondary to radiation 
therapy for low grade glioma (Table 22). 
13 patients (> 80%) received some chemotherapy prior to trial entry and only 3 
(GLU1-03, GLU1-04 and GLU1-15) had no chemotherapy prior to trial entry. Seven 
patients GLU1 -05, GLU1 -08, GLU1 -09, GLU1 -10, GLU1 -11, GLU1 -13 and 
GLU1 -16) received adriamycin & cisplatin prior to trial entry. 4 patients (GLU1-02, 
GLU1-06, GLU1-07 and GLU1-14) received combination of adriamycin & cisplatin 
and HD-MTX. 1 patient (GLU1-12) received combination of adriamycin & cisplatin 
and ifosfamide & etoposide and 1 patient (GLU1-01) received combination of 
adriamycin & cisplatin, ifosfamide & etoposide and HD-MTX.  
Demographics and treatment experience for each trial participant is described in 
details in Appendix 12. 
Table 22: PATIENT CHARACTERISTICS 
 Number of patients % 
Sex 
Male 13 81 
Female 3 19 
Diagnosis 
High grade intramedullary osteosarcoma 12 75 
High grade telangiectatic osteosarcoma 2 12.5 
133 
 Number of patients % 
High grade spindle cell sarcoma 2 12.5 
Primary tumour site 
Distal femur 2 12.5 
Proximal tibia 3 18.75 
Proximal humerus 2 12.5 
Distal tibia 2 12.5 
Pelvis 2 12.5 
Vertebrae & ribs 2 12.5 
Skull & face bones 2 12.5 
Metatarsal bones 1 6.25 
Localised/metastatic disease 
Localised disease 10 62.5 
Metastatic disease 6 37.5 
Prior chemotherapy 
No prior chemotherapy 3 18.75 
AP 7 43.75 
AP & MTX 4 25 
AP & IE 1 6.25 
AP & IE & MTX 1 6.25 
Randomisation arm 
Arm B (glucarpidase in cycle 1) 7 43.75 
Arm A (glucarpidase in cycle 2) 9 56.25 
 
5.3. GLU 1 CLINICAL TRIAL: “DAY 15” ASSESSMENT ACCORDING TO 
RESCUE REGIMEN 
7 patients (7/16, 44%) were randomised to treatment arm B and received 
glucarpidase in cycle 1 and 9 patients (9/16, 56%) were randomised to treatment 
arm A and received glucarpidase in cycle 2 (Table 23). 10 patients (10/16, 62.5%) 
received all four MTX courses, one patient received three MTX courses, three 
patients received two MTX courses and two patients only managed to received one 
MTX course whilst on the GLU 1 clinical trial. The median number of MTX courses 
received per participant was 4, whereas the mean number of MTX courses was 3.2. 
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In all cases the reason for not receiving the planned four MTX courses was impaired 
renal function (Table 23). 
The primary objective of the GLU 1 study was to investigate whether glucarpidase 
rescue after HD-MTX reduces delay to subsequent cycle of chemotherapy due to 
MTX toxicity. In order to meet our primary objective trial participants were assessed 
for fitness to receive chemotherapy on day 15 of each cycle. Patients were 
considered fit to receive chemotherapy if eight criteria were fulfilled: neutrophils ≥ 
0.75x109/L or WCC ≥ 2x109/L; platelets ≥ 100x109/L; bilirubin ≤ 1.5xULN; GFR 
(estimated) ≥ 70 ml/min/1.73m2; mucositis (clinical and functional): grade ≤ 1 
(CTCAE v3.0); no clinical evidence of infection; no pyrexia; and good overall clinical 
condition. 
27 treatment cycles were given within the GLU 1 clinical trial. Among them, 14 
cycles (52%) were given with glucarpidase and folinic acid rescue and 13 cycles 
(48%) were given with folinic acid rescue (Table 23 and Table 24). Patient GLU1-05 
required emergency management with glucarpidase following unblinding of his 
treatment due to his renal impairment and delayed methotrexate excretion after the 
first dose of MTX. This patient’s data were analysed on intention to treat basis and 
his treatment was included in the group of cycles given with folinic acid rescue. 
Among the cycles given with glucarpidase and folinic acid rescue, “day 15” criteria 
were met in 8/14 (57%) cycles and not met in 6/14 (43%) cycles. Among the cycles 
given with folinic acid rescue, “day 15” criteria were met in 3/13 (23%) cycles and 
not met in 10/13 (77%) cycles. Reasons for not meeting the “day 15” criteria in the 
glucarpidase and folinic acid rescue group included impaired renal function, delayed 
MTX elimination with or without deterioration in renal function and mucositis. 
Reasons for not meeting the “day 15” criteria in the folinic acid rescue group 
included impaired renal function, delayed MTX elimination with or without 
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deterioration in renal function, mucositis, bone marrow suppression and knee 
effusion (Table 24). Overall, “day 15” criteria were not met in 59% (16/27) of all 
given cycles. 
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Table 23: NUMBER OF MTX COURSES RECEIVED AND ASSESSMENT ON DAY 15 OF EACH CYCLE ACCORDING TO TREATMENT 
ARM 
Trial patient Treatment arm 
Day 15 criteria met (YES, NO, N/A: not applicable) 
Treatment cycles with glucarpidase highlighted 
Number of MTX courses 
received 
(Reason if fewer than 4 
courses) 
Cycle 1 
(reason if NO) 
Cycle 2 
(reason if NO) 
GLU1-01 B YES 
NO 
(mucositis, bone marrow 
suppression) 
4 
GLU1-02 A 
NO 
(mucositis) 
YES 4 
GLU1-03 B 
NO 
(mucositis) 
NO 
(impaired renal function) 
3 
(impaired renal function) 
GLU1-04 B 
NO 
(delayed MTX elimination) 
N/A 
2 
(impaired renal function) 
GLU1-05 A 
NO 
(impaired renal function)* 
N/A 
1 
(impaired renal function) 
GLU1-06 A 
NO 
(mucositis) 
YES 4 
GLU1-07 B 
NO 
(delayed MTX elimination) 
NO 
(delayed MTX elimination) 
4 
GLU1-08 B YES YES 4 
GLU1-09 A YES YES 4 
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Trial patient Treatment arm 
Day 15 criteria met (YES, NO, N/A: not applicable) 
Treatment cycles with glucarpidase highlighted 
Number of MTX courses 
received 
(Reason if fewer than 4 
courses) 
Cycle 1 
(reason if NO) 
Cycle 2 
(reason if NO) 
GLU1-10 A 
NO 
(mucositis) 
YES 4 
GLU1-11 A YES YES 4 
GLU1-12 B 
NO 
(impaired renal function, mucositis) 
N/A 
2 
(impaired renal function) 
GLU1-13 A 
NO 
(impaired renal function, mucositis) 
N/A 
2 
(impaired renal function) 
GLU1-14 A 
NO 
(knee effusion) 
N/A 
1 
(knee effusion) 
GLU1-15 B 
NO 
(mucositis) 
NO 
(mucositis) 
4 
GLU1-16 A 
NO 
(mucositis) 
YES 4 
*Patient GLU 1-05 received glucarpidase outside the study as an emergency in view of nephrotoxicity and delayed MTX elimination 
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Table 24: RESCUE REGIMEN USED AND FITNESS TO PROCEED ON DAY 15 OF 
EACH CYCLE 
Rescue regimen Number of 
treatment cycles 
that “day 15” 
criteria WERE met 
(% out of total 
number of cycles on 
the same rescue) 
Number of 
treatment cycles 
that “day 15” 
criteria WERE NOT 
met 
(% out of total 
number of cycles on 
the same rescue) 
Reason for not 
meeting “day 15” 
criteria 
Glucarpidase & 
folinic acid 
8 (57%) 6 (43%) 
Impaired renal 
function 
Delayed 
methotrexate 
elimination 
Mucositis 
Folinic acid 3 (23%) 10 (77%) 
Impaired renal 
function 
Delayed 
methotrexate 
elimination 
Mucositis 
Knee effusion 
 
In the interim analysis, in examining efficacy based on patient’s fitness to receive 
chemotherapy on day 15 of each cycle, the O’Brien-Fleming method for judging 
significance of results from a McNemar’s test was used with a significance level of 
0.005. There was no statistically significant benefit of glucarpidase with P < 0.005. 
However, this was expected as only 50% of intended trial sample size was studied. 
To assess whether glucarpidase may be delaying further chemotherapy, the 
McNemar’s test with a one sided significance level of 5% was used in the interim 
analysis. Treatment with glucarpidase and folinic acid was not found to be significantly 
worse than standard treatment using an one-sided test with P < 0.05.  
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5.4. INCIDENCE AND SEVERITY OF MTX RELATED TOXICITY 
All AEs attributed to MTX related to study participants documented on the individual’s 
Case Record Form (CRF) (Appendix 6) and graded for severity according to Common 
Terminology for Adverse Events (CTCAE) v.3.0 are shown in Table 25 and Table 26.  
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Table 25: MTX RELATED TOXICITY PER PATIENT, TREATMENT CYCLE AND TREATMENT COURSE  
 
   CTCAE v3.0,  grading scale (0-5) 
(max = worse documented toxicity per treatment cycle, cycles with glucarpidase rescue highlighted) 
mls/min/1.73m
2
 
Patient 
ID 
Cycle Course 
Mucositis 
(clinical) 
Mucositis 
(functional) 
↑Creat ↑ALT ↑Bili ↓Phos ↓Mg ↓Hb ↓Neuts ↓Plts GFR 
01 
1 
1 0 0 0 2 0 0 0 2 0 0 119 
2 0 0 0 3 0 0 0 2 0 0  
Day 15 0 0 0 2 0 0 0 1 0 1 193 
max 0 0 0 3 0 0 0 2 0 1  
2 
1 2 1 0 3 2 0 0 1 0 1 176 
2 2 1 0 2 2 0 0 1 0 2  
Day15 3 2 0 1 2 0 0 3 0 3 182 
max 3 2 0 3 2 0 0 3 0 3  
02 
1 
1 2 0 0 2 0 3 0 1 0 0 73 
2 2 0 0 2 0 3 0 1 0 0  
Day 15 2 0 0 1 0 0 0 1 0 0 126 
max 2 0 0 2 0 3 0 1 0 0  
2 
1 0 0 0 1 0 3 0 1 0 0 156 
2 0 0 0 3 0 2 0 1 0 1  
Day15 1 0 0 - - - - 1 0 0 141 
max 1 0 0 3 0 3 0 1 0 0  
03 1 
1 1 0 0 4 0 3 0 0 0 0 94 
2 1 0 0 3 2 3 0 0 0 0  
Day15 2 0 0 3 0 0 0 0 0 0 79 
max 2 0 0 4 2 3 0 0 0 0  
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Table 25: MTX RELATED TOXICITY PER PATIENT, TREATMENT CYCLE AND TREATMENT COURSE  
 
   CTCAE v3.0,  grading scale (0-5) 
(max = worse documented toxicity per treatment cycle, cycles with glucarpidase rescue highlighted) 
mls/min/1.73m
2
 
Patient 
ID 
Cycle Course 
Mucositis 
(clinical) 
Mucositis 
(functional) 
↑Creat ↑ALT ↑Bili ↓Phos ↓Mg ↓Hb ↓Neuts ↓Plts GFR 
2 
1 1 0 1 3 0 3 0 0 0 0 69 
2 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a  
Day 15 0 0 1 2 0 0 0 0 0 0 50 
max 1 0 1 3 0 3 0 0 0 0  
04 1 
1 0 0 0 3 0 0 0 1 0 0 103 
2 0 0 1 3 0 0 0 2 1 1  
Day 15 0 0 0 2 0 0 0 2 1 1 90 
max 0 0 1 3 0 0 0 2 1 1  
05 1 
1 0 0 4 3 0 1 0 0 0 0  
2 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a  
Day 15 0 0 2 0 0 0 0 0 0 0 44 
max 0 0 4 3 0 1 0 0 0 0  
06 
1 
1 2 0 0 3 0 2 0 0 0 0 116 
2 2 0 0 4 0 2 0 0 0 0  
Day 15 3 3 0 4 0 0 0 0 0 0 199 
max 3 3 0 4 0 2 0 0 0 0  
2 
1 0 0 0 3 0 0 0 0 0 0 142 
2 0 0 0 3 0 0 0 0 0 0  
Day 15 0 0 0 3 0 0 0 0 0 0 101 
max 0 0 0 3 0 0 0 0 0 0  
142 
Table 25: MTX RELATED TOXICITY PER PATIENT, TREATMENT CYCLE AND TREATMENT COURSE  
 
   CTCAE v3.0,  grading scale (0-5) 
(max = worse documented toxicity per treatment cycle, cycles with glucarpidase rescue highlighted) 
mls/min/1.73m
2
 
Patient 
ID 
Cycle Course 
Mucositis 
(clinical) 
Mucositis 
(functional) 
↑Creat ↑ALT ↑Bili ↓Phos ↓Mg ↓Hb ↓Neuts ↓Plts GFR 
07 
1 
1 0 0 1 3 0 2 0 2 0 0 129 
2 0 0 1 4 0 2 0 2 0 0  
Day 15 0 0 0 3 0 3 0 2 0 0 103 
max 0 0 1 4 0 3 0 2 0 0  
2 
1 0 0 1 4 0 3 0 2 0 0 115 
2 0 0 1 4 0 4 0 2 0 0  
Day 15 0 0 0 2 0 0 0 2 0 0 115 
max 0 0 1 4 0 4 0 2 0 0  
08 
1 
1 0 0 0 3 0 0 0 3 0 0 106 
2 0 0 0 3 0 2 0 2 0 0  
Day 15 0 0 0 1 0 0 0 2 0 0 187 
max 0 0 0 3 0 2 0 3 0 0  
2 
1 0 0 0 3 0 0 0 2 0 0 205 
2 0 0 0 3 0 2 0 2 0 0  
Day 15 0 0 0 1 0 0 0 2 0 0 187 
max 0 0 0 3 0 2 0 2 0 0  
09 1 
1 0 0 0 1 0 0 0 2 0 0 175 
2 0 0 0 1 0 0 0 2 0 0  
Day 15 0 0 0 2 0 0 0 2 0 0 204 
max 0 0 0 2 0 0 0 2 0 0  
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Table 25: MTX RELATED TOXICITY PER PATIENT, TREATMENT CYCLE AND TREATMENT COURSE  
 
   CTCAE v3.0,  grading scale (0-5) 
(max = worse documented toxicity per treatment cycle, cycles with glucarpidase rescue highlighted) 
mls/min/1.73m
2
 
Patient 
ID 
Cycle Course 
Mucositis 
(clinical) 
Mucositis 
(functional) 
↑Creat ↑ALT ↑Bili ↓Phos ↓Mg ↓Hb ↓Neuts ↓Plts GFR 
2 
1 0 0 0 3 0 0 0 2 0 0 117 
2 0 0 0 3 0 1 0 2 0 0  
15 0 0 0 2 0 0 0 2 0 0 171 
max 0 0 0 3 0 1 0 2 0 0  
10 
1 
1 1 0 0 3 0 3 0 2 0 0 98 
2 3 2 1 3 0 0 0 2 0 1  
Day 15 3 2 0 3 0 0 0 2 1 1 90 
max 3 2 1 3 0 3 0 2 1 1  
2 
1 0 0 0 3 2 2 0 2 2 1 95 
2 0 0 1 3 1 0 0 2 2 1  
Day 15 0 0 0 3 0 0 0 1 2 1 72 
max 0 0 1 3 2 2 0 2 2 1  
11 
1 
1 0 0 0 4 0 3 0 1 0 0 111 
2 0 0 0 4 0 3 0 1 0 1  
Day 15 0 0 0 2 0 - 0 1 0 1 215 
max 0 0 0 4 0 3 0 1 0 1  
2 
1 0 0 0 4 0 0 0 1 0 0 264 
2 0 0 0 3 0 1 0 1 0 1  
Day 15 0 0 0 2 0 - 0 1 0 1 228 
max 0 0 0 4 0 1 0 1 0 1  
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Table 25: MTX RELATED TOXICITY PER PATIENT, TREATMENT CYCLE AND TREATMENT COURSE  
 
   CTCAE v3.0,  grading scale (0-5) 
(max = worse documented toxicity per treatment cycle, cycles with glucarpidase rescue highlighted) 
mls/min/1.73m
2
 
Patient 
ID 
Cycle Course 
Mucositis 
(clinical) 
Mucositis 
(functional) 
↑Creat ↑ALT ↑Bili ↓Phos ↓Mg ↓Hb ↓Neuts ↓Plts GFR 
12 1 
1 0 0 0 3 2 2 0 1 0 0 77 
2 2 2 2 3 0 2 0 2 0 0  
Day 15 2 2 1 2 0 0 0 2 0 0 45 
Also on day 15 of cycle 1: enteritis grade 1, hypocalcaemia grade 3 and hypoalbuminaemia grade 2  
max 2 2 2 3 2 2 0 2 0 0  
13 1 
1 2 0 1 3 0 2 0 0 0 0 87 
2 1 0 1 4 0 3 0 0 0 0  
Day 15 1 0 0 3 0 0 0 0 0 0 51 
max 2 0 1 4 0 3 0 0 0 0  
14 1 
1 0 0 0 3 0 2 0 1 0 0 106 
2 0 0 0 2 0 0 0 1 0 0 136 
Day 15 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a  
max 0 0 0 3 0 2 0 1 0 0  
15 
1 
1 0 0 0 2 0 3 0 0 0 0 88 
2 0 0 0 1 0 2 0 0 0 0  
Day 15 3 2 0 1 0 0 0 0 0 0 190 
max 3 2 0 2 0 3 0 0 0 0  
2 
1 0 0 0 2 0 1 0 0 0 0 154 
2 0 0 1 2 0 3 0 0 0 1  
Day 15 2 1 0 1 0 0 0 0 0 1 118 
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Table 25: MTX RELATED TOXICITY PER PATIENT, TREATMENT CYCLE AND TREATMENT COURSE  
 
   CTCAE v3.0,  grading scale (0-5) 
(max = worse documented toxicity per treatment cycle, cycles with glucarpidase rescue highlighted) 
mls/min/1.73m
2
 
Patient 
ID 
Cycle Course 
Mucositis 
(clinical) 
Mucositis 
(functional) 
↑Creat ↑ALT ↑Bili ↓Phos ↓Mg ↓Hb ↓Neuts ↓Plts GFR 
15 2 max 2 1 1 2 0 3 0 0 0 1  
16 
1 
1 1 0 0 3 0 3 0 1 0 0 94 
2 1 0 0 3 0 3 0 1 0 0  
Day 15 1 2 0 3 0 0 0 1 0 0 124 
max 1 2 0 3 0 3 0 1 0 0  
2 
1 0 0 0 3 0 3 0 1 0 0 145 
2 0 0 0 3 0 1 0 1 0 0  
Day 15 0 0 0 3 0 0 0 1 0 0 136 
max 0 0 0 3 0 3 0 1 0 0  
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Table 26: COMPARISON OF GRADING OF MTX RELATED TOXICITY IN CYCLES WITH GLUCARPIDASE AND FOLINIC ACID 
RESCUE (glu/FA) AND CYCLES WITH FOLINIC ACID RESCUE ALONE (FA)  
CTCAE 
v3.0 
grades 
Mucositis 
clinical 
Mucositis 
functional 
↑ Creatinine ↑ ALT ↑ Bilirubin 
↑ Phos-
phate 
↓ Mg 
Haemo-
globin 
Neuts Platelets 
 glu/FA FA 
glu/F
A 
FA 
glu/F
A 
FA 
glu/F
A 
FA 
glu/F
A 
FA 
glu/F
A 
FA 
glu/F
A 
FA 
glu/F
A 
FA 
glu/F
A 
FA 
glu/F
A 
FA 
0 
9/14 
(64.3%) 
6/13 
(46.15%) 
12/14 
(85.7%) 
8/13 
(61.5%) 
9/14 
(64.3%) 
8/13 
(61.5%) 
0 0 
11/14 
(78.6%) 
12/13 
(92.3%) 
3/14 
(21.4%) 
2/13 
(15.4%) 
14/14 
(100%) 
13/13 
(100%) 
4/14 
(18.6%) 
4/13 
(18.6%) 
12/14 
(85.7%) 
12/13 
(92.3%) 
10/14 
(71.4%) 
9/13 
(69.2%) 
1 
1/14 
(7.14%) 
2/13 
(15.4%) 
0 
1/13 
(7.7%) 
4/14 
(18.6%) 
4/13 
(30.8%) 
0 0 0 0 
2/14 
(15.4%) 
1/13 
(7.7%) 
0 0 
3/14 
(21.4%) 
4/13 
(18.6%) 
1/14 
(7.14%) 
1/13 
(7.7%) 
4/14 
(18.6%) 
3/13 
(23.1%) 
2 
3/14 
(21.4%) 
2/13 
(15.4%) 
2/14 
(15.4%) 
3/13 
(23.1%) 
1/14 
(7.14%) 
0 
1/14 
(7.14%) 
3/13 
(23.1%) 
3/14 
(21.4%) 
1/13 
(7.7%) 
3/14 
(21.4%) 
3/13 
(23.1%) 
0 0 
6/14 
(43%) 
4/13 
(18.6%) 
1/14 
(7.14%) 
0 0 
1/13 
(7.14%) 
3 
1/14 
(7.14%) 
3/13 
(23.1%) 
0 
1/13 
(7.7%) 
0 0 
9/14 
(64.3%) 
7/13 
(53.8%) 
0 0 
6/14 
(43%) 
6/13 
(46.15%) 
0 0 
1/14 
(7.14%) 
3/13 
(23.1%) 
0 0 0 0 
4 0 0 0 0 0 
1/13 
(7.7%) 
4/14 
(18.6%) 
3/13 
(23.1%) 
0 0 0 
1/13 
(7.7%) 
0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Fourteen cycles were given with glucarpidase and folinic acid rescue (glu/FA) and 
thirteen cycles were given with folinic acid rescue alone (FA). The most commonly 
observed adverse events were elevated alanine transaminase, mucositis, 
hypophosphataemia, renal impairment and mild bone marrow suppression. 
a. HEPATOTOXICITY 
All the GLU 1 treatment cycles were associated with acute transient ALT elevation. ALT 
CTCTAE v3.0 grade ≥ 3 complicated 93% (13/14) and 77% (10/13) of glu/FA and FA 
treatment cycles respectively. Mild hyperbilirubinaemia (CTCTAE v3.0 grades 1 and 2) 
complicated 21% (3/14) and 8% (1/13) of glu/FA and FA treatment cycles respectively. 
We did not document any severe hyperbilirubinaemia (CTCTAE v3.0 grades 3 and 4). 
b. MUCOSITIS 
Mucositis-clinical complicated 36% (5/14) and 54% (7/13) of glu/FA and FA treatment 
cycles respectively. More severe mucositis-clinical (CTCAE v3.0 clinical grades ≥ 3) 
complicated 7% (1/14) and 23% (3/13) of glu/FA and FA treatment cycles respectively. 
Mucositis-functional complicated 15% (2/14) and 38% (5/13) of glu/FA and FA 
treatment cycles respectively. More severe mucositis-functional (CTCAE v3.0 grades ≥ 
3) complicated 8% (1/13) FA treatment cycles whereas severe mucositis-functional was 
not documented in any glu/FA treatment cycles. 
c. NEPHROTOXICITY 
Half (8/16) of the GLU 1 participants developed nephrotoxicity (serum creatinine level 
CTCAE v3.0 grade ≥ 1). 6 patients (6/16) developed CTCAE v3.0 grade 1 
nephrotoxicity and half of those did not complete their treatment due to renal 
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impairment. One patient (1/16) developed grade 2 nephrotoxicity and one patient (1/16) 
developed grade 4 nephrotoxicity. Both of those patients did not complete study 
treatment due to their renal impairment. The patient who developed grade 2 
nephrotoxicity had received rescue with glucarpidase/folinic acid. The patient who 
developed grade 4 nephrotoxicity received standard rescue with folinic acid. 
Fourteen (14/27) GLU 1 MTX cycles were given with glucarpidase/folinic acid rescue. 
Amongst those, nine (9/14) cycles were not associated with nephrotoxocity, four (4/14) 
led to grade 1 nephrotoxicity and one (1/14) led to grade 2 nephrotoxicity. Thirteen 
(13/27) MTX cycles were given with folinic acid alone. Amongst those, eight (8/13) were 
not associated with nephrotoxocity, four (4/13) led to grade 1 nephrotoxicity and one 
(1/13) led to grade 4 nephrotoxicity.  
d. MYELOSUPPRESSION 
Anaemia CTCAE v3.0 grades 1, 2 and 3 complicated 21% (3/14), 43% (6/14) and 7% 
(1/14) of glu/FA respectively and 19% (4/13), 19% (4/13) and 23% (3/13) of FA cycles 
respectively. Anaemia grade 4 was not documented in either treatment cycles. The 
majority of treatment cycles were not associated with neutropenia, with only 14% (2/14) 
and 8% (1/13) of glu/FA and FA treatment cycles respectively leading to CTCAE v3.0 
grade 1-2 neutropenia. More severe neutropenia (CTCAE v3.0 grade ≥ 3) was not 
documented. Similarly, the majority of treatment cycles were not associated with 
thrombocytopenia, with only 19% (4/14) and 31% (4/13) of glu/FA and FA treatment 
cycles respectively leading to CTCAE v3.0 grade 1-2 thrombocytopenia. More severe 
thrombocytopenia (CTCAE v3.0 grade ≥ 3) was not documented.  
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The difference in toxicity outcomes between cycles given with glucarpidase and cycles 
given without glucarpidase was examined. The severity of MTX related toxicity was 
graded from 0 to 4 (ordinal scale) as per the CTCTAE version 3.0. However, for most 
variables the majority of values were located at the lower end of the scale. To be able to 
easily allow for the data structure, toxicity outcomes were divided into two categories, a 
low and high toxicity and as such toxicity outcomes were considered as binary 
variables. The exact cut-off to create these groups varied depending on the individual 
adverse event and was decided bearing in mind that grading is not uniform across 
different adverse events in CTCAE version 3.0; i.e. grade 3 ALT is not necessarily 
equally severe as a grade 3 creatinine. (Table 27) 
Table 27: MTX RELATED TOXICITY: LOW AND HIGH TOXICITY SCORE 
Toxicity Low toxicity score High toxicity score 
Mucositis clinical Grade 0-1 Grades 2-4 
Mucositis functional Grades 0-1 Grades 2-4 
Creatinine Grade 0 Grades 1-4 
ALT Grades 0-3 Grade  4 
Bilirubin Grade 0 Grades 1-4 
Phosphate Grades 0-2 Grades 3-4 
Hb Grade 0-2 Grades 3-4 
Neutrophils Grade 0 Grades 1-4 
Platelets Grade 0 Grades 1-4 
 
The paired exact test was used to compare the toxicity outcomes between when glu/FA 
cyles and FA cycles, although this method did not take into account the period in which 
the treatment occurred. This analysis was restricted to the 11 subjects with toxicity data 
on both cycles and the results are shown in Table 28. The figures reported are the 
number and percentage of patients with a high toxicity score in each arm. No 
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differences in the toxicity outcomes between glu/FA cyles and FA cycle were observed. 
However, it should be noted that the number of patients in the analysis was small, and 
so there was a low power to detect differences in these outcomes between arms.  
Table 28: EFFECT OF GLUCARPIDASE ON THE TOXICITY OUTCOMES 
Toxicity High toxicity 
score 
No Glucarpidase  
N (%) 
Glucarpidase  
N (%) 
P-value 
Mucositis clinical Grades 2-4 4 (36%) 3 (27%) 1.00 
Mucositis 
functional 
Grades 2-4 2 (18%) 3 (27%) 
1.00 
Creatinine Grades 1-4 2 (18%) 4 (36%) 0.50 
ALT Grade 4 3 (27%) 3 (27%) 1.00 
Bilirubin Grades 1-4 3 (27%) 0 (0%) 0.25 
Phosphate Grades 3-4 5 (45%) 7 (64%) 0.50 
Hb Grades 3-4 2 (18%) 0 (0%) 0.50 
Neutrophils Grades 1-4 1 (9%) 1 (9%) 1.00 
Platelets Grades 1-4 3 (27%) 4 (36%) 1.00 
We also examined the effects of MTX Cmax and AUC upon the various toxicity 
variables, such as mucositis (clinical), mucositis (functional), raised creatinine, raised 
ALT, hyperbilirubinaemia, hypophosphataemia, anaemia, neutropenia, and 
thrombocytopenia. There was no toxicity related to hypomagnesaemia and so it was not 
included in our analysis.  
The analysis of MTX Cmax was performed for cycles given with and without 
glucarpidase combined. Multilevel logistic regression was used to examine the effect of 
MTX Cmax upon the toxicities. The analysis results are shown in Table 29. The first 
column indicates what constitutes a 'high' toxicity value. The next column gives the size 
of effect of MTX Cmax upon each outcome in the form of an odds ratio. These are 
presented as the change in the odds of a high toxicity value for a 100-unit increase in 
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MTX Cmax. An odds ratio above 1 would imply an increased likelihood of a high toxicity 
with a higher MTX Cmax value. 
Table 29: EFFECT OF MTX Cmax UPON METHOTREXATE-RELATED TOXICITY IN 
ALL TREATMENT CYCLES COMBINED. 
Toxicity High toxicity score Odds Ratio (95% CI) P-value 
Mucositis clinical Grades 2-4 1.06 (0.84, 1.33) 0.65 
Mucositis functional Grades 2-4 0.95 (0.73, 1.24) 0.71 
Creatinine Grades 1-4 1.70 (0.73, 3.94) 0.22 
ALT Grade 4 1.33 (0.80, 2.21) 0.26 
Bilirubin Grades 1-4 1.36 (0.96, 1.93) 0.09 
Phosphate Grades 3-4 1.04 (0.54, 2.01) 0.91 
Hb Grades 3-4 0.70 (0.42, 1.16) 0.17 
Neutrophils Grades 1-4 0.93 (0.32, 2.71) 0.90 
Platelets Grades 1-4 1.40 (0.56, 3.47) 0.47 
 
No strong evidence was found that MTX Cmax was associated with any of the toxicity 
outcome. There was very weak evidence that higher values of MTX Cmax were 
associated with an increased occurrence of higher bilirubin toxicity, but this result was 
not quite statistically significant. 
The analysis of AUC was performed separately for glu/FA cycles and FA cycles; 
standard logistic regression was used for the analyses. The results are shown in Table 
30, where the odds ratios represent the change in the odds of a high toxicity for a 1000-
unit increase in AUC. No evidence that AUC was associated with any of the toxicity 
outcomes was observed. 
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Table 30: EFFECT OF AUC UPON METHOTREXATE-RELATED TOXICITY IN 
GLU/FA CYCLES AND FA CYCLES  
Toxicity High toxicity score Odds Ratio (95% CI) P-value 
FA cycles 
Mucositis clinical Grades 2-4 0.79 (0.50, 1.27) 0.34 
Mucositis functional Grades 2-4 0.80 (0.50, 1.28) 0.35 
Creatinine Grades 1-4 1.13 (0.77, 1.66) 0.55 
ALT Grade 4 1.16 (0.76, 1.79) 0.48 
Bilirubin Grades 1-4 (*) - 
Phosphate Grades 3-4 1.14 (0.78, 1.66) 0.50 
Hb Grades 3-4 (*) - 
Neutrophils Grades 1-4 1.00 (0.53, 1.88) 0.99 
Platelets Grades 1-4 1.02 (0.70, 1.49) 0.89 
glu/FA cycles 
Mucositis clinical Grades 2-4 1.22 (0.88, 1.70) 0.24 
Mucositis functional Grades 2-4 1.06 (0.76, 1.48) 0.74 
Creatinine Grades 1-4 1.53 (0.93, 2.52) 0.10 
ALT Grade 4 1.30 (0.89, 1.88) 0.18 
Bilirubin Grades 1-4 1.43 (0.92, 2.22) 0.11 
Phosphate Grades 3-4 1.00 (0.76, 1.33) 0.99 
Hb Grades 3-4 0.69 (0.39, 1.20) 0.19 
Neutrophils Grades 1-4 1.01 (0.68, 1.50) 0.96 
Platelets Grades 1-4 1.04 (0.76, 1.41) 0.82 
(*) No patients with toxicity when glucarpidase was not given 
The effects of age upon MTX-related toxicity were examined. Separate analyses were 
performed for glu/FA cycles and FA cycles. The toxicity outcomes were dealt with on a 
binary scale, and so Fisher's exact test was used. As shown in Table 31, age was not 
significantly associated with any of the toxicity outcomes in either of the two study arms. 
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Table 31: EFFECTS OF AGE UPON MTX-RELATED TOXICITY 
Toxicity High toxicity 
score 
Age < 20, N (%) Age ≥ 20, N (%) P-value 
FA cycles  (n=8) (n=4)  
Mucositis clinical Grades 2-4 1 (13%) 2 (50%) 0.24 
Mucositis 
functional 
Grades 2-4 2 (25%) 1 (25%) 1.00 
Creatinine Grades 1-4 1 (13%) 3 (75%) 0.07 
ALT Grade 4 3 (38%) 0 (0%) 0.49 
Bilirubin Grades 1-4 0 (%) 0 (0%) (*) 
Phosphate Grades 3-4 4 (50%) 3 (75%) 0.58 
Hb Grades 3-4 0 (0%) 0 (0%) (*) 
Neutrophils Grades 1-4 0 (0%) 1 (25%) 0.33 
Platelets Grades 1-4 1 (13%) 3 (75%) 0.07 
glu/FA cycles  (n=8) (n=6)  
Mucositis clinical Grades 2-4 2 (25%) 4 (67%) 0.28 
Mucositis 
functional 
Grades 2-4 1 (13%) 2 (33%) 0.54 
Creatinine Grades 1-4 2 (25%) 3 (50%) 0.58 
ALT Grade 4 2 (25%) 2 (33%) 1.00 
Bilirubin Grades 1-4 1 (13%) 3 (50%) 0.25 
Phosphate Grades 3-4 3 (38%) 3 (50%) 1.00 
Hb Grades 3-4 1 (13%) 1 (17%) 1.00 
Neutrophils Grades 1-4 0 (0%) 2 (33%) 0.17 
Platelets Grades 1-4 1 (13%) 3 (50%) 0.25 
(*) No patients with toxicity when glucarpidase was not given 
Similar analysis was performed to examine the effects of gender upon MTX related 
toxicity. Again, separate analyses were performed for glu/FA cycles and FA cycles. The 
toxicity outcomes were dealt with on a binary scale, and so Fisher's exact test was 
used. As shown in Table 32, there were no significant differences in toxicity outcomes 
between genders either for glu/FA or FA cycles. 
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Table 32: EFFECTS OF GENDER UPON TOXICITY 
Toxicity High toxicity 
score 
Male 
N (%) 
Female 
N (%) 
P-
value 
FA cycles  (n=10) (n=2)  
Mucositis clinical Grades 2-4 3 (30%) 0 (0%) 1.00 
Mucositis functional Grades 2-4 3 (30%) 0 (0%) 1.00 
Creatinine Grades 1-4 3 (30%) 1 (50%) 1.00 
ALT Grade 4 3 (30%) 0 (0%) 1.00 
Bilirubin Grades 1-4 0 (%) 0 (0%) (*) 
Phosphate Grades 3-4 6 (60%) 1 (50%) 1.00 
Hb Grades 3-4 0 (0%) 0 (0%) (*) 
Neutrophils Grades 1-4 1 (10%) 0 (0%) 1.00 
Platelets Grades 1-4 4 (40%) 0 (0%) 0.52 
glu/FA cycles  (n=11) (n=3)  
Mucositis clinical Grades 2-4 4 (36%) 2 (67%) 0.54 
Mucositis functional Grades 2-4 3 (27%) 0 (0%) 1.00 
Creatinine Grades 1-4 4 (34%) 1 (33%) 1.00 
ALT Grade 4 2 (18%) 2 (67%) 0.18 
Bilirubin Grades 1-4 3 (27%) 1 (33%) 1.00 
Phosphate Grades 3-4 4 (36%) 2 (67%) 0.54 
Hb Grades 3-4 1 (9%) 1 (33%) 0.40 
Neutrophils Grades 1-4 2 (18%) 0 (0%) 1.00 
Platelets Grades 1-4 4 (36%) 0 (0%) 0.51 
(*) No patients with toxicity when glucarpidase was not given 
We also examined the GFR measurements on day 15 in glu/FA and FA cycles. There 
was no major difference in GFR measurements on day 15 among treatment cycles 
given with glucarpidase/folinic acid rescue and cycles given with folinic acid rescue 
alone (Table 33). For all treatment cycles, the median and average GFR on day 15 
were 124 and 129.5 mls/min/1.73m2 respectively. The median and average GFR on day 
15 were 119.5 and 127.6 mls/min/1.73m2 respectively for treatment cycles given with 
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glucarpidase and folinic acid and 124 and 131.8 respectively for treatment cycles given 
with folinic acid alone. 
Table 33: COMPARISON OF GFR ON DAY 15 IN CYCLES WITH GLUCARPIDASE 
AND FOLINIC ACID RESCUE (glu/FA) AND CYCLES WITH FOLINIC ACID 
RESCUE ALONE (FA) 
 Median 
(mls/min/1.73m
2
) 
Average 
(mls/min/1.73m
2
) 
Range 
(mls/min/1.73m
2
) 
All cycles 124 129.5 44-228 
Glu/FA cycles  119.5 127.6 45-228 
FA cycles 124 131.8 22-215 
 
In order to evaluate the severity of mucositis further four different assessment tools 
were used; the World Health Organisation Toxicity Criteria for Oral Mucositis, the 
National Cancer Institute Common Terminology criteria for Adverse Events, version 3.0 
(CTCAE v 3.0), the Oral Assessment Guide (OAG) and the Oral Mucositis Weekly 
Questionnaire (OMWQ). Grading of mucositis severity as per these assessment tools is 
shown on Table 34.  
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Table 34: MUCOSITIS GRADING ACCORDING TO WHO, OMWQ AND CTCAE V 3.0 
ID Cycle 
GLU 
1=YES 
0=NO 
WHO 
OAG
1 
OAG
2 
OAG
3 
OAG
4 
OAG
5 
OAG
6 
OAG 
7 
OAG
8 
OMW
Q1 
OMW
Q2 
OMW
Q3a 
OMW
Q3b 
OMW
Q3c 
OMW
Q3d 
OMW
Q3e 
OM
WQ4 
OM
WQ5 
OM
WQ6 
CTCTAE 
clinical 
CTCTAE 
functional 
1 1 1 0 1 1 1 1 1 1 1 1 8 1 0 0 0 0 0 1 0 0 0 0 
1 2 0 3 1 1 1 1 1 3 1 1 1 3 3 3 3 2 0 9 1 1 3 2 
2 1 0 2 1 1 3 1 1 1 1 1 7 0 0 0 0 0 0 0 1 2 2 0 
2 1 1 2 1 1 3 1 1 1 1 1 7 0 0 0 0 0 0 0 1 2 2 0 
3 1 1 2 1 1 3 1 1 1 1 1 5 3 2 0 1 0 0 5 0 0 2 0 
3 2 0 1 1 1 1 1 1 1 1 1 7 1 0 0 0 0 0 1 0 0 1 0 
4 1 1 0 1 1 1 1 1 1 1 1 1 4 3 2 1 3 1 7 0 0 0 3 
6 1 0 4 1 1 1 1 1 1 1 1 7 4 1 4 4 3 1 9 0 0 3 3 
6 2 1 0 1 1 1 1 1 1 1 1 9 1 0 1 1 1 0 1 0 0 0 0 
7 1 1 0 1 1 1 1 1 1 1 1 9 2 2 1 2 0 1 5 0 0 0 0 
7 2 0 0 1 1 1 1 1 1 1 1 9 1 0 0 0 0 0 1 0 0 0 0 
8 1 1 0 1 1 1 1 1 1 1 1 6 4 3 3 4 3 2 9 2 5 0 0 
8 2 0 0 1 1 1 1 1 1 1 1 4 2 0 0 0 0 0 0 1 1 0 0 
9 1 0 0 1 1 1 1 1 1 1 1 8 2 3 3 3 1 0 8 0 0 0 0 
9 2 1 0 1 1 1 1 1 1 1 1 9 0 0 0 0 0 0 0 0 0 0 0 
10 1 0 3 1 2 1 1 2 3 1 1 6 3 3 3 3 2 3 8 1 1 3 2 
10 2 1 0 1 1 1 1 1 1 1 1 8 3 3 3 2 1 3 8 0 0 0 0 
11 1 0 0 1 1 1 1 1 1 1 1 8 1 0 0 0 0 0 1 2 3 0 0 
11 2 1 0 1 1 1 1 1 1 1 1 8 0 0 0 0 0 0 0 0 0 0 0 
12 1 1 2 1 1 3 1 1 1 1 1 6 1 0 0 0 0 0 3 3 7 2 2 
13 1 1 0 1 1 1 1 1 1 1 1 7 0 0 0 0 0 0 0 0 0 2 0 
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ID Cycle 
GLU 
1=YES 
0=NO 
WHO 
OAG
1 
OAG
2 
OAG
3 
OAG
4 
OAG
5 
OAG
6 
OAG 
7 
OAG
8 
OMW
Q1 
OMW
Q2 
OMW
Q3a 
OMW
Q3b 
OMW
Q3c 
OMW
Q3d 
OMW
Q3e 
OM
WQ4 
OM
WQ5 
OM
WQ6 
CTCTAE 
clinical 
CTCTAE 
functional 
14 1 0 0 1 1 1 1 1 1 1 1 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 0 
15 1 1 2 1 1 3 1 1 2 1 1 9 0 0 0 0 0 0 0 0 0 0 0 
15 2 0 2 1 1 3 1 1 1 1 1 7 3 3 2 3 2 1 7 0 0 2 1 
16 1 0 2 1 2 3 1 1 3 1 1 9 3 2 0 2 1 0 6 0 0 1 2 
16 2 1 0 1 1 1 1 1 1 1 1 9 3 1 0 1 1 0 6 0 0 0 0 
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We compared the severity of mucositis in cycles given with and without glucarpidase 
assessed by the WHO criteria, OMWQ, CTCAE version 3.0 and OAG. Amongst 
these tools there were several mucositis related variables, each of which was 
measured on an ordinal scale. Due to the nature of the outcomes, and the small 
amount of data, it is difficult to perform any analysis which accounts for the period in 
which each treatment arm is administered. Therefore, for the purposes of these 
analyses the period in which the treatment was given was omitted from the 
analyses. 
The WHO, OMWQ and CTCAE variables had a range of scores, and thus the 
Wilcoxon matched-pairs test was used to compare between when glucarpidase was 
used and when it wasn't. The results of this analysis are summarised in Table 35. 
The figures presented are the median and range of grades in cycles given with and 
without glucarpidase, and the p-values indicating the significance of the results. 
Significant difference in CTCAE mucositis-functional between glu/FA and FA cycles 
was found. Although the median values were 0 in both groups, there were higher 
values in cycles without glucarpidase rescue. There was also slight evidence of a 
difference between groups for the first question of OMWQ and CTCAE clinical, 
although these results were not quite statistically significant. No other differences 
between glu/FA and FA cycles were observed. 
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Table 35: SEVERITY OF MUCOSITIS IN CYCLES GIVEN WITH AND WITHOUT 
GLUCARPIDASE (ASSESSED BY WHO, OWMQ AND CTCAE 
VERSION 3.0) 
Outcome 
No Glucarpidase  
Median (range) 
Glucarpidase  
Median (range) 
P-value 
WHO 2 (0, 4) 0 (0, 2) 0.13 
OMWQ1 7 (1, 9) 9 (5, 9) 0.06 
OMWQ2 2 (0, 4) 1 (0, 4) 0.34 
OMWQ3a 1 (0, 3) 0 (0, 3) 0.50 
OMWQ3b 0 (0, 4) 0 (0, 3) 0.34 
OMWQ3c 2 (0, 4) 1 (0, 4) 0.34 
OMWQ3d 1 (0, 3) 0 (0, 3) 0.17 
OMWQ3e 0 (0, 3) 0 (0, 3) 0.92 
OMWQ4 6 (0, 9) 1 (0, 9) 0.47 
OMWQ5 0 (0, 2) 0 (0, 2) 0.29 
OMWQ6 0 (0, 3) 0 (0, 5) 0.40 
CTCAE clinical 1 (0, 3) 0 (0, 2) 0.07 
CTCAE functional 0 (0, 3) 0 (0, 0) 0.03 
 
For the analysis of the OAG we used a different approach since pretty much all eight 
assessments (swallow, lips and corners of mouth, tongue, saliva, mucus membrane, 
mucus, teeth, voice) were graded as 1 for the vast majority of patients, with few 
other values. Therefore, this variable was categorised as a grade of 1 or grades of 
2-3, and the paired exact test was used for the analyses (Table 36). No differences 
between cycles given with glucarpidase and cycles given without glucarpidase were 
observed. 
160 
Table 36: SEVERITY OF MUCOSITIS IN CYCLES GIVEN WITH AND WITHOUT 
GLUCARPIDASE (ASSESSED BY OAG) 
Outcome No Glucarpidase  
N (%)* 
Glucarpidase  
N (%)* 
P-value 
OAG1 0 (0%) 0 (0%) - 
OAG2 2 (18%) 0 (0%) 0.50 
OAG3 3 (27%) 3 (27%) 1.00 
OAG4 0 (0%) 0 (0%) - 
OAG5 1 (9%) 0 (0%) 1.00 
OAG6 3 (27%) 1 (9%) 0.63 
OAG7 0 (0%) 0 (0%) - 
OAG8 0 (0%) 0 (0%) - 
* Number and percentage of patients in each arm who had a grade of 2 or more. 
5.5. PHARMACOKINETIC ANALYSIS OF MTX AND DAMPA 
Following each of the 4 MTX doses (on days 1 & 8 of cycles 1 and 2), blood 
samples were collected for MTX and DAMPA HPLC analysis at the following time 
points: at 0 hours (prior to starting MTX), 4 hours (immediately prior to the end of the 
MTX infusion), 24 hours (prior to glucarpidase administration), 24:20 hours (15 
minutes after glucarpidase administration), 48 hours and 72 hours after starting MTX 
and then daily until plasma MTX levels [MTX], measured by HPLC, were < 0.2 
μmol/L.  In addition, following each of the 4 MTX doses (on days 1 & 8 of cycles 1 
and 2), blood samples were collected for plasma MTX analysis by immunoassay at 
the following time points: at 24 hours (prior to glucarpidase administration), 48 hours 
and 72 hours after starting MTX and then daily until [MTX] were < 0.2 μmol/L. 
A total of 51 MTX courses were administered in the GLU1 clinical trial. Twenty eight 
of fifty one (55%) MTX courses were given with glucarpidase/folinic acid rescue and 
23 of 51 (45%) MTX courses were given with folinic acid rescue alone.  
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[MTX] at different time points per patient and per methotrexate course are shown in 
Table 37. For MTX courses given with both rescue regimens (folinic acid and 
glucarpidase/folinic acid), patients required a median of 72 hours (range, 48 to 312) 
to achieve [MTX] of < 0.2 μmol/L.  For MTX courses given with folinic acid alone, 
patients required a median of 72 hours (range, 72 to 144) to achieve [MTX] of < 0.2 
μmol/L, whereas for MTX courses given with glucarpidase/folinic acid, patients 
required a median of 60 hours (range 48 to 312 hours) (Table 38 and Table 39).   
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Table 37: [MTX] AT DIFFERENT TIME POINTS PER PATIENT AND PER MTX COURSE  
[MTX] in µM at different time points 
Courses 
given with 
glucarpidase 
highlighted 
0 h 
HPLC 
4 h 
HPLC 
24 h 
24.20 h 
HPLC 
48 h 
HPLC 
72 h 
HPLC 
96 h 
HPLC 
120 h 
HPLC 
144 h 
HPLC 
168 h 
HPLC 
192 h 
HPLC 
216 h 
HPLC 
240 h 
HPLC HPLC 
Immuno
-assay 
GLU1-01 
Course 1 0  4.99 5.34 0.16 0.08 0.09        
Course 2 0.3 1303.84 7.96 7.02 0.6 0.06 0.11        
Course 3 0 1144.8 14.47 15.57 11.86 0.71 0.20        
Course 4 0 1439.6 12.5 13.01 1.84 0.67 0.23        
GLU1-02 
Course 1 0 1298.42 18.30 22.79 14.54 0.54 0.13        
Course 2 0 896.2 16.71 20.47 11.89 0.46 0.06        
Course 3 0 1276.4 15.67 32.29 0 0 0        
Course 4 0 985.6 21.16 23.74 0.09 0.01 0        
GLU1-03 
Course 1 0 1673.68 11.78 9.12 0 0.03 0        
Course 2 0.10 1228 54.37 63.46 0.415 0.02 0.12        
Course 3 0.04 1370 20.13 24.45 17.76 1.37 0.81 0.47 0.25 0.18     
GLU1-04 
Course 1 0.03 845.4 12.17 17.44 0.07 0.01 0.02        
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Table 37: [MTX] AT DIFFERENT TIME POINTS PER PATIENT AND PER MTX COURSE  
[MTX] in µM at different time points 
Courses 
given with 
glucarpidase 
highlighted 
0 h 
HPLC 
4 h 
HPLC 
24 h 
24.20 h 
HPLC 
48 h 
HPLC 
72 h 
HPLC 
96 h 
HPLC 
120 h 
HPLC 
144 h 
HPLC 
168 h 
HPLC 
192 h 
HPLC 
216 h 
HPLC 
240 h 
HPLC HPLC 
Immuno
-assay 
Course 2 0.04 1179.4 54.32 70.16 0.79 0.14 0.45 0.4 0.34 0.26 0.28 0.16 0.1  
GLU1-05 (glucarpidase given as emergency treatment at 72 h post methotrexate, measurement pre and post glucarpidase available) 
Course 1 0 1400 30.11 33.22 13.94 1.39 0.58/0.03 0.03 0.09 0.15 0.11    
GLU1-06 
Course 1 0.02 922.46 10.85 12.55 7.16 0.27 0.07        
Course 2 0.06 932.44 3.79 3.55 2.77 0.22 0.10        
Course 3 0 983.4 13.3 12.76 0.21 0.02 0.04        
Course 4 0 1294.72 13.14 14.74 0.09 0.28 0.08        
GLU1-07 
Course 1 0.08 1176.4 95.66 95.92 0.852 0.06 0.17 0.08       
Course 2 0.12 1319.2 135.86 141.69 1 0.09 0.2 0.161       
Course 3 0.02 N.A. 152.62 149.78 135.24 8.61 0.98 0.39 0.24 0.15     
Course 4 0.318 1638 141.6 114.83 107.02 4.66 1.01 0.53 0.21      
GLU1-08 
Course 1 0.05 587.18 3.27 4.49 0.04 3.2? 0.04        
Course 2 0.08 524.42 7.69 9.06 0.10 0.09 0        
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Table 37: [MTX] AT DIFFERENT TIME POINTS PER PATIENT AND PER MTX COURSE  
[MTX] in µM at different time points 
Courses 
given with 
glucarpidase 
highlighted 
0 h 
HPLC 
4 h 
HPLC 
24 h 
24.20 h 
HPLC 
48 h 
HPLC 
72 h 
HPLC 
96 h 
HPLC 
120 h 
HPLC 
144 h 
HPLC 
168 h 
HPLC 
192 h 
HPLC 
216 h 
HPLC 
240 h 
HPLC HPLC 
Immuno
-assay 
Course 3 0.15 723.76 5.54 5.57 3.51 0.25 0.19        
Course 4 0.05 535.46 4.48 5.16 4.65 0.2 0.05        
GLU1-09 
Course 1 0.03 1337.72 7.31 7.26 6.15 0.33 0.09        
Course 2 0 1355.58 8.33 7.6 6.24 0.34 0.13        
Course 3 0.09 1219 6.95 8.4 0.09 0.02 0.04        
Course 4 0.03 1370.9 10.01 9.44 0.16 0.05 0.05        
GLU1-10 
Course 1 0.02 1355.9 29.83 28.42 25.6 1.13 0.15        
Course 2 0.1 1181.6 23.10 22.77 13.96 1.0 0.2        
Course 3 0.02 1558 36.06 41.23 0.26 0.48 0.07        
Course 4 0.06 1577.44 43.68 55.76 0.7 1.23 0.276 0.192       
GLU1-11 
Course 1 0.09 1741.60 31.95 28.03 19.10 0.84 0.23        
Course 2 0.07 1452.60 12.22 11.05 8.662 0.58 0.16        
Course 3 0.10 1387.20 16.18 16.94 0.40 0.19 0.18        
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Table 37: [MTX] AT DIFFERENT TIME POINTS PER PATIENT AND PER MTX COURSE  
[MTX] in µM at different time points 
Courses 
given with 
glucarpidase 
highlighted 
0 h 
HPLC 
4 h 
HPLC 
24 h 
24.20 h 
HPLC 
48 h 
HPLC 
72 h 
HPLC 
96 h 
HPLC 
120 h 
HPLC 
144 h 
HPLC 
168 h 
HPLC 
192 h 
HPLC 
216 h 
HPLC 
240 h 
HPLC HPLC 
Immuno
-assay 
Course 4 0.10 1370 18.9 20.44 0.53 0.23 0.14        
GLU1-12 
Course 1 Samples unsuitable for analysis as explained in Section 3.3.3. 0.19 0.27 0.2      
Course 2 0.19 1968.44 253.54 259.94 3.19 3.6 3.15 1.82 1.12 0.83 0.9 0.74 0.54 0.43 
 264 h: 0.32; 288 h: 0.27; 312 h: 0.16 
GLU1-13 
Course 1 0 1698 16.35 17.47 0.43 0.61 0.63 N.A. N.A. 0.18     
Course 2 0.17 2225.8 44.4 43.86 0.82 0.83 0.57 0.30 0.11      
GLU1-14 
Course 1 0.09 1901.72 25.62 30.04 16.96 1.04 0.34 0.09       
GLU1-15 
Course 1 0.17 709.92 10.76 12.78 0.41 0.5 0.32        
Course 2 0 811.84 15.18 16.89 1.022 0.425 0.16        
Course 3 0.07 954.68 23.01 26.12 15.34 1.07 0.41 0.13       
Course 4 0.08 1296.08 16.76 23.19 9.76 0.96 0.58 0.15       
GLU1-16 
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Table 37: [MTX] AT DIFFERENT TIME POINTS PER PATIENT AND PER MTX COURSE  
[MTX] in µM at different time points 
Courses 
given with 
glucarpidase 
highlighted 
0 h 
HPLC 
4 h 
HPLC 
24 h 
24.20 h 
HPLC 
48 h 
HPLC 
72 h 
HPLC 
96 h 
HPLC 
120 h 
HPLC 
144 h 
HPLC 
168 h 
HPLC 
192 h 
HPLC 
216 h 
HPLC 
240 h 
HPLC HPLC 
Immuno
-assay 
Course 1 0 1155.8 14.96 18.38 10.78 0.80 0.209        
Course 2 0.04 1127.1 11.8 20 10.2 0.82 0.24        
Course 3 0.05 1321.2 18.9 26 0 0.44 0.16        
Course 4 0.07 967 14.4 16.97 0.7 0.48 0.09        
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Table 38: HOURS REQUIRED TO ACHIEVE [MTX] OF < 0.2 µM FOR BOTH 
RESCUE REGIMENS, PER PATIENT AND PER COURSE  
GLU1-01 GLU1-09 
Course 1 48 h Course 1 72 h 
Course 2 48 h Course 2 72 h 
Course 3 72 h Course 3 48 h 
Course 4 72 h Course 4 48 h 
GLU1-02 GLU1-10 
Course 1 72 h Course 1 72 h 
Course 2 72 h Course 2 72 h 
Course 3 48 h Course 3 72 h 
Course 4 48 h Course 4 96 h 
GLU1-03 GLU1-11 
Course 1 48 h Course 1 72 h 
Course 2 48 h Course 2 72 h 
Course 3 144 h Course 3 48 h 
GLU1-04 Course 4 72 h 
Course 1 48 h GLU1-12 
Course 2 192 h Course 1 120 h 
GLU1-05 Course 2 312 h 
Course 1 96* h GLU1-13 
GLU1-06 Course 1 144 h 
Course 1 72 h Course 2 120 h 
Course 2 72 h GLU1-14 
Course 3 48 h Course 1 96 h 
Course 4 72 h GLU1-15 
GLU1-07 Course 1 72 h 
Course 1 48 h Course 2 72 h 
Course 2 48 h Course 3 96 h 
Course 3 144 h Course 4 96 h 
Course 4 120 h GLU1-16 
GLU1-08 Course 1 72 h  
Course 1 72 h Course 2 72 h  
Course 2 48 h Course 3 72 h 
Course 3 72 h Course 4 72 h 
Course 4 72 h   
(courses given with glucarpidase are highlighted) 
* glucarpidase given as emergency treatment 72 hours pot methotrexate 
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Table 39: HOURS REQUIRED TO ACHIEVE [MTX] OF < 0.2 µM FOR EACH 
RESCUE REGIMEN AND FOR BOTH REGIMENS 
Hours to achieve [MTX] of 0.2 µM (from the start of MTX infusion) 
 
Both rescue 
regimens 
folinic acid 
rescue regimen 
Glucarpidase/folinic 
acid rescue regimen 
Mean 82 h 84.5 h 80 h 
Median 72 h 72 h 60 h 
Range 48-312 h 72-144 h 48-312 h 
 
Median [MTX] measured by HPLC at 24 hours after starting the infusion was 15.9 
µM (range, 3.27 to 253.54) for courses given with both rescue regimens (Table 20 
and Table 23). For courses given with folinic acid alone, the median [MTX] 
measured by HPLC at 24 hours after starting the infusion was 16.71 µM (range, 
3.79 to 152.62). For courses given with glucarpidase/folinic acid the median [MTX] 
measured by HPLC at 24 hours after starting the infusion was 15.67 µM (range, 
3.27 to 253.54) (Table 40). 
Median [MTX] measured by immunoassay at 24 hours after starting the infusion 
was 19.2 µM (range, 3.55 to 259.94) for courses given with both rescue regimens 
(Table 37 and Table 40). For courses given with folinic acid alone median [MTX] 
measured by immunoassay at 24 hours after starting the infusion was 20.47 µM 
(range, 3.55 to 149.78). For courses given with glucarpidase/folinic acid median 
[MTX] measured by immunoassay at 24 hours post starting the infusion was 17.44 
µM (range, 4.49 to 259.94) (Table 40). 
Median [MTX] measured by HPLC at 4 hours post starting the infusion was 1295.4 
µM (range, 524.42 to 2225.8) for courses given with both rescue regimens (Table 37 
and Table 40). For courses given with folinic acid alone median [MTX] measured by 
HPLC at 4 hours post starting the infusion was 1298.42 µM (range, 535.46 to 
1901.72). For courses given with glucarpidase/folinic acid, median [MTX] measured 
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by HPLC at 4 hours post starting the infusion was 1294.72 µM (range, 524.42 – 
2225.8) (Table 40). 
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Table 40: [MTX] AT 4 HOURS AND 24 HOURS POST STARTING THE INFUSION OF MTX 
 [MTX] at 4 hours (HPLC, µM) [MTX] at 24 hours (HPLC, µM) [MTX] at 24 hours (immunoassay, µM) 
 
Both rescue 
regimens 
Placebo & 
folinic acid 
Glucarpidase 
& folinic acid 
Both rescue 
regimens 
Placebo & 
folinic acid 
Glucarpidase 
& folinic acid 
Both rescue 
regimens 
Placebo & 
folinic acid 
Glucarpidase 
& folinic acid 
Median 1295.40 1298.42 1294.72 15.92 16.71 15.67 19.19 20.47 17.44 
Mean 1244.25 1242.42 1263.81 31.85 27.65 35.43 33.94 27.99 39.01 
Minimum 524.42 535.46 524.42 3.27 3.79 3.27 3.55 3.55 4.49 
Maximum 2225.8 1901.72 2225.8 253.54 152.62 253.54 259.94 149.78 259.94 
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In order to compare the effect of glucarpidase on the time to eliminate MTX, the 
distribution of our data was examined. Our measurements were found to have highly 
skewed distribution (Figure 9). Since it was not possible to normalize it by log 
transformation (or any other transformation) the outcome measurements were 
assumed to have a Poisson distribution. 
Figure 9: GRAPHICAL ILLUSTRATION OF THE DISTRIBUTION OF DATA 
RELATED TO TIME TO ELIMINATE MTX 
 
 
Additionally, as the study had a crossover design, it was necessary to take account 
of the repeat measurements for each subject in the analysis. This was done using 
multilevel statistical methods, assuming that individual measurements were nested 
within patients. To allow for both the data structure and distribution of values, 
multilevel Poisson regression was used for the analysis.  
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The multilevel Poisson regression analyses suggested that there was some 
evidence of a carryover of the effects of glucarpidase on time to clear MTX 
(p=0.007). The presence of such interaction suggests that the effects of 
glucarpidase were different in the two treatment cycles (i.e. different effects of 
glucarpidase when it was given in the first treatment cycle to when it was given in 
the second) and a carryover of the effects of glucarpidase to the second treatment 
cycle.  
Two different approaches were used to examine the effect of glucarpidase on the 
time to eliminate MTX: a) data from both treatment cycles were analysed assuming 
that the period by treatment effect was not present, and b) only the results from the 
first treatment cycle were analysed as these were unaffected by carryover. 
The time to clear MTX was found to be significantly less with the use of glucarpidase 
when data from both cycles was analysed (p <0.001, Table 41). There was no 
significant effect when the analysis was restricted to the first cycle only. However, 
given the significant period by treatment interaction, all these analyses should be 
viewed with some caution. 
Table 41: EFFECT OF GLUCARPIDASE ON THE TIME TO ELIMINATE MTX  
Outcome Data used in analysis Ratio* (95% CI) P-value 
Time to eliminate 
methotrexate 
Both periods 0.70 (0.65, 0.74) <0.001 
1
st
 cycle only 1.23 (0.82, 1.87) 0.32 
*The effect of glucarpidase on the time to eliminate MTX is reported in the form of 
ratios. This is given as the ratio of the outcome value when glucarpidase was given 
compared to when it wasn't. A ratio of above 1 suggests higher values of the 
outcome when glucarpidase was given, whilst a ratio below 1 would suggest lower 
values. 
For MTX courses given with standard rescue, [MTX] measured by HPLC and 
immunoassay (IA) are shown on Table 42. 
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Table 42: MTX COURSES WITH STANDARD RESCUE: AGREEMENT BETWEEN HPLC AND IMMUNOASSAY (IA)  
MTX courses with standard rescue: [MTX] in µM at different time points  
 24h 48 h 72 h 96 h 120 h 144 h 
 HPLC IA HPLC IA HPLC IA HPLC IA HPLC IA HPLC IA 
GLU1-01 
Course 3 14.47 15.57 0.71 0.94 0.20 0.27       
Course 4 12.5 13.01 0.67 0.64 0.23 0.19       
GLU1-02 
Course 1 18.30 22.79 0.54 0.65 0.13 0.16       
Course 2 16.71 20.47 0.46 0.53 0.06 0.11       
GLU1-03 
Course 3 20.13 24.45 1.37 1.92 0.81 1.18 0.47 0.44 0.25 0.24 0.18 0.14 
GLU1-05 
Course 1 30.11 33.22 1.39 1.8 0.58 0.97 Post 72 hours, glucarpidase given as emergency treatment 
GLU1-06 
Course 1 10.85 12.55 0.27 0.35 0.07 0.09       
Course 2 3.79 3.55 0.22 0.22 0.1 0.19       
GLU1-07 
Course 3 152.62 149.78 8.61 8.66 0.98 1.31 0.39 0.43 0.24 0.28 0.15 0.13 
Course 4 141.6 114.83 4.66 4.24 1.01 0.92 0.53 0.41 0.21 0.14   
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MTX courses with standard rescue: [MTX] in µM at different time points  
 24h 48 h 72 h 96 h 120 h 144 h 
 HPLC IA HPLC IA HPLC IA HPLC IA HPLC IA HPLC IA 
GLU1-08 
Course 3 5.54 5.57 0.25 0.25 0.19 0.08       
Course 4 4.48 5.16 0.2 0.21 0.05 0.07       
GLU1-09 
Course 1 7.31 7.26 0.33 0.35 0.09 0.09       
Course 2 8.33 7.6 0.34 0.32 0.13 0.08       
GLU1-10 
Course 1 29.83 28.42 1.13 0.68 0.15 0.09       
Course 2 23.10 22.77 1 0.96 0.2 0.17       
GLU1-11 
Course 1 31.95 28.03 0.84 0.6 0.23 0.11       
Course 2 12.22 11.05 0.58 0.57 0.16 0.1       
GLU1-14 
Course 1 25.62 30.04 1.04 0.86 0.39 0.25 0.09 0.10     
GLU1-15 
Course 3 23.01 26.12 1.07 1.24 0.41 0.3 0.13 0.13     
Course 4 16.76 23.19 0.96 0.73 0.58 0.42 0.15 0.18     
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MTX courses with standard rescue: [MTX] in µM at different time points  
 24h 48 h 72 h 96 h 120 h 144 h 
 HPLC IA HPLC IA HPLC IA HPLC IA HPLC IA HPLC IA 
GLU1-16 
Course 1 14.96 18.38 0.80 0.39 0.209 0.13       
Course 2 11.8 20 0.82 0.58 0.24 0.15       
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The agreement between [MTX] measured by HPLC and immunoassay (IA) was 
examined. Since both methods measure the same quantity, it seemed appropriate 
to examine the agreement between them rather than the correlation. This was 
assessed using the intra-class correlation (ICC) coefficient which divides the total 
variability in the data in that between patients, and that between repeat 
measurements of the same patient. The ICC is the proportion of the total variability 
that is between patients. If the agreement is good, then the majority of the variability 
in the data should be between patients, with very little variability between methods 
for the same patient, and thus the ICC value should be close to 1. For this analysis, 
data from all time points were analysed in a single analysis. Additionally due to the 
skewed nature of outcome values, the analysis was performed on the log scale. 
The analysis indicated an ICC value of 0.99, i.e. 99% of all variability was between 
different observations, and only 1% of variability in the data was due to differences 
between the chromatography and immunoassay methods for the same 
measurements. This extremely high value suggests very good agreement between 
the two methods.  
For MTX courses given with glucarpidase/folinic acid rescue, plasma concentrations 
of MTX and DAMPA 15 minutes after glucarpidase as well as the reduction of 
plasma MTX concentrations 15 minutes after glucarpidase are shown in Table 18. 
Blood samples taken for HPLC analysis at T=0 hours, 4 hours, 24 hours, 24.20 
hours and 48 hours from the GLU1-12 patient following his first course of MTX 
became jelly like with the addition of HCL. Therefore they were unsuitable for HPLC 
analysis. In the remaining twenty seven courses, plasma MTX concentrations 
decreased from a median of 15.67 µM (range, 3.27 to 253.4) prior to glucarpidase to 
a median of 0.4 µM (range, 0 to 3.195) 15 minutes after glucarpidase administration. 
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Glucarpidase resulted in a rapid 92.5 to100% reduction (median, 98.05%) in all 
patients. 
The median DAMPA plasma concentration 15 minutes after glucarpidase was 4.92 
µM (range, 1.7 to 75.70) as shown in Table 43. DAMPA plasma concentration 15 
minutes after glucarpidase administration was 15-62% of methotrexate plasma 
concentration prior to glucarpidase administration (median 34%, mean 35.4%).  
A small rebound increase in [MTX] was observed in 21% (6/28) of MTX courses 
given with glucarpidase/folinic acid rescue (Table 44). The median [MTX] prior to 
glucarpidase administration was 24.87 µM (range 10.76 to 253.54 µM) in those 
patients. The median [MTX] 15 minutes after glucarpidase administration was 0.335 
µM (range 0 to 3.19 µM). The median peak rebound [MTX] was 0.49 µM (range 0.03 
to 3.6 µM). Rebound occurred at a median of 24 hours after administration of 
glucarpidase. 
Table 43: [MTX] AND [DAMPA] 15 MINUTES POST GLUCARPIDASE AND 
REDUCTION OF [MTX] 15 MIN POST GLUCARPIDASE 
 
Plasma concentration measured by HPLC (µM) Reduction of 
[MTX], 15 
minutes post 
glucarpidase 
(%) 
[MTX]  
at 24 h 
[MTX]  
at 24:20 h 
[DAMPA] at 
24:20 h (*) 
GLU1-01 
Course 1 4.99 0.16 2.2 (44%) 96.8 
Course 2 7.96 0.6 2.5 (31%) 92.5 
GLU1-02 
Course 3 15.66 0 5.86 (37%) 100 
Course 4 21.16 0.09 8.60 (41%) 99.6 
GLU1-03 
Course 1 11.78 0 3.96 (34%) 100 
Course 2 54.37 0.41 33.5 (62%) 98.5 
GLU1-04 
Course 1 12.17 0.07 5.09 (42%) 99.4 
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Plasma concentration measured by HPLC (µM) Reduction of 
[MTX], 15 
minutes post 
glucarpidase 
(%) 
[MTX]  
at 24 h 
[MTX]  
at 24:20 h 
[DAMPA] at 
24:20 h (*) 
Course 2 54.32 0.79 31.92 (59%) 98.5 
GLU1-06 
Course 3 13.3 0.208 1.96 (15%) 98.4 
Course 4 13.14 0.1 2.58 (20%) 99.2 
GLU1-07 
Course 1 95.66 0.85 40.54 (42%) 99.1 
Course 2 135.86 1 45.18 (34%) 99.3 
GLU1-08 
Course 1 3.95 0.04 1.81 (46%) 99 
Course 2 7.69 0.1 1.7 (22%) 98.7 
GLU1-09 
Course 3 6.95 0.09 2.21 (32%) 98.7 
Course 4 10.01 0.16 2.95 (29%) 98.4 
GLU1-10 
Course 3 36.06 0.26 14.08 (39%) 99.3 
Course 4 43.68 0.7 16.12 (37%) 98.4 
GLU1-11 
Course 3 16.18 0.40 6.4 (40%) 97.5 
Course 4 18.9 0.53 5.6 (30%) 97.2 
GLU1-12 
Course 1 Samples unsuitable for analysis Not applicable 
Course 2 253.54 3.195 75.70 (30%) 98.7 
GLU1-13 
Course 1 16.35 0.43 4.36 (27%) 97.4 
Course 2 44.4 0.82 23.5 (53%) 98.1 
GLU1-15 
Course 1 10.76 0.41 2.47 (23%) 96.2 
Course 2 15.18 1.02 4.46 (29%) 93.3 
GLU1-16 
Course 3 18.9 0 4.92 (26%) 100 
Course 4 14.4 0.7 4.8 (33%) 95.1 
Mean reduction of [MTX] 15 min post glucarpidase 98.05% 
Median reduction of [MTX] 15 min post glucarpidase 98.5% 
Range of reduction of [MTX] 15 min post glucarpidase 92.5%-100% 
*[DAMPA] at 24.20 hours in comparison to [MTX] at 24 hours 
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Table 44: REBOUND INCREASE IN [MTX] AFTER GLUCARPIDASE 
ADMINISTRATION  
Number of treatment courses given with 
glucarpidase/folinic acid rescue 
28 
Number of treatment courses given with 
glucarpidase/folinic acid rescue where rebound 
increase in [MTX] noted 
8 
[MTX] pre glucarpidase at 24 h 
Median 24.87 µM 
Range 10.76  µM - 253.54  µM 
[MTX] post glucapidase at 24.20 h 
Median 0.335 µM 
Range 0 µM - 3.19 µM 
Peak rebound* in [MTX] 
Median 0.49 µM 
Range 0.03 µM - 3.6 µM 
*Rebound occurred at a median of 24 hours after the administration of glucarpidase 
[MTX] at different time points per patient and per MTX course as measured by 
HPLC are also presented in graphs (Figure 10.1 to Figure 10.16) 
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Figure 10: [MTX] AT DIFFERENT TIME POINTS PER PATIENT AND PER MTX 
COURSE AS MEASURED BY HPLC  
Figure 10.1: PATIENT GLU1-01 
 
 
Figure 10.2: PATIENT GLU1-02 
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Figure 10.3: PATIENT GLU1-03 
 
 
Figure 10.4: PATIENT GLU1-04 
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Figure 10.5: PATIENT GLU1-05 
 
 
Figure 10.6: PATIENT GLU1-06 
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Figure 10.7: PATIENT GLU1-07 
 
 
Figure 10.8: PATIENT GLU1-08 
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Figure 10.9: PATIENT GLU1-09 
 
 
Figure 10.10: PATIENT GLU1-10 
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Figure 10.11: PATIENT GLU1-11 
 
 
Figure 10.12: PATIENT GLU1-12 
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Figure 10.13: PATIENT GLU1-13 
 
 
Figure 10.6: PATIENT GLU1-14 
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Figure 10.15: PATIENT GLU1-15 
 
 
Figure 10.16: PATIENT GLU1-16 
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drug concentrations and the respective time spans over which they had been 
obtained (Table 45). AUC0-24 (area under the curve from the start of MTX infusion to 
24 hours) and AUC24-72 (from 24 hours to 72 hours after the start of the infusion) 
were also calculated for treatment courses given with and without glucarpidase 
(Table 46). 
The median AUC0-T in MTX courses given with both regimens (i.e. folinic acid alone 
and glucarpidase/folinic acid rescue) was 15101 μMh (range, 5874 to 27192 μMh). 
There was very little difference in the AUC observed in MTX courses given with 
folinic acid rescue and MTX courses given with glucarpidase/folinic acid rescue. The 
median AUC0-T in MTX courses given with folinic acid rescue was 14653 μMh 
(range, 6462 to 23290 μMh) whereas the median AUC0-T in MTX courses given with 
glucarpidase/folinic acid rescue was 15233 μMh (range, 5874 to 27192 μMh) (Table 
29). This is because AUC0-24 represents the greatest proportion (98%) of the AUC0-T, 
and reflects the exposure to MTX prior to glucarpidase administration.  
Table 45: AUC AND PEAK [MTX] (Cmax) PER PATIENT AND COURSE OF MTX  
GLU 1 
patient 
COURSE AUC(0-T) AUC(0-24) AUC(24-72) Cmax 
GLUC 
1: yes 
0: no 
01 
1 12267.8467 12257.41666 4.992466666 1018 1 
2 15741.928 15714.81466 9.739999999 1303.84 1 
3 14046.647 13872.79 159.8198333 1144.8 0 
4 17431.071 17388.20333 40.47766666 1439.6 0 
02 
1 15901.8206 15709.2165 179.516875 1298.42 0 
2 11006.9851 10845.42417 142.627625 896.2 0 
3 15454.7773 15452.03614 0 1276.4 1 
4 11967.8043 11962.17644 1.224166667 985.6 1 
03 
1 20069.4279 20061.505 0.69375 1673.68 1 
2 15233.5173 15197.96583 6.827499999 1228 1 
3 16926.1923 2740.074 249.3433334 1370 0 
04 
1 10265.4515 10259.52471 1.294166666 845.4 1 
2 14755.2037 14686.24536 18.01366666 1179.4 1 
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GLU 1 
patient 
COURSE AUC(0-T) AUC(0-24) AUC(24-72) Cmax 
GLUC 
1: yes 
0: no 
05 1 N/A N/A N/A 1400 0 
06 
1 11270.0468 11170.28242 90.45375 922.46 0 
2 11259.5272 11219.55403 38.8245 932.44 0 
3 9483.83171 9468.65 3.195541666 983.4 1 
4 15667.9637 15657.12118 8.52625 1294.72 1 
07 
1 14678.5806 14596.5315 12.87716667 1176.4 1 
2 17252.0646 17177.1065 16.11825 1319.2 1 
3 N/A N/A N/A N/A 0 
4 20997.3277 19441.336 1259.293334 1638 0 
08 
1 7090.48285 7080.879074 1.8693 587.18 1 
2 5874.24277 5837.986 3.101666667 524.42 1 
3 8347.15811 8285.060775 45.80154167 723.76 0 
4 6462.9393 6402.937775 57.33802501 535.46 0 
09 
1 16200.3296 16114.57943 79.13342501 1337.72 0 
2 16451.6036 16338.90407 81.32 1355.58 0 
3 14692.5626 14687.46375 1.982166667 1219 1 
4 16422.7749 16338.90407 81.32 1355.58 1 
10 
1 16910.7263 16557.87062 331.6176666 1355.9 0 
2 14653.0678 14400.5525 191.4026666 1181.6 0 
3 19071.2825 19043.6565 15.333 1558 1 
4 19406.9292 19353.05416 40.86299999 1577.44 1 
11 
1 21195.2204 20923.28834 240.4649167 1741.6 0 
2 17341.0917 17187.3505 113.6346667 1452.6 0 
3 16718.1677 16689.06833 11.225 1387 1 
4 15560.8803 15529.65417 12.60566667 1370 1 
12 
1 N/A N/A N/A N/A 1 
2 26550.1785 26140.64678 161.3121666 1968.44 1 
13 
1 20613.2894 20525.21375 26.17375 1698 1 
2 27192.6615 27135.02166 34.37866667 2225.8 1 
14 1 23290.8083 23060.9344 216.6788334 1901.72 0 
15 
1 8309.7118 8266.64 19.9214 709.92 1 
2 9273.61223 9204.696665 22.57765 811.84 1 
3 11198.1271 10953.1253 195.535 954.68 0 
4 14190.3097 14014.02 128.8066666 1296.08 0 
16 1 13894.5843 13726.51 142.3086667 1155.8 0 
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GLU 1 
patient 
COURSE AUC(0-T) AUC(0-24) AUC(24-72) Cmax 
GLUC 
1: yes 
0: no 
2 13446.4534 13263.64666 136.695 1127.1 0 
3 14968.7619 14926.75 11.9301075 1321.2 1 
4 11408.36 11380.115 20.06583334 967 1 
Median 15101.1396 14807.1068 36.6016 1285.56 
 Mean 14966.9653 14546.8022 97.2761 1235.9662 
 Minimum 5874.2428 2740.074 0 524.42 
 Maximum 27192.6615 27135.0217 1759.2933 2225.8 
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Table 46: MEDIAN, MEAN, MINIMUM AND MAXIMUM AUC AND MTX Cmax FOR BOTH RESCUE REGIMENS AND EACH RESCUE 
REGIMEN (PLACEBO/FOLINIC ACID AND GLUCARPIDASE/FOLINIC ACID) 
 AUC(0-T) AUC(0-24) AUC(24-72) CMAX 
 
Both 
rescue 
regimens 
Placebo & 
FA 
Glu & 
FA 
Both 
rescue 
regimens 
Placebo & 
FA 
Glu & 
FA 
Both 
rescue 
regimens 
Placebo & 
FA 
Glu & 
FA 
Both 
rescue 
regimens 
Placebo & 
FA 
Glu & 
FA 
Median 15101.1396 14653.0678 15233.5173 14807.1068 14014.02 15197.9658 36.6016 142.3086 11.9301 1285.56 1296.08 1276.4 
Mean 14966.9653 14877.2398 15036.7517 14546.8022 13981.6981 14986.3275 97.2761 196.2426 20.3023 1235.9662 1226.7390 1243.1429 
Minimum 5874.2428 6462.9393 5874.2427 2740.074 2740.074 5837.986 0 38.8245 0 524.42 535.46 524.42 
Maximum 27192.6615 23290.8083 27192.6615 27135.0217 23060.9344 27135.0216 1759.2933 1259.2933 161.3122 2225.8 1901.72 2225.8 
(AUC(0-T): area under curve from 0 hours to T=last blood sample collected, AUC(0-24): area under curve from 0 hours to 24 hours, AUC (24-
72): area under curve from 24 hours to 72 hours) 
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To assess whether there was a difference in AUC0-24, AUC24-72 and AUC0-T between 
treatment courses given with and without glucarpidase, an ANOVA model that 
accounted for the crossover design with repeated measures was fitted. In addition to 
the treatment term (i.e. with or without glucarpidase), carryover, sequence and 
period effects were included. The model was fitted to each of the 3 outcomes AUC0-
24, AUC24-72 and AUC0-T.  
The use of glucardpidase was estimated to reduce the AUC0-T value by an average 
of (-)1060.3 µMh (95%CI:  -2671.1, 550.6), although this was not statistically 
significant (p=0.188). For AUC0-24 the treatment effect was not significant either 
(p=0.667), estimated as 471.4 µMh (95%CI:  -1750.9, 2693.6). However, the effect 
of glucardpidase on AUC24-72 was highly significant (p=0.0008), reducing the AUC by 
an average of (-)206.1 µMh (95% CI: -317.8, -94.4). In all 3 models there was no 
evidence at all of any carryover, sequence or period effects.   
The correlation between MTX Cmax and AUC0-T was studied. For all MTX courses 
(either with standard folinic acid or glucarpidase/folinic acid rescue) there was strong 
and highly significant correlation between MTX Cmax and AUC0-T and less strong 
correlation between MTX Cmax and AUC24-72, although the latter was not statistically 
significant.  
In particular, for MTX courses with standard folinic acid rescue, there was strong 
and highly significant correlation between Cmax and AUC0-T (r=0.994; p<0.0001), 
adjusting for the clustered data (repeated measures). There was less strong 
correlation between Cmax and AUC24-72 although this was not statistically significant 
(r=0.412; p=0.158).  
Similarly, for MTX courses given with glucarpidase/folinic acid rescue, there was 
strong and highly significant correlation between Cmax and AUC0-T (r=0.989; 
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p<0.0001). There was less strong correlation between Cmax and AUC24-72 although 
this was not statistically significant (r=0.486; p=0.118).  
The within-subject and inter-individual variation in MTX Cmax and AUC values was 
examined using the intra-class correlation (ICC) coefficient which divides the total 
variability in the data in that between patients, and that between repeat 
measurements of the same patient. The ICC was calculated from a multilevel linear 
regression model, with the MTX course number and the treatment arm accounted 
for. The variation was measured after taking account of any effects caused by 
course number and treatment with or without glucarpidase. The AUC values from 
24-72 hours were found to have a highly skewed distribution, and thus the analysis 
of this outcome was performed on the log scale. 
The results are shown in Table 47. There was a reasonably high ICC for AUC0-t, 
suggesting that 73% of the total variation in AUC values can be put down to 
between subject variation, with the smaller amount down to variation between 
repeat measurements. However, this is still a reasonable amount of within-subject 
variation. The results for MTX Cmax, showed a similar amount of inter-individual 
variation to those for the AUC0-t values. In particular 72% of the total variation in 
MTX Cmax values can be put down to between subject variation, with the smaller 
amount down to variation between repeat measurements. There was more inter-
individual variation for the AUC0-24 and AUC24-72 measurements, where the ICC 
values were lower. For AUC0-24 the difference between repeat measurements of the 
same subjects was of a similar size to the differences between individuals. For 
AUC24-72 the within-individual variation was the major source of variation. 
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Table 47: WITHIN-SUBJECT AND INTER-INDIVIDUAL VARIATION IN MTX 
Cmax AND AUC VALUES 
Outcome Between-subject SD Within-subject SD ICC 
AUC 0-t (µMh) 3837 2334 0.73 
AUC 0-24 (µMh) 3411 3242 0.52 
AUC 24-72 (µMh)
 (*)
 0.41 0.84 0.20 
MTX Cmax (µM) 305 191 0.72 
(*) Variable analysed on the log scale 
5.6. GLUCARPIDASE RELATED TOXICITY 
In the previously described PD, NCI and Berlin Studies 52 glucarpidase-related 
adverse events (AEs) were reported in 26/318 patients (Section 1.4.3). 
Glucarpidase is a recombinant bacterial protein and it therefore has the potential to 
induce an immune response. Allergic reaction was the most common glucarpidase-
related AE, occurring in 45 of patients treated. The most common non-allergic AE 
considered related to treatment with glucarpidase were paraesthesia (0.6% of 
patients), nausea (0.6% of patients) and hypotension (0.6% of patients). Two 
serious adverse events (SAEs) hypertension and arrhythmia that may have been 
related to glucarpidase administration were also reported. 
In the GLU clinical trial, a total of 51 doses of HD-MTX were administered. 
Glucarpidase rescue was delivered following twenty seven of those doses (27/51, 
53% of the doses). A further dose of glucarpidase was given to the GLU 1-05 patient 
as emergency treatment post his first dose of HD-MTX as he developed delayed 
MTX elimination due to impaired renal function. His treatment arm was unblinded as 
per study protocol; he was found to have been randomised to treatment arm B and 
therefore had not received glucarpidase as part of the study treatment. A total of 28 
doses of glucarpidase were administered in 15 patients. The patient GLU 1-14, 
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randomised to treatment arm B, did not receive any glucarpidase as his treatment 
was discontinued early, due to knee effusion, following the first dose of HD-MTX. 
AEs related to glucarpidase were recorded in the Glucarpidase Adverse Event form 
(part of the CRF) and followed-up until their resolution. AEs not related to 
glucarpidase were followed until the end of study, i.e. day 21 of cycle 2. No adverse 
events related to glucarpidase occurred to any of the GLU 1 participants. 
5.7. ECONOMIC IMPACT OF USING GLUCARPIDASE VERSUS STANDARD 
RESCUE 
In order to investigate the economic impact of using glucarpidase versus standard 
rescue, we reviewed the number of days required in hospital and total folinic acid 
dose per course. 28 MTX courses were given with glucarpidase and folinic acid 
(glu/FA) and 23 were given with folinic acid alone (FA). 
Folinic acid requirements and length of hospital stay per patient and course are 
shown in Table 48. 
The median and average folinic acid dose required in glu/FA courses was 
189.5mg/m2 and 478mg/m2 respectively (range 117-5454 mg/m2), whereas the 
median and average folinic acid dose required in FA courses was 192mg/m2 and 
336mg/m2 respectively (range 116-1371 mg/m2).  
The median and average length of hospital stay per patient and course was 4 and 
4.9 days respectively (range 4-13 days). The median and average length of patient’s 
hospital stay per glu/FA course was 4 and 5.04 days respectively (range 4-13 days), 
whereas the median and average length of patient’s hospital stay per FA course 
was 4 and 4.77 days respectively (range 4-10 days). 
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Table 48: FOLINIC ACID REQUIREMENTS PER PATIENT AND COURSE 
GLU study 
patient 
MTX courses  
(glu/FA courses highlighted) 
FA dose per course Days in hospital 
01 
Course 1 119 mg/m
2
 4 
Course 2 119 mg/m
2
 4 
Course 3 146 mg/m
2
 4 
Course 4 116 mg/m
2
 4 
02 
Course 1 199 mg/m
2
 4 
Course 2 143 mg/m
2
 4 
Course 3 250 mg/m
2
 4 
Course 4 180 mg/m
2
 4 
03 
Course 1 167 mg/m
2
 4 
Course 2 466 mg/m
2
 4 
Course 3 764 mg/m
2
 7 
04 
Course 1 136 mg/m
2
 4 
Course 2 1168 mg/m
2
 10 
05 Course 1 983 mg/m
2
 10 
06 
Course 1 192 mg/m
2
 4 
Course 2 199 mg/m
2
 4 
Course 3 196 mg/m
2
 4 
Course 4 194 mg/m
2
 5 
07 
Course 1 722 mg/m
2
 5 
Course 2 944 mg/m
2
 5 
Course 3 1371 mg/m
2
 7 
Course 4 967 mg/m
2
 6 
08 
Course 1 131 mg/m
2
 4 
Course 2 117 mg/m
2
 4 
Course 3 191 mg/m
2
 4 
Course 4 171 mg/m
2
 4 
09 
Course 1 153 mg/m
2
 4 
Course 2 153 mg/m
2
 4 
Course 3 153 mg/m
2
 4 
Course 4 134 mg/m
2
 4 
10 
Course 1 209 mg/m
2
 4 
Course 2 177 mg/m
2
 4 
Course 3 243 mg/m
2
 4 
Course 4 462 mg/m
2
 5 
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GLU study 
patient 
MTX courses  
(glu/FA courses highlighted) 
FA dose per course Days in hospital 
11 
Course 1 208 mg/m
2
 4 
Course 2 158 mg/m
2
 4 
Course 3 156 mg/m
2
 4 
Course 4 153 mg/m
2
 4 
12 
Course 1 326 mg/m
2
 7 
Course 2 5454 mg/m
2
 13 
13 
Course 1 225 mg/m
2
 8 
Course 2 560 mg/m
2
 6 
14 Course 1 300 mg/m
2
 5 
15 
Course 1 154 mg/m
2
 4 
Course 2 248 mg/m
2
 4 
Course 3 253 mg/m
2
 5 
Course 4 320 mg/m
2
 5 
16 
Course 1 129 mg/m
2
 4 
Course 2 144 mg/m
2
 4 
Course 3 165 mg/m
2
 4 
Course 4 141 mg/m
2
 4 
 
We compared the effect of glucarpidase on the dose of folinic acid and length of 
hospital stay in cycles given with and without glucarpidase. Both outcomes 
measurements were found to have highly skewed distribution (Figure 11). Since it 
was not possible to normalize it by log transformation (or any other transformation) 
the outcome measurements were assumed to have a Poisson distribution. 
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Figure 11: GRAPHICAL ILLUSTRATION OF THE DISTRIBUTION OF DATA 
RELATED TO FOLINIC ACID DOSE AND LENGTH OF HOSPITAL 
STAY 
 
 
 
 
Additionally, as the study had a crossover design, it was necessary to take account 
of the repeat measurements for each subject in the analysis. This was done using 
multilevel statistical methods, assuming that individual measurements were nested 
within patients. To allow for both the data structure and distribution of values, 
multilevel Poisson regression was used for the analysis.  
The multilevel Poisson regression analyses suggested that there was some 
evidence of a carryover of the effects of glucarpidase on folinic acid dose (p<0.001), 
and to a less degree the length of hospital stay (p=0.05). The presence of such 
interaction suggests that the effects of glucarpidase were different in the two 
treatment cycles (i.e. different effects of glucarpidase when it was given in the first 
treatment cycle to when it was given in the second) and a carryover of the effects of 
glucarpidase to the second treatment cycle.  
Two different approaches were used to examine the effect of glucarpidase on the 
dose of folinic acid and length of hospital stay: a) data from both treatment cycles 
were analysed assuming that the period by treatment effect was not present, and b) 
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only the results from the first treatment cycle were analysed as these were 
unaffected by carryover. Given the significant period by treatment interaction, the 
latter analysis should be viewed with some caution. 
As shown in Table 49, there was no strong evidence of an effect of glucarpidase 
upon length of hospital stay using either analysis approach. Nevertheless, there was 
some slight evidence that glucarpidase increased the length of stay when only data 
from the first cycle was analysed, although this effect was not quite statistically 
significant.  
There was a significant effect of glucarpidase upon the dose of folinic acid using 
both analysis approaches. Using the data from both treatment cycles, glucarpidase 
was found to reduce the folinic acid dose, on average by around 13%. However, if 
the analysis is restricted to the first treatment cycle, then glucarpidase is associated 
with 3 fold higher folinic acid dose.  
This latter result highlighted that calculating the total folinic acid dose per course 
was not a good indicator of the economic impact of using glucarpidase versus 
standard rescue. GLU 1 participants had their dose of folinic acid adjusted based 
upon the pre-glucarpidase/placebo plasma MTX levels. The dose of folinic acid was 
maintained unchanged for 48 hours after glucarpidase/placebo. Hence, the total 
folinic acid dose did not reflect the effect of glucarpidase on MTX plasma levels at 
48 hours and 72 hours.  
Table 49: EFFECT OF GLUCARPIDASE ON FOLINIC ACID DOSE AND LENGTH 
OF HOSPITAL STAY.  
Outcome 
Data used in 
analysis 
Ratio* (95% CI) P-value 
Length of hospital 
stay 
Both periods 1.11 (0.86, 1.44) 0.42 
1
st
 cycle only 1.37 (0.98, 1.94) 0.06 
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Folinic acid dose 
Both periods 0.87 (0.84, 0.91) <0.001 
1
st
 cycle only 3.63 (1.68, 7.84) 0.001 
*The effect of glucarpidase on the dose of folinic acid and length of hospital stay is 
reported in the form of ratios. This is given as the ratio of the outcome value when 
glucarpidase was given compared to when it wasn't. A ratio of above 1 suggests 
higher values of the outcome when glucarpidase was given, whilst a ratio below 1 
would suggest lower values. 
5.8. ANTI-GLUCARPIDASE ANTIBODY RESPONSE FOLLOWING 
GLUCARPIDASE ADMINISTRATION 
Blood samples for anti-glucarpidase antibody assessment and enzyme 
neutralisation assay were collected as part of the GLU 1 study on days 1, 8 and 15 
of cycle 1 and days 1, 8, 15 and 30 of cycle 2 and at 3 and 6 months after starting 
cycle 2 if the sample on day 30 of cycle 2 was positive. 
Millipore BioPharma Services analysed all collected blood samples for anti-
glucarpidase antibodies using Bridging ELISA. The interim analytical report follows 
in Appendix 13. 
Covance Laboratories Ltd analysed all bloods samples with positive 
antiglucarpidase antibody response for enzyme neutralisation assay, using a UV 
spectrophotometric procedure. The draft report follows in Appendix 14. 
The results of the anti-glucarpidase antibody response are shown on Table 50. 14 
patients had more than one glucarpidase doses although no patients experienced 
allergic reaction following the second glucarpidase dose. Patient GLU1-05 required 
emergency treatment with glucarpidase (single dose) and had no blood samples 
assessed for anti-glucarpidase antibodies. Patient GLU1-14 only had one 
methotrexate course on the study and did not receive glucarpidase; therefore no 
blood samples were assessed for anti-glucarpidase antibodies for this patient.  
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Table 50: ANTIGLUCARPIDASE IgG RESPONSE PER GLU 1 PATIENT AND TREATMENT COURSE 
Antiglucarpidase IgG response (positive/negative), samples taken post glucarpidase highlighted  
(processed by Millpore BioPharma Services, complete report in Appendix 13) 
Patient number 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 
Received courses of 
methotrexate (received 
doses of glucarpidase) 
4 (2) 4 (2) 3(2) 2 (2) 1 (1) 4 (2) 4 (2) 4 (2) 4 (2) 4 (2) 4 (2) 2 (2) 2 (2) 1(1) 4 (2) 4 (2) 
Cycle 1 
Day 1 neg neg neg neg 
N
o
 s
a
m
p
le
s
 
p
ro
c
e
s
s
e
d
 
neg neg neg neg neg neg neg neg 
N
o
 s
a
m
p
le
 
p
ro
c
e
s
s
e
d
 
neg neg 
Day 8 neg neg neg neg neg neg neg neg neg neg neg neg neg neg 
Day 15 neg neg neg neg neg neg neg neg neg neg neg - neg neg 
Cycle 2 
Day 1 neg neg neg - 
P
a
ti
e
n
t 
re
c
e
iv
e
d
 g
lu
c
a
rp
id
a
s
e
 a
s
 
e
m
e
rg
e
n
c
y
 t
re
a
tm
e
n
t 
7
2
 h
o
u
rs
 p
o
s
t 
s
ta
rt
in
g
 m
e
th
o
tr
e
x
a
te
 
neg pos pos - neg neg - - 
N
o
 g
lu
c
a
rp
id
a
s
e
 g
iv
e
n
 
neg neg 
Day 8 neg neg - - neg neg neg neg neg neg - - neg pos 
Day 15 neg neg neg 
neg on 
day 30 
of cycle 
1 
neg pos neg pos neg neg 
neg on 
day 30 
of cycle 
1 
neg on 
day 30 
of cycle 
1 
pos pos 
Day 30 - - - - neg 
pos day 
23 of 
cycle 2 
neg neg - neg - - 
pos on 
day 30 
of cycle 
2 
- 
Day 90 - - 
neg on 
day 120 
- neg - neg neg neg neg - - - - 
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Antiglucarpidase IgG response (positive/negative), samples taken post glucarpidase highlighted  
(processed by Millpore BioPharma Services, complete report in Appendix 13) 
Patient number 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 
Received courses of 
methotrexate (received 
doses of glucarpidase) 
4 (2) 4 (2) 3(2) 2 (2) 1 (1) 4 (2) 4 (2) 4 (2) 4 (2) 4 (2) 4 (2) 2 (2) 2 (2) 1(1) 4 (2) 4 (2) 
Day 180 
neg on 
day 120 
pos 
neutrali
sing 
reactive 
neg - - neg neg - - - - - - - 
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Positive antibody response was found in 43% (6/14) of patients. Patient GLU1-02 had 
positive response at a concentration of 2526.2 ng/mL on day 180 of cycle 2, having 
received 2 doses of glucarpidase in cycle 2 of trial treatment. Patient GLU1-07 had 
positive response on days 1, 15 and 30 of cycle 2 having received glucarpidase in cycle 
1. The measured antibody equivalent concentrations were 526.7 ng/mL, 172.4 ng/mL 
and 123.9 ng/mL on day 1, 15 and 23, respectively. His response was interestingly 
negative on day 8 of cycle 2 and also negative on the follow-up sample on day 180. 
Patient GLU1-08 had positive response on day 1 of cycle 2 having received 
glucarpidase in cycle 1 of his treatment. His response was negative in the rest of blood 
samples on days 8, 15, 30, 90 and 180 of cycle 2. Patient GLU1-09 had positive 
response on day 15 of cycle 2, having received glucarpidase in cycle 2 of his treatment. 
His response became negative on days 30 and 90 of cycle 2. Patient GLU1-15 had 
positive response on days 15 and 30 of cycle 2, having received glucarpidase in cycle 1 
of his treatment. There are no follow-up blood samples. Patient GLU1-16 had positive 
response on days 8 and 15 of cycle 2, having received glucarpidase in cycle 2 of his 
treatment. Similarly no follow-up blood samples have been analysed. The positive 
samples from patients GLU1-08, GLU1-09, GLU1-15 and GLU1-16 gave low measured 
antibody equivalent concentrations that were below the limit of quantitation of the assay 
(<62.5 ng/mL). Patients GLU1-01, GLU1-03, GLU1-04, GLU1-06, GLU1-10, GLU1-11, 
GLU1-12 and GLU1-13 did not develop any anti-glucarpidase antibodies.  
It is worth noting that no patients became antiglucarpidase antibody positive after a 
single dose of glucarpidase. 
In total, 61 blood samples were taken after glucarpidase administration and analysed 
for antiglucarpidase IgG response. Of those, 16% (10/61) were found to be positive but 
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only 10% (1/10) of the samples with positive response were found to be neutralising 
reactive (Table 51). The activity of glucarpidase was inhibited in 17% (1/6) of patients 
with positive antibody response.  
Table 51: NEUTRALISING ANTIGLUCARPIDASE ANTIBODIES  
Neutralising antiglucarpidase antibodies  
(processed by Covance Laboratories Ltd, draft report in Appendix 14) 
Patient Number Time Point 
Antiglucarpidase 
IgG Response 
(positive/negative) 
Neutralising 
Reactive (yes/no) 
GLU1-02 Day 180 of cycle 2 positive yes 
GLU1-07 
Day 1 of cycle 2 positive no 
Day 15 of cycle 2 positive no 
Day 23 of cycle 2 positive no 
GLU1-08 Day 1 of cycle 2 positive no 
GLU1-09 Day 15 of cycle 2 positive no 
GLU1-15 
Day 15 of cycle 2 positive no 
Day 30 of cycle 2 positive no 
GLU1-16 
Day 8 of cycle 2 positive no 
Day 15 of cycle 2 positive no 
 
5.9. ASSESSMENT OF QUALITY OF LIFE IN TRIAL PARTICIPANTS 
For study participants aged 15 and under, Quality of Life was assessed using the 
“PedsQL 3.0 Cancer Module Acute Version questionnaire” (Appendix 10: Quality of Life 
questionnaires), whereas for study participants aged 16 and over at registration, quality 
of life was assessed using the European Organisation for Research and Treatment of 
Cancer (EORTC) QLQ-C30 version 3 (Aaronson et al. 1993; Fayers et al 2001) and the 
Functional Assessment of Cancer Therapy Scale-General (FACT-G) (Cella et al. 1993) 
questionnaires (Appendix 10: Quality of Life questionnaires).  
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Patient compliance with questionnaire completion was high and more than 94% of the 
scheduled questionnaires were returned (Table 52). 
Table 52: PATIENT COMPLIANCE WITH COMPLETION OF QUALITY OF LIFE 
QUESTIONNAIRES  
GLU 1 Patient’s ID 
QLQ-C30 or PedsQL 
(completed/requested 
questionnaires) 
FACT-G return 
(completed/requested 
questionnaires) 
1 6/6 6/6 
2 6/6 6/6 
3 5/5 5/5 
4 3/3 3/3 
5 1/1 1/1 
6 6/6 N/A 
7 5/6 5/6 
8 5/6 5/6 
9 6/6 N/A 
10 6/6 6/6 
11 6/6 6/6 
12 3/3 3/3 
13 2/3 2/3 
14 1/1 1/1 
15 5/6 5/6 
16 6/6 6/6 
Overall completion 72/76 (95%) 60/64 (94%) 
 
The responses of the quality of life questionnaires were not formally analysed at this 
time point since the trial is still ongoing. Following discussions with national experts in 
this subject, it was felt that the Oral Mucositis Weekly Questionnaires should be instead 
reviewed since mucositis seemed to have been the main toxicity that could have 
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compromised the quality of life of trial participants. The results of the Oral Mucositis 
Weekly Questionnaires are described in Section 5.4. 
5.10. GLU 1 INTERIM ANALYSIS: INDEPENDENT DATA MONITORING 
COMMITTEE (IDMC) REPORT 
The IDMC reviewed the data of the trial after completion of trial treatment of the first 16 
participants (Appendix 15: GLU 1 interim analysis, IDMC report). 
Analysis of the primary outcome did not show a statistically significant benefit of 
glucarpidase with P<0.005. Treatment with glucarpidase and folinic acid was not found 
to be significantly worse than standard treatment using an one-sided test with P<0.05.  
Recruitment rate was lower than expected. From June 2007 to May 2009 16 patients 
were recruited in over 22 months, while the expected accrual was 10-15 patients per 
year.  
The drop-out rate was significantly higher than expected with only 11 out of 16 
participants contributing to complete data set. The expected drop-out rate was 5% while 
the actual drop-out rate has been 31%. The trial sample size would need to be re-
calculated assuming that the drop-out rate will remain around 30%.   
There were no AEs related to the IMP. 
Two SAEs were reported between the opening of the trial and the interim analysis, both 
unrelated to the IMP. The reported SAEs have not been considered to be a safety issue 
that might alter the current benefit-risk assessment.  
SAE 1 was reported on 18 October 07 regarding the patient GLU1-05; Short description 
of the SAE 1: acute renal impairment after treatment with high-dose methoterexate; 
207 
reason for seriousness: prolongation of patient’s hospitalization; causality assessment 
regarding the IMP: unrelated; causality assessment regarding protocol treatment apart 
from the IMP: related to MTX; resolution: 27 November 2007. 
SAE 2 was reported on 27 March 08 regarding the patient GLU1-08; Short description 
of the SAE 2: right sided tension pneumothorax caused by patient’s extensive 
pulmonary disease; reason for seriousness: life threatening required admission to 
Intensive Care Unit; causality assessment regarding protocol treatment apart from the 
IMP: unrelated; causality assessment regarding the IMP: unrelated; resolution: 09 April 
2008 
The expiry date on the Voraxaze trial stock (BN 2090601) was March 2009 (36 months 
post manufacture date). At the point of the GLU 1 interim analysis, there was new 
stability data to support extension of the IMP shelf-life to 48 months. A substantial 
amendment to the protocol was planned in order to increase the IMP shelf-life to 48 
months (new expiry date: March 2010).  
Another issue that was addressed at the interim analysis was the blinding of the study. 
In treatment cycles where patients received glucarpidase, both MTX and DAMPA were 
identified and measured by HPLC. In treatment cycles where patients received placebo, 
only MTX was identified and measured by HPLC. DAMPA was not present. Therefore it 
was obvious to the investigators from the HPLC findings when patients had received 
glucarpidase and when they had placebo; treatment was therefore not blind to the 
investigators.  
The IDMC suggested that the design of the study needed to be changed from “double-
blind randomised” to “unblind randomised”. In order to minimize any bias both “Day 15” 
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assessments needed to be performed by the on duty registrars and not the 
investigators. 
Also, the timings of the blood samples for anti-glucarpidase antibody assessment and 
enzyme neutralisation assay were reviewed at the interim analysis. 
Blood samples for anti-glucarpidase antibody qualitative assessment and enzyme 
neutralisation assay were collected on days 0, 1, 8 and 15 of cycle 1 and days 1, 8, 15 
and 30 of cycle 2. If anti-glucarpidase antibodies were present on day 30 of cycle 2, 
patients were followed up for a further blood test, at 3 and 6 months after starting cycle 
2. However, there was a limited supply of one of the reagents used in the anti-
glucarpidase antibody qualitative assay. In order to get the most use out of this reagent, 
30 samples were analysed per assay run.  This meant that sometimes it was not 
possible to have the results for the first time points (days 0, 1, 8 and 15 of cycle 1 and 
days 1, 8, 15 and 30 of cycle 2) and two further blood samples (at 3 and 6 months after 
starting cycle 2) were collected. 
In view of that, the IDMC suggested that the trial protocol needed to be amended so 
that blood samples for anti-glucarpidase antibody qualitative assessment and enzyme 
neutralisation assay were collected on days 0, 1, 8 and 15 of cycle 1 and days 1, 8, 15 
and 30 of cycle 2 and at 3 and 6 months after starting cycle 2.   
Further to the GLU 1 interim analysis, a protocol amendment was planned to cover the 
following issues: 
 Extension of IMP shelf life 
 Amendment of the design of the study to unblind randomized  
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 Amendment of time points for collection of blood samples for anti-glucarpidase 
antibody assessment and enzyme neutralisation assay  
 Administrative amendment: sponsor contact details for SAE submission 
 Administrative amendment: updated arrangements for anti-glucarpidase antibody 
qualitative assessment and enzyme neutralisation analysis 
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6. DISCUSSION 
6.1. MTX IN OSTEOSARCOMA TREATMENT 
HD-MTX (12 g/m2) with folinic acid rescue is one of the standard chemotherapy agents 
used in the management of patients with osteosarcoma and approximately two thirds of 
newly diagnosed patients with non-metastatic resectable primary osteosarcoma can 
achieve prolonged disease free survival with multi-agent chemotherapy regimens 
containing doxorubicin, cisplatin and HD-MTX (Meyers et al. 2008). 
In early studies, MTX-related severe toxicity occurred in approximately 10% of patients 
and there was a 6% mortality rate (Ahmad et al. 1978). The introduction of pre-
treatment hydration, alkalinisation of urine, routine monitoring of [MTX] and 
pharmacokinetically adjusted folinic acid rescue has decreased the incidence of severe 
and life threatening MTX-related toxicity to less than 1% (Jüergens et al. 1983; Allegra 
et al. 1990; Buchen et al. 2005). 
However, despite currently used supportive measures, MTX related toxicity still occurs, 
resulting in increased morbidity, suboptimal chemotherapy doses, delays in subsequent 
chemotherapy administration and potentially reduced treatment efficacy. 
It is evident in the literature that the fewer the MTX-related delays in osteosarcoma 
treatment, the better the outcome of those patients (Frei at al., 1980; French Tumour 
Study Group, 1988; Bacci et al., 2001; Delepine et al., 1996). 
Nevertheless, there is currently no available literature on the incidence of delays in 
subsequent chemotherapy due to MTX toxicity in patients with osteosarcoma. 
Information is only available on the incidence of delayed MTX elimination in patients 
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with osteosarcoma which may then result in subsequent chemotherapy delays (Saeter 
et al., 1991; Winkler et al., 1988; Bacci et al., 2006; Zelcer et al., 2005). 
6.2. DELAYS IN CHEMOTHERAPY ADMINISTRATION DUE TO MTX TOXICITY 
In order to establish the incidence of chemotherapy delays due to MTX toxicity we 
reviewed the management of 56 osteosarcoma patients (aged 6 to 47 years, median 
age 20 years), treated with HD-MTX (12 g/m2) at our institution between January 2004 
and January 2005. MTX-induced toxicity resulted in delays in 47% of subsequent 
chemotherapy cycles in this cohort of patients. These findings were rather unexpected 
and were presented at the 38th Congress of International Society of Paediatric 
Oncology (SIOP) and the 12th annual meeting of the Connective Tissue Oncology 
Society (CTOS) (Appendix 16: SIOP 2006 poster and CTOS 2006 abstract). The 
feedback from the audience included surprise at this high incidence, though not 
supported by any similar data on MTX-induced treatment delays from their institutions. 
Valuable comments on the potential skew of our results due to the inclusion of patients 
aged ≥ 40 years led to a further audit where the incidence of chemotherapy delays due 
to MTX toxicity in different age groups (< 40 years and ≥ 40 years) in our institution was 
examined. However, no major difference in the delays in subsequent chemotherapy 
cycles between the two groups was seen. In the ≥ 40 years age group (median age 
44.5 years) MTX-induced toxicity resulted in delays in 58.5% of subsequent 
chemotherapy cycles. In the < 40 years age group (median age 15 years) MTX-induced 
toxicity resulted in delays in 52.2% of subsequent chemotherapy cycles.  
The main limitation in both audits was the subjectivity in clinical thresholds for initiating 
treatment. Although haematological and biochemical criteria for initiating treatment were 
objective (neutrophils ≥ 1x109/L and platelets ≥ 100x109/L; GFR ≥ 70 ml/min/1.73m2; 
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bilirubin ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, albumin > LLN; urinary pH > 7.0 immediately 
prior to MTX and good urine output), assessment of patient’s clinical status including 
mucositis was subjective and may have been influenced by the experience of the 
clinician. Less experienced clinicians may have been more reluctant to decide that a 
patient is fit to proceed with further chemotherapy whereas more experienced clinicians 
may have been more permissive.  
It would have been particularly informative to be able to compare our findings against 
similar institutions in the UK and Europe. However, such information is not available up-
to-date. 
 Both our audits showed that around half of subsequent chemotherapy cycles in the 
treatment of osteosarcoma were delayed due to MTX toxicity despite current supportive 
measures. Since fewer chemotherapy delays in osteosarcoma treatment are associated 
with better outcome, it was felt imperative to examine novel rescue regimens for MTX; 
less MTX toxicity would then lead to less chemotherapy delays and better treatment 
efficacy for patients with osteosarcoma.   
6.3. GLU 1 CLINICAL TRIAL: COULD GLUCARPIDASE PROVIDE SOME 
ADVANTAGE IN THE DELIVERY OF HD-MTX? 
Glucarpidase (Voraxaze™ or Carboxypeptidase G2) seemed to offer a promising 
opportunity for rescue from MTX toxicity. It has been used in the emergency setting to 
effectively treat patients with MTX-induced renal dysfunction (Widemann et al. 2006). A 
single intravenous dose of glucarpidase (50 units/kg) after MTX has resulted in the 
reduction of plasma MTX levels to the non-toxic range within minutes without causing 
toxicity. It has much higher affinity for MTX than for folinic acid so even high circulating 
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folinic acid levels are unlikely to interfere with extracellular MTX inactivation. Moreover, 
since glucarpidase is a high molecular weight protein and does not gain intracellular 
access, it is unlikely that it could counteract the anti-tumour effect of MTX. It was felt 
sensible to examine the use of glucarpidase in the routine setting after high-dose MTX.  
In order to investigate the efficacy and safety of glucarpidase for routine use after high 
dose MTX in patients with bone sarcoma, a phase II clinical trial (GLU 1) was set up.  
In view of the wide inter- and intra-patient variability in the pharmacokinetics and 
tolerance of MTX, a “randomised crossover” design was used. So as to minimize any 
cumulative dose effect which may interfere with MTX pharmacokinetics and associated 
toxicity, patients were randomised to receive either 2 courses of HD-MTX with standard 
rescue with folinic acid (cycle M) followed by 2 courses of HD-MTX with standard folinic 
acid rescue and glucarpidase (cycle GluM), or to receive cycle GluM first followed by 
cycle M. A crossover design was used to allow for smaller sample size, since patients 
acted as their own controls. The trial design was initially “double-blind randomised”. 
However, it became apparent that treatment with glucarpidase could not be blinded to 
the investigators since DAMPA, the catabolic product of glucarpidase action on MTX, 
was present in HPLC assays in all treatment cycles given with glucarpidase. Therefore, 
following the interim analysis, the trial design was changed from “double-blind 
randomised” to “unblind randomised”. 
The trial sample size was calculated assuming that rescue with glucarpidase would 
result in “fitness on day 15” in at least 90% of treatment cycles. Based on our audit 
findings (Section 2.1), only 55% of the patients in the standard rescue group were 
expected to be treatable on day 15 of each cycle.  Glucarpidase is currently used very 
rarely in the emergency setting and, therefore, is incredibly expensive. The assumption 
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that 90% of patients in the glucarpidase rescue group would be treatable on day 15 of 
each cycle was intentionally optimistic.  It was felt that only a confidently advantageous 
result could be meaningful and persuasive and lead to practice change.  
The primary objective of the trial was to examine whether glucarpidase rescue after HD-
MTX reduces delay resulting from MTX toxicity to subsequent cycles of chemotherapy.  
This endpoint was chosen as it is clinically relevant to patients with osteosarcoma 
treated with standard MAP chemotherapy (HD-MTX, adriamycin and cisplatin) who 
receive 2 courses/doses of MTX on consecutive weeks and are expected to be fit to 
receive further chemotherapy with adriamycin and cisplatin 15 days after the first MTX 
course/dose of each treatment cycle. The fitness criteria used in MAP regimen at that 
time point (general clinical condition permitting chemotherapy including no evidence of 
infection, no pyrexia, mucositis or diarrhoea; no serous effusions including ascites and 
pleural effusions; neutrophils ≥ 0.75x109/L and platelets ≥ 100x109/L; GFR ≥ 70 
ml/min/1.73m2; bilirubin ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, albumin > LLN; urinary pH >7.0 
immediately prior to MTX and good urine output) are identical to the “day 15 fitness 
criteria” used for in the GLU 1 clinical trial.  
Secondary trial objective included the examination of MTX and DAMPA 
pharmacokinetics prior and after glucarpidase administration. Plasma MTX and DAMPA 
concentrations were evaluated at regular time points. DAMPA is known to cross-react 
with MTX in most commercial immunological assays (Albertioni F et al. 1996; Allegra 
CJ. 1990; and Widemann BC et al. 1997) and MTX plasma concentrations determined 
by commercial laboratories are unreliable following treatment with glucarpidase. Plasma 
MTX concentrations in the GLU 1 study were measured by both immunoassay and high 
performance liquid chromatography (HPLC). Plasma DAMPA concentrations were 
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measured by HPLC. Since HPLC is not routinely available, I undertook the validation of 
a HPLC method for measurement of MTX and DAMPA in human plasma for trial 
patients and all HPLC assessments. 
Another secondary trial objective was to establish whether routine glucarpidase rescue 
after HD-MTX reduces the incidence, severity and duration of MTX-related adverse 
effects. MTX-related toxicity was documented and graded using primarily CTCTAE 
v3.0. 
Further secondary trial objectives included the evaluation of any adverse effects 
associated with the use of glucarpidase and the assessment of the anti-glucarpidase 
antibody response. 
Finally, the economic impact of routine glucarpidase administration was evaluated by 
examining the length of hospital stay and the total dose of folinic acid use for each MTX 
course administered with and without glucarpidase. 
Numerous time consuming factors such as confirmation of the sponsor of the trial, 
agreement between the sponsor and the pharmaceutical company providing the 
Investigational Medicinal Product (glucarpidase), review of the trial protocol by all 
parties (sponsor, statistician and pharmaceutical company), Regulatory Authorities and 
Ethical Committee approval, validation of HPLC assay for assessment of plasma MTX 
and DAMPA concentrations for trial patients, availability of glucarpidase, and an 
amendment to the protocol due to an update in the Summary of Product Characterictics 
of the IMP, delayed the opening of the GLU 1 trial for more than a year.  
The first trial participant was enrolled in June 2007 and 16 patients were recruited until 
January 2009. An interim analysis was planned after completion of both courses in both 
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cycles of the first 14 trial participants (50% of sample size). However, this was revised 
to 16 patients as patients GLU1-05 and GLU1-14 did not contribute to the primary 
endpoint data. Patient GLU1-05 developed renal toxicity after one dose of MTX with 
standard rescue and trial treatment was discontinued. His treatment was unblinded as 
per trial protocol and he was offered emergency treatment with glucarpidase. Patient 
GLU1-14 developed postoperative knee effusion after one dose of MTX with standard 
rescue and his trial treatment was discontinued early. The interim analysis of the GLU 1 
study was carried out in May 2009, following completion of both courses in both cycles 
of the first 16 trial participants.  
In the GLU 1 interim analysis it was stated that the recruitment rate was lower than 
expected with 16 recruited patients in over 22 months (from June 2007 to May 2009), 
while the expected accrual was 10-15 patients per year. However, it is worth mentioning 
that since the IMP expired in March 2009, recruitment to the trial was not possible after 
January 2009. 16 patients were recruited in 19 months (between June 2007 and 
January 2009), which was not far from the expected accrual of 10-15 patients per year.  
GLU 1 is still ongoing. Further amendments to the protocol in view of an extension in 
the shelf life of the IMP, the results of the interim analysis and the recruitment of a new 
co-investigator contributed to the delay in completing the trial. Here the GLU 1 results 
up to the interim analysis of the trial are described.  
There were two major differences amongst the GLU 1 participants and patients with 
bone sarcoma treated on other clinical trials. Firstly, the GLU 1 participants were on 
average older (median age of 19 years; range, 13-47 years; IQR 17-30 years). The 
median age for patients treated on EURAMOS-1 was 14 years (IQR 11-17 years) 
(Whelan et al., 2012), whereas the median age of those treated on INT0133 study, 
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another large phase III osteosarcoma study, was 13 years (range 1-30 years) (Meyers 
et al., 2008). 
Secondly, most of the GLU 1 participants (80%) had been exposed to chemotherapy 
prior to trial entry with nearly 20% of them (3/16) being treated for relapsed disease. 
This is because most newly diagnosed patients with osteosarcoma were recruited in an 
international phase III study (EURAMOS-1), which ran concurrently at our institution. 
Patients not eligible for the phase III study, such as patients > 40 years old or 
previously treated, were offered participation in the GLU 1 study. This resulted in 
treating relatively older patients in the GLU 1 trial.  
6.4. ROUTINE USE OF GLUCARPIDASE AFTER HD-MTX: DOES IT REDUCE 
DELAYS IN OSTEOSARCOMA TREATMENT? 
In order to examine whether glucarpidase rescue after HD-MTX reduces delay to 
subsequent cycles of chemotherapy due to MTX toxicity, the fitness of the GLU 1 
participants to receive chemotherapy on day 15 of each cycle was assessed. “Day 15 
fitness criteria” are described in section 2.  
“Day 15 fitness criteria” were not met in 59% (16/27) of all given cycles. In other words, 
59% of subsequent chemotherapy cycles would have been delayed if MTX was given 
as part of the MAP regimen. This outcome was similar to the findings of the previously 
described audits on the incidence of treatment delays in MAP chemotherapy due to 
MTX toxicity and the tolerance of HD-MTX (12 g/m2) in patients aged ≥ 40 years. 
However, the GLU 1 findings were not the same when treatment cycles given with 
glucarpidase and treatment cycles given without glucarpidase were reviewed 
separately. Amongst cycles given with glucarpidase and folinic acid rescue, “day 15 
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fitness criteria” were met in 57% of cycles (8/14) and not met in 43% of cycles (6/14). 
Amongst cycles given with folinic acid rescue, “day 15 fitness criteria” were only met in 
23% of cycles (3/13) and not met in 77% of cycles (10/13). The unexpectedly high 
incidence of delays in subsequent chemotherapy due to MTX toxicity in this study may 
be due to the fact that most trial participants had been pre-treated with chemotherapy 
prior to their recruitment and therefore likely less tolerant to MTX.  
MTX-related toxicity in the GLU 1 study was not only associated with chemotherapy 
delays but also resulted in early discontinuation of treatment. The expected drop-out 
rate was 5% while the actual drop-out rate was 37.5%; only 62.5% (10/16) of the trial 
patients received all 4 courses of MTX.  
The incidence of early discontinuation of treatment due to MTX toxicity in GLU 1 was 
higher than that observed at our UCH audit on chemotherapy delays due to MTX 
toxicity. 10% (5/56) of audited patients with median age of 20 years had their treatment 
with MTX stopped early due to MTX adverse events. However, the drop-out rate was 
significantly higher in the second UCH audit involving patients aged ≥ 40 years (median 
age 44.5 years); 75% (12/16) of those had their treatment with MTX discontinued early 
due to MTX toxicity. Half of those patients developed mucositis and the other half 
developed nephrotoxicity.  
The incidence of early discontinuation of treatment due to MTX toxicity in GLU 1 was 
generally higher than that observed in the literature. A similar drop-out incidence was 
only reported by Rosen et al. (1984) who reviewed patients treated on the T10 protocol 
(neoadjuvant chemotherapy with 4 weekly courses of MTX at a dose 12 g/m2 for 
children and 8 g/m2 for adolescents). The majority of patients did not tolerate 4 weekly 
MTX treatments due to toxicity and approximately 30% had their treatment substituted 
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with bleomycin because of MTX toxicity. On the other hand, Goorin et al. (1987) 
observed a drop-out rate of 7% (3/46 patients) on the DFCI/TCH study III due to MTX-
related CNS toxicity. Similarly, in a more recent review of 65 osteosarcoma patients 
(median age 18 years; range, 9 to 51 years) who received a total of 288 MTX courses 
at a dose 12 g/m2 over 4 hours at the Norwegian Radium Hospital between 1994 and 
2003, 7.7% of patients (5/65) were excluded from further MTX treatment due to MTX 
toxicity (Holmboe et al., 2012).  In a further review of 97 patients with osteosarcoma 
(median age 16 years) who received 376 HD-MTX courses (8-12 g/m2) on the SSG-II 
clinical trial between 1982 and 1989, 4% of patients (4/97) had their HD-MTX treatment 
terminated due to MTX toxicity (Saeter et al. 1991). In another review of 343 patients 
who receive pre-operative treatment with MTX (8-12 g/m2) at the Instituti Orthopedici 
Rizzoli between 1983 and 2004, 2% of the patients (7/343) did not complete pre-
operative treatment with MTX due to toxicity (Bacci et al. 2006).  
A possible explanation for the high early drop-out rate in GLU 1 is the older age of the 
GLU 1 participants.  The GLU 1 patients in whom study treatment was discontinued 
early due to MTX induced toxicity had a median age of 30 years. In addition, the 
majority of the trial participants had been exposed to chemotherapy prior to trial entry 
and were potentially less able to tolerate further treatment. It is unlikely that renal 
function at trial entry could have predicted early trial drop out since median GFR at trial 
entry was 108 ml/min/1.73 m2 in patients completing all 4 MTX courses and 90 
ml/min/1.73 m2 in patients receiving less than 4 MTX courses.  
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6.5. ROUTINE USE OF GLUCARPIDASE AFTER HD-MTX: MTX AND DAMPA 
PHARMACOKINETICS 
As part of the GLU 1 study, the pharmacokinetics of MTX and DAMPA after 
glucarpidase administration were studied and MTX plasma concentrations, MTX AUC 
and DAMPA plasma concentrations were compared in MTX cycles given with standard 
folinic acid rescue and MTX cycles given with folinic acid and glucarpidase. 
Plasma MTX concentration decreased from a median of 15.67 µM prior to glucarpidase 
to a median of 0.4 µM 15 minutes after glucarpidase administration and glucarpidase 
resulted in a median reduction of serum MTX concentration of 98.05%.  
Our findings are comparable to those described in the literature although in most 
reports glucarpidase was mainly used as emergency treatment in the setting of delayed 
MTX elimination and MTX related renal dysfunction. Widemann et al. (1995) reported a 
98% decrease in MTX plasma concentration within 15 minutes after the first 
glucarpidase dose in a patient with osteosarcoma who experienced MTX-induced acute 
renal dysfunction. Similarly, Zoubek et al. (1995) reported a 99.7% decrease in MTX 
plasma concentration after 5 doses of glucarpidase (50 U/kg) in a patient with 
osteosarcoma who developed acute renal failure associated with delayed MTX 
elimination after HD-MTX. Likewise, Widemann et al. (1997) reviewed the use of 
glucarpidase (50 U/kg) in 20 patients with MTX related nephrotoxicity and reported a 
median reduction of 98.7% in plasma MTX concentrations within 15 minutes after the 
administration of glucarpidase. 6 of the patients received second and third doses of 
glucarpidase which did not result in a further decrease in plasma MTX concentrations. 
Also, Monty et al. (2000) described an 80% decrease in MTX plasma concentration in 
less than 15 minutes after the infusion of glucarpidase in a patient with MTX-related 
221 
severe renal failure. However, plasma MTX concentration was determined by 
fluorescence polarization immunoassay and not by HPLC. More recently, Buchen et al. 
(2005) reported 82 patients treated with HD-MTX (1-12 g/m2) with delayed MTX 
excretion and renal impairment who received glucarpidase at a dose of 50 U/kg and 
noted that serum MTX concentration was reduced by 97% 15 minutes after 
glucarpidase administration.  
The only study where glucarpidase was used routinely was reported by De Angelis et 
al. (1996). In this paper 4 patients with recurrent primary CNS lymphoma and normal 
renal function were treated with HD-MTX (3 g/m2) and received routinely 2 doses of 
glucarpidase (50 U/kg). Patients had a 97.2% decrease of MTX plasma concentration 
within 5 minutes of glucarpidase administration. The second dose of glucarpidase did 
not further diminish the already low plasma MTX level.  
In GLU 1 a small rebound increase in plasma MTX concentrations was observed in 
21% (6/28) of MTX courses given with glucarpidase/folinic acid rescue (Section 5.5, 
Table 44). Due to its molecular size glucarpidase is restricted to the extracellular 
compartment and the intracellular MTX concentration is initially unaffected by its use. In 
time, the changed equilibrium between intracellular and extracellular MTX results in the 
efflux of intracellular MTX back into the serum, resulting in a rise of serum MTX levels 
some hours after glucarpidase administration (Buchen et al., 2005). A rebound increase 
in serum/plasma MTX concentration after treatment with glucarpidase has been 
described in the literature and our findings are in keeping with those described by 
Widemann et al. 1997 and Monty et al. (2000). On the contrary, Widemann et al (1995) 
and De Angelis et al. (1996) reported no rebound increase in plasma MTX 
concentrations.  
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Nevertheless, despite the observed rebound increase in plasma MTX concentrations in 
treatment cycles given with glucarpidase in GLU 1, the time to eliminate MTX was 
found to be significantly less with the use of glucarpidase and therefore the rebound 
increase in plasma MTX concentrations after glucarpidase did not have any clinical 
significance (Section 5.5, Table 37 and Table 41).  
Following glucarpidase, MTX is rapidly metabolized to DAMPA and glutamate. In GLU 
1, DAMPA plasma concentrations 15 minutes after glucarpidase administration were on 
average 35% of the pre glucarpidase MTX serum concentrations (Section 5.5, Table 
43). In the literature, DAMPA plasma concentrations are generally equivalent to pre 
glucarpidase MTX plasma concentrations after systematic exposure to glucarpidase 
(De Angelis el al., 1996; Widemann et al., 1997; and Buchen et al., 2005).  
The difference in DAMPA plasma concentrations in relation to pre glucarpidase MTX 
plasma concentrations between our study and previous publications (De Angelis et al., 
1996, Widemann et al., 1997, and Buchen et al., 2005) may be due to the fact that, 
although blood samples for MTX and DAMPA plasma concentration analysis were 
collected 20 minutes after the start of glucarpidase administration, blood samples for 
MTX plasma concentration pre glucarpidase were not always collected immediately 
prior to glucarpidase administration. This was due to hospital logistics as all blood 
samples for MTX analysis by immunoassay had to be collected by 1 pm in order to be 
processed on the same day. In response to that, we aimed to start all MTX infusions at 
12 o’clock noon. However, this was not always possible. Patients whose MTX infusion 
started later than 1 pm had to have their 24 hour blood samples for MTX analysis taken 
at the latest by 1 pm. Since glucarpidase was always given at 24 hours after the start of 
MTX infusion, the time between pre glucarpidase MTX plasma concentration 
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measurements and post glucarpidase DAMPA plasma concentration measurements 
was longer than 20 minutes for some patients. If all pre glucarpidase MTX plasma 
concentration measurements were taken immediately prior to glucarpidase 
administration, DAMPA plasma concentrations 15 minutes post glucarpidase 
administration might have been similar to pre glucarpidase MTX plasma concentrations. 
6.6. MTX-RELATED TOXICITY WITH AND WITHOUT GLUCARPIDASE  
One of the objectives of the GLU 1 study was to examine whether routine glucarpidase 
rescue after HD-MTX reduces the incidence, severity and duration of MTX-related 
adverse effects. The incidence and grading of mucositis, renal toxicity, liver toxicity, 
neutropenia and thrombocytopenia was compared in MTX cycles given with standard 
folinic acid rescue and MTX cycles given with folinic acid rescue and glucarpidase. 
 Overall, there was no statistical difference in MTX-related toxicity between glu/FA 
cycles and FA cycles. However, since only data from the interim analysis are available, 
the number of patients in this report was small, and so there was a low power to detect 
differences in cycles given with and without glucarpidase.  
The most commonly observed adverse events were, as expected, elevated alanine 
transaminase, mucositis, hypophosphataemia, renal impairment and mild bone marrow 
suppression. None of the study participants developed neurotoxicity or skin related 
toxicity. 
Hepatotoxicity (mainly elevated alanine transaminase) was the most commonly seen 
MTX related toxicity and all the GLU 1 treatment cycles were associated with acute 
transient ALT elevation. However, it was temporary and it contributed neither to lack of 
“fitness on day 15” nor to early discontinuation of trial treatment. ALT CTCTAE v3.0 
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grade ≥ 3 complicated 93% and 77% of glu/FA and FA treatment cycles respectively. 
Mild hyperbilirubinaemia (CTCTAE v3.0 grades 1 and 2) complicated 21% and 8% of 
glu/FA and FA treatment cycles respectively. We did not document any severe 
hyperbilirubinaemia (CTCTAE v3.0 grades 3 and 4). No statistically significant 
differences in hepatotoxicity between glu/FA cyles and FA cycle were observed. 
However, as mentioned already the number of patients in the analysis was small, and 
so there was a low power to detect differences. Our findings were similar to those 
reported in the literature for treatment cycles given with standard rescue (Saeter et al., 
1991 and Holmboe et al., 2012) although Zelcer et al. (2008) observed lower incidence 
of ALT CTCTAE v3.0 grade ≥ 3.  
Mucositis (clinical and functional) was the second most common toxicity observed; it 
complicated 44% (12/27) of treatment cycles and led to lack of “fitness on day 15” in 
33% (8/27) of treatment cycles. The majority of these (6/27) were given with standard 
rescue and only 2 were given with glucarpidase. Mucositis did not contribute to early 
discontinuation of trial treatment.  
Mucositis-clinical complicated 36% and 54% of glu/FA and FA treatment cycles 
respectively. More severe mucositis-clinical (CTCAE v3.0 clinical grades ≥ 3) 
complicated 7% and 23% of glu/FA and FA treatment cycles respectively. These 
differences were not statistically significant but may indicate a trend in favour of 
glucarpidase. 
Interestingly, a significant difference in CTCAE mucositis-functional was found between 
the 2 rescue regimens with FA cycles being associated with higher CTCAE grades of 
mucositis-functional. Mucositis-functional complicated 15% and 38% of glu/FA and FA 
treatment cycles respectively. More severe mucositis-functional (CTCAE v3.0 grades ≥ 
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3) complicated 8% FA treatment cycles whereas severe mucositis-functional was not 
documented in any glu/FA treatment cycles.  
The incidence of MTX related mucositis in the literature was similar to our findings for 
treatment cycles given with standard rescue (FA cycles) (Sonis at al., 2004; Saeter et 
al., 1991; Holmboe et al., 2012). 
Apart from the National Cancer Institute Common Terminology criteria for Adverse 
Events (CTCAE v 3.0), 3 other assessment tools were used to evaluate the severity of 
mucositis in the GLU 1 patients and ensure comprehensive assessment; the World 
Health Organisation Toxicity Criteria for Oral Mucositis, the Oral Assessment Guide 
(OAG) and the Oral Mucositis Weekly Questionnaire (OMWQ). The CTCAE v 3.0 and 
WHO criteria were used because they are the most commonly used criteria for 
mucositis evaluation in clinical studies (Sonis et al., 2004). The Oral Assessment Guide 
(Eilers et al., 1988) was chosen as it is popular amongst nursing staff. The Oral 
Mucositis Weekly questionnaire was adapted from the Oral Mucositis Daily 
Questionnaire (Bellm et al., 2002 and Stiff et al, 2006) and chosen because it provided 
a patient-reported measure of oral mucositis. However, it was retrospectively felt that 
the CTCAE v3.0 tool would have been comprehensive enough to capture the severity of 
mucositis in the GLU 1 study; it is sensitive, universally used and takes into account 
both objective (i.e. assessor) and subjective (i.e. patient) mucositis assessment. 
Renal dysfunction was relatively common amongst the GLU 1 patients. Of the 16 trial 
patients, 8 developed nephrotoxicity (CTCAE v.3.0, grade ≥ 1) and 5 of those did not 
complete their treatment due to renal impairment. Routine administration of 
glucarpidase did not seem to make a difference in the incidence or severity of MTX-
related nephrotoxicity. The incidence of grade ≥ 2 nephrotoxicity in GLU 1 was 12.5%, 
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seven times greater than the incidence documented by Widemann et al. (2004) and 
nine times greater than that reported by Saeter et al. (1991). The incidence of severe 
nephrotoxicity (serum creatinine grade 3 or 4) was 6.25%, 10 times greater than that 
identified by Widemann et al. (2006). Nevertheless, there were no deaths in the trial 
due to nephrotoxicity.  
The high incidence of nephrotoxicity in GLU 1 could be explained as mentioned earlier 
by the older age of the participants and their previous exposure to chemotherapy. It is 
unlikely that renal function at trial entry could have predicted the development of 
nephrotoxicity since median GFR at trial entry was 108 ml/min/1.73 m2 in patients who 
did not develop nephrotoxicity during their trial treatment and 96 ml/min/1.73 m2 in 
patients who developed nephrotoxicity.  
6.7. ROUTINE USE OF GLUCARPIDASE: ECONOMIC IMPACT 
In order to investigate the economic impact of using glucarpidase versus standard 
rescue, we compared the number of days required in hospital for MTX cycles given with 
standard folinic acid rescue and MTX cycles given with folinic acid rescue and 
glucarpidase. The average length of patient’s hospital stay per glu/FA and FA course 
was 5.04 days (range 4-13 days) and 4.77 days (range 4-10 days) respectively.  
At present, it is a regulatory requirement that rescue with folinic acid continues for at 
least 48 hours after the administration of glucarpidase in order to compensate for any 
reduced exposure to folinic acid caused by its potential interaction with glucarpidase 
(VoraxazeTM Investigator’s brochure, 2009). Interestingly, this requirement increased 
the hospital stay of the GLU 1 patients receiving rescue with glucarpidase by more than 
1 day. If patients were discharged home as soon as MTX plasma concentration was < 
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0.2 µM, the average length of patient’s hospital stay per glu/FA course would have been 
3.88 days rather than 5.04 days.  
We also compared the total folinic acid dose required in MTX cycles given with 
standard folinic acid rescue with MTX cycles given with folinic acid rescue and 
glucarpidase. Nevertheless, it became apparent that the total folinic acid dose per 
course was not a good indicator of the economic impact of using glucarpidase versus 
standard rescue. This was because the GLU 1 participants had their dose of folinic acid 
adjusted based upon the pre-glucarpidase/placebo plasma MTX levels and the dose of 
folinic acid was maintained unchanged for 48 hours after glucarpidase/placebo. Hence, 
the total folinic acid dose did not reflect the effect of glucarpidase on MTX plasma levels 
at 48 hours and 72 hours.  
Currently available information on the interaction of folinic acid with glucarpidase is 
based on the LV interaction study (section 1.4.2.2.). When glucarpidase was 
administered in healthy subjects, their exposure to folinic acid was reduced by about 
50% in the absence of methotrexate (VoraxazeTM Investigator’s brochure, 2009). 
Further studies are needed to examine the interaction of glucarpidase with folinic acid 
in the presence of methotrexate. Since glucarpidase has > 10-fold higher affinity for 
MTX than for folinic acid, it might not be necessary to use such high doses of folinic 
acid in patients who are “rescued” with glucarpidase and/or it might be possible that 
patients are discharged home as soon as MTX plasma concentration was < 0.2 µM. 
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6.8. GLUCARPIDASE RELATED ADVERSE EVENTS AND ANTIBODY RESPONSE 
IN GLU 1  
No adverse events related to glucarpidase were experienced by any of the GLU 1 
patients. Our findings are similar to those published by De Angelis et al. (1996) and 
Mohty et al. (2000) who observed no glucarpidase-related adverse events. 
Nonetheless, Widemann et al. (1995, 1997, and 2006), Buchen et al. (2005) and 
Schwartz et al. (2004) observed easily reversible glucarpidase related toxicity in a small 
minority of patients treated.  
Glucarpidase is a recombinant bacterial protein and it therefore has the potential to 
induce an immune response. This could produce an allergic reaction on subsequent 
administration of glucarpidase or reduce its efficacy by neutralizing the activity of 
glucarpidase.  
In GLU 1 none of the 14 patients who had more than one glucarpidase dose 
experienced an allergic reaction. However, positive anti-glucarpidase IgG response was 
observed in 43% (6/14) of trial patients although the activity of glucarpidase was only 
inhibited in 17% (1/6) of patients with positive antibody response. Our results are in 
keeping with the literature (Voraxaze™ Investigator’s Brochure, PR001-CLN-IB2007, 
released in February 2009).  
Positive antiglucarpidase IgG response in patients GLU1-07, GLU1-08 and GLU1-09, 
became negative in follow-up samples. Patient GLU1-02, who had a positive 
antiglucarpidase IgG response on day 180 of cycle 2, had no further follow-up samples. 
This was in accordance with the trial protocol as “day 180 of cycle 2” is the last time 
point blood samples are collected for anti-glucarpidase antibody analysis. However, it is 
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unfortunate there is no follow-up data since this is the only patient where neutralising 
response was observed. Follow-up samples on patients GLU1-15 and GLU1-16, who 
developed positive antiglucarpidase IgG response, have not been analysed yet. 
It is essential to know if repeated doses of glucarpidase could result in the development 
of anti-glucarpidase antibodies and subsequent inhibition of the activity of glucarpidase. 
However, it is reassuring that despite the presence of anti-glucarpidase antibodies in 
almost half of the trial patients, the activity of the enzyme was found to be inhibited only 
in 1 patient.  
6.9. GLU 1 CLINICAL TRIAL: LIMITATIONS 
There are some limitations with the GLU 1 clinical trial. Recruitment to GLU 1 was 
rather slow because most of the patients with bone sarcoma were eligible for and 
recruited to a phase III clinical trial which ran concurrently with GLU 1. This also 
explains why the GLU 1 participants were older compared to the average patient with 
bone sarcoma and why the majority of them had previous exposure to chemotherapy. 
GLU 1 included patients with relapsed disease who had chemotherapy-induced toxicity 
prior to entering the trial. Older age of trial participants and previous exposure to 
chemotherapy agents have likely contributed to the increased renal toxicity seen. 
Other limitations included potential cumulative toxicity from other chemotherapy agents 
administered to study participants prior to their enrolment to GLU 1 (such as 
doxorubicin and cisplatin) and carryover of the effects of glucarpidase in the second 
GLU 1 treatment cycle for patients who received glucarpidase as part of their first 
treatment cycle. Also, a limited number of four MTX courses were studied instead of the 
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twelve MTX courses that are given to patients with osteosarcoma as part of the MAP 
regimen. 
In addition, although most of the “fitness criteria on day 15”, such as haematological 
and biochemical parameters, are objective, assessment of patient’s clinical status 
including assessment of mucositis is subjective and possibly depends on the 
experience of the clinician. Furthermore, if a patient was due to start trial treatment on a 
Friday but found unfit, he/she would have been asked to attend for review the Monday 
of the following week, leading to an at least 3-day delay. However, if the same patient 
was due treatment in the beginning of the week but found unfit, his/her treatment would 
have perhaps been less delayed, i.e. 1- or 2-day delay. 
Finally, the impact of glucarpidase on the anti-tumour effect of MTX was intentionally 
not included in the trial objectives. It was felt that this would have been beyond the remit 
of a phase II study. Nonetheless, there was no difference in peak plasma MTX 
concentration with and without glucarpidase as glucarpidase was given twenty hours 
after peak plasma MTX concentrations were achieved. Moreover, there was no 
statistical difference in the MTX AUC0-T in courses given with and without glucarpidase. 
Peak plasma MTX concentration and MTX AUC0-T could perhaps be used as surrogate 
endpoints for the anti-tumour effect of MTX in view of their relationship with the 
outcome of osteosarcoma treatment (Bacci et al. 1998; Bacci et al. 1996; Delepine et 
al. 1988; Graf et al. 1994; Crews et al. 2004; Aquerreta et al. 2004). 
6.10. Conclusions - Implications for Future Research  
HD-MTX has been an essential component in the management of osteosarcoma in the 
last forty years. There are no indications that this will change soon. However, although 
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well established supportive care is standard practice, HD-MTX is still associated with 
significant morbidity. Glucarpidase is the only available agent which offers a promising 
opportunity for rescue from MTX-related toxicity. A phase II study has been undertaken 
to investigate the efficacy and safety of glucarpidase for routine use after HD-MTX in 
patients with bone sarcoma. My responsibilities included the design of the GLU 1 trial 
and writing of the trial protocol, submission of all appropriate documentation and 
subsequent amendments to the trial protocol to the Regulatory Authorities and Ethics 
Committee, validation of a HPLC assay for the measurement of MTX and DAMPA 
plasma levels and assessment of MTX and DAMPA plasma levels for trial patients with 
HPLC, informed consent and enrolment of trial participants, involvement in the clinical 
management of trial participants, nursing and medical staff training on the trial, and data 
management and safety management of the trial. Here the findings up to the interim 
analysis of the study are presented.  
So far it is apparent that glucarpidase can be safely administered as part of routine 
rescue after HD-MTX with reduction in MTX levels after a single dose. Furthermore, 
interim analysis of the study revealed a lower incidence of severe mucositis in patients 
receiving glucarpidase. If the trial, when completed, indicates that routine rescue with 
glucarpidase improves the delivery of HD-MTX in patients with bone sarcoma it would 
be necessary to be followed up by a larger phase III clinical trial where glucarpidase is 
administered after all the 12 MTX courses included in the MAP chemotherapy regimen. 
Further studies are necessary to examine the interaction of glucarpidase with folinic 
acid in the presence of MTX. Additional hurdles that need to be overcome before 
glucarpidase could be introduced routinely as standard rescue after HD-MTX should 
include the assessment of the inhibition of the enzyme with repeated administrations of 
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glucarpidase and the relationship of glucarpidase with the anti-tumour effectiveness of 
MTX. 
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APPENDIX 2. GLU 1 CLINICAL TRIAL, PATIENT AND PARENT INFORMATION 
SHEETS 
The following information sheets were available: 
 Information sheet for participants aged 16+ with newly diagnosed 
osteosarcoma (version 2.0, 2 April 2007) 
 Information sheet for participants aged 16+ (version 2.0, 2 April 2007)  
(for all other eligible patients aged 16+) 
 Parent information sheet (patients with newly diagnosed osteosarcoma) 
(version 2.0, 2 April 2007) 
 Parent information sheet (version 2.0, 2 April 2007)  
(all other eligible patients) 
 Information sheet for children aged 13 to 15 with newly diagnosed 
osteosarcoma (version 2.0, 2 April 2007) 
 Information sheet for children aged 13 to 15 (version 2.0, 2 April 2007) 
(for all other eligible patients aged 13 to 15) 
 Information sheet for children aged 6 to 12 (version 2.0, 2 April 2007) 
 Information sheet for children aged 5 (version 2.0, 2 April 2007) 
As an example, the information sheet for for participants aged 16+ with newly 
diagnosed osteosarcoma (version 2.0, 2 April 2007) was as follows: 
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APPENDIX 3. GLU 1 CLINICAL TRIAL, GENERAL PRACTITIONER 
INFORMATION SHEETS 
The following information sheets were available for participants’ general 
practitioners: 
 General Practitioner information sheet for patients with newly diagnosed 
osteosarcoma (version 2.0, 2 April 2007) 
 General Practitioner information sheet for all other eligible patients (version 
2.0, 2 April 2007) 
As an example, the General Practitioner information sheet for patients with newly 
diagnosed osteosarcoma (version 2.0, 2 April 2007) was as follows: 
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APPENDIX 4. GLU 1 CLINICAL TRIAL, PATIENTS’ CONSENT FORMS 
 Consent form for patients aged 16+ (version 2.0, 2 April 2007) 
 Parent consent form (version 2.0, 2 April 2007) 
 Assent form for children (version 2.0, 2 April 2007) 
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APPENDIX 5. REGISTRATION FORM FOR GLU 1 CLINICAL TRIAL 
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APPENDIX 6. CRF FOR GLU 1 CLINICAL TRIAL 
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APPENDIX 7. PERFORMANCE STATUS FOR GLU 1 STUDY 
 
Lansky score 
(1-16 years) 
 
Karnofsky score 
(> 16 years) 
100 Fully active, normal. 100 
Normal; no complaints; no 
evidence of disease. 
90 
Minor restrictions in physically 
strenuous activity. 
90 
Able to carry on normal activities; 
minor signs or symptoms of 
disease. 
80 Active, but tires more quickly. 80 
Normal activity with effort; some 
signs and symptoms of disease. 
70 
Both greater restriction of, and 
less time spent in, active play. 
70 
Cares for self but unable to carry 
on normal activity or to do work. 
60 
Up and around, but minimal 
active play; keeps busy with 
quieter activities. 
60 
Requires occasional assistance 
but is able to care for most of 
personal needs. 
50 
Gets dressed, but lies around 
much of the day; no active play; 
able to participate in all quiet 
play and activities. 
50 
Requires frequent assistance and 
medical care. 
40 
Mostly in bed; participates in 
quiet activities. 
40 
Disabled; requires special care 
and assistance. 
30 
In bed; needs assistance even 
for quiet play. 
30 
Severely disabled; hospitalization 
is indicated though death not 
imminent. 
20 
Often sleeping; play entirely 
limited to very passive activity. 
20 
Very ill; hospitalization and active 
supportive care necessary. 
10 
No play, does not get out of bed. 
Moribund. 
10 
Moribund, fatal processes 
progressing rapidly. 
0 Unresponsive. Dead. 0 Unresponsive. Dead. 
    
WHO PERFORMANCE SCALE 
0 Asymptomatic 
1 Symptomatic but completely ambulant 
2 Symptomatic, <50% in bed during the day 
3 Symptomatic, >50% in bed during the day 
4 Bed bound 
5 Death 
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APPENDIX 8. GLU 1 CLINICAL TRIAL, DRUG INTERACTIONS WITH MTX 
The following are contraindicated in patients receiving methotrexate: 
 Salicylates, sulfonamides, probenecid, cephalothin, penicillins (carbenicillin, 
ticarcillin) in high concentrations, omeprazole:  known to compete with methotrexate 
for membrane transport, and thus may reduce renal tubular secretion. 
 Salicylates, sulfonamides, phenylbutazone, hypoglycaemics, diphenylhydantoins, 
tetracyclins, chloramphenicol, p-aminobenzoic acid and acidic anti-inflammatory 
drugs: known to displace methotrexate from its binding sites on plasma proteins, 
and thus may increase free methotrexate levels in plasma 
 Theophylline or methionine could enhance methotrexate cytotoxicity 
 NSAIDs reduce the tubular secretion of methotrexate 
 Co-trimoxazole, nitrous oxide and trimethoprime are folate-antagonists and may 
increase methotrexate cytotoxicity 
 Chloramphenicol and tetracycline could interfere with the enterohepatic circulation 
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APPENDIX 9. GLU 1 CLINICAL TRIAL, MEASURING RENAL FUNCTION 
The suggested formulae for GFR estimation are: 
Schwartz Formula [age 1-18]1 
Estimated creatinine clearance (ml/min/1.73m2) = 
F x Height [cm] x 88.4 
Serum creatinine (mol/L) 
Where F is proportional to body muscle mass, hence depending on age and gender: 
 Infants (< 1 year of age) F = 0.45 
 Male, 1-16 years  F = 0.55 
 Female, 1-21 years  F = 0.55 
 Male, 16-21 years F = 0.70 
Normal values [ml/min/1.73m²]: mean value =120, normal range 90-150 
Cockcroft – Gault Formula (>18 years) 2  
Estimated creatinine clearance for females 
(ml/min/1.73m2) 
= 
1.05 x [140 - age (yrs)] x wt (kg) 
serum creatinine (mol/L) 
 
Estimated creatinine clearance for males 
(ml/min/1.73m2) 
= 
1.25 x [140 - age (yrs)] x wt (kg) 
serum creatinine (mol/L) 
Note: the accuracy of these formulae have been incompletely evaluated in patients 
receiving repeated cycles of intensive chemotherapy or in adolescents.  Renal 
function may be over-estimated by these methods. 
REFERENCES 
1. Schwartz GJ et al. The use of plasma creatinine concentration for estimating 
glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am, 
1987; 34(3):571-90. 
2. Cockcroft DW et al.  Prediction of creatinine clearance from serum creatinine. 
Nephron, 1976; 16(1):31-41. 
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APPENDIX 10.  GLU 1 CLINICAL TRIAL, QUALITY OF LIFE QUESTIONNAIRES 
For patients aged 16 and over at registration, quality of life will be assessed using the 
EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 
version 3 1-2 and the FACT-G (Functional Assessment of Cancer Therapy Scale-
General)3 questionnaires.  
The QLQ-C30 questionnaire is a reliable and valid measure of the quality of life of 
cancer patients in multicultural clinical research settings. It incorporates nine multi-item 
scales: five functional scales (physical, role, cognitive, emotional and social); three 
symptom scales (fatigue, pain, nausea and vomiting); and a global health and quality of 
life scale. The average time required to complete the questionnaire is 11 minutes, and 
most patients will not require assistance1. 
The FACT-G is a 33-item questionnaire that can be easily completed in 5 minutes, 
usually without assistance3. It meets all requirements for use in an oncology clinical trial 
including ease of administration, brevity, reliability, validity and responsiveness to 
clinical change. It includes questions on physical, social/family, emotional and functional 
well-being along with questions on relationship with the doctor. 
For patients aged 15 and under, Quality of Life will be assessed using the “PedsQL 
3.0 Cancer Module Acute Version questionnaire”.  It encompasses 8 scales: pain and 
hurt (2 items), nausea (5 items), procedural anxiety (3 items), treatment anxiety (3 
items), worry (3 items), cognitive problems (5 items), perceived physical appearance (3 
items), and communication (3 items). PedsQL4 has questionnaires for different age 
groups including 5-7 years, 8-12 years and 13-18 years. There are self-report 
questionnaires and parent proxy reports. Both the self-reporting and the parent proxy 
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questionnaire will be completed. Patients who become 16 years old during the course 
of the trial should continue to use the paediatric instrument for further assessments, as 
PedsQL has been validated up to the age of 18. 
The QLQ-C30 English and PedsQL Cancer module are widely available. 
FACT-G (version 4) questionnaire 
Below is a list of statements that other people with your illness have said are important. 
By circling one number per line, please indicate how true each statement has 
been for you during the past 7 days. 
 
PHYSICAL WELL-BEING  
Not at 
all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
 GP1  I have a lack of energy   0 1 2 3 4 
 GP2 I have nausea  0 1 2 3 4 
 GP3 Because of my physical condition, I have 
trouble  meeting the needs of my family  
0 1 2 3 4 
 GP4 I have pain  0 1 2 3 4 
 GP5 I am bothered by side effects of treatment  0 1 2 3 4 
 GP6 I feel ill  0 1 2 3 4 
 GP7  I am forced to spend time in bed   0 1 2 3 4 
 
SOCIAL/FAMILY WELL-BEING  
Not at 
all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
 GS1 I feel close to my friends  0 1 2 3 4 
 GS2 I get emotional support from my family  0 1 2 3 4 
 GS3 I get support from my friends  0 1 2 3 4 
 GS4 My family has accepted my illness  0 1 2 3 4 
 GS5 I am satisfied with family communication 
about my illness  
0 1 2 3 4 
 GS6 I feel close to my partner (or the person who 
is my main support)  
0 1 2 3 4 
 Q1 
GS7 
Regardless of your current level of sexual activity, please answer the following 
question.   If you prefer not to answer it, please check this box □ and go to the 
next section       
I am satisfied with my sex life  0 1 2 3 4 
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By circling one number per line, please indicate how true each statement has 
been for you during the past 7 days. 
 EMOTIONAL WELL-BEING  Not at 
all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
 GE1  I feel sad   0 1 2 3 4 
 GE2 I am satisfied with how I am coping with my 
illness  
0 1 2 3 4 
 GE3 I am losing hope in the fight against my 
illness  
0 1 2 3 4 
 GE4 I feel nervous  0 1 2 3 4 
 GE5 I worry about dying  0 1 2 3 4 
 GE6 I worry that my condition will get worse  0 1 2 3 4 
 
FUNCTIONAL WELL-BEING  
Not at 
all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
 GF1 I am able to work (include work at home)   0 1 2 3 4 
 GF2 My work (include work at home) is fulfilling  0 1 2 3 4 
 GF3 I am able to enjoy life  0 1 2 3 4 
 GF4 I have accepted my illness  0 1 2 3 4 
 GF5 I am sleeping well  0 1 2 3 4 
 GF6 I am enjoying the things I usually do for fun  0 1 2 3 4 
 GF7  I am content with the quality of my life right 
now  
0 1 2 3 4 
REFERENCES 
1. Aaronson NK et al.  The European Organization for Research and Treatment of 
Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in 
oncology. Journal of the National Cancer Institute 1993, 85, 365-376. 
2. Fayers PM et al.  EORTC QLQ-C30 Scoring Manual. Brussels: EORTC, 1995 
3. Cella D et al. The Functional Assessment of Cancer Therapy Scale: development 
and validation of the general measure. J Clin Oncol, 1993, 11:570-579  
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4. Varni JW et al.  The PedsQL in pediatric cancer: reliability and validity of the 
Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue 
Scale, and Cancer Module.  Cancer 2002, 94, 2090-2106. 
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APPENDIX 11. GLU 1 CLINICAL TRIAL, MUCOSITIS ASSESSMENT TOOLS 
Oral and gastro-intestinal mucositis is a frequent complication of treatment with high-
dose methotrexate. Prolonged or profound mucositis leads to significant pain and 
morbidity, excess costs for supportive care and hospitalisation, increased frequency of 
infection, and chemotherapy delays and dose reductions1,2.  In an analysis of 3 studies 
involving 132 patients receiving methotrexate chemotherapy, 23% developed grade 3-4 
oral mucositis3. 
It is important to be able to describe precisely, classify objectively and measure 
reproducibly the severity of mucosal damage. In an analysis of approximately 400 trials, 
as a component of the evidence-based review for the Multidisciplinary Association of 
Supportive Care in Cancer (MASCC) clinical practice guidelines, it was determined that 
most of the studies utilised the National Cancer Institute (NCI) (43%) or World Health 
Organization (WHO) (38%) scales. A further 10% of the studies utilised a study-specific 
scale. 5% of the studies used a cooperative group scale, such as those used by the 
Radiation Therapy Oncology Group (RTOG)3, 4. 
No single scale meets all requirements of a mucositis assessment tool or is universally 
accepted. Therefore, in this study four different assessment tools will be used: 
1. National Cancer Institute Common Terminology criteria for Adverse Events, version 
3.0 (CTCAE v 3.0)5 
2. World Health Organisation Toxicity Criteria for Oral Mucositis6 
3. Oral Assessment Guide7 
4. Oral Mucositis Weekly Questionnaire8 
The NCI CTCAE v3.0 and WHO scoring scales have been chosen as assessment tools 
in view of their widespread use in other studies studying mucositis. Both the scales 
measure anatomical, symptomatic and functional components of oral mucositis.  In 
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addition, the NCI CTCAE v3.0 scale, also grades enteritis, colitis, diarrhoea and 
abdominal distension /bloating.  
The Oral Assessment Guide is a validated instrument, which has been extensively used 
in adults with cancer. It is designed to objectively assess the physiological changes of 
the oral cavity following the administration of chemotherapy and radiotherapy. An 
adapted version has now been validated for paediatric use (by Gibson F et al, awaiting 
publication in Eur J Cancer). 
The Oral Mucositis Weekly Questionnaire has been adapted from the Oral Mucositis 
Daily Questionnaire, which is developed as a mucositis specific questionnaire to assess 
patient-reported outcomes9. It is designed to assess the severity and impact of oral 
mucositis by evaluating mouth and throat soreness and the degree to which these 
interfere with activities of daily life such as eating, swallowing, drinking, talking and 
sleeping. It also assesses the overall health of the patient and the severity of diarrhoea. 
It has been shown to be a feasible, reliable, valid and responsive patient-reported 
measure of oral mucositis toxicity8. 
WHO TOXICITY CRITERIA: ORAL MUCOSITIS 6 
0 1 2 3 4 
None 
Soreness, 
erythema 
Eryrhema, 
Ulcers, ability to 
eat solids 
Ulcers, requires 
liquid diet 
Alimentation not 
possible 
 
Grade 1 may include buccal mucosa scalloping with or without erythema. No ulcers. 
Patient can swallow solid diet. 
Grade 2 must include ulcers with or without erythema. Patient can swallow solid diet. 
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Grade 3 must include ulcers with or without (extensive) erythema. Patient is able to 
swallow liquid, but not solid diet. 
Grade 4 means mucositis to the extent that alimentation is not possible. If total 
parenteral nutrition was started for reasons other that mucositis, a determination of the 
subject’s ability to swallow must be made using the above criteria. 
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EXCERPT FROM COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE), v 3.0: GASTRO-INTESTINAL 
TOXICITY SCALE (Published December 12, 2003) 5 
GASTROINTESTINAL 
Grade 
ADVERSE EVENT 1 2 3 4 5 
Diarrhea 
 
Increase of < 4 stools 
per day over 
baseline; mild 
increase in ostomy 
output compared to 
baseline 
Increase of 4-6 stools 
per day over 
baseline; IV fluids 
indicated<24 hrs; 
moderate increase in 
ostomy output 
compared to 
baseline; not 
interfering with ADL* 
Increase of 7 stools 
per day over 
baseline;  
incontinence; IV fluids 
≥24 hrs; 
hospitalization; 
severe increase in 
ostomy output 
compared to 
baseline; interfering 
with ADL* 
Life-threatening 
consequences (e.g. 
hemodynamic 
collapse) 
Death 
Remark: Diarrhea includes diarrhea of small bowel or colonic origin, and/or ostomy diarrhea 
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EXCERPT FROM COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE), v 3.0: GASTRO-INTESTINAL 
TOXICITY SCALE (Published December 12, 2003) 5 
GASTROINTESTINAL 
Grade 
ADVERSE EVENT 1 2 3 4 5 
Mucositis/stomatitis 
(clinical exam) 
-Select: 
- Anus 
- Esophagus 
- Large Bowel 
- Larynx 
- Oral Cavity 
- Pharynx 
- Rectum 
- Small Bowel 
- Stomach 
- Trachea 
Erythema of the 
mucosa 
Patchy ulcerations or 
pseudomembranes 
 
Confluent ulcerations 
or 
pseudomembranes; 
bleeding with minor 
trauma 
Tissue necrosis; 
significant 
spontaneous 
bleeding; life-
threatening 
consequences 
Death 
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EXCERPT FROM COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE), v 3.0: GASTRO-INTESTINAL 
TOXICITY SCALE (Published December 12, 2003) 5 
GASTROINTESTINAL 
Grade 
ADVERSE EVENT 1 2 3 4 5 
Mucositis/stomatitis 
(functional/ 
symptomatic) 
-Select: 
- Anus 
- Esophagus 
- Large Bowel 
- Larynx 
- Oral Cavity 
- Pharynx 
- Rectum 
- Small Bowel 
- Stomach 
- Trachea 
Upper aerodigestive 
tract sites: Minimal 
symptoms, normal 
diet; minimal 
respiratory symptoms 
but not interfering 
with function 
Lower GI** sites: 
Minimal discomfort, 
intervention not 
indicated 
Upper aerodigestive 
tract sites: 
Symptomatic but can 
eat and swallow 
modified diet; 
respiratory symptoms 
interfering with 
function but not 
interfering with ADL* 
Lower GI** sites: 
Symptomatic, 
medical intervention 
indicated but not 
interfering with ADL* 
Upper aerodigestive 
tract sites: 
Symptomatic and 
unable to adequately 
aliment or hydrate 
orally; respiratory 
symptoms interfering 
with ADL* 
Lower GI**sites: 
Stool incontinence or 
other symptoms 
interfering with ADL* 
Symptoms 
associated with life-
threatening 
consequences 
Death 
Colitis Asymptomatic, 
pathologic or 
radiographic findings 
only 
Abdominal pain; 
mucus or blood in 
stool 
Abdominal pain,fever, 
change in bowel 
habits with ileus; 
peritoneal signs 
Life-threatening 
consequences (e.g. 
perforation, bleeding, 
ischaemia, necrosis, 
toxic megacolon) 
Death 
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EXCERPT FROM COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE), v 3.0: GASTRO-INTESTINAL 
TOXICITY SCALE (Published December 12, 2003) 5 
GASTROINTESTINAL 
Grade 
ADVERSE EVENT 1 2 3 4 5 
Enteritis 
(inflammation of the 
small bowel) 
Asymptomatic, 
pathologic or 
radiographic findings 
only 
Abdominal pain; 
mucus or blood in 
stool 
Abdominal pain, 
fever, change in 
bowel habits with 
ileus; peritoneal signs 
Life-threatening 
consequences (e.g. 
perforation, bleeding, 
ischaemia, necrosis) 
Death 
Distension /bloating, 
abdominal 
Asymptomatic Symptomatic, but not 
interfering with GI** 
function 
Symptomatic,  
interfering with GI** 
function 
– – 
* ADL: Activities of Daily Living 
** GI: Gastro-intestinal  
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ORAL ASSESSMENT GUIDE FOR CHILDREN AND YOUNG PEOPLE   
Oral assessment guide adapted from Eilers J et al. 19887, by F. Gibson et al (awaiting publication) 
CATEGORY METHOD OF ASSESSMENT 1 2 3 
SWALLOW 
Ask the child to swallow or observe the 
swallowing process. Ask the parent if there 
are any notable changes. 
Normal. 
Without difficulty 
 
Difficulty in swallowing 
Unable to swallow at all. 
Pooling, dribbling of 
secretions 
LIPS AND CORNER 
OF MOUTH 
Observe appearance of tissue 
 
Normal. 
Smooth, pink and moist 
Dry, cracked or swollen 
 
Ulcerated or bleeding 
 
TONGUE 
 
Observe the appearance of the tongue using 
a pen-torch to illuminate the oral cavity 
Normal. 
Firm without fissures (cracking 
or splitting) or prominent 
papillae. Pink and moist 
Coated or loss of papillae with a 
shiny appearance with or without 
redness and/or oral Candida 
Ulcerated, sloughing or 
cracked 
SALIVA 
Observe consistency and quality of saliva 
Normal. 
Thin and watery 
Excess amount of saliva, 
drooling 
Thick, ropy or absent 
MUCOUS 
MEMBRANE 
Observe the appearance of tissue using a 
pen-torch to illuminate the oral cavity 
Normal. 
Pink and moist 
Reddened or coated without 
ulceration and/or oral Candida 
Ulceration and sloughing, 
with or without bleeding 
GINGIVA 
 
Observe the appearance of tissue using a 
pen-torch to illuminate the oral cavity 
Normal. 
Pink or coral with a stippled 
(dotted) surface. Gum margins 
tight and well defined, no 
swelling. 
Oedematous with or without 
redness, smooth 
Spontaneous bleeding 
 
TEETH  
(IF NO TEETH 
SCORE 1) 
Observe the appearance of teeth using a 
pen-torch to illuminate the oral cavity 
Normal. 
Clean and no debris 
Plaque or debris in localised 
areas 
Plaque or debris generalised 
along gum line 
VOICE 
Talk and listen to the child.  
Ask the parent if there are any notable 
changes 
Normal tone and quality when 
talking or crying 
Deeper or raspy 
Difficult to talk, cry or not 
talking at all 
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ORAL ASSESSMENT GUIDE FOR ADULTS 7 
CATEGORY TOOLS FOR 
ASSESSMENT 
METHOD OF 
ASSESSMENT 
1 2 3 
VOICE Auditory Converse with patient Normal Deeper or raspy Difficulty talking or painful 
SWALLOW Observation 
Ask patient to swallow. To 
test gag reflux, gently 
place blade on back of 
tongue and depress 
Normal swallow Some pain on swallow Unable to swallow 
LIPS Visual/palpatory Observe and feel tissue 
Smooth and pink and 
moist 
Dry or cracked Ulcerated or bleeding 
TONGUE Visual/palpatory
 Feel and observe 
appearance of tissue 
Pink and moist and 
papillae present 
Coated or loss of papillae 
with a shiny appearance 
with or without redness 
Blistered or cracked 
SALIVA Tongue blade 
Insert blade into mouth, 
touching the centre of the 
tongue and the floor of the 
mouth 
Watery Thick or ropy Absent 
MUCOUS MEMBRANES Visual 
Observe appearance of 
tissue 
Pink and moist 
Reddened or coated 
(increased whiteness 
without ulceration) 
Ulcerations with or without 
bleeding 
GINGIVA Tongue blade and visual 
Gently press tissue with 
tip of blade 
Pink and stippled and firm 
Oedematous with or 
without redness 
Spontaneous bleeding or 
bleeding with pressure 
TEETH 
 
Visual 
Observe appearance of 
teeth or denture bearing 
area 
Clean and no debris 
Plaque or debris in 
localized areas (between 
teeth if present) 
Plaque or debris 
generalized along gum 
line or denture bearing 
area 
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APPENDIX 12. GLU 1 CLINICAL TRIAL, TREATMENT EXPERIENCE FOR EACH 
PARTICIPANT 
HEOL-01 
Date of birth 05 July 1983 (24 years), male 
Date of diagnosis 10 October 2006 
Diagnosis High grade osteosacoma of right proximal humerous, osteoblastic 
type, with multiple bilateral small pulmonary metastases 
Other medical problems Already received 1 course of cisplatin 120 mg/m
2
 and doxorubicin 
75 mg/ m
2
, 6 courses of ifosfamide 14gr/m
2
 and etoposide 500 
mg/ m
2 
and 8 doses of methotrexate 12 gr/m
2
 
05 February 2007: right forequarter amputation 
Date of consent 13 June 2007 
Concomitant medication 
at trial entry 
Trimovate cream, topically on inguinal creases, routine 
mouthcare with Nystatin and Corsodyl mouthwash 
Examination at trial entry Unremarkable apart from some settling erythema on inguinal 
creases and  right forequarter amputation  
GFR prior to trial entry 119 ml/min/1.73 m
2
 on 11 June 2007 
HEOL started treatment on the the GLU 1 clinical trial on 03 July 2007. He was 
randomised to arm B and received glucarpidase in cycle 1. 
CYCLE 1 
His clinical and laboratory (FBC, renal and liver function) assessments on day 1 of cycle 
1 were unremarkable apart from Hb of 10.1 gr/dl (CTCAE toxicity grade 1).  
MTX dose 1: HEOL had his first dose of methotrexate on 03 July 2007. He had 
glucarpidase on 04 July 2007. Folinic acid rescue was started on the same day.  
Methotrexate plasma levels at 24 hours were 5.34 µmol/L. Methotrexate was cleared 
within 48 hours post dose. His serum creatinine prior to first methotrexate dose was 59 
µmol/L and remained within normal range post methotrexate (CTCAE toxicity grade 0). 
His serum phosphate and bilirubin remained within normal range. ALT peaked at 244 
IU/L on day 4 post methotrexate (CTCAE toxicity grade 2). No further bone marrow 
suppression was noted following the first dose of methotrexate. There were no adverse 
events related to glucarpidase. 
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His clinical examination on day 8 of cycle 1 revealed no changes and he had no 
mucositis. He remained on Trimovate cream topically on his inguinal creases. A swab 
from the inguinal creases taken on 02 July 2007 did not reveal any pathogens. He was 
also on laxatives. Creatinine was 56 µmol/L (CTCAE toxicity grade 0) and calculated 
GFR was 207 ml/min/1.73 m2. ALT was elevated at 176 IU/L (CTCAE toxicity grade 2). 
His phosphate was normal at 1.09 mmol/L. His haemoglobin dropped to 9.6 gr/dl 
(CTCTAE toxicity grade 2). He was fit to proceed to his second dose of methotrexate on 
time. 
MTX dose 2: HEOL had his second dose of methotrexate on 10 July 2007. He had 
glucarpidase on 11 July 2007. Folinic acid rescue was started on the same day.  
Methotrexate plasma levels at 24 hours were 7.02 µmol/L. Methotrexate was cleared 
within 48 hours post dose. His serum creatinine, phosphate and bilirubin remained 
within normal range post methotrexate. ALT peaked at 275 IU/L on day 2 post 
methotrexate (CTCAE toxicity grade 3). No further bone marrow suppression was noted 
following the second dose of methotrexate. There were no adverse events related to 
glucarpidase. 
Assessment on day 15 of cycle 1 took place on 17 July 2007. His clinical examination 
was unremarkable. In particular there was no mucositis.  He remained on Trimovate 
cream and mouthcare. Calculated GFR and creatinine were within normal range at 193 
ml/min/1.73 m2 and 60µmol/L respectively. ALT was elevated at 195 IU/L (CTCAE 
toxicity grade 2). His serum phosphate and bilirubin were within normal range. His HB 
was stable at 10.6 gr/dl (CTCAE toxicity grade 1) although his platelets dropped to 148 
x 109/L (CTCAE toxicity grade 1). “Day 15” criteria were met.  
CYCLE 2 
Clinical assessment on day 1 of cycle 2 on 23 July 2007 was unremarkable. He 
remained on Trimovate cream topically. Creatinine was 69 µmol/L (CTCAE toxicity 
grade 0) and calculated GFR was within normal range at 176 ml/min/1.73 m2. His ALT 
was mildly raised at 95 IU/L (CTCAE toxicity grade 1). His serum phosphate and 
bilirubin were within normal range. His FBC was stable with haemoglobin of 12 gr/dl 
(CTCAE toxicity grade 1) and platelets of 182 x 109/L (CTCAE toxicity grade 0). He was 
fit to proceed to his third dose of methotrexate on time. 
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MTX dose 3: HEOL had the third dose of methotrexate on 24 July 2007. Folinic acid 
rescue was started on 15 July 2007. Methotrexate plasma levels at 24 hours were 
15.57 µmol/L. Methotrexate was cleared within 72 hours post dose. His serum 
creatinine and phosphate remained within normal range. His bilirubin peaked at 46 
µmol/L (CTCAE toxicity grade 2) on day 2 post methotrexate.  ALT peaked at 515 IU/L 
on day 2 post methotrexate (CTCAE toxicity grade 3). No further bone marrow 
suppression was noted following the third dose of methotrexate.  
On clinical assessment on day 8 of cycle 2, HEOL had two oral ulcers. He 
complained of sore throat but he was able to eat and drink although less than normally 
(CTCAE mucositis clinical toxicity grade 2, CTCAE mucositis functional toxicity grade 
1). Serum creatinine and phosphate were within normal range although his bilirubin was 
slightly raised at 26 µmol/L (CTCAE toxicity grade 1). His calculated GFR was 
187ml/min/1.73 m2. ALT was elevated at 155 IU/L (CTCAE toxicity grade 2). He was fit 
to receive his fourth dose of methothrexate on time. 
MTX dose 4: HEOL received his fourth dose of methotrexate on 31 July 2007. Folinic 
acid rescue was started on 01 August 2007. Methotrexate plasma levels at 24 hours 
were 13.01 µmol/L. Methotrexate was cleared within 72 hours post dose. His serum 
creatinine and phosphate remained within normal range. His bilirubin peaked at 
56µmol/L (CTCAE toxicity grade 2) on day 2 post methotrexate. His ALT remained 
stable (maximum of 155 IU/L on day 3 post methotrexate, CTCAE toxicity grade 2). His 
Hb remained stable although platelets dropped to 62 x109/L (CTCAE toxicity grade 2). 
Assessment on day 15 of cycle 2 took place on 07 August 2007, after four doses of 
methotrexate. HEOL was at his local hospital, attending for transfusion of red packed 
cell and platelets. He had mucositis (CTCAE mucositis clinical toxicity grade 3, CTCAE 
mucositis functional toxicity grade 2). His calculated GFR was 182 ml/min/1.73 m2. His 
serum creatinine was within normal range. His ALT was raised at 99 IU/L (CTCAE 
toxicity grade 1).  His bilirubin was also raised at 40 µmol/L (CTCAE toxicity grade 2). 
He was anaemic with Hb of 7.7 gr/dl (CTCAE toxicity grade 3), thrombocytopenic with 
platelets of 37 x109/L (CTCAE toxicity grade 3) and neutropenic with neutrophils of 0.9 
x109/L (CTCAE toxicity grade 3). In view of his mucositis and bone marrow 
suppression, “day 15” criteria were not met.  
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Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1 and also 
negative on days 1, 8, 15 of cycle 2.  
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ANME-02 
Date of birth 20 November 1988 (19 years), male 
Date of diagnosis 24 January 2007 
Diagnosis High grade intramedullary osteosacoma of left distal femur with 
multiple bilateral pulmonary metastases 
Other medical problems Already received 4 courses of cisplatin 120 mg/m
2
, 6 courses of 
doxorubicin 75 mg/ m
2
 and 8 doses of methotrexate 12 gr/m
2
 
Distal femoral replacement on 17/04/2007, good response to pre-
operative chemotherapy 
Date of consent 13 August 2007 
Concomitant medication 
at trial entry 
nil 
Examination at trial entry Unremarkable apart from distal femoral replacement on 
17/04/2007 
GFR prior to trial entry 73 ml/min/1.73 m
2
 on 06 June 2007 
ANME started treatment on GLU 1 clinical trial on 03 September 2007. He was 
randomised to arm A and received glucarpidase in cycle 2. 
CYCLE 1 
His clinical and laboratory (FBC, renal and liver function) assessments on day 1 of cycle 
1 were unremarkable apart from haemoglobin of 10 gr/dl (CTCAE toxicity grade 1) and 
platelets of 104 x 109/l (CTCAE toxicity grade 1).  
MTX dose 1: ANME had his first dose of methotrexate on 03 September 2007. Folinic 
acid rescue was started on 04 September 2007. Methotrexate plasma levels at 24 
hours were 22.79 µmol/L. Methotrexate was cleared within 72 hours post dose. His 
serum creatinine prior to first methotrexate dose was 69 µmol/L and remained within 
normal range post methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 
0.59mmol/L on day 4 post methotrexate (CTCAE toxicity grade 3). ALT peaked at 210 
IU/L on day 2 post methotrexate (CTCAE toxicity grade 2). No further bone marrow 
suppression was noted following the first dose of methotrexate.  
Assessment on day 8 of cycle 1 revealed one ulcer on lower lip (CTCAE mucositis 
clinical toxicity grade 2, CTCAE mucositis functional toxicity grade 0).  The patient did 
not need analgesia. Creatinine was 67 µmol/L (CTCAE toxicity grade 0) and calculated 
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GFR was 142.97 ml/min/1.73 m2. ALT was elevated at 128 IU/L (CTCAE toxicity grade 
1). His phosphate was normal at 1.42 mmol/L. He was fit to proceed to his 2nd dose of 
methotrexate on time. 
MTX dose 2: ANME had his 2nd dose of methotrexate on 10 September 2007. Folinic 
acid rescue was started on 11 September 2007. Methotrexate plasma levels at 24 
hours were 20.47 µmol/L. Methotrexate was cleared within 72 hours post dose. His 
serum creatinine remained within normal range post methotrexate. Phosphate dropped 
to 0.4 mmol/L on day 3 post methotrexate (CTCAE toxicity grade 3) and he received 
phosphate oral supplements for three days. ALT peaked at 201 IU/L on day 3 post 
methotrexate (CTCAE toxicity grade 2). No bone marrow suppression was noted 
following the second dose of methotrexate.  
Assessment on day 15 of cycle 1 took place on 17 September 2007, after two doses 
of methotrexate. ANME had multiple ulcers on his lower lip although they were not 
painful (CTCAE mucositis clinical toxicity grade 2, CTCAE mucositis functional toxicity 
grade 0). He was able to eat and drink as normal and required no analgesia. Calculated 
GFR and creatinine were within normal range at 126 ml/min/1.73 m2 and 76 µmol/L 
respectively. ALT was elevated at 116 IU/L (CTCAE toxicity grade 1). His serum 
phosphate and bilirubin were within normal range. No bone marrow suppression was 
noted throughout the first cycle of treatment. In view of his mucositis on day 15 of cycle 
1, “day 15” criteria were not met.  
CYCLE 2 
Clinical assessment on day 1 of cycle 2 on 01 October 2007 was unremarkable. He 
was on no medication. Creatinine was 77 µmol/L (CTCAE toxicity grade 0) and 
calculated GFR was within normal range at 156 ml/min/1.73 m2. His ALT, serum 
phosphate and bilirubin were all within normal range. His FBC was stable although he 
had and haemoglobin of 11.5 gr/dl (CTCAE toxicity grade 1) He was fit to proceed to his 
third dose of methotrexate. 
MTX dose 3: ANME had the third dose of methotrexate on 01 October 2007, delayed 
by 7 days in view of his mucositis. He had glucarpidase on 02 October 2007. Folinic 
acid rescue was started on the same day. Methotrexate plasma levels at 24 hours were 
395 
32.29 µmol/L. Methotrexate was cleared within 48 hours post dose. His serum 
creatinine and bilirubin remained within normal range. His phosphate dropped to 0.59 
mmol/L (CTCAE toxicity grade 3) on day 4 post methotrexate.  ALT peaked at 115 IU/L 
on day 2 post methotrexate (CTCAE toxicity grade 1). No further bone marrow 
suppression was noted following the third dose of methotrexate. There were no adverse 
events related to glucarpidase. 
Clinical assessment on day 8 of cycle 2 was unremarkable. In particular, there was 
no mucositis. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was 136ml/min/1.73 m2. ALT was slightly elevated at 66 IU/L (CTCAE 
toxicity grade 1). He was fit to receive his fourth dose of methothrexate on time. 
MTX dose 4: ANME received his fourth dose of methotrexate on 08 October 2007. He 
had glucarpidase on 09 October 2007. Folinic acid rescue was started on the same 
day. Methotrexate plasma levels at 24 hours were 23.74 µmol/L. Methotrexate was 
cleared within 48 hours post dose. His serum creatinine and bilirubin remained within 
normal range. His phosphate dropped to 0.69 mmol/L (CTCAE toxicity grade 2) on day 
4 post methotrexate. ALT peaked at 121 IU/L on day 2 post methotrexate (CTCAE 
toxicity grade 3). His Hb and Plts dropped to 10.8 gr/dl (CTCTAE toxicity grade 1) and 
142 x109/L (CTCAE toxicity grade 1) respectively. There were no adverse events 
related to glucarpidase. 
Assessment on day 15 of cycle 2 took place on 15 October 2007, after four doses of 
methotrexate. He had 1 small healing ulcer over the fraenulum. Otherwise his clinical 
examination was unremarkable and he required no analgesia. His calculated GFR was 
141 ml/min/1.73 m2. His serum creatinine was within normal range. The blood sample 
taken for bilirubin, phosphate and ALT was slightly haemolysed and therefore there are 
no results. His haemoglobin and platelets peaked up at to 12.8 gr/dl (CTCTAE toxicity 
grade 1) and 152 x109/L (CTCAE toxicity grade 0) respectively. “Day 15” criteria were 
met.  
Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1 and 1, 8 and 
15 of cycle 2.  
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JACA-03 
Date of birth 03 December 1959 (37 years), female 
Date of diagnosis 23 July 2007 
Diagnosis High grade intramedullary osteosacoma of 7
th
 right rib, 
osteoblastic type 
Other medical problems Surgical excision of 7
th
 right rib prior to starting treatment for 
osteosarcoma 
Date of consent 25 September 2007 
Concomitant medication 
at trial entry 
Oxycontin 20 mg BD PO, Oxynorm 5 mg 2-4 hourly PRN PO, 
Paracetamol, 1gr QDS PO, Cyclizine 50 mg QDS PO, 
Tolterodine Tartate 4 mg OD PO (muscarinic receptor antagonist, 
to treat overactive bladder -frequency and urgency). 
Examination at trial entry Unremarkable apart from healing scar from surgical excision of 
7
th
 right rib 
GFR prior to trial entry 94 ml/min/1.73 m
2
 on 19 July 2007 
JACA started treatment on the GLU 1 clinical trial on 25 September 2007. She was 
randomised to arm B and received glucarpidase in cycle 1. 
CYCLE 1 
Her clinical and laboratory (FBC, renal and liver function) assessments on day 1 of 
cycle 1 were unremarkable.  
MTX dose 1: JACA had the first dose of methotrexate on 25 September 2007 with 
glucarpidase rescue on 26 September 2007. Folinic acid rescue was started on 26 
September 2007. Methotrexate plasma levels at 24 hours were 9.12 µmol/L. 
Methotrexate was cleared within 48 hours post dose. Creatinine prior to the first 
methotrexate dose was 57 µmol/L and peaked at 91 µmol/L, on day 4 post first dose of 
methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 0.41 mmol/L on day 2 
post methotrexate (CTCAE toxicity grade 3). ALT peaked at 736 IU/L on day 2 post 
methotrexate (CTCAE toxicity grade 4). No bone marrow suppression was noted 
following the first dose of methotrexate. There were no adverse events related to 
glucarpidase. 
Assessment on day 8 of cycle 1 revealed slight erythema at the back of her throat. 
The patient did not need analgesia. Creatinine was 75 µmol/L (CTCAE toxicity grade 0) 
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and calculated GFR was acceptable at 75 ml/min/1.73 m2. ALT was elevated at 155 
IU/L (CTCAE toxicity grade 1). Her phosphate was normal at 1.14 mmol/L. She was fit 
to proceed to her second dose of methotrexate on time. 
MTX dose 2: JACA had the second dose of methotrexate on 02 October 2007 with 
glucarpidase rescue on 03 October 2007. Folinic acid rescue was started on 03 
October 2007. Methotrexate plasma levels at 24 hours were 63.46 µmol/L. 
Methotrexate was cleared within 48 hours post dose. Calculated GFR prior to her 
second dose of methotrexate was 75 ml/min/1.73 m2. Creatinine prior to her second 
methotrexate dose was 75 µmol/L and remained stable with max of 89 µmol/L, on day 2 
post methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 0.46 mmol/L on day 
3 post methotrexate (CTCAE toxicity grade 3). ALT peaked at 654 IU/L on day 2 post 
methotrexate (CTCAE toxicity grade 3). Her bilirubin peaked at 31 µmol/L on day 2 post 
methotrexate (CTCAE toxicity grade 2). No bone marrow suppression was noted 
following the second dose of methotrexate. There were no adverse events related to 
glucarpidase.  
Assessment on day 15 of cycle 1 took place on 09 October 2007, post two doses of 
methotrexate. There were two to three small ulcers on her lips (CTCAE for mucositis 
clinical, toxicity grade 2). JACA felt nauseated although she was able to eat and drink. 
Calculated GFR and creatinine were within normal range at 79.25 ml/min/1.73 m2 and 
69µmol/L respectively. ALT was elevated at 386 IU/L (CTCAE toxicity grade 3). No 
bone marrow suppression was noted throughout the first cycle of treatment. In view of 
her mucositis on day 15 of cycle 1, “day 15” criteria were not met.  
CYCLE 2 
Assessment on day 1 of cycle 2 on 15 October 2007 revealed no lip ulcers; however 
there were some residual changes on her left cheek and some throat erythema 
(CTCAE toxicity grade 0-1).Eating and drinking was not compromised. Creatinine was 
79 µmol/L (CTCAE toxicity grade 0) and calculated GFR was almost acceptable at 69.2 
ml/min/1.73 m2. ALT was elevated at 342 IU/L (CTCAE toxicity grade 3). Her phosphate 
was normal at 1.19mmol/L. She was fit to proceed to her third dose of methotrexate. 
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MTX dose 3: JACA had the third dose of methotrexate on 16 October 2007, delayed by 
7 days in view of her mucositis. She had glucarpidase rescue on 17 October 2007. 
Folinic acid rescue was started on 17 October 2007. Methotrexate plasma levels at 24 
hours were 24.45 µmol/L. Methotrexate clearance was delayed and methotrexate 
plasma levels were <0.2µmol/L at 144 hours post dose. Her creatinine peaked at 111 
µmol/L, on day 4 post third dose of methotrexate (CTCAE toxicity grade 1). Phosphate 
dropped to 0.56 mmol/L on day 2 post methotrexate (CTCAE toxicity grade 3). ALT 
peaked at 658 IU/L on day 2 post methotrexate (CTCAE toxicity grade 3). Her bilirubin 
remained within normal range. No bone marrow suppression was noted following the 
third dose of methotrexate. There were no adverse events related to glucarpidase. 
Assessment on day 8 of cycle 2 revealed no mucositis. Creatinine was 95 µmol/L 
(CTCAE toxicity grade 1) and calculated GFR dropped to 57.56 ml/min/1.73 m2. ALT 
was elevated at 248 IU/L (CTCAE toxicity grade 3). Her phosphate was normal at 1.3 
mmol/L. She was tearful and felt rather depressed. In view of her decreased GFR, her 
fourth dose of methotrexate was postponed by 7 days.  
Assessment on day 15 of cycle 2 took place on 29 October 2007, after three doses of 
methotrexate. There was no mucositis and the rest of her clinical examination was 
unremarkable. Calculated GFR dropped further at 50 ml/min/1.73 m2 and her creatinine 
was increased at 108 µmol/L (CTCAE toxicity grade 1). ALT was elevated at 139 IU/L 
(CTCAE toxicity grade 2). No bone marrow suppression was noted throughout her 
second cycle of treatment. In view of impaired renal function on day 15 of cycle 2, “day 
15” criteria were not met. Radionucleotide GFR on 31 October 2007 was 55 
ml/min/1.73 m2; therefore it was decided not to receive further methotrexate. 
Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1. There were 
also negative on days 1, 15 and 120 of cycle 2. 
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NIFI-04 
Date of birth 25 March 1960 ( 47 years), male 
Date of diagnosis 24 July 2007 
Diagnosis High grade intramedullary chondrosarcoma of left pelvis grade 2 
and 3. In addition, there is a high grade spindle cell intravascular 
component regarded as de-differentiated chondrosarcoma 
Post surgery, bulky intravascular ( left femoral and external iliac 
vein) and local recurrence (on MR pelvis 28/09/07) 
Other medical problems Total internal hemipelvectomy on 24 July 2007 and insertion of 
femoral prosthesis prior to starting chemotherapy/trial treatment 
IVC filter inserted 28 September 2007 
Date of consent 28 September 2007 
Concomitant medication 
at trial entry 
MST 10 mg mane, 20mg nocte, PO, Amitryptiline, Pregabalin, 
Tramadol, Ranitidine, Lactulose, Senna, Fragmin 
Examination at trial entry Total internal hemipelvectomy and insertion of femoral prosthesis 
on 24 July 2007, left leg sensation normal but left foot drop and 
some pain in left foot 
GFR prior to trial entry 103 ml/min/1.73 m
2
 on 26 September 2007 
NIFI started treatment on the GLU 1 clinical trial on 01 October 2007. He was 
randomised to arm B and received glucarpidase in cycle 1. 
CYCLE 1 
On clinical examination on day 1 of cycle 1 NIFI had left foot drop and was wearing a 
brace. There was also some pain at his left foot. His laboratory (FBC, renal and liver 
function) assessment on day 1 of cycle 1 was unremarkable apart from haemoglobin of 
10.4 gr/dl (CTCAE grade 1).  
MTX dose 1: NIFI had his first dose of methotrexate on 01 October 2007. Glucarpidase 
was given on 02 October 2007. Folinic acid rescue was started on 02 October 2007. 
Methotrexate plasma levels at 24 hours were 17.44 µmol/L (immunoassay). 
Methotrexate was cleared within 48 hours post dose. His serum creatinine prior to first 
methotrexate dose was 56 µmol/L and peaked at 95 µmol/L on day 3 post 
methotrexate, remaining within normal range (CTCAE toxicity grade 0). Phosphate 
remained within normal range. ALT peaked at 891 IU/L on day 2 post methotrexate 
(CTCAE toxicity grade 3). His serum bilirubin remained within normal range. No bone 
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marrow suppression was noted following the first dose of methotrexate. There were no 
adverse events related to glucarpidase. 
Assessment on day 8 of cycle 1 revealed no mucositis. There was left leg and left 
sided pedal oedema but no other new problems. He remained on MST 30 mg OD, PO, 
Amitryptilline 75mg OD nocté, Pregabalin 75mg am, 150mg pm, PO and Fragmin 
15.000 units OD, SC. His creatinine was 100 µmol/L (CTCAE toxicity grade 0) but 
calculated GFR dropped to 72ml/min/1.73 m2. ALT was elevated at 267 IU/L (CTCAE 
toxicity grade 3). His phosphate and bilirubin remained within normal range. He was fit 
to proceed to his second dose of methotrexate on time. 
MTX dose 2: NIFI had his second dose of methotrexate on 08 October 2007. 
Glucarpidase was given on 09 October 2007.  Folinic acid rescue was started on 09 
October 2007. Methotrexate plasma levels at 24 hours were high at 70.16 µmol/L. He 
had delayed methotrexate elimination. Methotrexate was eventually cleared at 216 
hours post second dose. His serum creatinine peaked at 127 µmol/L on day 3 post 
methotrexate (CTCAE toxicity grade 1). Phosphate and bilirubin remained within normal 
range. ALT remained elevated and peaked at 470 IU/L on day 2 post methotrexate 
(CTCAE toxicity grade 3). Mild bone marrow suppression was noted following the 
second dose of methotrexate. His haemoglobin dropped to 8.8 gr/dl (CTCAE toxicity 
grade 2) on day 7 post second methotrexate and he received a blood transfusion on 14 
October 2007. His platelets dropped to 98 (CTCAE toxicity grade 1) and neutrophils to 
1.55 (CTCAE toxicity grade 1) on day 8 post second methotrexate.  
Assessment on day 15 of cycle 1 took place on 15 October 2007, after two doses of 
methotrexate. NIFI did not clear his second methotrexate dose until 17 October 2007; 
10 days post his second dose. His mouth remained healthy although his fluid intake 
was not brilliant. He remained on intravenous hydration in view of delayed methotrexate 
elimination. He had no diarrhoea. His creatinine was 102 µmol/L (CTCAE toxicity grade 
0). His calculated GFR was 90 ml/min/1.73 m2.  ALT was elevated at 139 IU/L (CTCAE 
toxicity grade 2). His serum phosphate was normal at 1.35 mmol/L.  Mild bone marrow 
suppression was noted following the second dose of methotrexate. His haemoglobin 
dropped down to 8.8 gr/dl (CTCAE toxicity grade 2) post second methotrexate and he 
received a blood transfusion on 14 October 2007. His platelets dropped to 98 (CTCAE 
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toxicity grade 1) and neutrophils to 1.55 (CTCAE toxicity grade 1) post second 
methotrexate. In view of delayed methotrexate elimination, on day 15 of cycle 1, “day 
15” criteria were not met.  
Antiglucarpidase antibodies were negative on days 1, 8, 15 and 30 of cycle 1.  
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SHHI-05 
Date of birth 08 July 1977 (30 years), male 
Date of diagnosis February 1998: high grade osteosarcoma of left proximal tibia 
April 2007: single left sided pulmonary metastasis 
October 2007: metastatic osteosarcoma of sacrum, with small 
volume pulmonary metastases 
Diagnosis February 1998: high grade osteosarcoma of left proximal tibia, 
managed with doxorubicin and cisplatin (BO06 clinical trial, 
randomised to receive GCSF) and proximal tibial replacement, 
treatment completed in June 1998 
April 2007: single left sided pulmonary metastasis, managed with 
surgical excision on 27 June 2007 
October 2007; metastatic high grade osteosarcoma of sacrum, 
fibroblastic type with small volume pulmonary metastases 
Other medical problems nil 
Date of consent 8 October 2008 
Concomitant medication 
at trial entry 
Tramadol 100 mg QDS PO, Paracetamol 1 gr QDS PO, Morphine 
Sulphate M/R 20 mg am & 30 mg pm, PO,Lansoprazole 30 mg 
OD PO, Lactulose 10 mg BD PO, Diclofenac 75 mg BD PO 
(discontinued prior to starting methotrexate) 
Examination at trial entry Previous left proximal tibial replacement 
Persistent back pain settling with analgesia 
GFR prior to trial entry 82 ml/min/1.73 m
2
 on 05/10/07 
SHHI started treatment on the GLU 1 clinical trial on 09 October 2007. He was 
randomised to arm A; therefore he did not receive glucarpidase in cycle 1. 
His clinical and laboratory assessments on day 1 of cycle 1 were unremarkable. 
MTX dose 1: SHHI had his first dose of methotrexate on 09 October 2007. Folinic acid 
rescue was started on 10 October. Methotrexate plasma levels at 24 hours were 33.22 
µmol/L. Methotrexate plasma levels at 72 hours were 0.44 µmol/L. His creatinine was 
82 µmol/L prior to methotrexate. It remained within normal range on days 2 and 3 post 
methotrexate. However, it started to escalate from 13 October 2007, day 4 onwards. 
The patient developed oliguria. His creatinine was 17 7 µmol/L on day 4, 353 µmol/L on 
day 5, 464 µmol/L on day 6, 556 µmol/L on day 7, 631 µmol/L on day 8 and peaked at 
677µmol/L on day 9 post first dose of methotrexate (CTCAE toxicity grade 3). His urine 
output gradually improved. Phosphate went also up from day 5 onwards and peaked at 
2.57 mmol/L on day 9 post methotrexate (CTCAE toxicity grade 1). ALT peaked at 289 
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IU/L on day 2 post methotrexate (CTCAE toxicity grade 3). In view delayed 
methotrexate clearance and impaired renal function his treatment arm was unblinded as 
per protocol. He was found the have been randomised to arm A; therefore he had not 
receive glucarpidase at 24 hours post methotrexate, He received emergency treatment 
with glucarpidase (50 units/kg) on 13 October 2007 as per protocol. Methotrexate 
plasma levels dropped to < 0.2 µmol/L immediately post glucarpidase and remained < 
0.2 µmol/L thereafter. There were no adverse events related to glucarpidase. 
In view of acute renal failure post methotrexate, it was decided not to receive further 
methotrexate. He was started on doxorubicin with dexrazoxane protection on 23 
October i.e. prior to day 15 of cycle 1. 
Assessment on day 15 of cycle 1 took place on 22 September 2008, after only one 
dose of methotrexate. There was no mucositis. Calculated GFR and creatinine were 
abnormal at 44 ml/min/1.73 m2 and 301 µmol/L respectively. ALT was normal at 35 IU/L 
(CTCAE toxicity grade 0). Phosphate levels were back to normal. No bone marrow 
suppression was noted throughout the first cycle of treatment. In view of acute renal 
failure related to methoterexate “day 15” criteria were not met. 
Radionucleotide GFR was 84 ml/min/1.73 m2 on 27 November 2007. His creatinine was 
back to normal when measured on 05 December 2007. 
Antiglucarpidase antibodies were not assessed as this patient did not receive 
glucarpidase as part of the trial and only received one dose glucarpidase as emergency 
treatment. 
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SAWI-06 
Date of birth 04 May 1992 (15 years), male 
Date of diagnosis 12 September 2007 
Diagnosis High grade intramedullary osteosacoma of left proximal humerus, 
largely osteoblastic type with some chondroblastic differentiation 
with metastases in skull and T9 
Other medical problems Already received 3 cycles of MAP (methotrexate 3 doses of 12 
gr/m
2
, adriamycin and cisplatin) 
December 2007: left forequarter amputation 
Date of consent 28 January 2008 
Concomitant medication 
at trial entry 
Gabapentin 300 mg TDS PO 
Fentanyl patch 12 mcg/hr for 72 hours 
Sodium Docusate 100 mg TDS PO 
Examination at trial entry Unremarkable apart from left fore quarter amputation 
GFR prior to trial entry 116 ml/min/1.73 m
2
 on 07 January 2008 
SAWI started treatment on the GLU 1 clinical trial on 28 January 2008. He was 
randomised to arm A and received glucarpidase in cycle 2. 
CYCLE 1 
His clinical and laboratory (FBC, renal and liver function) assessments on day 1 of cycle 
1 were unremarkable apart from slightly raised ALT at 71 IU/L (CTCAE toxicity grade 
1).  
MTX dose 1: SAWI had his first dose of methotrexate on 28 January 2008. Folinic acid 
rescue was started on 29 January 2008. Methotrexate plasma levels at 24 hours were 
12.55 µmol/L. Methotrexate was cleared within 72 hours post dose. His serum 
creatinine prior to first methotrexate dose was 39 µmol/L and remained within normal 
range post methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 0.69 mmol/L 
on day 4 post methotrexate (CTCAE toxicity grade 2). ALT peaked at 446 IU/L on day 8 
post methotrexate (CTCAE toxicity grade 3). No bone marrow suppression was noted 
following the first dose of methotrexate.  
Assessment on day 8 of cycle 1 revealed two tiny oral ulcers (CTCAE mucositis 
clinical toxicity grade 2) although the patient could eat and drink normally (CTCAE 
mucositis functional toxicity grade 0).  The patient did not need analgesia. Creatinine 
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was 45 µmol/L (CTCAE toxicity grade 0) and calculated GFR was 111.58 ml/min/1.73 
m2. ALT was elevated at 446 IU/L (CTCAE toxicity grade 3). His phosphate was normal 
at 1.8 mmol/L. He was fit to proceed to his second dose of methotrexate on time. 
MTX dose 2: SAWI had his second dose of methotrexate on 04 February 2008. Folinic 
acid rescue was started on 05 February 2008. Methotrexate plasma levels at 24 hours 
were 3.55 µmol/L. Methotrexate was cleared within 72 hours post dose. His serum 
creatinine remained within normal range post methotrexate. Phosphate dropped to 0.65 
mmol/L on day 2 post methotrexate (CTCAE toxicity grade 2). ALT dropped to 430 IU/L 
on day 2 post methotrexate (CTCAE toxicity grade 3) and dropped further to 317 IU/L 
on day 2 post methotrexate (CTCAE toxicity grade 3). However, it climbed up to 1056 
IU/L 8 days post methotrexate (CTCAE toxicity grade 4). No bone marrow suppression 
was noted following the second dose of methotrexate.  
Assessment on day 15 of cycle 1 took place on 11 February 2008, after two doses of 
methotrexate. SAWI had severe mucositis and was not able to open his mouth to be 
examined due to pain (CTCAE for mucositis clinical, toxicity grade 3). He could not eat 
or drink (CTCAE for mucositis functional, toxicity grade 3) and was tachycardic due to 
pain and dehydration. He was mildly hypertensive with BP of 128/85 mmHg. He 
required analgesia. Calculated GFR and creatinine were within normal range at 199.3 
ml/min/1.73 m2 and 40 µmol/L respectively. ALT was elevated at 1056 IU/L (CTCAE 
toxicity grade 4). His serum phosphate and bilirubin were within normal range. No bone 
marrow suppression was noted throughout the first cycle of treatment. In view of his 
severe mucositis on day 15 of cycle 1, “day 15” criteria were not met.  
CYCLE 2 
Clinical assessment on day 1 of cycle 2 on 25 February 2008 was unremarkable 
apart from his left forequarter amputation and a bit of erythema around the entry site of 
his PICC line for which he was on iv Teicoplanin. He was off Gabapentin and continued 
on Sodium Docusate. Creatinine was 56 µmol/L (CTCAE toxicity grade 0) and 
calculated GFR was within normal range at 142 ml/min/1.73 m2. ALT was elevated at 
102 IU/L (CTCAE toxicity grade 1). His serum phosphate and bilirubin were within 
normal range. He was fit to proceed to his third dose of methotrexate. 
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MTX dose 3: SAWI had the third dose of methotrexate on 25 February 2008, delayed 
by 7 days in view of his mucositis. He had glucarpidase on 26 February 2008. Folinic 
acid rescue was started on 26 February 2008. Methotrexate plasma levels at 24 hours 
were 12.76 µmol/L. Methotrexate was cleared within 48 hours post dose. His serum 
creatinine, phosphate and bilirubin remained within normal range. ALT peaked at 317 
IU/L on day 2 post methotrexate (CTCAE toxicity grade 3). No bone marrow 
suppression was noted following the third dose of methotrexate. There were no adverse 
events related to glucarpidase. 
Clinical assessment on day 8 of cycle 2 was unremarkable. In particular, there was 
no mucositis. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was 153.34 ml/min/1.73 m2. ALT was elevated at 373 IU/L (CTCAE 
toxicity grade 3). He was fit to receive his fourth dose of methothrexate on time. 
MTX dose 4: SAWI’s PICC line required repositioning and he received his fourth dose 
of methotrexate on 04 March 2008, delayed by one day. He had glucarpidase on 06 
March 2008. Folinic acid rescue was started on 06 March 2008. Methotrexate plasma 
levels at 24 hours were 14.74 µmol/L. Methotrexate was cleared within 72 hours post 
dose. His serum creatinine, phosphate and bilirubin remained within normal range. ALT 
peaked at 604 IU/L on day 2 post methotrexate (CTCAE toxicity grade 3). No bone 
marrow suppression was noted following the fourth dose of methotrexate. There were 
no adverse events related to glucarpidase. 
Assessment on day 15 of cycle 2 took place on 11 March 2008, after four doses of 
methotrexate. There was no mucositis and the rest of his clinical examination was 
unremarkable. His calculated GFR was 100.9 ml/min/1.73 m2. His serum creatinine, 
phosphate and bilirubin were within normal range. ALT was elevated at 592 IU/L 
(CTCAE toxicity grade 3). No bone marrow suppression was noted throughout the 
second cycle of treatment. “Day 15” criteria were met.  
Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1. There were 
negative on days 1, 8, 15, 30 and 90 of cycle 2. 
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IFOK-07 
Date of birth 03 November 1990 (17 years), male 
Date of diagnosis 05 September 2007 
Diagnosis High grade osteosarcoma of left proximal tibia (telangiectatic 
type) 
Other medical problems Already received 6 courses of methotrexate at a dose of 12 
gr/m
2
/course, 4 courses of adriamycin at a dose of 75 
mg/m
2
/course and 4 courses of  cisplatin at a dose of120 
mg/m
2
/course 
December 2007: excision of tumour and left tibial replacement 
Date of consent 17 February 2008 
Concomitant medication 
at trial entry 
nil 
Examination at trial entry Unremarkable apart from scar from proximal tibial replacement 
GFR prior to trial entry 129 ml/min/1.73 m
2
 on 07 January 2008 
IFOK started treatment on the GLU 1 clinical trial on 18 February 2008. He was 
randomised to arm B and received glucarpidase in cycle 1. 
CYCLE 1 
His clinical and laboratory (FBC, renal and liver function) assessments on day 1 of cycle 
1 were unremarkable apart from Hb of 9.9 gr/dl (CTCAE toxicity grade 2).  
MTX dose 1: IFOK had his first dose of methotrexate on 18 February 2008. 
Glucarpidase was given on 19 February 2008. Folinic acid rescue was started on 19 
February 2008. Methotrexate plasma levels at 24 hours were rather high at 
95.92µmol/L. Methotrexate was cleared within 72 hours post dose. His serum creatinine 
prior to first methotrexate dose was 79 µmol/L and peaked at 127 µmol/L on day 3 post 
methotrexate (CTCAE toxicity grade 1). Phosphate dropped to 0.71mmol/L on day 5 
post methotrexate (CTCAE toxicity grade 2). ALT peaked at 729 IU/L on day 2 post 
methotrexate (CTCAE toxicity grade 3). His haemoglobin dropped to 8.8 gr/dl on days 4 
and 5 post methotrexate (CTCAE toxicity grade 2). There was neither 
thrombocytopenia nor neutropenia following the first dose of methotrexate. There were 
no adverse events related to glucarpidase. 
408 
His second dose of methotrexate was due on 25 February 2008; however this was 
delayed to 28 February 2008 due to oral mucositis. Clinical assessment on 28 
February 2008, “day 8” of cycle 1, was unremarkable. Prior to starting his second 
dose of methotrexate on trial, his creatinine was 90 µmol/L (CTCAE toxicity grade 0) 
and calculated GFR was 176 ml/min/1.73 m2. ALT was slightly elevated at 66 IU/L 
(CTCAE toxicity grade 1). His haemoglobin was low at 8.8 gr/dl (CTCAE toxicity grade 
2) but the rest of his bone marrow function was unremarkable. He was fit to proceed to 
his second dose of methotrexate with a 3 day delay in view of mucositis.  
MTX dose 2: IFOK had his second dose of methotrexate on 28 February 2008. 
Glucarpidase was given on 29 February 2008. Folinic acid rescue was started on 29 
February 2008. Methotrexate plasma levels at 24 hours were elevated at 141.69 
µmol/L. However, methotrexate was cleared within 96 hours post dose.  His serum 
creatinine peaked at 139 µmol/L on day 3 post methotrexate (CTCAE toxicity grade 1). 
Phosphate dropped to 0.58 mmol/L on day 2 post methotrexate (CTCAE toxicity grade 
3). ALT peaked at 1070 IU/L on day 2 post methotrexate (CTCAE toxicity grade 4) No 
bone marrow suppression was noted following the second dose of methotrexate, 
although haemoglobin remained between 8.8 and 9.1 gr/dl. There were no adverse 
events related to glucarpidase. 
Assessment on day 15 of cycle 1 took place on 03 March 2008, after two doses of 
methotrexate. He remained on intravenous hydration and folinic acid rescue as he did 
not clear his methotrexate until the following day, 4th March 2008. He was also on 
Movicol and domperidone. IFOK did not have mucositis and the rest of his clinical 
examination was unremarkable. Calculated GFR and creatinine were within normal 
range at 103 ml/min/1.73 m2 and 108µmol/L respectively. ALT was elevated at 275 IU/L 
(CTCAE toxicity grade 3). His serum phosphate was low at 0.58 mmol/L (CTCAE 
toxicity grade 3). His bilirubin was within normal range. No bone marrow suppression 
was noted throughout the first cycle of treatment although Hb remained low at 9.1 gr/dl 
(CTCAE grade 2). In view of the delay in methotrexate elimination, “day 15” criteria 
were not met.  
CYCLE 2 
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Clinical assessment on day 0 of cycle 2 on 16 March 2008 was unremarkable. He 
was on no medication. Creatinine was 98 µmol/L (CTCAE toxicity grade 0) and 
calculated GFR was within normal range at 115 ml/min/1.73 m2. ALT and serum 
phosphate were within normal range. His haemoglobin remained low at 9.3 gr/dl 
(CTCAE toxicity grade 2). He was fit to proceed to his third dose of methotrexate. 
MTX dose 3: IFOK had the third dose of methotrexate on 17 March 2008. Folinic acid 
rescue was started on 18 March 2008. Methotrexate plasma levels at 24 hours were 
high at 149.78 µmol/L. Methotrexate was cleared within 144 hours post dose. His serum 
creatinine peaked at 136 µmol/L on day 3 post methotrexate (CTCAE toxicity grade 1). 
Phosphate dropped to 0.57 mmol/L on day 3 post methotrexate (CTCAE toxicity grade 
3) and he received phosphate supplements. ALT peaked at 684 IU/L on day 2 post 
methotrexate (CTCAE toxicity grade 4). His Hb remained stable and no further bone 
marrow suppression was noted following the third dose of methotrexate.  
In view of the delay in the elimination of IFOK’s third dose of methotrexate, he did not 
receive his fourth dose until the 27th March 2008. Clinical assessment prior to his 
fourth dose was unremarkable. In particular, there was no mucositis. He was on no 
medication. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was 125.8 ml/min/1.73 m2. ALT was slightly elevated at 66 IU/L 
(CTCAE toxicity grade 1).  
MTX dose 4: IFOK had his fourth dose of methotrexate on 27th March 2007. Folinic 
acid rescue was started on 27 March 2008. Methotrexate plasma levels at 24 hours 
were elevated at 114.83 µmol/L. Methotrexate was cleared within 120 hours post dose.  
His serum creatinine peaked at 125 µmol/L on day 2 post methotrexate (CTCAE toxicity 
grade 1). Phosphate dropped to 0.29mmol/L on day 5 post methotrexate (CTCAE 
toxicity grade 4) and he received phosphate supplements. ALT peaked at 1241 IU/L on 
day 2 post methotrexate (CTCAE toxicity grade 4). His Hb remained stable (minimum 
Hb 8.8.gr/dl, CTCTAE grade 2) and no further bone marrow suppression was noted 
following the forth dose of methotrexate.  
Assessment on day 15 of cycle 2 took place on 01 April 2008, after four doses of 
methotrexate. There was no mucositis and the rest of his clinical examination was 
unremarkable. His calculated GFR was 115.5 ml/min/1.73 m2. His serum creatinine and 
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bilirubin were within normal range. His serum phosphate was 0.98mmol/L and he 
remained on phosphate supplements. ALT was elevated at 222 IU/L (CTCAE toxicity 
grade 2). His haemoglobin remained low at 8.2 gr/dl (CTCAE grade 2) but no further 
bone marrow suppression was noted throughout the second cycle of treatment. “Day 
15” criteria were not met as IFOK was still clearing his forth methotrexate dose.  
Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1. There were 
positive on day 1 of cycle 2, negative on day 8 of cycle 2 and then again positive on 
days 15 and 23 of cycle 2.  
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PAHE-08 
Date of birth 17 August 1990 (17 years), female 
Date of diagnosis 23 January 2008 
Diagnosis High grade osteosarcoma of left inferior pelvis with large volume 
pulmonary metastases 
Other medical problems Already received 1 course of cisplatin 120 mg/m
2
 and doxorubicin 
75 mg/ m
2
 on 25 January 2008 
Date of consent 17 February 2008 
Concomitant medication 
at trial entry 
Paracetamol 1gr QDS, PO, Oxycontin 10mg BD,PO, Gabapentin 
300mg TDS, PO, Norethisterone 5 mg tds,po, Fragmin 9000 units 
BD, SC, Lanzoprazole 30mg, OD,PO, Dexamethasone 4mg 
OD,PO reducing dose 
Examination at trial entry Dry skin, very swollen left leg, on treatment dose of fragmin, 
reduction of left hip flexion 2/5, left hip extension 3/5, left knee 
flexion and extension 3/5, left ankle flexion ¾ and left ankle 
extension 4/5, due to compressive symptoms of her large tumour  
GFR prior to trial entry 106 ml/min/1.73 m
2
 on 11 February 2008 
PAHE started treatment on the GLU 1 clinical trial on 18 February 2008. She was 
randomised to arm B and received glucarpidase in cycle 1. 
CYCLE 1 
Her laboratory (FBC, renal and liver function) assessments on day 1 of cycle 1 were 
unremarkable apart from haemoglobin of 8.4 gr/dl (CTCAE toxicity grade 2). She had 
dry skin, very swollen left leg (on treatment dose of fragmin), reduction of left hip flexion 
2/5, left hip extension 3/5, left knee flexion and extension 3/5, left ankle flexion 3/4 and 
left ankle extension 4/5, due to compressive symptoms of her large tumour. 
MTX dose 1: PAHE had her first dose of methotrexate on 18 February 2008. She had 
glucarpidase on 19 February 2008. Folinic acid rescue was started on the same day.  
Methotrexate plasma levels at 24 hours were 4.49 µmol/L. Methotrexate was cleared 
within 72 hours post dose. Her serum creatinine prior to first methotrexate dose was 42 
µmol/L and remained within normal range post methotrexate (CTCAE toxicity grade 0). 
Serum phosphate levels remained within normal range. ALT peaked at 307 IU/L on day 
2 post methotrexate (CTCAE toxicity grade 3). Her haemoglobin dropped further to 7.8 
gr/dl (CTCAE toxicity grade 3) and she was transfused with red packed cells. No further 
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bone marrow suppression was noted following the first dose of methotrexate. There 
were no adverse events related to glucarpidase. 
Day 8 treatment was delayed by 1 day due to issues with patient’s transport. On clinical 
examination “on day 8” of cycle 1 on 26 February 2008, she was found to have oral 
thrush. Her skin remained dry and flaky. Clinical examination of her right leg remained 
unchanged.  PAHE had no mucositis. She was on Oxycontin 10mg BD,PO, Oxynorm 
2.4 mg QDS,PO, Gabapentin 300mg TDS, PO, Norethisterone 5 mg tds,po, Fragmin 
9000 units BD, SC, Fluconazole, 5mls, BD, PO and sucralfate 5mls, BD, PO. She 
remained in pain despite Oxycontin and regular Oxynorm. The dose of oxycontin was 
increased to 15mg, BD, PO and Paracetamol was added regularly. 
Creatinine was 47 µmol/L (CTCAE toxicity grade 0) and calculated GFR was 189 
ml/min/1.73 m2. ALT was only slightly elevated at 48 IU/L (CTCAE toxicity grade 1). Her 
phosphate was normal at 1.39 mmol/L. She was fit to proceed to her second dose of 
methotrexate. 
MTX dose 2: PAHE had her second dose of methotrexate on 26 February 2008, 
delayed by one day due to issues with hospital transport. She had glucarpidase on 27 
February 2008. Folinic acid rescue was started on the same day. Methotrexate plasma 
levels at 24 hours were 9.06 µmol/L. Methotrexate was cleared within 48 hours post 
dose. Her serum creatinine remained within normal range post methotrexate. 
Phosphate dropped to 0.7 mmol/L on day 2 post methotrexate (CTCAE toxicity grade 
2). ALT peaked at 211 IU/L on day 2 post methotrexate (CTCAE toxicity grade 3). No 
further bone marrow suppression was noted following the second dose of methotrexate. 
There were no adverse events related to glucarpidase. 
Assessment on day 15 of cycle 1 took place on 03 March 2008, after two doses of 
methotrexate. PAHE had dry skin as before. Clinical assessment of her right leg 
remained unchanged. Her oral thrush had settled and she had no mucositis. Calculated 
GFR and creatinine were within normal range at 187 ml/min/1.73 m2 and 44 µmol/L 
respectively. ALT was slightly elevated at 51 IU/L (CTCAE toxicity grade 1). Her serum 
phosphate and bilirubin were within normal range. No further bone marrow suppression 
was noted throughout the first cycle of treatment. “Day 15” criteria were met.  
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CYCLE 2 
Clinical assessment on day 1 of cycle 12 March 2008 was unremarkable apart from the 
unchanged issues with her swollen right leg. She remained on Oxycontin 15mg BD, 
PO, Gabapentin 300mg TDS, PO, Norethisterone 5 mg, TDS, PO, Paracetamol 1gr, 
QDS, PO and Fragmin 9000 units BD, SC. Creatinine was 40 µmol/L (CTCAE toxicity 
grade 0) and calculated GFR was within normal range at 205 ml/min/1.73 m2. Her ALT 
remained slightly elevated at 55 IU/L (CTCAE toxicity grade 1). Her serum phosphate 
and bilirubin remained within normal range. Her haemoglobin remained stable at 8 gr/dl 
(CTCAE toxicity grade 2).  She was fit to proceed to third dose of methotrexate on time. 
MTX dose 3: PAHE had her third dose of methotrexate on 13 March 2008. Folinic acid 
rescue was started on 14 March 2008. Methotrexate plasma levels at 24 hours were 
5.57 µmol/L. Methotrexate was cleared within 72 hours post dose. Her serum 
creatinine, phosphate and bilirubin remained within normal range.  ALT peaked at 185 
IU/L (CTCAE toxicity grade 3) on day 2 post methotrexate. No further bone marrow 
suppression was noted following the third dose of methotrexate. On 19 March she was 
found to have thrush and was prescribed fluconazole, PO.  
Clinical assessment on day 8 of cycle 2 was unremarkable. In particular, there was no 
mucositis. Serum creatinine, phosphate and bilirubin were within normal range. Her 
calculated GFR was 195 ml/min/1.73 m2. ALT was elevated at 63 IU/L (CTCAE toxicity 
grade 1). She was fit to receive her fourth dose of methothrexate on time. 
MTX dose 4: PAHE received her fourth dose of methotrexate on 19 March 2008, one 
day early in view of Easter Holidays. Folinic acid rescue was started on 20 March 2008. 
Methotrexate plasma levels at 24 hours were 5.16 µmol/L. Methotrexate was cleared 
within 72 hours post dose. Her serum creatinine and bilirubin remained within normal 
range. Her phosphate dropped to 0.74 mmol/L (CTCAE toxicity grade 2) on day 3 post 
methotrexate. ALT peaked at 193 IU/L (CTCAE toxicity grade 3) on day 2 post 
methotrexate. No further bone marrow suppression was noted following the fourth dose 
of methotrexate.  
Assessment on day 15 of cycle 2 took place on 27 March 2008, after four doses of 
methotrexate. She had no mucositis and examination of her right leg remained 
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unchanged. She remained on Oxycontin 15mg BD, PO, Gabapentin 300mg TDS, PO, 
Norethisterone 5 mg, TDS, PO and Fragmin 9000 units BD, SC. Her calculated GFR 
was 187 ml/min/1.73 m2. Her serum creatinine, bilirubin and phosphate were all within 
normal range. Her ALT was slightly elevated at 56 IU/L (CTCAE toxicity grade 1). No 
further bone marrow suppression was noted following the forth dose of methotrexate.  
“Day 15” criteria were met.  
PAHE developed right sided tension pneumothorax (CTCAE v3.0, grade 4) during her 
hospital admission for her forth dose of methotrexate. She required admission to 
Intensive Care Unit. In view of that, the event was reported as Serious Adverse Event 
as per trial protocol. It was thought unrelated to trial medication and related to patient’s 
extensive pulmonary disease. 
Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1. There were 
positive on day 1 of cycle 2 but negative on days 8, 15, 30 and 90 of cycle 2.  
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PEFR-09 
Date of birth 30 October 1994 (13 years), male 
Date of diagnosis 14 March 2008 
Diagnosis Localised high grade osteosarcoma of the sphenoid bone with 
diffuse chondroblastic differentiation likely secondary to radiation 
therapy for low grade glioma in May 1997  
Other medical problems 1997: Low grade glioma, received radical radiotherapy, 50 Gy in 
30 fractions, between 17 June and 29 July 1997  
Prior to starting GLU 1 clinical trial, already received 2 courses of 
cisplatin 120 mg/m
2
 and doxorubicin 75 mg/ m
2
  
Date of consent 23 April 2008 
Concomitant medication 
at trial entry 
Lansoprazole 30mg, OD,PO, and magnesium glycerophosphate 
4 mls, TDS, PO 
Examination at trial entry Erythema on buttocks, managed with sudocream PRN 
III and XI cranial nerve palsy on right side, right sided 
hemiparesis, hyperreflexia, more in lower limbs, improving right 
sided ptosis with emerging diplopia  
GFR prior to trial entry 174.6 ml/min/1.73 m
2
 calculated at trial entry  
PEFR started treatment on the GLU 1 clinical trial on 12 May 2008. He was randomised 
to arm A and received glucarpidase in cycle 2. 
CYCLE 1 
His laboratory (FBC, renal and liver function) assessments on day 1 of cycle 1 were 
unremarkable apart from haemoglobin of 8.1 gr/dl (CTCAE toxicity grade 2). He had 
some erythema on his buttocks, managed with sudocream PRN. He also had III and XI 
cranial nerve palsy on the right side, improving right sided ptosis with emerging 
diplopia, right sided hemiparesis and hyperreflexia, more in lower limbs,  
MTX dose 1: PEFR had his first dose of methotrexate on 12 May 2008. Folinic acid 
rescue was started on 13 May 2008. Methotrexate plasma levels at 24 hours were 7.26 
µmol/L. Methotrexate was cleared within 72 hours post dose. His serum creatinine prior 
to first methotrexate dose was 49 µmol/L and remained within normal range post 
methotrexate (CTCAE toxicity grade 0). His serum phosphate and bilirubin remained 
within normal range. No further bone marrow suppression was noted following the first 
dose of methotrexate.  
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Assessment on day 8 of cycle 1 revealed no mucositis although the patient complained 
of sore throat (CTCAE mucositis clinical toxicity grade 0, CTCAE mucositis functional 
toxicity grade 0) and some epigastric discomfort. The rest of his clinical examination 
remained unchanged. PEFR remained on the same medication that he was at the 
beginning of the trial treatment. Creatinine was 49 µmol/L (CTCAE toxicity grade 0) and 
calculated GFR was 162 ml/min/1.73 m2. ALT was mildly elevated at 116 IU/L (CTCAE 
toxicity grade 1). His phosphate was normal at 1.4 mmol/L. He was fit to proceed to his 
second dose of methotrexate on time. 
MTX dose 2: PEFR had his second dose of methotrexate on 19 May 2008. Folinic acid 
rescue was started on 20 May 2008. Methotrexate plasma levels at 24 hours were 7.6 
µmol/L. Methotrexate was cleared within 72 hours post dose. His serum creatinine, 
phosphate and bilirubin remained within normal range post methotrexate. ALT peaked 
at 124 IU/L on day 2 post methotrexate (CTCAE toxicity grade 1). No further bone 
marrow suppression was noted following the first dose of methotrexate.  
Assessment on day 15 of cycle 1 took place on 27 May 2008, after two doses of 
methotrexate. His clinical examination was unremarkable apart from mild bilateral 
blepharitis. The patient remained on the same medication that he was at the beginning 
of the trial treatment. Calculated GFR and creatinine were within normal range at 204 
ml/min/1.73 m2 and 42 µmol/L respectively. ALT was elevated at 164 IU/L (CTCAE 
toxicity grade 2). His serum phosphate and bilirubin were within normal range. His 
haemoglobin was 9.2 gr/dl (CTCAE toxicity grade 2). “Day 15” criteria were met.  
CYCLE 2 
On clinical examination on day 1 of cycle 2 on 02 June 2008, his blepharitis was still 
present and both eyes were red and sticky. Eye swabs taken on 28 May 2008 grew 
staphylococcus aureus and haemophilus influenza and PEFR was started on 
chlorampenicol eye drops. He remained on Lansoprazole 30mg, OD, PO, and 
magnesium glycerophosphate 4 mls, TDS, PO. Creatinine was 48 µmol/L (CTCAE 
toxicity grade 0) and calculated GFR was within normal range at 117 ml/min/1.73 m2. 
His serum ALT, phosphate and bilirubin were within normal range. His haemoglobin 
was stable at 9.5gr/dl (CTCAE toxicity grade 2). He was fit to proceed to his third dose 
of methotrexate on time. 
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MTX dose 3: PEFR had the third dose of methotrexate on 02 June 2008. He had 
glucarpidase on 03 June 2008. Folinic acid rescue was started on the same day. 
Methotrexate plasma levels at 24 hours were 8.4 µmol/L. Methotrexate was cleared 
within 48 hours post dose. His serum creatinine, phosphate and bilirubin remained 
within normal range. ALT peaked at 91 IU/L on day 2 post methotrexate (CTCAE 
toxicity grade 1). No further bone marrow suppression was noted following the third 
dose of methotrexate. There were no adverse events related to glucarpidase. 
Clinical assessment on day 8 of cycle 2 revealed III and IX cranial nerve palsy, brisk 
reflexes on right upper and lower extremities, mild dysdiachokinesia and past pointing 
bilaterally more pronounced on the right side. His eyes cleared and he had no 
mucositis. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was stable at 126 ml/min/1.73 m2. ALT was elevated at 278 IU/L 
(CTCAE toxicity grade 3). His haemoglobin was 10.4 gr/dl (CTCAE toxicity grade 1).  
He was fit to receive his fourth dose of methothrexate on time. 
MTX dose 4: PEFR received his fourth dose of methotrexate on 09 June 2008. He had 
glucarpidase on 10 June 2008. Folinic acid rescue was started on the same day. 
Methotrexate plasma levels at 24 hours were 9.44 µmol/L. Methotrexate was cleared 
within 48 hours post dose. His serum creatinine and bilirubin remained within normal 
range. His phosphate dropped to 0.8 mmol/L (CTCAE toxicity grade 1) on day 3 post 
methotrexate. His ALT did not go further up post methotrexate. No further bone marrow 
suppression was noted following the forth dose of methotrexate. There were no adverse 
events related to glucarpidase. 
Assessment on day 15 of cycle 2 took place on 16 June 2008, after four doses of 
methotrexate. PEFR described intermittent soreness at his perianal area, although this 
was not visible on clinic examination. He had some dizziness on walking, blurred vision 
on the right, minor medial, upward and downward movement of his right eye, no pupil 
reaction on the right, minor right-sided facial palsy and right-sided hearing impairment. 
There was some pus around his Hickman line exit site. He had no mucositis. His 
calculated GFR was 171 ml/min/1.73 m2. His serum creatinine, phosphate and bilirubin 
were within normal range. No further bone marrow suppression was noted following the 
fourth dose of methotrexate.  “Day 15” criteria were met.  
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Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1. They were 
negative on day 8 of cycle 2, positive on day 15 of cycle 2 and again negative on days 
30 and 90 of cycle 2. No results are available from blood sample taken on day 1 of 
cycle 2, on 02 June 2008. 
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CHWC-10 
Date of birth 05 March 1978 (29 years), male 
Date of diagnosis 21 January 2008 
Diagnosis Intramedullary osteosacoma of left first metatarsal on the 
background of giant cell tumour of bone   
Other medical problems 1999: Giant cell tumour of left first metatarsal, treated with 
curettage, fibula strut graft and adjuvant radiotherapy (50 Gy in 
25 fractions) 
2006 & 2007: pain 
2008 Intramedullary osteosacoma of left first metatarsal on the 
background of giant cell tumour of bone   
Already received 1 course of adriamycin and cisplatin on 14 April 
2008 
Date of consent 23 May 2008 
Concomitant medication 
at trial entry 
Codeine phosphate as required, nil else 
Examination at trial entry Unremarkable  
GFR prior to trial entry 98 ml/min/1.73 m
2
 on 19 May 2008 
CHWC started treatment on the GLU 1 clinical trial on 16 May 2008. He was 
randomised to arm A and received glucarpidase in cycle 2. 
CYCLE 1 
His clinical and laboratory (FBC, renal and liver function) assessments on day 1 of cycle 
1 were unremarkable apart from haemoglobin of 8.6 gr/dl (CTCAE toxicity grade 2).  
MTX dose 1: CHWC had his first dose of methotrexate on 26 May 2008. Folinic acid 
rescue was started on 27 May 2008. Methotrexate plasma levels at 24 hours were 
28.42 µmol/L. Methotrexate was cleared within 72 hours post dose. His serum 
creatinine prior to first methotrexate dose was 77 µmol/L and remained within normal 
range post methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 0.53 mmol/L 
on day 4 post methotrexate (CTCAE toxicity grade 3). ALT peaked at 531 IU/L on day 2 
post methotrexate (CTCAE toxicity grade 3). No further bone marrow suppression was 
noted following the first dose of methotrexate.  
Assessment on day 8 of cycle 1 revealed two to three erythematous areas on oral 
mucous membranes with a small ulcer (CTCAE mucositis clinical toxicity grade 1-2, 
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CTCAE mucositis functional toxicity grade 0).  The patient needed Difflam mouthwash 
for analgesia. Creatinine was 79 µmol/L (CTCAE toxicity grade 0) and calculated GFR 
was 123.57 ml/min/1.73 m2. ALT was elevated at 141 IU/L (CTCAE toxicity grade 2). 
His phosphate was normal at 1.47mmol/L. He was fit to proceed to his second dose of 
methotrexate on time. 
MTX dose 2: CHWC had his second dose of methotrexate on time on 02 June 2008. 
Folinic acid rescue was started on 03 June 2008. Methotrexate plasma levels at 24 
hours were 22.77 µmol/L. Methotrexate was cleared within 72 hours post dose. His 
serum creatinine peaked at 144 µmol/L on day 3 post second dose of methotrexate 
(CTCAE toxicity grade 1). Phosphate remained within normal range. ALT peaked at 601 
IU/L on day 2 post methotrexate (CTCAE toxicity grade 3). His haemoglobin remained 
stable at 9.2 gr/dl (CTCAE toxicity grade 2) although his platelets dropped to 132 x109/L 
(CTCAE toxicity grade 1).  
Assessment on day 15 of cycle 1 took place on 09 June 2008, after two doses of 
methotrexate. CHWC had confluent ulcers in his oral cavity (CTCAE for mucositis 
clinical, toxicity grade 3). He was still able to drink although his solid intake was 
compromised (CTCAE for mucositis functional, toxicity grade 2) His mouth pain was not 
controlled on regular codeine phosphate and paracetamol and kept him awake at night. 
He had no abdominal pain. Calculated GFR and creatinine were within normal range at 
90.39 ml/min/1.73 m2 and 108 µmol/L respectively. ALT was elevated at 320 IU/L 
(CTCAE toxicity grade 3). His serum phosphate and bilirubin were within normal range. 
His haemoglobin and platelets remained stable at 9 gr/dl (CTCAE toxicity grade 2) and 
106 x109/L respectively (CTCAE toxicity grade 1). His neutrophils were 1.83 x109/L 
(CTCAE toxicity grade 1) on day 15 of cycle 1 on 09 June 2010 but dropped further to 
0.79 x109/L (CTCAE toxicity grade 3) on 23 June 2008, 20 days post his second 
methotrexate dose. 
In view of his mucositis on day 15 of cycle 1, “day 15” criteria were not met.  
CYCLE 2 
Clinical assessment on day 1 of cycle 2 on 26 June 2008 was unremarkable CHWC 
was on no medication. Creatinine was 101 µmol/L (CTCAE toxicity grade 0) and 
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calculated GFR was within normal range at 95 ml/min/1.73 m2. His ALT, serum 
phosphate and bilirubin were within normal range. His neutrophils were 1.28 x109/L 
(CTCAE toxicity grade 2). He was fit to proceed to his third dose of methotrexate. 
MTX dose 3: CHWC had his third dose of methotrexate on 26 June 2008, delayed by 
10 days in view of his mucositis and neutropenia. He had glucarpidase on 27 June 
2008. Folinic acid rescue was started on 27 June 2008. Methotrexate plasma levels at 
24 hours were 41.23 µmol/L. Methotrexate was cleared within 72 hours post dose. His 
serum creatinine remained within normal range. His phosphate dropped to 0.72 mmol/L 
(CTCAE toxicity grade 2) on day 2 post methotrexate. His bilirubin and ALT peaked at 
32 µmol/L (CTCAE toxicity grade 2) and 801 IU/L (CTCAE toxicity grade 3) on day 2 
post methotrexate. His Plts dropped at 103 x109/L (CTCAE toxicity grade 1) on day 8 
post third dose of methotrexate. No further bone marrow suppression was noted. There 
were no adverse events related to glucarpidase. 
Clinical assessment on day 8 of cycle 2 was unremarkable. In particular, there was 
no mucositis. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was 109.3 ml/min/1.73 m2. ALT was elevated at 368 IU/L (CTCAE 
toxicity grade 3). His haemoglobin remained stable at 10.1 gr/dl (CTCAE toxicity grade 
2) although his platelets dropped to 103 x109/L (CTCAE toxicity grade 1).  
He was fit to receive his fourth dose of methothrexate on time. 
MTX dose 4: CHWC received his fourth dose of methotrexate on 03 July 2008. He had 
glucarpidase on 04 July 2008. Folinic acid rescue was started on 04 July 2008. 
Methotrexate plasma levels at 24 hours were 55.76 µmol/L. Methotrexate was cleared 
within 96 hours post dose. His serum creatinine peaked at 145 µmol/L (CTCAE toxicity 
grade 1) on day 4 post methotrexate. His phosphate remained within normal range. His 
bilirubin and ALT peaked at 25 µmol/L (CTCAE toxicity grade 1) and 580 IU/L (CTCAE 
toxicity grade 3) on day 2 post methotrexate. His platelets dropped further to 82x109/L 
(CTCAE toxicity grade 1) on day 5 post fourth dose of methotrexate. There were no 
adverse events related to glucarpidase. 
Assessment on day 15 of cycle 2 took place on 10 July 2008, after four doses of 
methotrexate. There was slight erythema on his buccal mucosa but no ulcers (CTCAE 
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for mucositis clinical, toxicity grade 0, CTCAE for mucositis functional, toxicity grade 0). 
The rest of his clinical examination was unremarkable. His calculated GFR was 72.3 
ml/min/1.73 m2. His serum creatinine was elevated at 135 µmol/L (CTCAE toxicity 
grade 1). Phosphate and bilirubin were within normal range. ALT was elevated at 273 
IU/L (CTCAE toxicity grade 3). His haemoglobin and platelets remained stable at 11.9 
gr/dl (CTCAE toxicity grade 1) and 89 x109/L (CTCAE toxicity grade 1) respectively.  
“Day 15” criteria were met.  
Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1 and remained 
negative on days 1, 8, 15 and 90 of cycle 2. 
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JASH-11 
Date of birth 10 December 1991 (17 years), male 
Date of diagnosis 09 February 2008 
Diagnosis Localised high grade telangiectatic ostesarcoma of left distal tibia 
Other medical problems Already received 3 courses of cisplatin 120 mg/m
2
 and 
doxorubicin 75 mg/ m
2
 and 3 courses of methotrexate 12gr/m
2 
Below knee amputation, April 2008 
Date of consent 27 May 2008 
Concomitant medication 
at trial entry 
Gabapentin 300mg, BD,PO, Lansoprazole 30mg, OD,PO 
Examination at trial entry Unremarkable apart from amputation of left foot 
GFR prior to trial entry 111 ml/min/1.73 m
2
 on 23 April 2008 
JASH started treatment on the GLU 1 clinical trial on 27 May 2008. He was randomised 
to arm A and received glucarpidase in cycle 2. 
CYCLE 1 
His clinical and laboratory assessments on day 1 of cycle 1 were unremarkable apart 
from left below knee amputation and haemoglobin of 10.5 gr/dl (CTCAE toxicity grade 
1).  
MTX dose 1: JASH had his first dose of methotrexate on 27 May 2008. Folinic acid 
rescue was started on 28 May 2008. Methotrexate plasma levels at 24 hours were 
28.03 µmol/L. Methotrexate was cleared within 72 hours post dose. His serum 
creatinine prior to first methotrexate dose was 43 µmol/L and remained within normal 
range post methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 0.47 mmol/L 
on day 3 post methotrexate (CTCAE toxicity grade 3). ALT peaked at 1384 IU/L on day 
2 post methotrexate (CTCAE toxicity grade 4). His serum bilirubin remained within 
normal range. No further bone marrow suppression was noted following the first dose of 
methotrexate.  
Assessment on day 8 of cycle 1 revealed no mucositis but loose bowel motions, 2-3 
times per day. The patient remained on the same medication that he was at the 
beginning of the trial treatment. Creatinine was 48 µmol/L (CTCAE toxicity grade 0) and 
calculated GFR was 228 ml/min/1.73 m2. ALT was elevated at 258 IU/L (CTCAE toxicity 
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grade 3). His phosphate was normal at 1.41 mmol/L. He was fit to proceed to his 
seconddose of methotrexate on time. 
MTX dose 2: JASH had his second dose of methotrexate on 03 June 2008. Folinic acid 
rescue was started on 04 June 2008. Methotrexate plasma levels at 24 hours were 
11.05 µmol/L. Methotrexate was cleared within 72 hours post dose. His serum 
creatinine remained within normal range post methotrexate. Phosphate dropped to 0.58 
mmol/L on day 3 post methotrexate (CTCAE toxicity grade 3). ALT peaked at 1410 IU/L 
on day 2 post methotrexate (CTCAE toxicity grade 4). His platelets dropped to 123 x 
109/L on day 3 post methotrexate (CTCAE toxicity grade 1).  
Assessment on day 15 of cycle 1 took place on 10 June 2008, after two doses of 
methotrexate. His clinical examination was unremarkable. The patient remained on the 
same medication that he was at the beginning of the trial treatment. Calculated GFR 
and creatinine were within normal range at 215 ml/min/1.73 m2 and 51 µmol/L 
respectively. ALT was elevated at 164 IU/L (CTCAE toxicity grade 2). His serum 
bilirubin was within normal range. There was no documentiation of his serum 
phosphate. His haemoglobin was 9.9 gr/dl (CTCAE toxicity grade 2) and platelets 129 x 
109/L (CTCAE toxicity grade 1). “Day 15” criteria were met.  
CYCLE 2 
Clinical assessment on day 1 of cycle 2 on 15 June 2008 was unremarkable. He 
remained on Gabapentin 300mg, BD,PO, Lansoprazole 30mg, OD,PO. Creatinine was 
41 µmol/L (CTCAE toxicity grade 0) and calculated GFR was within normal range at 
264 ml/min/1.73 m2. His ALT remained elevated at 71 IU/L (CTCAE toxicity grade 1). 
His serum phosphate and bilirubin were within normal range. His Hb was stable at 
11.5gr/dl (CTCAE toxicity grade 1) but his platelets normalised. He was fit to proceed to 
his third dose of methotrexate on time. 
MTX dose 3: JASH had the third dose of methotrexate on 16 June 2008. He had 
glucarpidase on 17 June 2008. Folinic acid rescue was started on the same day. 
Methotrexate plasma levels at 24 hours were 16.94 µmol/L. Methotrexate was cleared 
within 48 hours post dose. His serum creatinine, phosphate and bilirubin remained 
within normal range. ALT peaked at 1710 IU/L on day 2 post methotrexate (CTCAE 
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toxicity grade 4). His platelets dropped to 175 x 109/L (CTCAE toxicity grade 1). There 
were no adverse events related to glucarpidase. 
Clinical assessment on day 8 of cycle 2 was unremarkable. In particular, there was no 
mucositis. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was 249ml/min/1.73 m2. ALT was elevated at 296 IU/L (CTCAE toxicity 
grade 3). His platelets remained slightly low at 188 x 109/L (CTCAE toxicity grade 1).  
He was fit to receive his fourth dose of methothrexate on time. 
MTX dose 4: JASH received his fourth dose of methotrexate on 23 June 2008. He had 
glucarpidase on 24 June 2008. Folinic acid rescue was started on the same day. 
Methotrexate plasma levels at 24 hours were 20.44 µmol/L. Methotrexate was cleared 
within 72 hours post dose. His serum creatinine and bilirubin remained within normal 
range. His phosphate dropped to 0.72 mmol/L (CTCAE toxicity grade 1) on day 3 post 
methotrexate. ALT peaked at 466 IU/L on day 2 post methotrexate (CTCAE toxicity 
grade 3). No further bone marrow suppression was noted following the forth dose of 
methotrexate. There were no adverse events related to glucarpidase. 
Assessment on day 15 of cycle 2 took place on 30 June 2008, after four doses of 
methotrexate. JASH was tired and had a productive cough. His chest X-ray was normal. 
He had no mucositis. He remained on Gabapentin 300mg, BD,PO, Lansoprazole 30mg, 
OD,PO. His calculated GFR was 228 ml/min/1.73 m2. His serum creatinine and bilirubin 
were within normal range. His serum phosphate was not measured. No further bone 
marrow suppression was noted following the forth dose of methotrexate.  “Day 15” 
criteria were met.  
Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 1 and on days 
1, 8, 15, 30 and 90 of cycle 2. Blood sample was also collected on 30 January 2009 
(day 180 of cycle 2) but was not processed as antiglucarpidase antibodies were found 
to be negative on day 90 of cycle 2. 
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SAPH-12 
Date of birth 03 August 1991 (17 years), male 
Date of diagnosis 03 April 2008 
Diagnosis Localised high grade osteoblastic osteosacoma of T12 
2 right sided pulmonary nodules (<5mm) of uncertain significance 
Other medical problems Initially he received 2 courses of adriamycin and cisplatin, 
following which he developed cord compression and required 
vertebrectomy (24 May 2008). Following the above 
chemotherapy he received 2 courses of Ifosfamide and etoposide 
prior to starting treatment on GLU 1 clinical trial 
Date of consent 07 August 2008 
Concomitant medication 
at trial entry 
MST 30mg BD, PO 
Ibuprofen 400 mg BD, PO, stopped prior to starting methotrexate 
Omeprazole 20 mg OD, PO 
Fragmin18.000 units OD, SC 
Examination at trial entry Morbidly obese 
Minimal pulmonary effusion , unlikely to interfere with 
methotrexate clearance 
GFR prior to trial entry 77 ml/min/1.73 m
2
 on 01 August 2008 
SAPH started treatment on the GLU 1 clinical trial on 07 August 2008. He was 
randomised to arm B and received glucarpidase in cycle 1. 
CYCLE 1 
On clinical examination on day 1 of cycle 1 SAPH was found to be morbidly obese. He 
had extensive steroid induced striae and two pressure induced blisters on his back. His 
laboratory (FBC, renal and liver function) assessment on day 1 of cycle 1 was 
unremarkable apart from mildly decreased albumin of 30 g/L (CTCAE toxicity grade 1).  
MTX dose 1: SAPH had his first dose of methotrexate on 07 August 2008. 
Glucarpidase was given on 08 August 2008. Folinic acid rescue was started on 08 
August 2008. Methotrexate plasma levels at 24 hours were 52.05 µmol/L. Samples 
taken for HPLC at T=0 hours, 4 hours, 24 hours, 24.20 hours and 48 hours became 
jelly like with the addition of HCL as per protocol. Therefore they were unsuitable for 
HPLC analysis. His plasma methotrexate levels measured by HPLC were <0.2 µmol/L 
at 72 hours post methotrexate. Since there were no previous samples that were 
measured with HPLC to confirm a trend in plasma methotrexate excretion, folinic acid 
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was continued and the dose was adjusted based on plasma methotrexate levels at 72 
hours as measured by immunoassay. His plasma methotrexate levels measured by 
HPLC were 0.27 µmol/L at 96 hours post methotrexate, so folinic acid rescue was 
continued as appropriate. Methotrexate was cleared within 120 hours post dose. His 
serum creatinine prior to first methotrexate dose was 41 µmol/L and peaked at 112 
µmol/L on day 4 post methotrexate, although it remained within normal range (CTCAE 
toxicity grade 0). His potassium was up to 5.2 mmol/L on day 4 post methotrexate but 
settled subsequently (CTCAE toxicity grade 1). His albumin remained normal post 
methotrexate. Phosphate dropped to 0.72 mmol/L on day 7 post methotrexate (CTCAE 
toxicity grade 1). ALT peaked at 285 IU/L on day 6 post methotrexate (CTCAE toxicity 
grade 3). Bilirubin peaked at 34 µmol/L on day 8 post methotrexate (CTCAE toxicity 
grade 2). No bone marrow suppression was noted following the first dose of 
methotrexate. There were no adverse events related to glucarpidase. 
Assessment on day 8 of cycle 1 revealed no mucositis or other new problems. He 
remained on MST 30 mg OD, PO, Omeprazole 20 mg OD, PO and Fragmin 18.000 
units OD, SC. His creatinine was 105 µmol/L (CTCAE toxicity grade 0) and calculated 
GFR was 103.13ml/min/1.73 m2. ALT was elevated at 268 IU/L (CTCAE toxicity grade 
3). His phosphate was low at 0.72 mmol/L (CTCAE toxicity grade 2). His bilirubin was 
elevated at 34 µmol/L (CTCAE toxicity grade 2) as noted above. He was fit to proceed 
to his second dose of methotrexate on time. 
MTX dose 2: SAPH had his second dose of methotrexate on 14 August 2008. 
Glucarpidase was given on 15 August 2008.  Folinic acid rescue was started on 15 
February 2008. In view of the problems with the addition of HCL in his plasma samples 
post his first methotrexate dose, it was decided to process his HPLC samples with no 
HCL post second dose. Methotrexate plasma levels at 24 hours were really high at 
253.54 µmol/L. The patient’s treatment arm was unblinded as per trial protocol and it 
became clear that he had received glucarpidase at 24 hours post methotrexate. High 
dose folinic acid was started. Methotrexate was eventually cleared at 312 hours post 
second dose. His serum creatinine peaked at 247µmol/L on day 6 post methotrexate 
(CTCAE toxicity grade 2). Phosphate dropped to 0.72 mmol/L on day 3 post 
methotrexate (CTCAE toxicity grade 2). ALT remained elevated at maximum of 260 
IU/L on day 5 post methotrexate (CTCAE toxicity grade 3). His albumin dropped down 
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to 27 g/L on day 5 post methotrexate (CTCAE toxicity grade 2). No bone marrow 
suppression was noted following the second dose of methotrexate despite his delayed 
clearance.  
Assessment on day 15 of cycle 1 took place on 21 August 2008, after two doses of 
methotrexate. SAPH did not clear his second methotrexate dose until 27 August 2008; 
14 days post his second dose. SAPH had oral candidiasis and a small ulcer on his 
lower lip (CTCAE for mucositis clinical and functional, toxicity grade 2). He also had 
diarrhoea (CTCAE toxicity grade 1). He had right iliac fossa pain and generalised 
abdominal tenderness. An abdominal X-ray revealed dilated small bowel loops and 
possibly oedematous bowel wall (enteritis CTCAE toxicity grade 1) which were 
managed conservatively. His creatinine was elevated at 238 µmol/L (CTCAE toxicity 
grade 1). His calculated GFR was low at 45.5 ml/min/1.73 m2.  ALT was elevated at 126 
IU/L (CTCAE toxicity grade 2). His serum phosphate was elevated at 2.11mmol/L and 
his calcium was low at 1.66 mmol/L (CTCAE toxicity grade 3). His albumin was also low 
at 27 g/L (CTCAE toxicity grade 2). No significant bone marrow suppression was noted 
throughout the first cycle of treatment. In view of delayed methotrexate excretion, renal 
deterioration and mucositis on day 15 of cycle 1, “day 15” criteria were not met.  
In view of renal deterioration it was decided not to receive further treatment with 
methotrexate. 
Antiglucarpidase antibodies were negative on days 1, 8, 15 and 30 of cycle 1.  
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TRGO-13 
Date of birth 09 April 1978 (30 years), female 
Date of diagnosis December 2005 chondroblastic osteosarcoma of proximal tibia 
February 2008 pulmonary metastases 
Diagnosis December 2005: chondroblastic osteosarcoma of proximal tibia, 
treated with chemotherapy (?agents), excision and 
reconstruction, all treatment given in Nantes, France 
February 2008: pulmonary embolism and pulmonary metastases, 
inoperable, decided to be managed with methotrexate followed 
by ifosfamide and etoposide 
Other medical problems Suicidal symptoms 
Date of consent 2 September 2008 
Concomitant medication 
at trial entry 
Duloxetine 60 mg, nocte, antidepressant (serotonin–
norepinephrine reuptake inhibitor) 
Aripiprazole 15 mg, nocte, antipsychotic, antidepressant 
Asthma inhalers 
Had been on warfarin until 18 August 2009, stopped in view of 
pending portacath insertion 
Examination at trial entry Unremarkable apart from previous right tibial replacement 
GFR prior to trial entry 87 ml/min/1.73 m
2
 on 20
th
 May 2008 
TRGO started treatment on the GLU 1 clinical trial on 02 September 2008. She was 
randomised to arm B and received glucarpidase in cycle 1. 
Her clinical and laboratory assessments on day 1 of cycle 1 were unremarkable.  
MTX dose 1: TRGO had the first dose of methotrexate on 02 September 2008 with 
glucarpidase rescue on 03 September 2008. Folinic acid rescue was started on 03 
September 2008. Methotrexate plasma levels at 24 hours were 17.47 µmol/L. 
Methotrexate was cleared at 72 hours. Creatinine prior to the first methotrexate dose 
was 74 µmol/L but peaked at 114 µmol/L, on day 5 post first dose of methotrexate 
(CTCAE toxicity grade 1). Phosphate dropped to 0.67 mmol/L on day 3 post 
methotrexate (CTCAE toxicity grade 2). ALT peaked at 506 IU/L on day 8 post 
methotrexate (CTCAE toxicity grade 3). No bone marrow suppression was noted 
following the first dose of methotrexate. There were no adverse events related to 
glucarpidase. 
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Assessment on day 8 of cycle 1 revealed one oral ulcer and erythema in the oral 
cavity. The patient needed analgesia (Difflam mouthwash). There was also eruptive 
facial rash which was attributed to steroids used as part of antisickness regimen. 
Creatinine was elevated at 107 µmol/L (CTCAE toxicity grade 1) although calculated 
GFR was acceptable at 78.6 ml/min/1.73 m2. ALT was also elevated at 506 IU/L 
(CTCAE toxicity grade 3).  In view of the elevated creatinine and mucositis thesecond 
dose of methotrexate was delayed by one week. 
MTX dose 2: TRGO had the second dose of methotrexate on 15 September 2008 with 
glucarpidase rescue on 16 September 2008. Folinic acid rescue was started on 16 
September 2008. Methotrexate plasma levels at 24 hours were 43.86 µmol/L. 
Methotrexate was cleared at 120 hours. Calculated GFR prior to second dose of 
methotrexate was 106 ml/min/1.73 m2. Creatinine prior to the second methotrexate 
dose was 83µmol/L but peaked at 141 µmol/L, on day 5 post methotrexate (CTCAE 
toxicity grade 1). Phosphate dropped to 0.59 mmol/L on day 3 post methotrexate 
(CTCAE toxicity grade 3). ALT peaked at 1017 IU/L on day 8 post methotrexate 
(CTCAE toxicity grade 4). No bone marrow suppression was noted following the second 
dose of methotrexate. There were no adverse events related to glucarpidase.  
Assessment on day 15 of cycle 1 took place on 15 September 2008, prior to the 
second of methotrexate. It revealed one small recovering ulcer on the left side of her 
tongue. The patient was still requiring analgesia (Difflam mouthwash). Calculated GFR 
and creatinine were within normal range at 106 ml/min/1.73 m2 and 83 µmol/L 
respectively. ALT was elevated at 319 IU/L (CTCAE toxicity grade 3). No bone marrow 
suppression was noted throughout the first cycle of treatment. In view of the one week 
delay for the second dose of methotrexate “day 15” criteria were not met.  
In view of delayed methotrexate excretion and creatinine elevation post second dose of 
methotrexate, patient’s GFR (radioisotope) was examined on 24 September 2008 and 
was found to be decreased at 51 ml/min/1.73 m2. Therefore it was decided not to 
proceed with further doses of methotrexate. 
Antiglucarpidase antibodies were negative on days 1, 8 and 30 of cycle 1. 
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ABBS-14 
Date of birth 27 November 1992 (14 years), male 
Date of diagnosis June 2008 
Diagnosis Localised chondroblastic osteosarcoma of right distal femur, 
intermediate grade 
Other medical problems Already received 2 courseS of cisplatin 120 mg/m
2
, 2 courses of 
doxorubicin 75 mg/ m
2
 and 4 courses of methotrexate 12 gr m
2
 
Excision of tumour and distal femoral replacement in the UK on 
03 November 2008, pathology: high grade periosteal 
osteosarcoma with chondroblastic and osteoblastic features, poor 
response to pre-operative chemotherapy with <90% necrosis 
Date of consent 17 November 2008 
Concomitant medication 
at trial entry 
Lactulose 15mls, BD, PO, Paracetamol 1 gr, QDS, PO, Fragmin, 
2500 units, OD, SC 
Examination at trial entry Unremarkable apart from distal femoral replacement  
GFR prior to trial entry 106 ml/min/1.73 m
2
 on 14 November 2008 
ABBS started treatment on the GLU 1 clinical trial on 17 November 2008. He was 
randomised to arm A and was planned to receive glucarpidase in cycle 2. 
CYCLE 1 
His clinical and laboratory assessments on day 1 of cycle 1 were unremarkable apart 
from haemoglobin of 9.7 gr/dl (CTCAE toxicity grade 1).  
MTX dose 1: ABBS had his first dose of methotrexate on 17 November 2008. Folinic 
acid rescue was started on 18 November 2008. Methotrexate plasma levels at 24 hours 
were 30.04 µmol/L. Methotrexate was cleared within 96 hours post dose. His serum 
creatinine prior to first methotrexate dose was 66 µmol/L and remained within normal 
range post methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 0.64 mmol/L 
on day 4 post methotrexate (CTCAE toxicity grade 2). ALT peaked at 333 IU/L on day 4 
post methotrexate (CTCAE toxicity grade 3). No further bone marrow suppression was 
noted following the first dose of methotrexate.  
Assessment on day 8 of cycle 1 revealed no oral mucositis. However, he had oral 
thrush. There was some mild central abdominal discomfort but bowel sounds were 
present and he was not constipated. His right knee was swollen, hot and tender and 
ABBS was reluctant to move his right knee due to pain. He remained on the same 
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medication as prior to starting GLU 1 trial treatment. Creatinine was 71 µmol/L (CTCAE 
toxicity grade 0) and calculated GFR was 136 ml/min/1.73 m2. ALT was elevated at 223 
IU/L (CTCAE toxicity grade 2). His phosphate and bilirubin were within normal range. In 
view of his effusion he was started on IV teicoplanin. Blood cultures from 14 November 
2008 grew acinobacter calcoaceticus and IV ciprofloxacin was added to his antibiotic 
treatment. His right knee effusion was tapped on 26 November 2008. In view of his 
knee effusion, GLU 1 clinical trial treatment was discontinued and “day 15 of cycle 1” 
criteria were not met.  
Blood sample for antiglucarpidase antibodies was collected on day 1 of cycle 1 but not 
processed as patient off treatment by day 8 of cycle 1, prior to receiving any 
glucarpidase.  
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SETI-15 
Date of birth 14 May 1971 (37 years), male 
Date of diagnosis 15 December 2008 
Diagnosis Localised high-grade osteosarcoma of maxilla 
Other medical problems Nil of note 
Date of consent 25 January 2009 
Concomitant medication 
at trial entry 
nil 
Examination at trial entry Unremarkable apart from ulcerated area in the oral cavity at the 
site of his primary disease (palate and maxilla) 
GFR prior to trial entry 88 ml/min/1.73 m
2
 on 14 January 2009 
SETI started treatment on the GLU 1 clinical trial on 26 January 2009. He was 
randomised to arm B and received glucarpidase in cycle 1. 
CYCLE 1 
His clinical and laboratory assessments on day 1 of cycle 1 were unremarkable apart 
from ulcerated area in the oral cavity at the site of his primary disease.  
MTX dose 1: SETI had his first dose of methotrexate on 26 January 2009. He had 
glucarpidase on 27 January 2009. Folinic acid rescue was started on the same day.  
Methotrexate plasma levels at 24 hours were 12.78 µmol/L. Methotrexate was cleared 
within 72 hours post dose. His serum creatinine prior to first methotrexate dose was 
79µmol/L and remained within normal range post methotrexate (CTCAE toxicity grade 
0). Phosphate dropped to 0.5 mmol/L on day 3 post methotrexate (CTCAE toxicity 
grade 3). ALT peaked at 130 IU/L on day 2 post methotrexate (CTCAE toxicity grade 2). 
No further bone marrow suppression was noted following the first dose of methotrexate. 
There were no adverse events related to glucarpidase. 
Assessment on day 8 of cycle 1 revealed no mucositis. There was an ulcerated area in 
his oral cavity at the site of his primary disease as before. In view of his 
hypophosphataemia he was started on Phosphate Sandoz 2 tablets, BD, PO. He was 
also on Lanzoprazole 30mg, OD, orally. Creatinine was 72 µmol/L (CTCAE toxicity 
grade 0) and calculated GFR was 188 ml/min/1.73 m2. ALT was slightly elevated at 64 
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IU/L (CTCAE toxicity grade 1). His phosphate and bilirubin were within the normal 
range. He was fit to proceed to his second dose of methotrexate on time. 
MTX dose 2: SETI had his second dose of methotrexate on 02 February 2009. He had 
glucarpidase on 03 February 2009. Folinic acid rescue was started on the same day. 
Methotrexate plasma levels at 24 hours were 16.89 µmol/L. Methotrexate was cleared 
within 72 hours post dose. His serum creatinine remained within normal range post 
methotrexate. Phosphate dropped to 0.66 mmol/L on day 4 post methotrexate (CTCAE 
toxicity grade 2). ALT peaked at 107 IU/L on day 2 post methotrexate (CTCAE toxicity 
grade 1). No further bone marrow suppression was noted following the second dose of 
methotrexate. There were no adverse events related to glucarpidase. 
Assessment on day 15 of cycle 1 took place on 09 February 2009, after two doses of 
methotrexate. SETI had confluent ulcers at the back of his mouth and his lower lips. 
The rest of his oral mucosa was erythematous (CTCAE mucositis clinical toxicity grade 
3, CTCAE mucositis functional toxicity grade 2). He remained on Lanzoprazole 30mg, 
OD, PO. Calculated GFR and creatinine were within normal range at 190 ml/min/1.73 
m2 and 71µmol/L respectively. ALT was elevated at 70 IU/L (CTCAE toxicity grade 1). 
His serum phosphate and bilirubin were within normal range. No further bone marrow 
suppression was noted throughout the first cycle of treatment. In view of his mucositis 
on day 15 of cycle 1, “day 15” criteria were not met.  
CYCLE 2 
On clinical assessment on day 1 of cycle 2 on 16 February 2009 his oral ulcers were 
almost healed (CTCAE mucositis clinical toxicity grade 1, CTCAE mucositis functional 
toxicity grade 0). He was on Lanzoprazole 30mg, OD, PO, DIfflam mouthwash, Aspirin 
mouthwash and Phosphate Sandoz 2 tablets, BD, PO. Creatinine was 83µmol/L 
(CTCAE toxicity grade 0) and calculated GFR was within normal range at 154 
ml/min/1.73 m2. His ALT was only slightly elevated at 59 IU/L (CTCAE toxicity grade 1). 
His serum phosphate and bilirubin were within normal range. His Hb was 12.1gr/dl 
(CTCAE toxicity grade 1). He was fit to proceed to his third dose of methotrexate on 
time. 
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MTX dose 3: SETI had the third dose of methotrexate on 16 February 2009. Folinic acid 
rescue was started on 17 February 2009. Methotrexate plasma levels at 24 hours were 
26.12 µmol/L. Methotrexate was cleared within 96 hours post dose. His serum 
creatinine remained within normal range. His phosphate dropped to 0.82 mmol/L 
(CTCAE toxicity grade 1) on day 3 post methotrexate.  His ALT peaked at 162 IU/L on 
day 2 post methotrexate (CTCAE toxicity grade 2). No further bone marrow suppression 
was noted following the third dose of methotrexate.  
Clinical assessment on day 8 of cycle 2 was unremarkable apart from folliculitis at the 
inner thighs for which he was started on Canesten cream topically. There was no 
mucositis. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was 137ml/min/1.73 m2. ALT was elevated at 110 IU/L (CTCAE toxicity 
grade 1). He was fit to receive his fourth dose of methothrexate on time. 
MTX dose 4: SETI received his fourth dose of methotrexate on 23 February 2009. 
Folinic acid rescue was started on 24 February 2009. Methotrexate plasma levels at 24 
hours were 23.19 µmol/L. Methotrexate was cleared within 96 hours post dose. His 
serum creatinine peaked at 136 µmol/L on day 4 post methotrexate (CTCAE toxicity 
grade 1). His ALT peaked at 185 IU/L (CTCAE toxicity grade 2) on day 2 post 
methotrexate. His phosphate dropped to 0.48 mmol/L (CTCAE toxicity grade 3) on day 
3 post methotrexate. His bilirubin remained within normal range.  His haemoglobin 
remained stable but his platelets dropped to 132 x 109/L (CTCAE toxicity grade 1) on 
day 5 post methotrexate.  
Assessment on day 15 of cycle 2 took place on 02 March 2009, after four doses of 
methotrexate. His inner thigh folliculitis was healing. He had an ulcer on his lower lip 
and one on his uvula. The rest of his oral mucosa was erythematous (CTCAE mucositis 
clinical toxicity grade 2, CTCAE mucositis functional toxicity grade 1). Otherwise his 
clinical examination was unremarkable. He remained on Lansoprazole 30mg, OD, PO, 
Canesten cream topically on inner thighs and domperidone 20 mg, QDS, PO. His 
calculated GFR was 118 ml/min/1.73 m2. His serum creatinine, bilirubin and phosphate 
were within normal range. His ALT was slightly elevated at 75 IU/L (CTCAE toxicity 
grade 1). No further bone marrow suppression was noted following the fourth dose of 
methotrexate.  “Day 15” criteria were not met in view of his mucositis.  
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Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle and 1 and 8 of 
cycle 2. They were present on days 15 and 30 of cycle 2.  
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DAOA-16 
Date of birth 07 January 1990 (19 years), male 
Date of diagnosis 11 December 2008 
Diagnosis High grade spindle cell sarcoma of right distal tibia 
Other medical problems Already received 1 course of cisplatin 120 mg/m
2
 and doxorubicin 
75 mg/ m
2
 
Date of consent 26 January 2009 
Concomitant medication 
at trial entry 
MTS 20mg BD,PO 
Sodium Docusate 200mg TDS,PO 
Examination at trial entry Unremarkable apart from pain and swelling at his right ankle at 
the site of his primary disease 
GFR prior to trial entry 94 ml/min/1.73 m
2
 on 21 January 2009 
DAOA started treatment on the GLU 1 clinical trial on 27 January 2009. He was 
randomised to arm A and received glucarpidase in cycle 2. 
CYCLE 1 
His clinical and laboratory assessments on day 1 of cycle 1 were unremarkable apart 
from pain and swelling at his right ankle at the site of his primary disease and 
haemoglobin of 12.6 gr/dl (CTCAE toxicity grade 1).  
MTX dose 1: DAOA had his first dose of methotrexate on 27 January 2009. Folinic acid 
rescue was started on 28 January 2009. Methotrexate plasma levels at 24 hours were 
18.38µmol/L. Methotrexate was cleared within 72 hours post dose. His serum creatinine 
prior to first methotrexate dose was 81 µmol/L and remained within normal range post 
methotrexate (CTCAE toxicity grade 0). Phosphate dropped to 0.49 mmol/L on day 3 
post methotrexate (CTCAE toxicity grade 3). ALT peaked at 499 IU/L on day 2 post 
methotrexate (CTCAE toxicity grade 3). No further bone marrow suppression was noted 
following the first dose of methotrexate.  
Assessment on day 8 of cycle 1 revealed one healing ulcer and two tiny almost healed 
lesions on the left side of his buccal mucosa (CTCAE mucositis clinical toxicity grade 1, 
CTCAE mucositis functional toxicity grade 0).  The patient remained on the same 
medication that he was at the beginning of the trial treatment, i.e. MTS 20mg BD, PO 
and Sodium Docusate 200mg TDS, PO as well as Senna 2 tablets nocte and Difflam 
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mouthwash. Creatinine was 62 µmol/L (CTCAE toxicity grade 0) and calculated GFR 
was 168 ml/min/1.73 m2. ALT was elevated at 551 IU/L (CTCAE toxicity grade 3). His 
phosphate was normal at 1.24 mmol/L. He was fit to proceed with his second dose of 
methotrexate on time. 
MTX dose 2: DAOA had his second dose of methotrexate on 4th February 2009, 
delayed by 1 day due to weather conditions. Folinic acid rescue was started on 5th 
February 2009. Methotrexate plasma levels at 24 hours were 20 µmol/L. Methotrexate 
was cleared within 72 hours post dose. His serum creatinine remained within normal 
range post methotrexate. Phosphate dropped to 0.58 mmol/L on day 4 post 
methotrexate (CTCAE toxicity grade 3). ALT peaked at 803 IU/L on day 7 post 
methotrexate (CTCAE toxicity grade 3). No further bone marrow suppression was noted 
following the second dose of methotrexate.  
Assessment on day 15 of cycle 1 took place on 10 February 2009, after two doses of 
methotrexate. DAOA had mucositis on the left side of his buccal mucosa (CTCAE 
mucositis clinical toxicity grade 1, CTCAE mucositis functional toxicity grade 2). He was 
able to eat and drink as long as he used Difflam mouth spray. Calculated GFR and 
creatinine were within normal range at 134 ml/min/1.73 m2 and 84 µmol/L respectively. 
ALT was elevated at 803 IU/L (CTCAE toxicity grade 3). His serum phosphate and 
bilirubin were within normal range. No further bone marrow suppression was noted 
throughout the first cycle of treatment. In view of his mucositis on day 15 of cycle 1, 
“day 15” criteria were not met.  
CYCLE 2 
Clinical assessment on day 1 of cycle 2 on 16 February 2009 was unremarkable and 
his mucositis had settled completely. He remained on MST, Senna and Sodium 
Docusate. Creatinine was 75 µmol/L (CTCAE toxicity grade 0) and calculated GFR was 
within normal range at 145 ml/min/1.73 m2. His ALT remained elevated at 276 IU/L 
(CTCAE toxicity grade 3). His serum phosphate was within normal range. His 
haemoglobin was stable at 12 gr/dl (CTCAE toxicity grade 1) but his neutrophils 
dropped to 1.9 x 109/L (CTCAE toxicity grade 1). He was fit to proceed to his third dose 
of methotrexate on time. 
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MTX dose 3: DAOA had the third dose of methotrexate on 17 February 2009. He had 
glucarpidase on 18 February 2009. Folinic acid rescue was started on the same day. 
Methotrexate plasma levels at 24 hours were 26 µmol/L. Methotrexate was cleared 
within 72 hours post dose. His serum creatinine remained within normal range. His 
phosphate dropped to 0.49 mmol/L (CTCAE toxicity grade 3) on day 3 post 
methotrexate.  ALT was not measured until 23 February 2009 when it was 290 IU/L 
(CTCAE toxicity grade 3). No further bone marrow suppression was noted following the 
third dose of methotrexate. There were no adverse events related to glucarpidase. 
Clinical assessment on day 8 of cycle 2 was unremarkable. In particular, there was no 
mucositis. Serum creatinine, phosphate and bilirubin were within normal range. His 
calculated GFR was 136ml/min/1.73 m2. ALT was elevated at 290 IU/L (CTCAE toxicity 
grade 3). He was fit to receive his fourth dose of methothrexate on time. 
MTX dose 4: DAOA received his fourth dose of methotrexate on 24 February 2009. He 
had glucarpidase on 25 February 2009. Folinic acid rescue was started on the same 
day. Methotrexate plasma levels at 24 hours were 16.97 µmol/L. Methotrexate was 
cleared within 72 hours post dose. His serum creatinine and bilirubin remained within 
normal range. His phosphate dropped to 0.82 mmol/L (CTCAE toxicity grade 1) on day 
3 post methotrexate. ALT was not measured until 03 March 2009 when it was 426 IU/L 
(CTCAE toxicity grade 3). No further bone marrow suppression was noted following the 
forth dose of methotrexate. A mouth swab taken on 27 February 2009 revealed a 
moderate growth of candida (CTCAE toxicity grade 2 for infection with normal ANC). 
There were no adverse events related to glucarpidase. 
Assessment on day 15 of cycle 2 took place on 02 March 2009, after four doses of 
methotrexate. He had a small ulcer on his lower lip. His right ankle, site of primary 
disease, remained swollen. Otherwise his clinical examination was unremarkable. He 
remained on MST 15mg BD, PO, Senna and Sodium Docusate.. His calculated GFR 
was 136 ml/min/1.73 m2. His serum creatinine was within normal range. His serum 
bilirubin and phosphate were within normal range. His ALT remained elevated at 426 
IU/L (CTCAE toxicity grade 3). No further bone marrow suppression was noted 
following the forth dose of methotrexate.  “Day 15” criteria were met.  
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Antiglucarpidase antibodies were negative on days 1, 8 and 15 of cycle 2 and day 1 of 
cycle 2. They were present on days 8 and 15 of cycle 2.  
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APPENDIX 13. ANTIGLUCARPIDASE ANTIBODY RESPONSE, INTERIM 
ANALYTICAL REPORT BY MILLIPORE BIOPHARMA 
(NOVEMBER 2011) 
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APPENDIX 14. NEUTRALISING ANTIGLUCARPIDASE ANTIBODIES, DRAFT 
REPORT BY COVANCE (MARCH 2012)  
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APPENDIX 15. GLU 1 INTERIM ANALYSIS: INDEPENDENT DATA MONITORING 
COMMITTEE (IDMC) REPORT  
Title: GLU 1 clinical trial 
Sponsor Protocol Number: 06/085 
Sponsor: UCL/UCLH 
Chief Investigator: Dr Jeremy Whelan 
EudraCT Number: 2006-003203-40 
CTA number 23151/0002/001-0001 
Date of MHRA approval: 10 October 2006 
Name of Investigational Medicinal 
Product(s): 
Voraxaze (glucarpidase) 
Details of latest approved protocol 
(date and version number): 
Version 3.0, 4 December 2007 
Trial design: 
Double-blind, randomised, cross-over, phase II study, 
to investigate the efficacy and safety of glucarpidase 
for routine use after high-dose methotrexate in 
patients with bone sarcoma. 
Start of trial: 3 July 2007 
Total number of subjects planned for 
the trial 
28 
Number of patients recruited so far  16 
Number of patients with complete 
data set 
11 
Date of IDMC meeting to discuss 
interim analysis report 
26 May 2009 
IDMC members 
Dr Beatrice Seddon 
Dr Anna Cassoni 
Dr Rumana Omar 
Interim analysis of the primary 
outcome 
Analysis of the primary outcome has not shown a 
statistically significant benefit of glucarpidase 
with P<0.005 
Treatment with glucarpidase and folinic acid has 
not been not found to be significantly worse than 
standard treatment using an one-sided test with 
P<0.05 
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Recruitment and drop-out rates Recruitment rate has been lower than expected. 
Since 13 June 2007 16 patients have been recruited 
in over 22 months (while the expected accrual was 
10-15 patients per year).  
The drop-out rate has been significantly higher 
than expected with only 11 out of 16 participants 
contributing to complete data set. The expected 
drop-out rate was 5% while the actual drop-out 
rate has been 31%. The trial sample size needs to 
be re-calculated assuming that the drop-out rate 
will remain around 30%.  
The competing EURAMOS 1 clinical trial will stop 
recruiting in June 2010. This will increase the number 
of eligible patients for the GLU 1 trial and boost 
recruitment rates.  
SAEs and AEs reported between 
10 October 2006 and 26 May 2009 
There were no AEs related to the IMP. 
Two SAEs were reported during this period, both 
unrelated to the IMP. The reported SAEs have not 
been considered to be a safety issue that might 
alter the current benefit-risk assessment.  
SAE 1 was reported on 18 October 07 regarding 
patient SHHI/GLU1/05; Short description of the SAE 
1: acute renal impairment after treatment with high-
dose methoterexate; reason for seriousness: 
prolongation of patient’s hospitalization; causality 
assessment regarding the IMP: unrelated; causality 
assessment regarding protocol treatment apart from 
the IMP: related to MTX 
Resolution: 27 November 2007. 
SAE 2 was reported on 27 March 08 regarding 
patient PAHE/GLU1/08; Short description of the SAE 
2: right sided tension pneumothorax caused by 
patient’s extensive pulmonary disease; reason for 
seriousness: life threatening required admission to 
Intensive Care Unit; causality assessment regarding 
protocol treatment apart from the IMP: unrelated; 
causality assessment regarding the IMP: unrelated; 
resolution: 09 April 2008 
IMP shelf life extension The expiry date on the current Voraxaze trial 
stock (BN 2090601) was March 2009 (36 months 
post manufacture date). There is now stability 
data to support extension of the IMP shelf-life to 
48 months. 
A substantial amendment to the protocol will be 
submitted in order to increase the IMP shelf-life to 
48 months. Once the amendment is approved 
Protherics will over-label the study stock (38 vials 
at UCH Pharmacy and 40 vials at Harley Street 
Pharmacy) with the new expiry date: March 2010.  
557 
Blinding of the study  DAMPA, the catabolic product of glucarpidase action 
on MTX, is known to cross-react with MTX in most 
commercial immunological MTX assays. 
Consequently MTX levels determined by commercial 
laboratories are unreliable following treatment with 
glucarpidase. In this study plasma MTX levels are 
measured by both immunoassay and high 
performance liquid chromatography (HPLC). Plasma 
DAMPA levels are measured by HPLC.  
Following each of the four MTX doses (on days 1 & 8 
of cycles 1 and 2), blood samples are collected for 
MTX and DAMPA HPLC analysis at the following 
time points:  
Prior to starting MTX 
At the end of MTX infusion i.e. at 4 hours after 
starting MTX 
At 24 hours after starting MTX 
At 24.20 hours after starting MTX, i.e. 15 minutes 
after glucarpidase/placebo administration 
At 48 hours after starting MTX 
At 72 hours after starting MTX 
and then daily until MTX plasma levels <0.2 µmol/L. 
At 24 hours after the administration of MTX patients 
receive either glucarpidase or placebo. Glucarpidase 
rapidly converts MTX to DAMPA.  Current literature 
suggests that 15 minutes after glucarpidase 
administration, plasma MTX concentrations decrease 
by >95%.  
When patients receive glucarpidase both MTX and 
DAMPA are identified and measured by HPLC. When 
patients receive placebo, only MTX is identified and 
measured. DAMPA is not present. Therefore it is 
obvious when patients receive glucarpidase and 
when they receive placebo. Therefore the study is not 
actually blind to the investigators.  
We suggest that the design of the study is 
changed from “double-blind randomised” to 
“unblind randomised”. In order to minimize any 
bias both “Day 15” assessments need to be 
performed by the on duty registrars and not the 
study chief or co-investigator. 
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Blood samples for anti-
glucarpidase antibody assessment 
and enzyme neutralisation assay 
Blood samples for anti-glucarpidase antibody 
qualitative assessment and enzyme neutralisation 
assay are collected on days 0, 1, 8 and 15 of cycle 1 
and days 1, 8, 15 and 30 of cycle 2. If anti-
glucarpidase antibodies are present on day 30 of 
cycle 2, patients are followed up for a further blood 
test, at 3 and 6 months after starting cycle 2. The 
samples are analysed by Covance Laboratories 
Limited, Otley Road, Harrogate, North Yorkshire, 
HG3 1PY.   
There is a limited supply of one of the reagents used 
in the anti-glucarpidase antibody qualitative assay. In 
order to get the most use out of this reagent Covance 
can assay 30 samples per assay run.  This means 
that sometimes it is not possible to have the results 
for the first time points (days 0, 1, 8 and 15 of cycle 1 
and days 1, 8, 15 and 30 of cycle 2) and we collect 
the two further blood samples (at 3 and 6 months 
after starting cycle 2). 
Further to the above a recent email from Protherics 
states that a new method has been developed by 
BioAnaLab for the qualification (screening) assay, 
and they (Protherics) would eventually like to have all 
antibody samples screened by BioAnaLab.  This will 
mean Covance will ship one aliquot of each antibody 
sample to BioAnaLab.  Any samples identified as 
positive on the qualification by BioAnaLab will then be 
confirmed by a confirmatory assay.  The percentage 
of samples confirmed as positive will be sent to 
Covance to undergo neutralization analysis. 
 BioAnaLab would report to UCL/UCLH on the 
qualification and confirmation results.  Covance 
would report to UCL/UCLH on the neutralization 
assay results.   
We suggest that the protocol is amended so that 
blood samples for anti-glucarpidase antibody 
qualitative assessment and enzyme neutralisation 
assay are collected on days 0, 1, 8 and 15 of cycle 
1 and days 1, 8, 15 and 30 of cycle 2 and at 3 and 
6 months after starting cycle 2.  The updated 
arrangements for anti-glucarpidase antibody 
qualitative analysis and enzyme neutralisation 
assay will also be included in the forthcoming 
protocol amendment. 
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Forthcoming protocol amendment The forthcoming protocol amendment will cover the 
following issues: 
Extension of IMP shelf life 
Amendment of the design of the study to unblind 
randomized  
Amendment of time points for collection of blood 
samples for anti-glucarpidase antibody assessment 
and enzyme neutralisation assay  
Administrative amendment: sponsor contact details 
for SAE submission 
Administrative amendment: new contact details for 
Protherics/BTG 
Administrative amendment: updated arrangements 
for anti-glucarpidase antibody qualitative assessment 
and enzyme neutralisation analysis 
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